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 ABSTRACT 
Prostate cancer is the leading invasive malignancy and the second most common 
cause of cancer death among American men. Despite compelling evidence that oxidative 
stress, ineffective DNA damage repair, and habitually low antioxidants intake may act in 
tandem to influence prostate carcinogenesis, few studies have examined gene-diet 
interactions involving these risk factors. Even fewer studies have examined such 
interactions in relation to prostate cancer aggressiveness. This study investigated whether 
single nucleotide polymorphisms (SNPs) in DNA repair- and oxidative stress-related 
genes modulated associations between antioxidant intake and prostate cancer 
aggressiveness. We utilized data from the North Carolina-Louisiana Prostate Cancer 
Project (PCaP) among African-American (n = 948) and European-American (n = 1,016) 
men. Antioxidant intake was assessed using a food frequency questionnaire, and 
genotypes of 30 germline SNPs were examined. 
 
Effect modification by certain polymorphic variants were observed with some 
variations by race, including variants in XRCC1 (rs2854508, T > A), XPA (rs3176644, G > 
T), NOS3 (rs1799983, G > T), OGG1 (rs1805373, G > A) and NQO1 (rs689453, C > T). For 
example, significant interaction was observed between XRCC1 (rs2854508) genotype and 
α-tocopherol intake among African Americans and European Americans, such that 
among those with the TT genotype, higher α-tocopherol intake was inversely related to 
prostate cancer aggressiveness, while higher α-tocopherol intake was positively related to 
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 high aggressive prostate cancer among those who harbor the AA or AT genotype. A 
similar pattern of effect modification by XRCC1 (rs2854508) was observed for the 
association between γ-tocopherol and prostate cancer aggressiveness, but only among 
African Americans. Lower odds of high aggressive prostate cancer was observed among 
European Americans who possess the CT or TT genotype of NQO1 (rs689453) and had 
higher lycopene intake, but not European Americans with the CC genotype, and there 
was no evidence of effect modification among African Americans. 
Reduced odds and increased odds of high aggressive prostate cancer were 
observed with higher intakes of certain antioxidants (i.e., α-tocopherol, γ-tocopherol and 
lycopene) dependent on genotype, indicating potentially differential dietary 
recommendations based on genetic susceptibility. Because germline genotype is 
unalterable, these findings underscore the importance of considering genetic risk 
variability as part of dietary intervention strategies to identify the subgroup of men who 
are likely to benefit from such interventions. 
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CHAPTER 1 
INTRODUCTION/BACKGROUND 
1.1     INTRODUCTION 
Prostate cancer (PCa) is the most prevalent invasive cancer and a leading cause of 
death in American men [1]. It is estimated that about 2.8 million American men are living 
with PCa with an estimated 241,740 new cases of PCa diagnosed in the U.S. in 2012 [1, 
2]. Due to improved early detection methods, particularly with the advent and subsequent 
widespread use of prostate-specific antigen (PSA) test for PCa screening and 
improvements in cancer treatment, the majority of men diagnosed with PCa die with, 
rather than of, the disease. Thus, PCa is often regarded as an indolent disease of aging 
[3]. However, aggressive forms of PCa are very lethal. PCa aggressiveness generally 
refers to the extent of cancer invasiveness and migration, and often is defined based on 
tumor grade (Gleason score), cancer stage, and PSA level at diagnosis [4, 5]. Men with 
high aggressive PCa have been reported to have as much as a 14-fold increased risk of 
dying from the disease when compared to those with less aggressive PCa [5]. It is also 
estimated that about 30% of prostate tumors progress aggressively [6]. Given the 
prevalence and magnitude of fatalities associated with aggressive PCa, much research has 
been devoted to identifying biomarkers that distinguish indolent disease from aggressive 
disease [7, 8]. On the contrary, less research has been dedicated to understanding the 
interplay between genetic susceptibility and environmental factors that influence PCa 
aggressiveness. Specifically, less attention has been given to interactions between single 
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nucleotide polymorphisms (SNPs) within coding regions of genes that have been 
implicated in carcinogenesis and dietary micronutrients such as antioxidants, which may 
offer new insights for preventing or reversing PCa aggressiveness. 
Similarly, researchers have, until recently, paid very little attention to the potential 
salutary effects of antioxidant-rich diet on PCa progression in men with biochemical 
recurrence of PCa. Biochemical recurrence of PCa is determined by the rising level of 
PSA after post-treatment nadir (lowest detectible level of PSA after treatment), and often 
an indicator of metastasis [9-12]. Men with biochemically recurrent PCa are traditionally 
treated with androgen ablation therapy (medical or surgical) to slow the disease 
progression and delay time to metastasis [9, 11-13]. However, androgen ablation is not a 
cure for PCa, does not always slow the disease progression, and it has been associated 
with life-altering side effects including erectile dysfunction, loss of bone density and 
cognitive decline; and long-term use of androgen ablation has also been associated with 
obesity, diabetes and cardiovascular disease [14-16]. Widespread recognition of these 
side effects has brought to the fore the need for new treatment options that could prevent, 
delay or reverse PCa progression in men with rising PSA levels after curative treatment 
for PCa without the side effects of androgen ablation. Epidemiologic studies suggest that 
diet is one of the important environmental factors that influence PCa initiation and 
progression [17]. Diets rich in antioxidants have also been shown to have 
chemopreventive effects [18]. Although promising, there is conflicting evidence on 
whether a plant-based, antioxidant-rich diet can halt PCa progression in men with 
biochemically defined PCa recurrence [9, 19-21]. However, these studies were limited by 
their inability to evaluate effects of bioactive antioxidants status (as markers of 
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antioxidant intake) on PCa progression. Thus, there is a need for well-designed, 
randomized clinical trials to examine effects of changes in bioactive levels of dietary 
antioxidant on PCa progression. 
 
1.2     EPIDEMIOLOGY OF PROSTATE CANCER  
PCa is the most commonly diagnosed invasive cancer and the second most 
virulent cancer in American men [1]. In 2012, PCa accounted for an estimated 29% 
(241,740) of all newly diagnosed cancers and 9% (28,170) of cancer deaths in American 
men [1]. At present, American men have an estimated 16% (one in six) risk of 
developing PCa during their lifetime, and a 3% (one in 36) risk of dying from the disease 
[22]. The introduction of PSA screening test in the late 1980’s, and subsequent 
widespread use of PSA testing for PCa diagnosis led to about a 10% rise in the number of 
reported cases of PCa each year in the U.S. from 1986 until 1992, when the incidence 
rate peaked at 237 new cases per 100,000 men [23]. Since 1992, the number of newly 
diagnosed cases of PCa has been declining, which suggests that the screening effect is 
diminishing as the pool of men with previously undiagnosed latent disease who were 
captured with the advent of the PSA screening test may have been exhausted [24-26]. 
Even with the decline in PCa incidence rate, the disease remains the most frequent 
malignancy in American men, with the exception of superficial skin cancer [27]. This has 
been attributed to a multiplicity of factors including  increasing life-expectancy, increased 
prevalence of environmental carcinogens, and improved diagnostic technology, 
particularly in the area of transurethral ultrasonography and biopsy technology [26, 28]. 
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PCa is a multifactorial disease with etiology involving both genetic and 
environmental components. The well-established risk factors for PCa are aging, 
race/ethnicity and family history. Other less-established, but “highly probable” risk 
factors (due to reasonably consistent evidence of their involvement in PCa) include 
androgens, inflammation, diet, physical activity/obesity, and tobacco use. Purported risk 
factors such as vasectomy, sexually transmitted diseases, benign prostatic hyperplasia 
(BPH), and human papilloma virus (HPV) infections are a subject of both persistent 
controversy and active research (reviewed in [26, 28, 29]). 
Perhaps the most distinguishable feature of PCa is its inseparable association with 
aging. PCa risk increases much faster with age than does other types of cancer [26]. In 
the U.S., the average age of prostate cancer diagnosis is 67 years. It is rarely diagnosed in 
men younger than age 50 years (3%); however, after this age the incidence increases 
exponentially with  about 97% of the cases diagnosed in men ≥ 50 years old, and 60%  
diagnosed in men ≥ 65 years old [1]. The probability of developing PCa for men ≤ 39 
years old is one in 8,499. This increases to one in 38 for men 40-50 years old, one in 15 
for men 60-69 years old, and one in eight for men ≥ 70 years of age. The risk of death 
from PCa also increases substantially with aging, with men ≥ 70 years old having the 
highest proportion of death from the disease [1]. Indeed, autopsy reports have shown that 
about 70% of men who die by age 80 or older have histological evidence of latent PCa 
[30, 31]. 
African ancestry is an established risk factor for PCa incidence, aggressiveness 
and mortality from the disease [1]. Men of African descent are more likely to be 
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diagnosed with PCa at an early age [1, 27], present with advance-staged disease [32, 33], 
higher PSA levels [34, 35], poorly differentiated tumors [36, 37], and are more likely to 
die from PCa as compared to men of European ancestry [38, 39]. In two recent studies of 
PCa mortality-to-incidence ratio in South Carolina and Georgia, African-American men 
were found to have 58% and 55% higher PCa specific mortality given incidence, 
respectively, when compared to European Americans [20, 40]. Reasons behind these 
marked racial differences remain unclear; however, plausible explanations include 
inherited genetic susceptibility along racial lines, as well as differences in environmental 
and socioeconomic factors [41]. 
The hereditary component of PCa is also well-documented. Men with family 
history of PCa, especially among first-degree relatives (father or brother) have about a 
three-fold increased risk of developing the disease regardless of race/ethnicity [42, 43]. 
First-degree male relatives of a PCa patient also tend to be diagnosed with PCa an 
average of 6 to 7 years earlier than those without family history of PCa [44]. Family 
history of PCa is also a risk for developing the more aggressive forms of the disease [45, 
46]. Additionally, familial clustering for PCa has also been found to be stronger than that 
of breast cancer and colon cancer, two malignancies that are well-recognized for their 
familial aggregation [47]. Also, several studies have reported significant associations 
between having a first-degree female relative (mother or a sister) with history of breast 
cancer and risk of PCa, as well as an increased risk for aggressive PCa [48-50].  
PCa is often described as an androgen-dependent disease. This is largely 
attributable to the Nobel Prize winning study of urologist Charles Huggins, which led to 
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the use of androgen deprivation therapy for treatment of advanced PCa [51]. While the 
evidence remains inconclusive, androgens, particularly testosterone, have been 
implicated in the initiation and progression of PCa [52]. As is the case with normal 
prostate growth and function, the induction and progression of PCa largely depends on 
androgens and androgen receptor signaling [53]. Experimental studies suggest that the 
enzyme 5 alpha-reductase which is found in the prostate gland converts testosterone into 
dihydrotestosterone (DHT), a more active androgen which binds to genomic 
deoxyribonucleic acid (DNA) and regulates the expression of oncogenes that cause PCa 
[54]. The role of androgens in prostate carcinogenesis is also supported by 
epidemiological studies that have found that eunuchs (i.e., males who are castrated before 
puberty) do not develop PCa, primarily because the main source of androgens has been 
removed from the body [26, 28]. It is, however, important to note that recent studies have 
reported conflicting evidence on the role of androgens in PCa, and its aggressiveness [55, 
56]. Similarly, the definitive role of specific androgens, timing of their effect, and their 
underlying mechanisms remains unclear [56]. 
Chronic inflammation has been implicated in the etiology of malignancy in 
several organs including the esophagus, lungs, pancreas, liver, stomach, colon, and 
urinary bladder [57]. Emerging evidence suggests that chronic inflammation may play a 
role in the neoplastic transformation of the prostate, and in PCa aggressiveness [10, 58]. 
The suggested mechanisms of inflammatory effect on prostate carcinogenesis include 
induction of oxidative stress-induced DNA damage, rapid cellular turnover and 
angiogenesis [58, 59]. Molecular and genetic studies also suggest that the sequelae of 
inflammatory effect on PCa involves formation of proliferative inflammatory atrophy 
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(PIA) in the prostate epithelium, which transitions into prostate intraepithelial neoplasia 
(PIN), a known precursor lesion of PCa [60]. Epidemiological studies have also reported 
associations between chronic prostatitis (inflammation of the prostate) and PCa [61, 62]. 
Several parallels have been drawn between dietary patterns and PCa; however, the 
evidence can, at best, be described as probable, rather than conclusive. A litany of 
epidemiological studies have found that excessive intake of energy (calories), calcium 
and dairy products (e.g., milk, cheese, cream, butter, etc.), animal fat and red meat 
increases risk for PCa and PCa aggressiveness (reviewed [17, 63, 64]). On the other hand, 
a diet rich in whole-grains, fruits, vegetables, isoflavones, nuts, seeds and berries appear 
to offer protection against PCa incidence [65, 66] and aggressiveness [67-69]. These 
protective effects are often attributed to the antioxidant micronutrients found in these 
diets. Antioxidants appear to modulate PCa incidence and aggressiveness by reducing 
oxidative DNA damage and gene mutations [70, 71]. However, the three largest 
randomized controlled trials conducted to examine associations between specific 
antioxidants and PCa (i.e., ATBC trial, the SELECT study, the Physicians’ Health Study 
II) failed to establish definitive chemopreventive effects of antioxidants on prostate 
carcinogenesis [72-74]. Notwithstanding, a number of studies have reported significant 
associations between dietary antioxidants, particularly vitamin E, β-carotene, vitamin C, 
lycopene, and selenium, and PCa incidence [75-77] and aggressiveness [67, 78, 79]. 
Nonetheless, the association between dietary antioxidants and PCa remain an issue of 
intense scrutiny and ongoing research. 
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Despite biologically plausible relations, there are inconsistent findings on whether 
physical activity reduces PCa risk (reviewed in [80, 81]). It has been postulated that 
regular physical activity modulates prostate carcinogenesis by reducing serum 
testosterone levels, mitigating oxidative DNA damage, and enhancing immune defenses 
against genomic alterations [82].  There has also been increasing evidence that regular, 
moderate-to-vigorous physical activity may reduce the risk of developing aggressive PCa 
[83-85]. Several studies have also reported associations between obesity and prostate 
cancer risk [86, 87] and aggressiveness [88, 89]. However, the evidence remains 
inconclusive. 
Tobacco smoke is a known carcinogen which is traditionally associated with lung 
cancer, but has also been associated with other malignancies, including cancers of the 
bladder, pancreas, esophagus, stomach, colon, and breast [90]. In recent years, there has 
been growing evidence that tobacco smoke is not only associated with PCa risk [91], but 
also PCa aggressiveness [92-94], recurrence [95, 96], and PCa specific mortality [38, 97]. 
The timing of the effect of tobacco smoke on PCa likely spans decades, and may be 
modulated by genetic susceptibility and/or gene-environment interaction. Nonetheless, at 
present, the epidemiological evidence on the association between tobacco smoke and PCa 
is not consistent (reviewed in [91, 92]). 
 
1.3     STUDY RATIONAL AND SIGNIFICANCE 
Dietary Antioxidant Intake and Prostate Cancer Progression  
Primary management of PCa involves radical prostatectomy or radiation 
treatment, with curative intent [98, 99]. Unfortunately, about one in three men treated 
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with radiation or prostatectomy will experience PCa recurrence within 10 years of 
treatment. This increases to one in two men after 15 years of definitive therapy [100]. A 
rising level of serum PSA is the earliest sign of PCa recurrence, and often referred to as 
biochemical recurrence of PCa [100, 101]. Although the definition of biochemical 
recurrence of PCa has been a subject of debate, it is generally defined as having three or 
more successive rises in PSA above 0.2-0.4 ng/ml from the lowest detectable level after 
definitive therapy [101-103]. Sustained rise in PSA level after definitive therapy is also 
an early sign of metastatic disease and poorer prognosis [9, 104]. Biochemical recurrence 
of PCa is often treated with androgen ablation to delay time to metastasis [99, 105]. 
However, androgen ablation is not a cure for PCa, is not always effective, and often 
inflicts severe side effects including erectile dysfunction, osteoporosis, gynecomastia, 
cognitive decline, weight gain, diabetes, and cardiovascular disease [14-16]. Thus, there 
is considerable interest in a search for novel biomarker-driven treatment options that 
would halt PCa progression and prevent metastases without the side effects of androgen 
ablation. 
There is ample evidence that a plant-based, antioxidant-rich diet, including a diet 
rich in fruits, vegetable, whole grains, soy and soy products may halt PCa progression in 
men with established disease [106]. Suggested mechanisms of dietary antioxidants’ effect 
on PCa progression include mitigation of oxidative DNA damage and suppression of 
LNCaP cell growth by down-regulating male sex hormones [18, 70]. While serum PSA 
level remains a controversial diagnostic test for PCa since a rising level of PSA is not 
exclusive to prostate carcinoma, but also common with benign prostatic hyperplasia 
(BPH) and prostatitis [107], sustained rise in PSA level is an established biomarker of 
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PCa progression [108]. Findings from recent studies suggest that antioxidant-rich dietary 
interventions may benefit men with PCa recurrence, as evidenced by a decline in serum 
PSA level [9, 19, 109, 110]. However, the evidence remains inconclusive thus far, with a 
number of studies reporting null associations [13, 111-113]. Perhaps these inconsistent 
findings may be due to the inability of these studies to measure and evaluate the 
therapeutic effects of bioavailable antioxidants as markers of antioxidant intake. Thus, 
there is a need for well-designed randomized trials to evaluate the effects of biomarkers 
of antioxidants intake such as serum carotenoids and tocopherols on PSA dynamics, and 
by extension, PCa progression. 
 
Oxidative Stress, Antioxidant Defense, and DNA Repair Pathways 
Oxidative DNA damage is a major focus of ongoing etiologic PCa research. 
Oxidative stress refers to a state of imbalance in intracellular levels of reactive oxygen 
species (ROS), and biochemical antioxidants, in favor of ROS [71]. While oxygen is 
essential for normal cell growth and function, molecular oxygen-overload often results in 
excessive production of ROS, which causes damage to cellular components of genetic 
material particularly, protein, lipids, and nucleic acid [71, 114, 115]. Under normal 
physiological conditions, excess molecular oxygen is reduced to water (H2O) through an 
elaborate system of electron transport involving series of oxygen-reduction reactions 
(redox) [70]. However, incomplete or partial reduction of oxygen results in the 
production of singlet oxygen (1O2), hydroxyl radical (.HO), superoxide anion radical (O2-) 
and hydrogen peroxide (H2O2), collectively referred to as oxygen free radicals or reactive 
oxygen species (ROS) [70, 71, 116].  
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It is estimated that about 5% of molecular oxygen load are eventually converted 
to ROS during normal mitochondrial oxygen metabolism [70]. High levels of ROS are 
often produced as a result of endogenous processes such as chronic inflammation and 
oxidative phosphorylation, or through exposure to exogenous substances such as ionizing 
radiation, environmental toxins and pharmaceuticals [70, 117]. To counterbalance 
elevated levels of ROS, antioxidant enzymes (e.g., superoxide dismutase, catalase, and 
glutathione peroxidase) and non-enzymatic antioxidants (such as dietary sources of α-
tocopherol, β-carotene, β-cryptoxanthin, lycopene, lutein, zeaxanthin, etc.), break down 
ROS to restore intracellular redox homeostasis [70]. Oxidative stress occurs when 
intracellular ROS levels exceed antioxidant defense capacity, resulting in oxidative DNA 
damage, altered gene expression, and cell death [70, 71]. Oxidative stress has been 
implicated in the etiology of several chronic diseases including cancer, neurodegenerative 
disorders, diabetes, arteriosclerosis, and pulmonary diseases [118]. 
Oxidative stress has been linked to PCa through its intimate association with 
known or potential risk factors for PCa, such as aging, androgens, and inflammation. 
Aging is the strongest risk factor for PCa, and is associated with inexorable decline in 
body functions including decline in antioxidant defense capacity [119]. Elevated levels of 
ROS and consequential oxidative DNA damage has been observed in aging tissues, 
including the prostate [117, 120]. Similarly, elevated levels of androgens can alter 
intracellular redox status in favor of ROS [70, 71]. This is also supported by findings 
from studies that show that androgen deprivation therapy reduces ROS levels in PCa cells 
(LNCaP), resulting in delayed disease progression [121, 122]. Likewise, chronic 
inflammation, particularly inflammation of the prostate (i.e., prostatitis), also appears to 
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increase ROS production through activation of phagocytes, such as neutrophils and 
macrophages, resulting in increased oxygen-uptake which, in turn, increases ROS 
production in prostate epithelial cells [70, 117]. It has also been clearly demonstrated that 
oxidative stress in PCa cells is essential for their aggressiveness (i.e., invasion and 
migration), with aggressive forms of PCa displaying higher degree of oxidative stress 
than do less aggressive forms [123]. 
Oxidative DNA damage is marked by the formation of oxidized base lesions or 
adducts which, if unrepaired, can result in mutation, altered gene expression, and 
transformation of normal cells into malignancy [8, 70]. Cellular response to oxidative 
DNA damage involves activation of several oxidative stress-mediating genes/pathways, 
including DNA repair pathways and antioxidant enzymes, in order to prevent further 
DNA damage, recover from mutagenesis, and restore genomic stability [124, 125]. Four 
categories of DNA repair pathways are known to operate on different types of DNA 
damage by reversing and/or removing damaged elements: (1) base excision repair (BER), 
which repairs small lesions such as oxidized DNA bases and nonbulky adducts; (2) 
nucleotide excision repair (NER), which removes bulky lesions and damaged single-
stranded fragments from environmental and oxidative stress-induced damage; (3) 
mismatch repair (MMR) that corrects DNA replication errors, specifically mispaired 
DNA bases; and (4) double-stranded breaks, which are repaired through complex 
pathways involving homologous recombination and end-joining DNA repair mechanisms 
[124-126]. 
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Single nucleotide polymorphisms (SNPs) in genes involved in oxidative stress 
and DNA repair pathways may influence susceptibility to PCa [8, 10]. Several studies 
have reported associations between SNPs in DNA repair and oxidative stress genes, and 
overall risk of PCa (summarized in a recent meta-analysis [127]). Existing evidence also 
suggests that associations between these SNPs and overall PCa risk may be modulated by 
dietary antioxidants [128-130]. Similarly, there is growing evidence that some of the 
SNPs in DNA repair and oxidative stress genes confer greater risk for developing 
aggressive PCa [131, 132]. However, just a handful of studies have investigated joint 
effects of these SNPs and antioxidant status in relations to PCa aggressiveness, with 
mixed findings [133-135]. These studies were limited by small sample size, lack of racial 
diversity, and inability to control for multiple potential confounders such as body mass 
index (BMI), physical activity, dietary factors including calcium and energy (calorie) 
intake. Thus, there is a need for a large, racially diverse, population-based study, with 
detailed data on demographics, personal and family health history, lifestyle, dietary 
patterns, PCa screening history, and clinical attributes of PCa. 
 
 
1.4     OBJECTIVES AND HYPOTHESES  
OBJECTIVE 1: To examine whether changes in dietary antioxidant intake (baseline to 3-
months) as measured by plasma concentrations of carotenoids and tocopherols are 
associated with PCa progression (assessed by changes in serum PSA level as an 
intermediate prognostic marker of disease progression) in African-American and 
European-American men with biochemically defined PCa recurrence after 
definitive therapy. 
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Hypotheses: 
i. Higher levels of plasma carotenoids and tocopherols at baseline will be 
associated with lower serum PSA levels at baseline. 
ii. Higher post-intervention plasma carotenoids and tocopherol levels (at 3 
months) will be associated with lower post-intervention PSA levels (at 3 
months, and at 6 months), after adjusting for baseline PSA level. 
iii. Change in plasma carotenoids and tocopherol levels (baseline to 3 months) 
will inversely correlate with serum PSA levels at 3 months and at 6 months.  
 
 
OBJECTIVE 2: To examine associations between antioxidant levels in adipose tissue, 
plasma and diet, and PCa aggressiveness among African American and European-
American men. 
Hypothesis: Lower levels of antioxidants in adipose tissue, plasma and diet are associated 
with high aggressive PCa, and these associations do not vary by race. 
 
OBJECTIVE 3: To examine whether SNPs in DNA repair and oxidative stress genes 
modulate associations between antioxidants in adipose tissue, plasma and diet, 
and PCa aggressiveness among African-American and European-American men. 
Hypothesis:  SNPs in DNA repair and oxidative stress genes modify associations between 
antioxidants in adipose tissue, plasma and diet, and PCa aggressiveness, and the 
degree of the effect modification vary by race. 
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 CHAPTER 2 
LITERATURE REVIEW  
2.1     DIETARY INTERVENTION TRIALS FOR RECURRENT PROSTATE CANCER AFTER 
DEFINITIVE 
 
Clinically localized PCa is traditionally managed with definitive therapy which 
consists of prostatectomy or radiation therapy, or prostatectomy followed by radiation 
therapy [9, 12, 100]. However, over a third of PCa patients treated with definitive therapy 
develop biochemically defined disease recurrence within 10 years of treatment [100]. 
Biochemical recurrence of PCa is marked by sustained rise in PSA after post-treatment 
nadir (lowest detectable level of PSA after treatment) [100-102]. A rising level of PSA is 
also a surrogate serum marker of PCa progression [9]. Men with biochemically recurrent 
PCa and rising level of PSA are often treated with androgen ablation with the hope of 
delaying the disease progression. Nonetheless, there is little evidence supporting the 
efficacy of androgen ablation in this population of men [136-138]. Androgen ablation has 
also been associated with severe, life-altering side effects [14, 15]. These reasons have 
motivated the search for new and innovative treatment strategies that could halt or delay 
the progression of recurrent PCa without the side effects of androgen ablation [9].  
There is growing evidence that recurrent PCa may be a diet-sensitive disease 
stage because a number of dietary intervention trials have found inverse associations 
between increased consumption of a plant-based, antioxidant-rich diet and serum PSA
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 levels [18, 19, 109, 139]. This suggests that plant-based diets that are rich in antioxidants 
may offer an alternate treatment option for recurrent PCa. However, the current evidence 
is limited and inconclusive, as other dietary intervention studies including well-designed 
randomized clinical trials have also found null associations between antioxidant-rich 
dietary interventions and PCa progression in men with biochemically defined recurrence 
([13, 112, 113], also reviewed in [111]). Thus, the exact role of dietary antioxidants in 
relations to PCa progression remains unclear. 
In a recent dietary intervention trial of men with biochemically defined PCa 
recurrence and rising PSA levels, Saxe et al. [9] investigated the effect of dietary 
modification involving a plant-based, antioxidant-rich diet, together with stress 
management training, on PCa progression. The study consisted of 13 men (supported by 
their spouses) who opted not to use conventional therapy for treatment of recurrent 
disease. The study participants were recruited through the Veterans Affairs hospitals in 
San Diego, California and followed over a 6-month period. The investigators utilized a 
pre-post design with each participant serving as his own control. The intervention in this 
study consisted of increased intake of whole grains, fruits, vegetables, and legumes, along 
with lessons on how to shop for, and cook the study-compliant diet. Study participants in 
the intervention group were also offered individual dietary counseling, instructional 
materials, and a series of group meetings to help reinforce the intervention. Stress 
management training was also offered to the intervention group to help relieve any form 
of stress that may have been associated with change in diet palatability and culinary 
habits. Pre-intervention PSA values were obtained from participants' medical records, 
and rates of pre-intervention PSA rise were calculated based on these PSA values, 
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 including the initial PSA values used to establish biochemical recurrence of the disease  
(i.e., three successive PSA values, at least 1 month apart) and all documented PSA values 
thereafter, until the start of intervention. The intervention rate of PSA rise was estimated 
based on PSA values measured at baseline, at 3-months, and at 6-months. The pre-
intervention and intervention rates of PSA rise, and PSA doubling time were estimated 
for each patient as the natural log of PSA by time (months) and natural log of two divided 
by the rate of change in PSA, respectively, using linear regression analyses. Results of 
the study show a significant decline in rates of PSA rise during intervention when 
compared with the pre-intervention rates of PSA rise (p< 0.01). Additionally, significant 
improvements were made in PSA doubling time during the intervention, which increased 
from a median doubling time of 11.9 months (pre-intervention) to 112.3 months over the 
6-month intervention period. This study suggests that plant-based, antioxidant-rich 
dietary modification combined with stress reduction may slow the progression of PCa as 
evidenced by decline in rates of PSA rise and prolonged PSA doubling time. 
Carmody et al. [21] also investigated whether men with recurrent PCa and rising 
level of PSA can make sustainable dietary changes after attending series of cooking 
lessons integrated with mindfulness training, and whether these dietary changes can 
influence quality of life and PCa progression. The study population consisted of 36 male 
residents of Massachusetts with biochemically defined PCa recurrence after receiving 
definitive therapy who had not received any disease-directed therapy after PCa 
recurrence. The study participants were randomized into intervention (n=17) and control 
(n =19) groups, and followed over a 3-month period. Participants in the intervention 
group (supported by spouses or partner of choice to help with dietary change) were 
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 offered 11 weekly diet and cooking lessons which emphasized increased intake of plant-
based diets that are rich in antioxidants, particularly foods that are rich in carotenoids, 
soy, and isoflavones; including vegetables, whole grains, and soybean and soybean 
products. The intervention also encouraged consumption of fish, especially salmon due to 
its ω-3 fatty acids content, and discouraged intake of poultry and dairy products 
(including meat) because of saturated fat and calcium contents, which have been 
associated with PCa incidence, aggressiveness, and progression [17]. Since dietary 
changes can be onerous and often difficult to adhere to, mindfulness training was offered 
as part of the intervention to help promote participants’ sense of control over change in 
dietary patterns. The intervention group was compared to a “wait-list” control group, who 
were offered an opportunity for the intervention at the end of the study. Diet assessment 
in both arms of the study was done using 24-hour diet recall interviews which provided 
estimates of nutrient intake including antioxidants, fat, protein, calcium and fiber at 
baseline, after 11 weeks of intervention, and at the end of the intervention (3 months). 
Change in quality of life was assessed using functional assessment questionnaires 
eliciting information on physical/functional status at the three study time points (baseline, 
11 weeks, and 3-months). Pre-intervention PSA values were obtained from participants’ 
medical records, and three additional PSA values were measured at the three study time 
points. The investigators calculated average pre-intervention PSA slopes for the 
intervention and control groups separately based on the two most current PSA values in 
participant’s medical records. Similarly, they estimated the average intervention PSA 
slopes between the two groups based on PSA assays measured at the three study time 
points. PSA velocity was also calculated as the natural log of PSA by time. Results of the 
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 study show that the intervention group was able make positive dietary changes including 
increased intake of antioxidants, particularly lycopene (p = 0.05), carotenoids (p = 0.05), 
and decreased intake of animal protein (p = 0.03), saturated fat (p <0.01) and calcium (p 
= 0.01). Additionally, the intervention group had significant improvements in quality of 
life when compared with the control group (p = 0.02). However, there were no 
differences in change in PSA slope between the two study groups (p = 0.28). 
Nonetheless, the average PSA doubling time was significantly prolonged for the 
treatment group by about 172% (from 21.5 months at baseline to 58.5 months at 3-
months), while that of the control group only increased by 1.6% (from 18.4 months at 
baseline to 18.7 months at 3-months). These findings suggest that men with recurrent 
PCa and rising PSA levels can make beneficial dietary changes involving antioxidants, 
and when integrated with mindfulness practice and partner support, these dietary 
modifications may improve quality of life and delay the progression of PCa. 
Hébert et al. [13] also investigated the efficacy of plant-based, antioxidant-rich 
dietary intervention, integrated with physical activity and stress reduction, on PCa 
progression in men with biochemically defined recurrence. This study (EASE Study) was 
conducted in South Carolina and consisted of 47 men who had been previously treated 
with definitive therapy for histologically confirmed adenocarcinoma of the prostate. The 
study participants were randomized into intervention (n = 26) and control (n = 21), and 
followed over a 6 month period. Participants in the intervention group were enrolled in 
the study along with a spouse or partner-of-choice to offer support in the process of 
lifestyle change. Those in the control arm of the study had the usual care with an 
opportunity for the intervention at the end of the study. The intervention consisted of 
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 individual diet and physical activity counseling sessions, as well as group sessions 
involving discussions on how to shop for, and cook study-compliant meals, physical 
activity goals, and practice of meditation that cultivates mindfulness. The diet aspect of 
the intervention emphasized increased intake of plant-based foods such as whole grains, 
fruits, vegetables, and legumes (particularly soybeans and soybean products), all of which 
are rich in antioxidant micronutrients. The intervention also emphasized reduced intake 
of meat and dairy products. The investigators integrated meditation and physical activity 
as part of the intervention to help reduce stress associated with comprehensive dietary 
change and to promote the overall well-being of the participants. Diet assessment was 
done using 24-hour diet recall interviews at baseline, and at 3 months and 6 months. 
Physical activity questionnaires were also used to ascertain activity levels and serum PSA 
assays were measured at each of the study time points (baseline, and at 3 months and 6 
months). Effectiveness of the intervention on serum PSA levels was evaluated using an 
intent-to-treat, mixed-effects model with repeated measures analysis of variance. Post 
hoc analyses were also performed using signal detection (i.e., decision tree) methods to 
examine effects of individual dietary components on serum PSA level. Results of the 
study show that there were no significant differences in change in serum PSA levels 
between the intervention and control groups (p = 0.45). However, the intervention group 
made positive dietary modifications including increased intake of fruits, vegetables, and 
fiber (albeit, statistically non-significant); and decreased intake of calories (p = 0.01), 
total fat (p = 0.02), and saturated fat (p <.01). Results from the signal detection analyses 
also show that irrespective of intervention status,  56% of men who increased  fruit intake 
had no rise in serum PSA levels compared to 29% of men who did not increase fruit 
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 intake. Similarly, 56% of men who increased fruit and fiber intake and decreased 
saturated fat intake had no rise in serum PSA levels compared to 44% of men who did 
not. Thus, this study provides suggestive evidence that increased consumption of fruits 
and fiber, along with decreased intake of saturated fat, may offer protection against PCa 
progression. 
Over the last two decades, a total of ten papers have been published defined by 
the authors as plant-based dietary interventional studies in relations to PCa progression 
[9, 11, 13, 18, 21, 112, 139-142], representing eight independent studies on plant-based 
diet intervention trials that have been conducted in the last 20 years. Five of these eight 
studies reported potential inhibitory effect of dietary modification on PCa progression as 
measured by change in serum PSA level [9, 11, 18, 21, 141]. Three of these studies found 
no effect of dietary modifications on PCa progression [13, 112, 140]. These mixed 
findings can be attributed to multiple factors, including the fact that conventional dietary 
interventions such as those described above are multifaceted, involving different 
combinations of diet, stress reduction, and physical activity which make it difficult to 
evaluate the independent effect of the prescribed diet. Secondly, diets used in dietary 
intervention trials usually have several components, such as increasing fruits, vegetables, 
and fiber intake, while decreasing consumption of meat and dairy products at the same 
time, which makes it difficult to evaluate independent effects of specific food 
constituents, including micronutrients such as antioxidants. There is also the possibility 
of treatment “contamination” between the intervention group and the control group, 
where health-conscious persons in the control group may have knowingly or 
inadvertently adopted the behavior change prescribed for the intervention group. These 
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 limitations provide justification for further high-impact translational research involving 
biomarkers of dietary antioxidant intake and predictive markers of PCa progression to 
help establish potential etiologic relationship. Such research would provide more 
definitive evidence on the efficacy of dietary intervention on PCa progression. 
Additionally, this could provide valuable information to clinicians that can facilitate the 
development of structured and monitored dietary intervention strategies as a cost-
effective treatment alternative for men with biochemically recurrent disease. 
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Table 2.1 Summary of findings from plant-based, dietary intervention trials in relation to prostate cancer progression among 
men with biochemically defined prostate cancer recurrence (PSA endpoint studies) 
 
Author Intervention Subjects and design Results 
  
Randomized trials 
 
Hébert et al., 2012 Diet, 
Physical activity &    
Stress reduction 
A six month follow-up study:  2.5-hr weekly 
sessions over 3 months, monthly booster 
sessions continued for another 3 months. 
Intervention (n = 26)  
Control (n = 21) 
 
Intervention emphasized increased intake of 
antioxidant-rich diet such as whole grains, 
fruits, vegetables, and legumes (particularly 
soybeans and soybean products). 
No difference in change in PSA 
level between the intervention 
and control group (p = 0.45) 
Mean PSA at 3-months:  
Intervention : 1.09 (0.54-2.18) 
Control         : 0.77 (0.36-1.68) 
 
Mean PSA at 6-months: 
Intervention : 0.78 (0.36-1.70) 
Control         : 0.84 (0.42-1.68) 
Carmody et al., 
2008 
Diet, 
Stress reduction 
A 23-week follow-up study of 36 male 
residents of Massachusetts randomized into 
intervention (n = 17) and control (19). 
Active intervention: 11weekly 2.5-hr sessions, 
and followed for additional 12 weeks. 
Intervention emphasized increased intake of 
carotenoids, soy, and isoflavones; including 
vegetables, whole grains, soybean, soybean 
products and fish (particularly salmon). 
No difference in change in PSA 
slope (p = 0.28) 
PSA doubling time: 
Intervention: ↑ from 21.5 months 
(pre-study) to 58.5 months 
(during intervention)  
Controls: ↑ from 18.4 (pre-study) 
to 18.7 months (during study 
period)     
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Table 2.2 (continued): Summary of findings from plant-based, dietary intervention trials in relation to prostate cancer progression 
among men with biochemically defined prostate cancer recurrence (PSA endpoint studies)  
 
Author Intervention Subjects and design Results 
  
Non-randomized trials (no controls) 
 
Saxe et al., 2001 Diet, 
Stress 
reduction 
Ten Massachusetts male residents followed over 4 
months. 
Twelve weekly intervention of 3-4 hrs each 
Intervention emphasized increased intake of whole 
grains, legumes, fresh green and yellow vegetables, 
seeds, legumes, soy products and fruit. 
Rate of PSA rise decreased in 8 of 10 
men. 
Median PSA doubling time increased 
by 2.7 folds [from 6.5 months (pre-
study) to 17.7 months]  
Saxe et al., 2006 Diet, 
Stress 
reduction 
Thirteen men from VA hospitals in San Diego, CA 
Ten 3 hour meetings over 6-months: 
 Once per week for first month 
 Once per month for month 2 to 5 
 Two in month 6  
Intervention emphasized same diets as Saxe et al., 
2001. 
Rate of PSA rise decline during 
intervention compared with the pre-
intervention rates of PSA rise (p < 
0.01).  
Median PSA doubling time increased 
by 9.4 folds [from 11.9 months (pre-
study) to 112.3 months] 
Nguyen et al., 
2006 
Diet, 
Stress 
reduction 
Same population as Saxe et al., 2006  
  
Examined rates of PSA rise at different intervals  
Rate of PSA rise decreased when 
comparing pre-study (0.06) to 0- to 3-
months (–0.002, P < .01). 
However, the rate of PSA rise 
increased when comparing the interval 
0- to 3-months (-0.002) with 3- to 6-
months (0.03, P = .43). 
 
 2.2     ASSOCIATIONS OF ANTIOXIDANTS AND PROSTATE CANCER RISK AND 
AGGRESSIVENESS 
 
Extensive research on carcinogenesis and chemoprevention (i.e., the use of diet, 
nutritional supplements and/or medications to prevent cancer) has led to a firm 
conclusion that one of the mechanisms by which diet modifies PCa risk and 
aggressiveness is through the consumption of antioxidant micronutrients, which are 
found in many foods including fruits, vegetables, and legumes [17, 18, 117, 123]. It has 
been clearly established that antioxidants protect cellular DNA from damage by oxidative 
stress through the elimination of intracellular reactive oxygen species (ROS) [8, 70]. 
Sustained oxidative stress (i.e., prolonged period of elevated levels of ROS beyond 
antioxidant repair capacity) can lead to changes to the prostatic microenvironment, 
including DNA base damage, DNA strand breaks, altered gene expression, and 
ultimately, PCa [70, 117]. Although numerous studies have examined associations 
between dietary antioxidants and PCa with some promising results, there is a lack of 
consistency in the outcome of these studies (reviewed in [64, 76, 143-149]). These 
inconsistencies emphasize the need for well-designed and well-executed studies to help 
delineate the role of individual antioxidants in PCa and PCa aggressiveness before 
widespread use of antioxidants for chemoprevention is encouraged. This summary 
includes reviews of benchmark studies and the current state of the science on 
relationships between antioxidants and PCa, with special emphasis on PCa 
aggressiveness. 
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 Vitamin E  
 
Vitamin E is thought to play an important role in PCa prevention because of its 
antioxidant effect. Vitamin E is a complex fat-soluble compound occurring in eight 
different chemical forms; four tocopherols [alpha (α), beta (β), gamma (γ), and delta (δ)] 
and four tocotrienols (α-, β-, γ-, and δ-tocotrienols) with varying levels of bioavailability 
and biologic significance [150]. The most bioactive form of vitamin E in human serum 
and tissues is α-tocopherol, which is also the most extensively researched form of 
vitamin E in relation to PCa [150-152]. The most common form of vitamin E in 
American diet is γ- tocopherol, while α-tocopherol is the most common type found in 
nutritional supplements [150, 153, 154]. Vitamin E is found in the human diet in various 
plant seeds, nuts, and oils [154]. Consumption of vitamin E from diet and nutritional 
supplements as well as serum and tissue levels of individual tocopherols and tocotrienols 
have been associated with PCa and PCa aggressiveness (reviewed in [64, 76, 154-158]). 
Unfortunately, the evidence is conflicting and often difficult to reconcile. 
Several clinical trials have examined antioxidant supplementation in relation to 
prostate cancer incidence. The Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer 
Prevention Trial is one of the benchmark studies in this area of research. The ATBC trial 
a randomized, double-blinded, placebo-controlled trial conducted among 29,133 Finish 
male smokers, aged 50-69 years, with a primary aim of exploring chemoprevention of 
lung cancer. The study participants were randomized into four treatment groups; (1) α-
tocopherol 50mg/daily; (2) β-carotene 20 mg/daily; (3) α-tocopherol 50mg/daily and β-
carotene 20 mg/daily; and  (4) placebo. Although the primary end-point was lung cancer, 
the investigators observed that after 5 to 8 years of follow-up, smokers assigned to the 
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 α−tocopherol group had a 32% (95% confidence interval [CI] = −47% to −12%) reduced 
risk of PCa incidence and 41% (95% CI = −65% to −1%) lower risk of death from PCa 
when compared to the placebo group [159]. Analysis of a 6-year post-intervention 
follow-up of this study showed that the protective effect in the α−tocopherol group 
reduced from 36% (RR = 66; 95% CI = 0.51-1.04) during the trial to 27% (RR = 0.73; 
95% CI = 0.51 – 1.04) 3 years post-trial, and finally to 6% (RR = 0.96; 95% CI = 0.72 – 
1.24) 6 years post-trial. This observation led to the conclusion that the beneficial effects 
of α−tocopherol against PCa require long-term use [160]. In a recent analysis of the 
ATBC trial with 19-year follow-up data, using biomarkers of antioxidant intake, 
Weinstein et al. [79] observed that higher levels of serum α−tocopherol reduced the risk 
of PCa by 20% (RR = 0.80; 95% CI = 0.66 - 0.96; highest vs. lowest quintile; Ptrend = 
0.03). Higher levels of serum α−tocopherol were also found to reduce the risk of 
advanced PCa by 44% (RR = 0.56; 95% CI, 0.36-0.85; Ptrend = 0.002). Other studies have 
also provided evidence on the beneficial effects of vitamin E on PCa [74, 161, 162]. For 
example, in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), 
Kirsh et al. [68] observed that among current and former smokers, daily intake of 400 IU 
of vitamin E was associated with a 71% (RR =  0.29; 95% CI = 0.12 to 0.68; Ptrend = .01) 
decreased risk of advanced PCa (i.e., Gleason score ≥ 7 or cancer stage II/IV) compared 
to a placebo group. Similarly, in a case-control study nested within the Physicians’ 
Health Study, male physicians with the highest levels of serum α−tocopherol were found 
to have a 36% lower risk of aggressive PCa, albeit, statistically non-significant (OR =  
0.64; 95% CI = 0.38 - 1.07). A subgroup analysis showed that the inverse association for 
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 aggressive PCa was stronger and statistically significant for current/former smokers (OR 
= 0.51; 95% CI = 0.26 - 0.98; highest vs. lowest quintile) [163]. 
However, these findings are contradicted by results from the Selenium and 
Vitamin E Cancer Prevention Trial (SELECT), which was established based on the 
promising results of the ATBC trial [73]. SELECT recruited 35,533 male residents of the 
US, Canada, and Puerto Rico, aged ≥ 50 years, who were randomized into selenium (200 
µg/day) only, vitamin E (α−tocopherol, 400 IU/day) only, a combination of selenium 
(200 µg/day) and vitamin E (α−tocopherol, 400 IU/day) or placebo. This trial was 
designed to span a minimum of seven years and maximum of 12 years, but did not 
continue after the initial phase of seven years due to a suspicion that the intervention with 
α-tocopherol may have been putting the study participants at risk for developing PCa 
[73]. After the 7-year follow-up period, those taking vitamin E alone had a 13% increased 
risk of PCa, albeit statistically non-significant (HR = 1.13; 99% CI = 0.95 -1.35) [73]. 
Analysis of data from additional 1.5 years of follow-up of SELECT showed a stronger 
and statistically significant increased risk of PCa in the study participants who received 
vitamin E alone (HR = 1.17; 95% CI = 1.004 - 1.36, Ptrend = 0.008) [164]. However, in 
another large randomized, placebo-controlled trial (The Physicians’ Health Study II), 
supplemental vitamin E (400 IU) taken every other day over a 10-year period did not 
have an effect on PCa incidence (HR = 0.97; 95% CI = 0.85-1.09) or PCa-specific 
mortality (HR = 1.01; 95% CI = 0.64-1.58) in US male physicians [74]. Additionally, 
analysis of data from the Nutritional Cohort of the Cancer Prevention Study II showed 
that daily intake of supplemental vitamin E (≥ 400 IU) does not have an effect on overall 
risk of PCa (RR =  0.98; 95% CI = 0.89-1.08) or risk of advanced-stage disease (RR =  
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 0.97; 95% CI = 0.74 – 1.26) [165]. A number of observational studies, particularly case-
control and cohort studies have also examined associations of vitamin E and PCa 
incidence [78, 152, 166-168] and advanced/aggressive PCa [169-171] with mixed 
findings. However, it is important to note that after reviewing evidence from cohort, case-
control, and ecological studies involving serum/plasma-based, questionnaire-based, and 
aggregate data, the World Cancer Research Fund and the American Institute for Cancer 
Research (WCRF/AICR) expert panel concluded in 2007 that although the evidence 
remains inconsistent, it is “probable” that vitamin E protects against PCa [172]. 
 
Carotenoids 
It has been suggested that carotenoids may decrease the risk and aggressiveness of 
PCa by neutralizing ROS, which play a role in PCa through oxidative DNA damage [117, 
123]. The most common carotenoids in the Western diet are α-carotene, β-carotene, β-
cryptoxanthin, lycopene, lutein, zeaxanthin, and retinol (vitamin A), all of which are 
found in a variety of foods [173, 174]. Carrots, pumpkin, and winter squash are the 
primary sources of α-carotene; while β-carotene, β-cryptoxanthin, lutein and zeaxanthin 
are most abundant in deep-yellow/orange fruits such as apricots, cantaloupes, and 
mangoes, as well as in dark-green leafy vegetables, such as spinach, kale, broccoli, 
Brussels sprouts, green beans, peas, and zucchini. Lycopene is primarily found in 
tomatoes and tomato-based products, particularly processed tomatoes [173, 174]. Several 
studies have examined associations between carotenoids and PCa. However, the evidence 
remains inconsistent, emphasizing the need for high-impact research to help delineate 
relationships between individual carotenoids and PCa; especially PCa aggressiveness, 
which has received very little attention in the literature.  
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 The US Physicians’ Health Study is one of the longest prospective studies 
conducted to examine associations between plasma concentrations of all the major 
carotenoids and PCa risk. Gann et al. [163] conducted a case-control study nested within 
the Physicians’ Health Study, involving 578 men with PCa who were age-matched to 
1294 controls. The investigators examined associations between plasma levels of α-
carotene, β-carotene, β-cryptoxanthin, lycopene, lutein and retinol, and PCa risk and 
observed that none of these carotenoids were associated with overall risk of PCa. 
However, lycopene was strongly and inversely associated with PCa aggressiveness (OR = 
0.56; 95% CI = 0.34 - 0.92, p = 0.02; highest vs. lowest quintile). Similarly, in a recent 
population-based, case-control study,  Zhang et al. [175] investigated associations 
between plasma concentrations of α-carotene, β-carotene, β-cryptoxanthin, lycopene, and 
lutein/zeaxanthin and PCa, and found that only plasma lycopene was inversely and 
significantly associated with PCa risk (OR =  0.45; 95% CI = 0.24 - 0.85; highest vs. 
lowest quartile; Ptrend = 0.042). 
Lycopene is considered a potent antioxidant, which in addition to its ability to 
neutralize ROS, is also thought to protect against PCa through the inhibition of IGF-
mediated cell proliferation and suppression malignant prostate cell growth [176, 177]. 
Lycopene consumption has been inversely associated with PCa in both serum-based and 
questionnaire-based studies; however, the evidence remains mixed (reviewed in [64, 143, 
145, 178]). In a meta-analysis of 10 cohort studies and 11 case-control studies, lycopene 
consumption appeared to offer protection against PCa. In the cohort studies, cooked 
tomato products were associated with a 19% (RR = 0.81; 95% CI = 0.71 - 0.92) reduced 
risk of PCa cancer, and consumption of raw tomatoes (200g/day) was associated with a 
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 22% (RR = 0.78; 95% CI = 0.66 - 0.92) lower risk of PCa in the case-control studies. 
Other sources of lycopene were not associated with PCa [179]. In addition, a fairly recent 
prospective study, lycopene consumption was found to reduce the risk of PCa in men 
with a family history of the disease (Ptrend = 0.04) [180]. In the European Prospective 
Investigation into Cancer and Nutrition (EPIC), plasma lycopene was inversely 
associated with advance-staged PCa (RR = 0.40; 95% CI = 0.19 - 0.88, highest vs. lowest 
quintile), but not localized disease (RR = 1.40; 95% CI = 0.89 - 2.21; lowest vs. highest 
quintile) [181]. Similarly, in the Third National Health and Nutrition Examination Survey 
(NHANES III), serum lycopene was associated with a 63% lower risk of aggressive PCa 
(RR = 0.37; 95% CI = 0.15–0.94; highest vs. lowest quartile; Ptrend = 0.04), but not 
overall PCa risk (RR = 0.65; 95% CI = 0.36–1.15; highest vs. lowest quartile; Ptrend = 
0.09) [182]. However, in a case-control study nested within the PLCO trial, serum 
lycopene status had no association with PCa risk (Ptrend = 0.28) or PCa aggressiveness 
(Ptrend = 0.43) [183]. Other studies have also reported null associations between 
serum/plasma- and questionnaire-based studies on lycopene level and PCa risk and 
aggressiveness [184-187]. Together, the weight of the evidence suggests that lycopene 
likely offers protection against PCa and may have greater influence on PCa 
aggressiveness; however, more research is needed for definitive conclusion. 
Perhaps the most puzzling association between individual carotenoids and PCa is 
that of β-carotene and PCa risk. In the ATBC trial, β-carotene was associated with a 23% 
(95% CI = −4% to −59%) increased risk of PCa and a 15% (95% CI = −30% to −89%) 
increased risk of death from PCa [159]. Also, in a nested case-control study using data 
from the PLCO trial, higher levels of serum β-carotene was associated with a 67% (OR =  
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 1.67; 95% CI = 1.03 - 2.72, highest vs. lowest quintile) increased risk of aggressive PCa 
(Gleason sum ≥ 7 or stage III or IV). This increased risk was much higher for advanced-
stage (stage III or IV) disease (OR = 3.16; 95% CI = 1.37 - 7.31, highest vs. lowest 
quintile) [183]. In another prospective study, high serum level of β-carotene was 
associated with a 2.3 fold increased risk of PCa (RR = 2.3; 95% CI = 1.12 - 4.66, highest 
vs. lowest tertile, Ptrend = 0.023) [187]. While assessing PCa as a secondary aim in the 
Carotene and Retinol Efficiency Trial (CARET) it was observed that daily 
supplementations of 30mg of β-carotene plus 25,000 IU of retinyl palmitate was 
associated with a 52% increased risk of aggressive PCa (RR =  1.52; 95% CI = 1.03 - 
2.24) [188]. Interestingly, other studies have reported inverse associations between β-
carotene and PCa. Kirsh et al. [68] observed that supplemental β-carotene of at least 2000 
µg/day was associated with a 48% lower risk of PCa in men with low dietary β-carotene 
intake (RR = 0.52; 95% CI = 0.33 - 0.81). In addition, a nested case-control study, high 
plasma β-carotene was also associated with a 69% PCa risk reduction (OR = 0.31; 95% 
CI = 0.15 – 62; higher than median vs. lower than median) [189]. However, in a recent 
meta-analysis, β-carotene was not associated with PCa incidence (RR =  0.99, 95% CI = 
0.91 - 1.07) [190]. Similarly, there is conflicting evidence on associations between 
serum/plasma levels and dietary intake of α-carotene, β-carotene, β-cryptoxanthin, 
lutein/zeaxanthin, and retinol on PCa risk and aggressiveness [17, 76, 190]. For example, 
Lu et al. [191] reported a 70% to 80% PCa risk reduction in men with higher plasma 
levels of β-cryptoxanthin, lutein and zeaxanthin, but retinol, α- and β-carotene were not 
associated with PCa risk. However, in a prospective cohort study, dietary intake of β-
cryptoxanthin was associated with an increased risk of PCa in a dose-response fashion 
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 (Ptrend < 0.01). There were no discernible associations between retinol, α- and β-carotene, 
lutein/zeaxanthin and PCa [171]. These apparent discrepancies may be explained by 
baseline antioxidant status of the studied populations. That is, antioxidant 
supplementation in a population that is nutritionally replete may not have a beneficial 
effect, whereas supplementing a population that is nutritionally deficient might have 
substantial health benefits [192-195]. 
 
 
Selenium  
 
Selenium is an essential micronutrient found in many food items, particularly 
plant-based foods such as bread and cereal (depending on soil concentrations), and in 
meat and fish products as well as nutritional supplements [17, 158]. It has been suggested 
that selenium may protect against PCa by inducing the antioxidant enzyme glutathione 
peroxidase, which neutralizes the free radical superoxide anion (.O2-) and also by 
inhibiting PCa cell proliferation through the suppression of angiogenesis [158, 196]. 
Dong et al. [197] have also demonstrated a dose dependent effect of selenium on PCa cell 
growth inhibition and apoptosis. Nonetheless, the role of selenium in prostate 
carcinogenesis remains a subject of ongoing debate. 
Interest in the role of selenium in the prevention of PCa was stimulated by the 
National Prevention of Cancer (NPC) trial, which was primarily designed to investigate 
the effect of selenium on the recurrence of nonmelanoma skin cancer [198]. In this 
double-blinded, randomized, placebo-controlled trial, 1,312 patients recruited from 
dermatology clinics located in the eastern seaboard of the US were randomized into 
treatment (200µg of selenium daily) and placebo. After 13 years of follow-up, it was 
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 observed that selenium did not have any effect on skin cancer recurrence; however, 
selenium was inversely associated with overall risk of PCa (RR = 0.51; 95% CI = 0.29 - 
0.87). Nonetheless, results from a subgroup analysis showed that the PCa risk reduction 
was only in men with baseline PSA level ≤ 4 ng/ml (RR = 0.33; 95% CI = 0.14 - 0.79), 
but not those with baseline PSA ≥ 4 ng/ml (RR = 0.95; 95% CI = 0.42 – 2.14). In a 
matched case-control study, Yoshizawa et al. [199] observed inverse associations 
between toenail levels of selenium and advanced-stage PCa (OR =  0.35, 95% CI = 0.16 - 
0.78, highest vs. lowest quintile, Ptrend = 0.03). Van den Brandt et al. [200] also examined 
association between toenail level of selenium and PCa risk in a cohort of 1,211 men and 
found that elevated toenail levels of selenium was protective against PCa (RR =  0.69, 
95% CI = 0.48 - 0.99, highest vs. lowest quintile, Ptrend = 0.008). However, subgroup 
analysis in this study also showed that the protective effect was only evident in former 
smokers (Ptrend = 0.003), and not current (Ptrend = 0.383) or non-smokers (Ptrend = 0.412). 
Three recent meta-analysis involving serum/plasma-, toenail- and questionnaire-based 
studies indicated that men with high intake of selenium have lower risk of developing 
PCa [144, 146, 201]. However, it is important to note that assessment of selenium intake 
in epidemiological studies is fraught with problems arising from the way food is 
prepared, digested and absorbed. 
In the SELECT trial (described above), daily supplementation of 200 µg selenium 
did not have an effect on PCa risk (HR = 1.09; 99% CI = 0.93 - 1.27, Ptrend = 0.18), 
neither did daily intake of 200 µg of selenium in combination with 400 IU of vitamin E in 
supplement form (HR = 1.05; 99% CI = 0.89 - 1.22, Ptrend = 0.46) [164]. In another 
randomized, placebo-controlled trial, Marshall et al. [202] investigated the effect of daily 
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 intake of 200 µg of selenium on high-grade prostatic intraepithelial neoplasia (HGPIN), a 
premalignant lesion of PCa. After a 3-year follow-up, it was observed that while 
selenium appears to be protective against PCa, the effect was not statistically significant 
(RR = 0.82; 95% CI = 0.40 - 1.69). In a nested case-control study conducted within the 
EPIC study, no associations were found between plasma selenium levels and PCa risk 
(RR = 0.96; 99% CI = 0.70 - 1.31, highest vs. lowest quintile, Ptrend = 0.25) [203]. Chan et 
al. also examined associations between plasma selenium level, SOD2 gene variants, and 
PCa aggressiveness in men with localized and locally advanced PCa, and found that 
selenium appears to increase the risk of developing aggressive PCa (RR =  1.35, 95% CI 
= 0.99 – 1.84) [134]. After reviewing the evidence from randomized controlled trails, 
Klein et al. [204] concluded that selenium does not appear to have any effect on PCa risk. 
However, in another review of the evidence from clinical and observational studies, 
Richman and Chan [147] concluded that while the relationship between selenium and 
PCa remain inconsistent, selenium is likely more relevant to the etiology of aggressive or 
advanced-stage PCa. Nevertheless, research on selenium intake and PCa aggressiveness 
is very limited, which emphasizes the need for more well-designed studies in this area 
involving the use of validated biomarkers that reflect long-term selenium intake. 
 
Vitamin C 
Vitamin C (ascorbic acid) is a water-soluble vitamin and a potent antioxidant that 
may confer protection against PCa by preventing oxidative DNA damage through the 
scavenging of ROS [205, 206]. In vitro and in vivo studies have also demonstrated dose 
and time dependent effects of vitamin C on PCa through the inhibition of PCa cell lines 
(i.e., LNCaP and PC-3) [207, 208]. Vitamin C is abundantly found in many plant and 
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 animal foods such as fruits (e.g., citrus, cantaloupe, pineapple, kiwi, and berries), 
vegetables (e.g., broccoli, brussels sprouts, potatoes, tomatoes, winter squash, and 
cauliflower) and organ meat (e.g., liver and kidney) [206, 209]. Although vitamin C has 
been associated with reduced risk of other cancers [206], the role of vitamin C in PCa is 
controversial because of conflicting findings from various studies. In a recent case-
control study, dietary intake of vitamin C was inversely associated with PCa risk (OR =  
0.60, 95% CI = 0.41 – 0.88), although the protective effect appeared to be confined only 
to European Americans (OR =  0.56, 95% CI = 0.38 – 0.85) and not African Americans 
(OR =  1.19, 95% CI = 0.34 – 4.24) [210]. In another case-control study, increased intake 
of vitamin C was strongly and inversely associated with PCa (OR =  0.49, 95% CI = 0.33 
– 0.74) [211]. Other studies have reported inverse associations between vitamin C and 
PCa risk [166, 212]. 
However, two double-blinded, randomized, placebo-controlled trials have 
investigated the role of vitamin C in PCa and have reported null effect [68, 74]. In the 
Physicians’ Health Study II trial, Gaziano et al. found that daily supplementation of 500 
mg of vitamin C did not have an effect on PCa incidence (HR; 1.02, 95% CI = 0.90 – 
1.15), but rather appeared to increase the risk of death from PCa (HR; 1.46, 95% CI = 
0.92 – 2.13) [74]. In the PLCO cancer screening trial, daily supplementation of 500 mg of 
vitamin C was also found not to be associated with PCa incidence (RR =  1.01; 95% CI = 
0.87 – 1.17, highest vs. lowest quartile, Ptrend = 0.98). A meta-analysis summarizing data 
from these two trials also indicated that vitamin C has no effect on PCa risk (RR =  0.98, 
95% CI = 0.91 – 1.06) [167]. In a case-control study conducted in Italy, prospective 
assessment of dietary intake of vitamin C was not associated with the incidence of PCa 
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 (OR =  0.88, 95% CI = 0.78 – 1.07, Ptrend = 0.09). Stratified analysis by age, BMI, and 
family history of PCa in that study also did not show any discernible associations 
between vitamin C and PCa [162]. Hodge et al. [213] and Schuurman et al. [171] have 
also investigated association between vitamin C intake and PCa incidence in a 
population-based case-control study and a cohort study, respectively, and both studies 
reported null associations. It is important to note that relative to the other antioxidants, 
fewer studies have been conducted on associations between vitamin C and PCa. 
Additionally, a thorough literature search did not show any study on vitamin C and PCa 
aggressiveness within the last two decades. Thus, in the light of these conflicting 
findings, research into vitamin C and PCa aggressiveness may offer much clearer 
evidence on the nature of the relationship. 
 
2.3     POLYMORPHISMS IN DNA REPAIR AND OXIDATIVE STRESS GENES AND THEIR 
INTERACTION WITH ANTIOXIDANTS IN RELATION TO PROSTATE CANCER 
 
Extensive research into prostate carcinogenesis has led to the discovery of several 
deleterious molecular events such as oxidative stress, which allow the occurrence of 
genetic aberrations including the formation of oxidized DNA base lesions, DNA strand 
breaks, altered gene expression, deletions, and ultimately mutagenesis [6, 8, 70]. Several 
lines of evidence suggest that oxidative DNA damage is causally linked to PCa, and the 
extent of DNA damage correlates with the degree of PCa aggressiveness [117, 123]. 
Different DNA repair pathways are known to operate on different types of DNA damage. 
For example, base excision repair (BER) pathway removes small lesions, such as 
nonbulky adducts. Nucleotide excision repair (NER) removes bulky lesions and damaged 
single-stranded fragments. Mismatch repair (MMR) corrects DNA replication errors such 
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 as mispaired bases, and double-stranded breaks are repaired through complex pathways 
involving homologous recombination and end-joining DNA repair mechanisms [124-
126]. It has been clearly demonstrated that genes involved in DNA repair harbor 
polymorphisms that are functionally relevant to PCa because of their pro- or 
anticarcinogenic properties [131, 214, 215]. Thus, individual variations in the capacity to 
repair oxidative DNA damage, and by implication, the ability to inhibit the initiation and 
progression of PCa may be due to polymorphisms in the DNA repair gene pathways. 
However, these polymorphisms may act alone or in combination with environmental 
factors, such as dietary antioxidants, to influence the occurrence and clinical behavior of 
PCa. 
Multiple polymorphisms in DNA repair genes have been investigated in relation 
to PCa susceptibility and aggressiveness with equivocal results [131, 132, 214, 215]. 
Additionally, studies have shown that the expressions of natural antioxidant enzymes 
such as glutathione peroxidase, catalase, and superoxide dismutase, which mitigate the 
harmful effects of oxidative stress, are lower in PCa tissues than in healthy prostate 
tissues [216, 217]. Hence, it is reasonable to speculate that increased intake of 
antioxidants may help reduce oxidative DNA damage, and by extension, PCa risk and 
aggressiveness. However, epidemiological data regarding the independent effect of 
antioxidants on PCa also remains largely inconsistent [17]. Perhaps, investigations of the 
joint effect of polymorphisms in DNA repair gene pathways and antioxidant intake may 
provide better understanding of how these factors interact to influence PCa.  
At least three recent case-control studies have examined joint effects of genetic 
variants of the superoxide dismutase 2 (SOD2) gene (a member of the mitochondrial 
38 
  
 Fe/MnSOD family and an important component of the BER defense system) and plasma 
antioxidant status in relation to PCa risk and aggressiveness [130, 133, 134]. First, Li et 
al. [130] investigated associations between valine (Val)/alanine (Ala) polymorphism 
(rs4880) in the SOD2 gene and prediagnostic plasma levels of selenium, lycopene, and α-
tocopherol on PCa risk and aggressiveness in a nested case-control study within the 
Physicians’ Health Study. In this study, none of the SOD2 genotypes (Val/Val, Val/Ala, 
and Ala/Ala) had independent associations with overall risk of PCa or PCa 
aggressiveness. However, among men with Ala/Ala genotype, high prediagnostic plasma 
selenium level was associated with a 67% lower risk of PCa (RR = 0.33; 95% CI = 0.16-
0.68; P trend = 0.002) and an 82% reduced risk of aggressive PCa (RR = 0.18; 95% CI = 
0.07-0.48; P trend <0.001) when compared to those with low levels. These inverse 
associations were weaker in men with Val/Val + Val/Ala genotypes (P interaction = 0.01). 
No evidence of effect modification by SOD2 genotype was observed for associations 
between plasma lycopene and α-tocopherol status, and PCa risk or aggressiveness. 
However,  a combined antioxidant score computed based on quartile levels of  plasma 
concentrations of selenium, lycopene, and α-tocopherol showed significant interaction 
between SOD2 genotype and prediagnostic antioxidant status on over risk of PCa (P 
interaction = 0.02)  and PCa aggressiveness (P interaction = 0.01).   
Subsequently, in a different population of PCa patients, using plasma selenium 
levels measured at the time of the cancer diagnosis or shortly thereafter, Chan et al. [134] 
observed a non-significant 40% lower risk of aggressive PCa in men with Ala/Ala 
genotype of the SOD2 gene (rs 4880) and high plasma selenium levels (RR =  0.60, 95% 
CI = 0.32 - 1.12; highest vs. lowest quintile, P trend = 0.06), which is consistent with the 
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 previous findings by Li et al. [130]. However, there is a major difference between the two 
studies. Chan et al. observed that men with Val/Val + Val/Ala genotype and high plasma 
selenium concentration had an 82% increased risk of aggressive PCa (RR =  1.82; 95% 
CI = 1.27 - 2.61; highest vs. lowest quintile, P trend = 0.0003), while this population of 
men had non-significant weak inverse association with aggressive PCa in the Li et al. 
study. Possible explanations for this inconsistency is that  Li et al. focused on 
prediagnostic plasma selenium concentrations, and contrasted PCa cases with controls; 
while Chan et al. utilized plasma selenium levels measured at the time of PCa diagnosis 
or shortly thereafter, and contrasted low aggressive PCa with intermediate/high 
aggressive PCa. Nonetheless, together, the evidence suggests that SOD2 variants 
modulate associations between plasma antioxidant levels and PCa risk/aggressiveness. 
More specifically, having Ala/Ala genotype of the SOD2 gene may be beneficial to men 
with high intake of selenium and perhaps other antioxidants. 
In a more recent study, Abe et al. [133] investigated the joint effect of SNPs in 
DNA repair genes (i.e., GPX1, GPX4, PPARGC1A, PPARGC1B, SOD1, SOD2, SOD3 
and XRCC1) and plasma selenium levels on PCa aggressiveness. Two SNPs in the SOD1 
gene were independently associated with PCa aggressiveness. One of these SNPs 
(rs17884057) was inversely associated with aggressive PCa (RR = 0.83; 95% CI = 0.70-
0.99), while the other (rs4816407) was associated with an increased risk of aggressive 
PCa (RR = 1.27; 95% CI = 1.02–1.57). No associations were found between SNPs in the 
other genes and PCa aggressiveness. However, two additional SNPs; one in SOD1 
(rs10432782) and another in SOD2 (rs2758330); were found to have modifying effects 
on associations between plasma selenium status and PCa aggressiveness (P trend = 0.04 
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 and <.0001, respectively), which suggest that these SNPs act in combination with 
antioxidants to influence PCa aggressiveness. 
Goodman et al. [129] also examined whether an association between lycopene 
and PCa can be modified by x-ray repair cross-complementing protein 1(XRCC1) 
genotype, a gene involved with BER. These investigators observed a borderline 
statistically significant inverse association between lycopene intake and PCa (OR = 0.49; 
95% CI = 0.24-0.99; highest vs. lowest tertile, P trend = 0.05). However, a stronger and 
statistically significant protective effect of lycopene was observed in men with Arg/Arg 
genotype (OR = 0.21; 95% CI = 0.06-0.71; highest vs. lowest tertile, P trend < 0.01), but 
not in those with Arg/Gln + Gln/Gln genotype (OR = 0.83; 95% CI = 0.33-2.01; highest 
vs. lowest tertile; P trend = 0.79). A much stronger inverse association was observed for 
combined antioxidant exposure (lycopene + α-tocopherol + β-carotene) and PCa among 
men with Arg/Arg genotype (OR = 0.11; 95% CI = 0.02-0.65; above vs. below median; 
Pinteraction= 0.01). However, the combined antioxidant exposure appeared to increase risk 
of PCa in men with Arg/Gln + Gln/Gln genotype (OR = 2.08; 95% CI = 0.46-9.43; above 
vs. below median); suggesting that the beneficial effect of antioxidant intake may be 
limited to men with Arg/Arg genotype. 
Van Gils et al. [218] also examined whether three common polymorphisms of the 
XRCC1 gene at codon 194 (Arg/Trp), codon 280 (Arg/His), and codon 399 (Arg/Gln) 
modify the effect of antioxidant intake on PCa risk. None of the polymorphisms 
examined at each of the three codons had independent associations with PCa. However, 
there was evidence of effect modification by XRCC1 genotype. Among men with 
Arg/Arg genotype, low vitamin E intake was associated with a 2.4-fold increased risk of 
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 PCa (OR = 2.4; 95% CI = 1.0-5.6, p = 0.04); however, a much lesser and statistically 
non-significant increased risk was observed in men with Arg/Gln + Gln/Gln genotype 
with low vitamin E intake (OR = 1.2; 95% CI = 0.5-2.8, p = 0.65). 
Similarly, Zhang et al. [128] examined joint associations between variants of 
XRCC1 and  hOGG1(two genes that are involved with BER ) in relation to PCa. In this 
population based-study, Arg/Gln + Gln/Gln genotype of the XRCC1 gene were found to 
increase risk of PCa by an estimated 56% (OR = 1.56; 95% CI = 1.01-2.45, p = 0.049), 
while a non-significant inverse association was observed between Ser/Cys + Cys/Cys 
genotype of the hOGG1gene and PCa risk (OR = 0.72; 95% CI = 0.46 - 1.10, p = 0.13). 
When stratified by plasma antioxidant status, Arg/Gln + Gln/Gln genotype of the XRCC1 
gene was associated with over 2-fold increased risk of PCa among men with lower than 
median levels of lutein/zeaxanthin (OR =  2.15; 95% CI = 1.17- 4.01, p = 0.015), β-
cryptoxanthin (OR =  2.64; 95% CI = 1.40-5.07, p = 0.003), and lycopene (OR = 2.05; 
95% CI = 1.07-3.98, P = 0.032) as compared to those with the Arg/Arg genotype. On the 
other hand, having Ser/Cys + Cys/Cys genotype of the hOGG1gene and lower than 
median levels of β-cryptoxanthin, lycopene, α-carotene, and α-tocopherol were 
associated with statistically significant 48–62% reductions in PCa risk when compared 
with the Ser/Ser genotype. Other studies have also reported similar effect modification 
and/or interaction between DNA repair gene variants and antioxidants on PCa [135, 219, 
220]. 
These findings suggest that potential etiologic associations between antioxidant 
intake and PCa most likely depend on polymorphisms or genetic variants within DNA 
repair gene pathways. Larger studies using biomarkers reflecting long-term antioxidant 
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 intake are required to provide supporting evidence and help better understand the 
underlying mechanisms for targeted interventions. Nonetheless, data on joint associations 
between antioxidant intake and polymorphisms in other genes that are involved in 
oxidative stress and DNA repair in relations to PCa are lacking. Thus, additional studies 
are also needed to examine the interplay between antioxidants and variants of these other 
genes such as those involved in double-stranded DNA break repair (e.g., XRCC2, 
XRCC4, and RAD51C); nucleotide excision repair (e.g., ERCC8, XPA, and XPC), and 
oxidative stress (e.g., NQO1, NOX3, and PPARG) in relation to PCa, particularly 
aggressive PCa, which is associated with high disease-specific mortality [5]. 
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Table 2.2 Summary of findings on gene-diet studies; interactions between antioxidants and oxidative stress/DNA repair genes in relation 
to prostate cancer 
 
Author  Gene & Dietary Agent  Subjects and Design  Results  
Studies examining prostate cancer aggressiveness 
Li et al., 
2005 
 Gene: polymorphism 
(rs4880) in SOD2 gene: 
valine (V) → alanine (A) 
 
 
Diet: prediagnostic 
plasma selenium, 
lycopene, and α-
tocopherol 
 
Nested case-control study within the 
Physicians’ Health Study (PHS) 
 
PCa cases, n = 567 
Controls, n = 764 
 
No data on race groups; however, the  
PHS is 93% European American  
Stratified analysis by genotype  
AA genotype + high selenium: lower overall risk of PCa 
(RR= 0.33; 95% CI, 0.16-0.68), and lower risk of 
aggressive PCa (RR= 0.18; 95% CI, 0.07-0.48). 
 
Weak, non-significant inverse association for men with (VV 
+ VA), and high selenium in relation to overall risk of PCa 
(RR = 0.6; 95% CI = 0.4 - 1.0), and PCa aggressiveness 
(RR= 0.7; 95% CI = 0.4 -1.2). 
 
A significant interaction observed between combined 
antioxidant score (selenium + lycopene + α-tocopherol) and 
SOD2 in relation to PCa aggressiveness (P interaction = 0.01). 
 
Chan et al., 
2009 
Gene: polymorphism 
(rs4880) in SOD2 gene: 
valine (V) → alanine (A) 
Diet: plasma selenium 
level (collect at, or 
immediately after 
diagnosis) 
A nested case-control study Data from 
Dana-Farber Cancer Institute: 489 
locally advanced PCa cases. 
Aggressiveness: Low  n = 276;  
Intermediate n = 167;  
High = 146. 
 
Whites  n = 468 
Other  n = 18 
Unknown  n = 3 
AA genotype + high plasma selenium; 40% lower risk of 
aggressive PCa (RR = 0.60, 95% CI = 0.32-1.12). 
VV + VA genotype, and high selenium: increased risk of 
aggressive PCa (RR = 1.82; 95% CI = 1.27 - 2.61).  
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Table 2.2 (continued) Summary of findings on gene-diet studies; interactions between antioxidants and oxidative stress/DNA repair 
genes in relation to prostate cancer  
 
Author  Gene & Dietary Agent  Subjects and Design  Results  
Studies examining prostate cancer aggressiveness 
Abe et al., 2011 Genes: GPX1, GPX4, 
PARGC1A, PPARGC1B, 
SOD1, SOD2, SOD3 and 
XRCC 
 
Diet: plasma selenium  
Same population as Chan et al. 2009 
 
Design: nested case control study  
(n =  753) 
 
Aggressiveness: 
Low  n = 394 
Intermediate n = 259 
High = 100 
 
Whites  n = 719 
Other  n = 30 
Unknown  n = 4 
SOD2 SNP (rs17884057) was 
inversely associated with high 
aggressive PCa (RR = 0.83; 95% CI 
= 0.70-0.99). 
 
SOD2 SNP (rs4816407) associated 
with increased risk of aggressive 
PCa (RR = 1.27; 95% CI = 1.02–
1.57). 
 
Two additional SNPs; SOD1 
(rs10432782) and SOD2 
(rs2758330) had modifying effects 
on associations between selenium 
and PCa aggressiveness (P
 trend
 = 
0.04 and <.0001, respectively). 
Mikhak et al., 2008  
Gene: SOD2 Ala16Val 
polymorphism 
 
Diet: Plasma carotenoids:  
α-carotene;  β-carotene;  
lycopene; β-cryptoxanthin;  
lutein/zeaxanthin  
Nested case-control study within the Health 
Professionals Follow-up Study (HPFS) 
 
Controls (n = 612) matched to PCa cases (n = 612) on 
year of birth, year of blood draw, history of PSA 
screening. 
 
No data on race groups; however, HPFS is 97% 
European American. 
 
Aggressive PCa: advanced stage (T3C, T4, N0M0, TN 
(1-3), T M1 or Gleason sum ≥ 7. None aggressive 
PCa: all others 
 
No association between SOD2 
genotype and risk of total or 
aggressive PCa 
 
No significant interaction between 
SOD2 genotype and any of the 
carotenoids 
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Table 2.2 (continued) Summary of findings on gene-diet studies; interactions between antioxidants and oxidative stress/DNA repair 
genes in relation to prostate cancer  
 
Author  Gene & Dietary Agent  Subjects and Design  Results  
Studies examining prostate cancer risk 
Goodman et al., 
2006 
 
 
 
 
Gene: XRCC1 genotypes; 
Arg/Arg, Arg/Gln, and Gln/Gln 
 
Diet: lycopene from FFQ, α-
tocopherol and β-carotene from 
plasma  
 
 
 
 
Case-control study 
conducted in North 
Carolina. 
 
Controls (n= 174) were 
age-matched to cases (n = 
77) [± 5 years]. 
 
Race groups: 
Blacks, n = 20 
Whites, n = 231 
 
 
Protective effect of lycopene observed in men with 
Arg/Arg genotype and high lycopene (OR = 0.21; 95% CI 
= 0.06-0.71; P trend < 0.01), but not those with Arg/Gln + 
Gln/Gln, and high lycopene (OR = 0.83; 95% CI = 0.33-
2.01; P trend = 0.79).  
 
Much stronger inverse association observed for combined 
antioxidant exposure (lycopene + α-tocopherol + β-
carotene) and PCa risk among men with Arg/Arg 
genotype (OR = 0.11; 95% CI = 0.02-0.65; above vs. 
below median; Pinteraction= 0.01). 
 
Combined antioxidant exposure appeared to increase risk 
of PCa in men with Arg/Gln + Gln/Gln (OR = 2.08; 95% 
CI = 0.46-9.43; above vs. below median). 
Van Gils et al., 
2002 
 
Gene: polymorphisms in XRCC1 
gene at codon 194 (Arg/Trp), 
codon 280 (Arg/His), and codon 
399 (Arg/Gln) 
 
Diet: vitamin A, C & E, β-carotene 
and lycopene 
Case-control study among 
North Carolina residents 
 
Controls (n = 183) were 
age-matched to cases (n = 
77) [± 5 years]. 
 
None of the polymorphisms had independent associations 
with PCa risk. 
 
Among men with Arg/Arg genotype, low vitamin E 
intake was associated with an increased risk of PCa (OR 
= 2.4; 95% CI = 1.0-5.6, p = 0.04). 
 
A much lesser and non-significant increased risk 
observed in men with Arg/Gln + Gln/Gln and low 
vitamin E intake (OR = 1.2; 95% CI = 0.5-2.8, p = 0.65). 
 
No effect modification by the other antioxidants 
  
  
 47 
 
Table 2.2 (continued): Summary of findings on gene-diet studies; interactions between antioxidants and oxidative stress/DNA    repair genes in 
relation to prostate cancer  
Author  Gene & Dietary Agent  Subjects and Design  Results  
Studies examining prostate cancer risk 
 
Zhang et al., 
2010 
 
 
Gene: XRCC1 (Arg399Gln 
polymorphism), and  
hOGG1 (Ser326Cys polymorphism) 
 
Diet: α-carotene, β-carotene, β-
cryptoxanthin, lycopene, 
Lutein/zeaxanthin and α-tocopherol 
 
 
 
A case-control study conducted 
in Arkansas. 
 
Cases, n = 193 
Controls, n = 197 
 
Race groups: 
 
Whites, n = 198  
Blacks, n = 192  
 
 
Arg/Gln + Gln/Gln genotype of the XRCC1 gene 
associated with an increased risk of PCa among men 
with lower than median levels of lutein/zeaxanthin (OR 
=  2.15; 95% CI = 1.17- 4.01, p = 0.015), 
 β-cryptoxanthin (OR = 2.64; 95% CI = 1.40-5.07, p = 
0.003), and lycopene (OR = 2.05; 95% CI = 1.07-3.98, p 
= 0.032) compared to those with the Arg/Arg genotype. 
 
Men with Ser/Cys + Cys/Cys genotype of the 
hOGG1gene and had lower than median levels of β-
cryptoxanthin, lycopene, α-carotene, and α-tocopherol 
had 48–62% reductions in PCa risk when compared 
with the Ser/Ser genotype. 
 
 
 
 
  
 2.4     DIETARY ASSESSMENT METHODS, ADVANTAGES AND DISADVANTAGES 
Food Frequency Questionnaire  
Epidemiological studies support hypotheses of associations between diet and 
chronic diseases such as cancer [17, 63-66, 221]. To better understand these associations, 
a measure of usual dietary intake is needed. Usual dietary intake is often measured by 
different dietary assessment instruments including food records, multiple 24-hour recalls, 
and food frequency questionnaires (FFQs) [222]. FFQs are the most suitable dietary 
assessment method for measurement of usual intake in large nutritional epidemiological 
studies due to issues of cost, time and feasibility [222-225]. FFQs are designed to 
measure usual intake of specific foods, food groups and nutrients over an extended period 
[222, 226, 227]. The rationale behind the FFQ approach is that long-term dietary intake, 
such as usual eating patterns over weeks, months or years are conceptually more relevant 
determinants of chronic diseases than intake on one or a few designated days [222]. The 
FFQ is commonly used to rank individuals according to their intake of specific foods or 
nutrients, and it has widespread applicability in case-control, cross-sectional and cohort 
studies of diet and diet-disease associations [228-230]. 
There are several FFQ instruments in circulation, some of which have been 
adapted and modified for different populations and purposes [231]. The most commonly 
used FFQs are the Willett FFQ [232], the Block FFQ [233], the Fred Hutchinson Cancer 
Research Center FFQ [234], and the National Cancer Institute Diet History Questionnaire 
(NCI-DHQ), a cognitive-based FFQ designed to enhance respondents comprehension in 
order to facilitate accurate reporting [235]. Despite continuous modification of existing 
standard FFQs and development of new FFQs, the overall design and analytic methods 
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 remain the same. Typically, FFQ instruments contains a listed of predefined food groups 
listed as line items. Respondents are asked to report frequency of consumption and 
portion sizes over a designated period (e.g., usually the previous year) [222, 235]. 
Questions on food purchasing habits and preparation methods may also be asked [235]. 
FFQs require a robust and appropriate nutrient database for translation of reported dietary 
intakes into nutrients, and for ranking individuals on specific foods and nutrients [236, 
237]. Nutrient intake from a FFQ are generally estimated by summing the product of a 
multiplication between the frequency of intake by nutrient density, and by portion size (if 
asked) over all foods consumed (i.e., nutrient intake = frequency x portion size x nutrient 
density) [222, 235, 238]. FFQs also require validation or calibration against other detailed 
and more accurate dietary assessment tools such as 7-day food records or multiple 24-
hour dietary recalls [222, 238]. Several “validation” studies have found the FFQ approach 
to be a reasonably accurate method for estimating food and nutrient intake when 
compared to multiple 24-hour recalls or food records as reference instruments [223, 235, 
238-244]. However, validation studies using recovery biomarkers as reference 
instruments suggest that FFQs may have significant measurement errors [245, 246].  
 
Advantages and disadvantages of food frequency questionnaires 
The merits of the FFQ approach to dietary assessment are a subject of ongoing 
debate [247-252]. It is important to note that FFQs differ widely, especially in terms of 
food list and level of detail, and some FFQs may be better than others with regards to 
food and nutrient assessment [235, 250, 253]. However, in general, FFQs are a 
convenient and relatively inexpensive approach to dietary assessment [222, 235, 254]. 
Additionally, FFQ instruments are often designed to be self-administered with low 
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 respondent burden (require about 45 minutes to complete), and can be administered either 
electronically or completed on scanner-readable forms which reduces the time, effort and 
cost of data collection [254, 255]. Moreover, the use of standardized responses facilitates 
quick data analysis [222]. Long-term exposures such as habitual eating patterns are 
conceptually more relevant in studies of chronic disease, which makes FFQ more suitable 
for investigating associations between diet and chronic diseases [222, 228, 233, 254]. 
Also, because FFQs solicit information about past dietary intake, they are able to 
circumvent recent dietary changes which may have been motivated by a recent diagnosis 
unrelated to the outcome of interest [255]. Statistically, FFQs are considered to be the 
only dietary assessment tool that can minimize intra-person, day-to-day variations in 
nutrient intake without the need for assessment of actual intake over several days [256, 
257]. Furthermore, inclusion of open-ended questions allows reporting of foods that are 
not listed on the FFQ [235]. In addition, standard FFQs are easy to modify to include 
foods that are commonly consumed by specific ethnic minority groups or populations of 
interest [258]. 
The limitations of FFQ have been discussed extensively, including substantial 
measurement errors resulting from incomplete listing of foods consumed by study 
participants, and inaccuracies in the estimation of portion size and frequency of intake 
[225, 227]. Incompleteness of food listing in FFQ is particularly problematic when the 
missing foods are major sources of nutrients in the study population,  leading to 
considerable inaccuracies in nutrient estimates for the group [225]. Quantitative studies 
also suggest that portion size estimation by study participants are often influenced by the 
type of food been considered, the role of the food item a meal (e.g., appetizer, main dish, 
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 or dissert) and personal food preferences, all of which can affect the accuracy of 
reporting [259]. Also, portion sizes in FFQ are generally categorized into small, medium 
and large, which may have different meaning for different respondents [260]. 
Additionally, when food is eaten as a mixed dish, it is often difficult to estimate portion 
sizes for individual components of the dish [261]. Studies have also shown that 
aggregation of food items in FFQs affects recall of food intake. For example, respondents 
are more likely to recall intake of beef when it is separated from lamb, pork and ham, 
than when they are all grouped together as a line item [253]. Reporting food intake can 
also be affected by social desirability bias, which can result in under-reporting of 
“unhealthy” foods and over-reporting of “healthy” foods [262]. Finally, given the 
retrospective nature of FFQ, reporting of intake generally rely on long-term memory with 
questionable accuracy, particularly among older adults. Despite these limitations, 
carefully developed FFQs have a conceptual advantage over other dietary assessment 
tools such 24-hour recalls and food records by providing estimates of usual intake over an 
extended period. Additionally, FFQs are practically and economically more feasible for 
large nutritional epidemiological studies, and impose lesser burden on participants 
relative to the other assessment tools [248, 250, 263, 264]. 
 
Biochemical measures of dietary intake  
Nutritional epidemiologists are acutely aware of the numerous methodological 
issues and limitations of the traditional dietary assessment methods such as FFQs, food 
records, and 24-hour dietary recall. The reality is that, a gold standard method of dietary 
assessment is lacking [250]. However, the traditional methods are fraught with 
considerable systematic and random measurement errors, which have increasingly 
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 motivated the use of nutritional biomarkers to complement the traditional methods [222, 
265-267]. Nutritional biomarkers can be loosely defined as biochemical indicators of 
dietary intake which reflects not only food and nutrient consumption, but also 
metabolism and biological effects of dietary intake [268]. The underlying assumption for 
the use of nutritional biomarkers is that, they are responsive to dietary intake, sensitive to 
intake levels, and independent of some kinds of biases and measurement errors [245, 
269]. An “ideal” nutritional biomarker will accurately reflect actual dietary intake levels, 
and be applicable to different populations [270]. However, existing nutritional 
biomarkers are not “ideal”, but are functional and have far-flung relevance in nutritional 
epidemiology including their use as reference measurements for validation of the 
traditional dietary assessment methods [268-271].  
Nutritional biomarkers are generally categorized into four groups; recovery, 
predictive, concentration and replacement biomarkers [269, 270, 272]. Recovery 
biomarkers are thought to provide absolute estimates of intake based on the concept that 
recovery of nutrient analytes from biologic samples are directly related to intake due to a 
fixed metabolic balance between intake and output over a specific period of time [273]. 
In other words, recovery biomarkers are not  subject to individual differences in 
metabolism over a specified time window, hence considered as the gold standard of 
biomarkers [222]. However, very few of these biomarkers actually exist, including 
doubly labeled water (use to measure total energy expenditure and metabolic rate), and 
urine nitrogen/potassium (for measuring total protein and total potassium intake, 
respectively) [269, 270, 272]. Predictive biomarkers are similar to recovery biomarkers in 
terms of responsiveness to intake, ability to reflect intake levels (dose-response relations), 
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 and time sensitivity. However, predictive biomarkers generally have lower recovery of 
analytes from biological samples [270]. Predictive biomarkers have recently been used as 
reference tool for correlation of sugars intake and recovery of sucrose and fructose from 
24-hour urinary samples [271]. Concentration biomarkers generally do not reflect 
absolute intake, but often correlate with the corresponding food or nutrient intake levels 
[271, 274]. Examples of concentration biomarkers include serological markers (i.e., 
plasma and serum) and adipose tissue levels of nutrients, as well as urinary electrolytes 
[269, 275]. Replacement biomarkers are also similar to concentration biomarkers. The 
name “replacement” is generally used when food composition data are either unavailable 
or unsatisfactory for specific nutrients such as aflatoxins [276], and some phytochemicals 
[277]. Several studies have examined the efficacy of the various types of nutritional 
biomarkers; however, this review will focus on concentration biomarkers in relation to 
antioxidants recovery from blood, adipose tissue, and toenail clippings. 
 
Advantages and disadvantages of biomarkers of antioxidant exposure 
Epidemiological studies involving biomarkers of antioxidant intake often rely on 
blood samples (i.e., plasma or serum), adipose tissue, and toenail clippings to measure 
exposure level [278, 279]. Plasma/serum antioxidant levels are thought to reflect short-
term intake, while adipose tissue and toenail antioxidant concentrations reflect long-term 
intake [280]. The use of these biomarkers in epidemiological research has several 
advantages. First, nutritional biomarkers are known to improve the validity of exposure 
estimates by eliminating information bias, particularly differential recall of intake in case-
control studies [279]. Secondly, since the bioavailability of antioxidants is influenced by 
individual differences in metabolism and absorption, nutritional biomarkers provide an 
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 assessment of the “biologically effective dose” of the nutrient of interest [279, 280]. 
Additionally, nutritional biomarkers are particularly advantageous for evaluating dose-
response associations as they are known to be responsive to intake, correlate with the 
corresponding food or nutrient intake levels, and measure the bioactive dose of the 
nutrient of interest [245, 271, 281]. Also, nutritional biomarkers are frequently used in 
dietary intervention studies to assess compliance and individual response to the 
intervention being studied [282]. Nonetheless, nutritional biomarkers are imperfect 
measures of dietary intake. 
Plasma/serum and adipose tissue antioxidant levels are often measured with high 
performance liquid chromatography (HPLC) [283, 284]. A major concern with the use of 
plasma/serum markers of antioxidant intake is that, they reflect recent rather than long-
term dietary intake. Hence, plasma/serum biomarkers are not suitable for evaluating 
etiological or temporal relationships between antioxidant intake and slow-progressing 
diseases [222, 285]. Also, plasma/serum antioxidant levels may be altered by the disease 
being studied, in which case some biomarkers would be inappropriate for use in case-
control studies [222]. Several lines of evidence also suggest that plasma/serum 
antioxidant levels are influenced by a variety of physiological and lifestyle factors 
independent of dietary intake such smoking status, obesity, and alcohol use [286-289]. 
Studies also suggest that adipose tissue sampling with the needle biopsy can lower 
participation rates in research studies [290]. Moreover, saponification of the adipose 
tissue specimen is generally required before HPLC can be performed, which often 
increases the cost of laboratory analysis [278]. Other limitations associated with 
biomarkers of specific nutrients and nutrient groups are discussed below. 
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 Carotenoids such as β-carotene, α−carotene, β-cryptoxanthin, lycopene, and 
lutein + zeaxanthine have been studied extensively in relation to PCa [67, 106, 175, 183]. 
Carotenoids levels in blood are influenced cooking methods (reviewed in [291]). For 
example, mild heating (such as steaming) is known to promote the extraction of β-
carotene from vegetables and increases its bioavailability in serological markers [292]. 
Similarly, processing of raw tomatoes into tomato paste or tomato sauce with mild heat 
treatment has been shown to increase the bioavailability of lycopene in plasma [293, 
294]. However, stir frying of green leafy vegetables has been found to reduce lutein 
content by as much as 89%, while cooking these vegetables for 8 minutes has  also been 
found to reduce lutein content by up to 428% [295]. Carotenoids are known to 
accumulate in adipose tissues because of their fat-soluble properties; however, their 
turnover rates remain unknown [278, 296]. Hence, the actual or average exposure time 
remains unclear. Studies have also shown that the distribution of carotenoids in adipose 
tissue differ by body fat sites (e.g., abdomen, buttock, and thigh) due to differences in 
carotenoid uptake and retention between the fat sites [280, 296]. Some researchers have 
suggested that the differential distribution of carotenoids in adipose tissue sites accounts 
for the poor reproducibility of carotenoid measurements from adipose tissue across 
studies [280, 297, 298].  
Vitamin E is primarily transported in the human blood by plasma lipoproteins, 
and performs a biologic function of protecting lipids form oxidative degradation [299]. 
Due to its close association with lipids, plasma/serum lipids (especially total cholesterol) 
must be measured and controlled for in multivariate models in studies involving plasma 
vitamin E levels [278]. Relative to dietary questionnaires, plasma/serum levels of vitamin 
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 E may represent a more relevant biologic measure of systemic exposure; however, it 
correlates poorly with estimates from dietary intake [278]. It has been suggested that 
observed correlations between intake estimates and plasma levels of vitamin E are largely 
due to vitamin E intake in supplement form, rather than from food intake [300, 301]. For 
example, Ford and Sowell examined associations between plasma α-tocopherol levels 
and dietary intake of α-tocopherol using 24-hour dietary recall in NHANES III and 
observed that these two measures do not correlate [300]. Another study of vitamin E 
supplementation showed that unlike dietary intake, the human blood responds well to 
vitamin E intake in supplement form [302]. However, it is reasonable to speculate that the 
poor correlation between dietary intake and plasma concentrations of vitamin E is likely 
due to food handling and preparation methods. Studies have also suggested that adipose 
tissue vitamin E concentrations have a low turnover rate [302]; however, findings from 
studies attempting to verify this hypothesis remain inconclusive [297, 303]. 
Unlike carotenoids and vitamin E which are fat-soluble, vitamin C is a water-
soluble micronutrient, thus easily destroyed by food handling practices such as cutting, 
shredding, chopping or peeling of fruits and vegetables as well as cooking with excessive 
water or excessive heat [304, 305]. Plasma/serum ascorbate (i.e., ascorbic acid) is often 
used to measure vitamin C intake by HPLC methods. However, the use of plasma 
ascorbate is problematic for a number of reasons. First, to avoid degradation of ascorbate 
in serological markers, blood samples must be preserved in an acid stabilizer (e.g., 
metaphosphoric acid) immediately after collection of the samples. This makes many 
archived plasma/serum samples that were not treated this way unsuitable for analysis of 
ascorbate concentrations [278]. Secondly, the human body is unable to produce vitamin C 
56 
 
 naturally, and since vitamin C is often eliminated from the body through urine, 
continuous dietary supply of vitamin C is required to maintain adequate levels in the 
body [306]. Thus, ascorbic acid levels in the blood fluctuate in response to dietary intake 
and renal clearance, which makes the use of fasting blood sample essential [278]. 
However, fasting blood samples usually estimate ascorbate at levels much lower than 
actual dietary intake levels [278]. The fluctuation of ascorbic acid in serological markers 
also implies that plasma/serum ascorbate is not a reliable measure of long-term intake 
[278, 279, 307]. Additionally, because of the water-soluble properties of vitamin C, they 
are not stored in adipose tissue [278, 307]. For these reasons, most researchers prefer the 
used dietary questionnaires such as the FFQ to assessment of vitamin C. 
Assessment of selenium intake with dietary questionnaires is also fraught with 
problems. Selenium content in food vary considerably according to the levels of selenium 
in the soil, and hence of crops and animal forage grown in the soil [308]. Selenium 
content in the same foods from different geographic locations can vary by many folds, in 
some cases by over 10-fold [309]. Thus, many researchers prefer biomarkers of selenium 
intake such as selenium levels in plasma/serum, urine or toenail clippings [310]. 
However, these biologic markers are influenced by factors other than selenium intake, 
such as general state of health, metabolism, past and present disease history, and smoking 
status [286, 311]. The use of toenail clippings is relatively more attractive than the other 
markers because it is easy to sample and store, and the sampling of toenail clippings 
usually does not cause discomfort to subjects [147, 312]. Moreover, toenail clippings are 
thought to reflect long-term intake. However, toenail levels of selenium are also 
influenced by factors such as the size and thickness of the nail plate, rate of nail growth 
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 and metabolism of selenium in nail beds [313, 314] In addition, the average time of 
selenium exposure reflected in toenail clippings remains unknown [314].  
Despite these limitations, nutritional biomarkers are very appealing to most 
researchers because of their ability to estimate internal dose of the nutrient of interest. 
However, some researchers have suggested that it may be best to measure biomarkers of 
dietary intake in target tissues of the disease of interest, rather than the use of surrogate 
markers of systemic exposure [310]. All issues considered, use of multiple measures of 
dietary intake such as plasma, adipose tissue and FFQ would provide complementary 
information and perhaps offer a more robust dietary assessment than any single measure 
of intake. 
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 CHAPTER 3  
 
STUDY METHODS 
 
3.1     OBJECTIVES AND HYPOTHESES  
OBJECTIVE 1: To examine whether changes in dietary antioxidant intake (baseline to 3-
months) as measured by plasma concentrations of carotenoids and tocopherols are 
associated with PCa progression (assessed by changes in serum PSA level as an 
intermediate prognostic marker of disease progression) in African-American and 
European-American men with biochemically defined PCa recurrence after 
definitive therapy. 
Hypotheses: 
i.Higher levels of plasma carotenoids and tocopherols at baseline will be 
associated with lower serum PSA levels at baseline. 
ii. Higher post-intervention plasma carotenoids and tocopherol levels (at 3 
months) will be associated with lower post-intervention PSA levels (at 3 
months, and at 6 months), after adjusting for baseline PSA level. 
iii. Change in plasma carotenoids and tocopherol levels (baseline to 3 months) 
will inversely correlate with serum PSA levels at 3 months and at 6 months.  
 
OBJECTIVE 2: To examine associations between antioxidant levels in adipose tissue, 
plasma and diet, and PCa aggressiveness among African American and European-
American men. 
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 Hypothesis: Lower levels of antioxidants in adipose tissue, plasma and diet are associated 
with high aggressive PCa, and these associations do not vary by race. 
 
OBJECTIVE 3: To examine whether SNPs in DNA repair and oxidative stress genes 
modulate associations between antioxidants in adipose tissue, plasma and diet, 
and PCa aggressiveness among African-American and European-American men. 
Hypothesis:  SNPs in DNA repair and oxidative stress genes modify associations between 
antioxidants in adipose tissue, plasma and diet, and PCa aggressiveness, and the 
degree of the effect modification vary by race. 
 
3.2     STUDY DESIGN AND METHODS 
OBJECTIVE 1 
Design & Data Source 
The first objective utilizes data from a previous study by Hébert et al. [13], which 
is a 6-month intervention trial involving diet, exercise and stress reduction conducted in 
South Carolina (the EASE Study). In brief, sixty men with histologically confirmed PCa 
and serum PSA levels after primary therapy with radical prostatectomy or radiation were 
recruited along with a partner of choice. Four participants were enrolled for the run-in 
period of the intervention to ascertain feasibility and potential issues with compliance. Of 
the remaining 54 participants, 29 (together with their partners) were randomized to 
intervention (dietary modification, physical activity and meditation practice) and 25 were 
randomized to usual care with an opportunity to receive the intervention at the end of the 
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 study. Full details of the randomization process and progression of the participants have 
been provided in Figure-1. 
Setting: The study participants were recruited from major urology practices 
located in the Midlands Region of South Carolina, covering seven counties [Richland 
county (67%),Lexington county (9%), Newberry (6%), Kershaw (6%), Orangeburg (6%), 
Sumter (4%) and Fairfield (2%) counties]. The intervention was administered under the 
supervision of the South Carolina Cancer Prevention and Control Program. Clinical data 
on the study participants were collected in the facilities of the Cancer Prevention and 
Control Program in Columbia. 
Study Population: Eligible participants are men with histologically-confirmed, 
adenocarcinoma of the prostate who: (1) have been treated by radical prostatectomy or 
radiation therapy as primary treatment for PCa; (2) have had 3 successive rise in serum 
PSA level of at least 1.5 ng/ml from post-treatment nadir (usually at or close to zero) 
measured at 2- to 3-month intervals; (3) were free of other malignancy in the previous 5 
years (except non-malignant skin cancer and primary PCa for which they were treated by 
radical prostatectomy or radiation therapy); (4) had not been taking thyroid medication, 
steroids, antibiotics or diuretics; (5) spoke English as first language; (6) were able to read 
at sixth grade level; (7) were of sound mind, memory and understanding; (8)  were 
willing to be randomized to intervention or usual care. Prospective participants were 
excluded from the study if they: (1) had received post-operative hormonal therapy for 
PCa; (2) had a diagnosis or symptoms of cardiovascular disease, pulmonary disease, 
Crohn's disease, active ulcerative colitis or metabolic disease; (3) had experienced 
unexpected weight loss of 5 pounds or more within the previous 3 months; (4) plan to use 
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 hormone supplements, fish oil, or other ω-3 fatty acids based supplements; or (5)  had a 
diagnosis of  post-traumatic stress disorder (PTSD). 
Intervention: Participants were assigned to intervention or control group using 
block randomization by age (± 5 years) and race (African American/European 
American). The study spanned 6 months, which included a 3-month period of active 
intervention followed by monthly booster session for the following 3 months. The 
intervention consisted of dietary modifications, physical activity, and mindfulness-based 
stress reduction training. The 3-month active phase of the intervention involved 
individual diet and physical activity counseling and goal setting sessions, as well as 
twelve weekly group meetings that included cooking classes and shared model meals. In 
addition, participants were given weekly assignments on how to shop for and cook study-
compliant meals, attain physical activity goals, and practice meditation for stress 
reduction. 
The diet aspect of the intervention emphasized increased intake of plant-based 
foods such as whole grains, fruits, vegetables, and legumes (particularly soybeans and 
soybean products) along with decreased intake of meat and dairy products. The physical 
activity aspect involved working with participants to identify activities that they enjoyed 
and reinforce those activities to promote physical fitness and overall well-being. The goal 
of the exercise routine was to ensure that each participant attain the Centers for Disease 
Control and American College of Sports Medicine (CDC/ACSM) recommendations of at 
least 30 minutes of moderate intensity physical activity for 5 days or more per week 
[315]. Because comprehensive dietary change can be difficult to maintain, participants 
were taught to meditate in a way that inculcates mindfulness about decisions concerning 
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 food choices in order to promote their sense of control over the change in diet and 
culinary habits [316]. Partner support was integrated to provide an encouraging 
environment for the process of change. Following the 3-month active phase, monthly 
booster sessions were held in a supportive group environment for another 3 months. 
These included frequent telephone calls to each participant and his partner for wellness 
checks and encouragement to sustain the intervention.  
Control condition: Participants in the control group underwent the same general 
assessment as those in the intervention group. There were no attempts made to restrict 
their access to psychosocial support or educational resources available to PCa patients in 
the community. These participants and partners were given the opportunity to take the 
intervention at the end of the 6-month study period at no cost to them.  
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 Assessed for eligibility
(n =56)
          Excluded (n = 2)
             ● Ineligible (n = 1)
             ● Dropped  ( n= 1)
Randomized
(n = 54)
Intervention
(n = 29)
Control
(n = 25)
      Dropout (n = 3)
        ● Medical Complication (n = 2)
        ● Time constraint  ( n= 1)
Analyzed
(n = 26)
       Dropout (n = 4)
        ● Medical Complication (n = 1)
        ● Time constraint  ( n= 3)
Analyzed
(n = 21)
 
FIGURE 3.1 Consort diagram showing participants recruitment, screening, randomization, 
and retention [13]. 
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 Exposure and outcome variables: Plasma carotenoid and tocopherol levels at 
baseline and at 3 months were the main exposure of interest. As part of the study 
requirements, participants provided peripheral blood samples at baseline, 3 months and 6 
months for analysis of biomarkers of food and nutrient intake as well as for analysis of 
serum PSA levels. The blood samples were collected by a trained phlebotomist after 
obtaining consent from the study participants. PSA was measured in serum at baseline, at 
3 months and at 6 months. Carotenoids and tocopherols were measured in plasma using 
high performance liquid chromatography (HPLC) by Craft Technologies [317]. Because 
of limited availability of samples, data on carotenoids and tocopherols were only 
measured at baseline and at 3 months. The following carotenoids and tocopherols were 
measured: α- and γ-tocopherol, α-carotene, cis- and trans-β-carotene, lutein, zeaxanthin, 
cis-lutein/zeaxanthin, α- and β-cryptoxanthin, cis- and all-trans-lycopene.  
Other study measures: Data on clinical and pathologic attributes of PCa were 
abstracted from participants’ medical records obtained from referring urologists. At 
baseline, participants responded to questionnaires that solicited information on 
demographics and health-related behaviors, including age, race, education, marital status, 
employment, and smoking status. Data on diet, physical activity, and anthropometry were 
obtained at each of the three study checkpoints: baseline, 3 months, and 6 months. Diet 
assessments used 24-hour dietary recalls on three randomly selected days that included 
two weekdays and one weekend day, as this method better captures daily variation in 
intake [318, 319]. Physical activity was assessed using a questionnaire designed for older 
adults that had been tested for reliability [320]. Physical activity was expressed as 
metabolic equivalent (MET) value based on description of the activity using the 
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 Compendium of Physical Activities [321], with one MET being equivalent to resting 
metabolic rate. Total METs of physical activity were estimated for each participant’s sum 
of METs from light, moderate, and vigorous physical activity per week. The 
anthropometric measurements obtained were standing height (cm), weight (kg), waist and 
hip circumference (cm) used to calculate waist-to-hip ratio, and bioelectric impedance 
measures of percent body fat and lean body mass.  
  
OBJECTIVE 2 & 3 
Data Source & Design 
Data from the North Carolina–Louisiana Prostate Cancer Project (PCaP) was used 
to evaluate objectives 2 and 3. PCaP is a large, racially diverse, population-based, 
multidisciplinary, cross-sectional, case-only, incident PCa study, designed to investigate 
racial/ethnic differences in PCa outcomes among African Americans and European 
Americans. The study population and methods have been published [4]. A total of 2,258 
men (African-American, n = 1,130; European-American; n =1,128) with histologically 
confirmed incident PCa were recruited through rapid case ascertainment in North 
Carolina and Louisiana. In North Carolina, 1,031 men (African Americans, n = 505; 
European Americans, n = 526) were recruited between July 2004 and October 2007. In 
Louisiana, the study participants were recruited in two phases due to the devastation 
caused by Hurricane Katrina. Pre-Hurricane Katrina cases were recruited between May 
2004 and June 2005 (n = 213; African Americans, n = 119; European Americans, n = 94), 
and Post-Hurricane Katrina cases were recruited between January 2006 and July 2009 (n 
= 1,014; African Americans, n = 506; European Americans n = 508). Although PCaP is a 
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 case-only study, a case-control analysis was used to compare men with high aggressive 
PCa (higher Gleason score, higher clinical stage, and higher PSA level) to those with 
low/intermediate aggressive PCa. 
Study population: Residents of the study catchment areas in North Carolina and 
Louisiana were eligible to participate in PCaP if they: (1) had a first diagnosis of  
histologically confirmed adenocarcinoma of the prostate; (2) were between the ages 40-
79 years at the time of diagnosis; (3) self-reported race/ethnicity as white/Caucasian 
American or as black/African American; (4) Spoke English as a first language; and  (5) 
did not reside in an institution (e.g., nursing home). Prospective participants were 
excluded if they: (1) were cognitively impaired or in a severely debilitated physical state; 
(2) were under the influence of alcohol, severely medicated, or had apparent psychosis as 
evaluated by recruiting staff. 
Exposures: Three measures of antioxidant intake were assessed: (1) dietary 
assessment of average daily nutrient intake using a modified National Cancer Institute 
Diet History-Food Frequency Questionnaire (NCI-DHQ) [322]; (2) Supplemental 
antioxidants intake assessed with a validated questions [323]; and (3) abdominal adipose 
tissue antioxidant concentrations. The decision to use more than one measure of 
antioxidant intake was based on the inherent limitations of each of these measures. First, 
food frequency questionnaire (FFQ) is an imperfect dietary assessment tool because: (a) 
reporting of food intake relies on respondent’s memory which may not accurately reflect 
actual intake; (b) there is the possibility of over-reporting of “healthy” foods and under-
reporting of “unhealthy” foods which may contribute to random error; (c) FFQ’s are 
generally less sensitive to absolute intake of specific nutrients due to the use of standard 
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 portion sizes; (d) categorization of foods in the FFQ limits reporting of details about 
specific foods which may be relevant to nutrient estimation; (e) exclusion of foods that 
are major contributors of certain nutrients may affect the validity of the nutrient estimates 
[247, 261, 324, 325]. Reporting of supplement intake is also prone to recall bias [323]. 
Second, although adipose tissue concentrations of antioxidants are useful biomarker of 
internal dose, individual variations in the absorption and metabolism of antioxidants can 
affect bioavailability, bioconversion, and bioefficiency of these micronutrients [266, 326, 
327]. Thus, concentration biomarkers do not reflect total antioxidant exposure. Therefore, 
examining three separate measures of antioxidant exposure would provide more 
comprehensive and perhaps more reliable data about the association between antioxidant 
intake and PCa severity than would any one of these measures alone. 
The NCI-DHQ was modified to include Southern foods, and had questions 
pertaining to frequency of intake and portion sizes for 124 different food items as well as 
questions about methods of food preparation. The questionnaire asked study participants 
to recall food intake over the year prior to PCa diagnosis. Responses to the questions 
were linked to an updated NCI nutrient database through which nutrient intake were 
estimated using NCI Diet*Calc software [4]. Adipose tissue antioxidant concentrations 
were measured from samples collected by PCaP study nurses during in-home visits after 
obtaining written consent from the participants. Adipose tissue samples were collected 
from the abdominal area. PCaP research nurses who were specifically trained for adipose 
tissue sampling, followed a standardized procedure involving the insertion of a 15-gauge 
needle into the subcutaneous fat and applying negative pressure by a 15 ml vacutainer 
tube after prepping the overlying skin. The aspirated tissue was trapped in the needle and 
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 luer lock adapter, which was placed in a separate cryovial and transported on ice 
immediately after collection to a designated storage facility where aliquots were prepared 
and stored at -80oC until assayed. Individual carotenoids were measured by high 
performance liquid chromatography at the Nutrition Analyses Laboratory of Craft 
Technologies, Incorporated (Wilson, NC) using methods outlined by Craft et al. [328, 
329]. The adipose tissue contents of α-, γ-, and δ-tocopherol, α-carotene, cis- and trans-
β-carotene, α-cryptoxanthin, β-cryptoxanthin, lutein, zeaxanthin, and cis- and trans-
lycopene were quantified at a minimum detection limit of 0.07 µg/g for tocopherols and 
0.003 µg/g for carotenoids. 
Outcome classification: The outcome of interest for objectives 2 and 3 was PCa 
aggressiveness; defined by a combination of PSA level at diagnosis, clinical stage of PCa 
at diagnosis and Gleason sum [4]. Information on these clinical attributes of PCa were 
abstracted from participant’s medical records by trained personnel. To assess consistency 
of abstractors and to ensure data quality, about 10% of the medical records were selected 
at random and abstracted by a second  staff  member [330]. PCa aggressiveness was 
categorized into three groups: high aggressive (Gleason sum ≥8 or PSA >20 ng/mL, or 
Gleason sum ≥ 7 and clinical stage T3–T4); low aggressive (i.e., Gleason sum < 7 and 
stage T1-T2 and PSA<10 ng/ml); and intermediate aggressive (all others). 
SNP Selection: Candidate SNPs selected and genotyped by the PCaP consortiums 
were used for executing objective 3. The SNPs were selected using the SNPinfo web 
server (http://snpinfo.niehs.nih.gov) previously described in detail elsewhere [331].  In 
brief, SNPinfo provides a platform that allows investigators to specify genes or linkage 
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 regions of interest and select SNPs based on results from genome-wide association 
studies (GWAS), population-specific linkage disequilibrium (LD) structure, and detailed 
functional predictions including coding, transcription factor binding, micro-ribonucleic 
acid (miRNA) binding, and splicing [331]. The PCaP consortium used six separate SNP 
selection procedures [131]. The first selection process was based on primary and 
secondary data from GWAS and validation studies, which identified 286 SNPs that were 
associated with PCa in published literature at the time of the SNP selection. The second 
process involved a thorough review of literature on candidate genes associated with PCa 
etiology or aggressiveness. Eight hundred and forty eight candidate genes were identified 
through this process. Three hundred and six of these genes were  retained for SNP 
selection because: (a) they were  listed in the CGEMS GWAS project as having  p-values 
< 0.05 (associated with PCa susceptibility or aggressiveness); or (b) had inadequate  SNP 
coverage in the 550K GWAS panel to sufficiently assess the gene. The SNPinfo’s 
candidate gene SNP selection pipeline (GenePipe) was subsequently used to select 583 
SNPs determined to be functionally significant to PCa based on p-values and multiple 
population LD tag SNPs for both European Americans and African Americans from the 
306 candidate genes. The third process utilized prioritized selection of SNPs in the 
CGEMS GWAS 550K panel in conjunction with SNPinfo’s GWAS functional SNP 
selection pipeline (GenomePipe). SNPs were selected from the CGEMS GWAS 550K 
panel if they had small p-value (associated with PCa susceptibility or aggressiveness) and 
were predicted to have functional effects, or had small p-value and were in high LD with 
SNPs predicted to have functional effects. Six thousand and thirty four SNPs were 
identified from the CGEMS GWAS 550K panel as having small p-values (p ≤ 0.01). 
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 SNPinfo’s GenomePipe was used to identify 41,755 SNPs that were in high LD (r2 ≥ 0.8) 
with at least one of the SNPs from the CGEMS GWAS 550K panel. Of these, 379 
common SNPs (minor allele frequency (MAF ≥ 0.05) predicted to have functional effects 
by at least one of the biological function prediction methods were selected. 
The fourth selection procedure was based on linkage regions. At the time of the 
SNP selection, 43 non-overlapping linkage regions were reported to be associated with 
PCa. The CGEMS GWAS 550K panel p-values (based on PCa susceptibility or 
aggressiveness) were used together with SNPinfo's GWAS SNP selection in linkage loci 
pipeline (LinkPipe) to select a maximum of seven SNPs from each of the 43 non-
overlapping linkage regions. The fifth involved overlap between small p-values for SNPs 
that were reported in multiple PCa GWAS. Only the Framingham GWAS and the 
CGEMS GWAS project had publicly available data on SNPs associated with PCa at the 
time of the SNP selection. Thus, fifty-eight SNPs with p-values <0.01 in the CGEMS 
project and the Framingham GWAS were included. 
Finally, fifty ancestry informative markers (AIM) were selected using allele 
frequency data in HapMap phase I + II (http://hapmap.ncbi.nlm.nih.gov) to control for 
stratification in three populations: Utah residents with ancestry from Northern and 
Western Europe (CEU) from the Centre d’Etude du Polymorphisme  Humain (CEPH) 
collection representing European ancestry; Yuroba individuals in Ibadan Nigeria (YRI) 
representing African ancestry; and individuals from Han, China (CHB) and Tokyo, Japan 
(JTP) collectively representing Asian ancestry (HapMap CHB plus JTP). Twenty-five of 
these SNPs were monoallelic [variant allele frequency (VAF = 0)] in CEU, rare in Asians 
(VAF < 0.01) but common YRI (VAF > 0.25). The other 25 SNPs were monoallelic in 
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 (YRI) (VAF = 0), rare in Asians (VAF <0.5) and but very common in CEU (VAF > 0.5). 
The SNP selection process has been described in sufficient detail elsewhere [131]. 
Additional information on the ancestry informative markers for the PCaP study 
participants is presented in Table 3.1. 
Genotyping: Germline DNA was extracted from blood samples  (n = 1,630) or 
buccal cells  (n = 118) by the University of North Carolina (UNC, Chapel Hill) 
Biospecimen Processing Facility or from peripheral blood mononuclear cells 
immortalized by the UNC Tissue Culture Facility (n = 216). Genotyping was done at the 
National Institutes of Health (NIH) Center for Inherited Disease Research (CIDR) using a 
custom designed Illumina GoldenGate array. There was an excellent genotyping call rate 
(99.93%) and inter-assay agreement with blinded duplicates (99.99%). Further details of 
the genotyping process and quality control measures have been published [332].   
 
SNPs in DNA repair and oxidative stress genes 
The PCaP consortium maintains a repository containing over 1,536 GWAS and 
candidate SNPs among European Americans and African Americans. Data on SNPs in 
DNA repair pathways (i.e., base excision repair, nucleotide excision repair, and double-
stranded DNA break repair) and oxidative stress-related genes, which were considered 
for analysis. A complete list of the SNPs that were evaluated is presented in Table 3.2.  
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Table 3.1 Ancestry informative markers proportions by race and geographic region in the North 
Carolina-Louisiana Prostate Cancer Project (PCaP) [333]. 
 Self-Reported Race Study site Mean YRI 
(%) 
Mean 
CEU  
(%) 
Mean CHB plus JTP 
(%) 
p-value 2 
 
African Americans 
 n = 1043 
Louisiana  
n = 594 
86.9 11.9 1.2  
0.03 North Carolina  
n = 449 
 
89.5 
 
9.3 
 
1.2 
 
European Americans 
 n = 1063 
Louisiana  
n = 582 
1.8 96.9 1.3  
 
0.001 North Carolina  
n = 481 
 
0.8 
 
98.4 
 
0.8 
Non-ethnic African 
Americans 1 
n = 930 
Louisiana  
n = 485 
89.2 9.5 1.3  
 
0.78 North Carolina  
n = 445 
 
89.4 
 
9.4 
 
1.2 
Non-ethnic European 
Americans 1 
n = 824 
Louisiana  
n = 354 
1.5 97.3 1.2  
 
0.002 North Carolina  
n = 470 
 
0.8 
 
98.6 
 
0.6 
 
Abbreviations: YRI- Yoruba individuals in Nigerians (represents African ancestry), CEU- Utah residents with 
ancestry from Northern and Western Europe (represents European Americans), CHB plus JTP - individuals from 
Han, China and Tokyo, Japan (representing Asian ancestry). 
 
1 includes ONLY individuals reporting “no” ethnicity membership. 
 
2 One-way multivariate analysis of variance (MANOVA) models comparing mean CEU and YRI ancestry estimates 
between research subjects in North Carolina and Louisiana.  
 
 
 
 3.3    SAMPLE SIZE CALCULATION 
OBJECTIVE 1 
The data for Objective 1 (EASE study) has complete information on plasma 
carotenoid and tocopherol levels for 39 participants at baseline and 35 participants at 3 
months. No data on carotenoids or tocopherols are available for the 6-month time point; 
thus, the 3–month data on tocopherols and carotenoids was analyzed in relation the 6-
month PSA levels. Calculation of statistical power for this Objective assumed unmatched 
data. The outcomes for computing statistical power were mean PSA levels at baseline, 
and at 3 months and 6 months comparing participants with high versus low plasma 
carotenoid and tocopherol level. The null hypothesis was that mean PSA values are equal 
in both groups (H0: µ1 = µ2). Based on findings from a previous study [11],  a two-sided 
test at level α = 0.05 and sample size of 39 and 35, a power of 86% and 81%, 
respectively, were achieved to observe a difference as large as that observed in the 
previous study (mean change PSA level of 0.09). The power calculation was performed 
using the PASS software version 12. 
  
OBJECTIVE 2 
Complete data on dietary antioxidants intake and PCa aggressiveness were 
available for 2102 PCaP study participants (African American, n = 1,023; European 
Americans, n = 1,079). Analysis were performed separately for African Americans (high 
aggressive PCa, n = 206; low/intermediate aggressive PCa, n = 817) and European 
Americans (high aggressive PCa, n = 164; low/intermediate aggressive PCa, n = 915). 
Previous studies have reported as much as 63–80% lower overall risk of PCa or lower 
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 risk high aggressive PCa among men with higher antioxidant intake [191, 334]. Thus, 
assuming a 63% difference in odds of high aggressive PCa among men with low versus 
high intake of antioxidants, based on a two-sided test at significance level α = 0.05 and 
sample sizes of 1,023 and 1,079, a statistical power of 87% and 81% for African 
Americans and European Americans respectively. 
 
OBJECTIVE 3 
Data on SNP genotypes and PCa aggressiveness also were available for 1,964 
PCaP participants (African American, n = 948; European Americans, n = 1,016). Similar 
to the analysis of main effect of the antioxidants, the gene-dietary analysis were 
performed separately for African Americans (high aggressive PCa, n = 188; 
low/intermediate aggressive PCa, n = 760) and European Americans (high aggressive 
PCa, n = 153; low/intermediate aggressive PCa, n = 863). Calculation of statistical power 
for gene-diet interaction was informed by findings from two recent studies. Li et al. [130] 
observed a statistically significant 82% lower risk of aggressive PCa in men with Ala/Ala 
genotype of the SOD2 gene polymorphism (rs4880) with high selenium intake. Goodman 
et al. [129] also observed a statistically significant 89% lower risk of PCa in men with 
Arg/Arg genotype of the XRCC1 gene and high antioxidant intake (lycopene + α-
tocopherol + β-carotene). Therefore assuming 89% difference in odds of high aggressive 
PCa among men with low versus high intake of antioxidants by gene (dichotomous: 
homozygous wild-type allele vs. homozygous + heterozygous variants), based on a two-
sided test at significance level α = 0.05 and sample sizes of 948 and 1,016, 42%  and 43% 
power was achieved for African Americans and European Americans respectively. The 
analyses based on these data were underpowered and may have concealed some modest 
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 association. Thus, replication in larger studies is encouraged. The power calculations for 
specific objectives 2 and 3 were performed using the NCI power and sample size 
calculation software version 3.0. 
 
 
3.4     STATISTICAL ANALYSES 
 
OBJECTIVE 1 
Differences in patient characteristics were compared between the intervention and 
control groups using t-test for continuous variables and Fisher’s exact test for categorical 
variables. Linear regression models were used to estimate least squares means and P 
values for test of difference between group means, modeling PSA values as continuous 
variable. Natural log transformation was performed on the positively skewed PSA data in 
order to achieve normality; results were back transformed for presentation. Plasma 
carotenoids and tocopherols were categorized into binary groups (< vs. ≥ median) 
because of nonlinear distribution pattern assessed by the generalized additive model 
procedure in SAS (PROC GAM). A total antioxidant score also was computed as a 
measure of overall antioxidant status following the method described by Li et al. [335]. In 
estimating the antioxidant score, the carotenoid and tocopherol variables (i.e., α- and γ-
tocopherol, α-carotene, cis- and trans-β-carotene, α- and β-cryptoxanthin, lutein, 
zeaxanthin, and cis- and trans-lycopene) were categorized into quartiles and scores were 
assigned to each quartile in multiples of 3 (i.e., 3 to 12, from low to high). The scores 
were summed for each participant across all carotenoids and tocopherols, and then 
categorized into median groups (< vs. ≥ median).  
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 Analyses were performed in minimally adjusted (adjusting for age, race and 
randomized group) and multivariable adjusted linear regression models. Covariates 
selected for inclusion in the multivariable adjusted models were age (continuous); race 
(African American, European American); education (high school graduate or less, high 
school and some college, college graduate); marital status (Married or with partner, 
Widowed, divorced, or single); employment (yes, full time; yes, part time; no); smoking 
status (never, former, current); Gleason score (<5,5–6, ≥7); BMI (continuous); physical 
activity (metabolic equivalent/week); energy intake (continuous); and randomized 
condition (treatment, control). These variables were selected based on evaluation of 
confounding effect (>10% change in effect estimates) in conjunction with the backward 
elimination method. Additional variables considered but not included in the final analyses 
were: type of PCa treatment received; body fat mass; fruit, vegetables, fiber and dairy 
intake; and total dietary fat and omega-3 fatty acids intake., fiber and dairy intake; and 
total dietary fat and ω-3 fatty acids intake. 
Analysis for hypothesis-1 was based on baseline data, which compared mean PSA 
values between participants with high versus low carotenoid or tocopherol using P values 
as a for differences between group means. For hypothesis 2, mean PSA values levels at 3 
months and at 6 months (modeled separately) were compared between participants with 
high versus low carotenoid or tocopherol at 3 months, adjusting for baseline PSA values. 
Hypothesis 3, examined percent change in carotenoid and tocopherol levels (from 
baseline to 3 months) in relation to PSA levels at 3 months and at 6 months, adjusting for 
baseline PSA values. The sign for the percent change values was reserved to ensure that a 
positive value represented an increase in plasma carotenoid and tocopherol levels. The 
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 percent change variables were also categorized into binary (increase vs. decrease) as well 
as tertile [decrease, minimal increase (1–20%), or substantial increase (>20 %)] groups 
for evaluation of whether mean PSA level vary with substantial increase in plasma levels.  
 
Statistical models for Objective 1: 
Models-1: Y1 = β0 + β1 (antioxidanti) + ……....................................+ βk (Xk) + ε 
Models-2: Y2 = β0 + β1 (antioxidantii) + β2 (baseline PSA level) ......+ βk (Xk) + ε 
Model-3:  Y2 = β0 + β1(antioxidant∆) + β2 (baseline PSA level) ......+ βk (Xk) + ε  
                 𝜀𝜀  ~𝑖𝑖𝑖𝑖𝑖𝑖 N (0,σ2 ) 
 
Where Y1 = serum PSA level at baseline  
            Y2 = serum PSA level at 3 months and 6 months modeled separately  
                                 β0 = intercept, βj, j = 1…….....k, = slope 
antioxidanti = plasma antioxidants at baseline (i.e., α- and γ-tocopherol, α-
carotene, cis- and trans-β-carotene, lutein, zeaxanthin, cis-
lutein/zeaxanthin, α- and β-cryptoxanthin, cis- and all-trans-
lycopene and antioxidant score). 
 
antioxidantii  = individual plasma antioxidants at 3 months, and antioxidant score 
at 3 months 
antioxidant∆ = percent change in antioxidants from baseline to month 3 
 
                 Xj, j = 1...........k, = age, race, education, marital status, employment, smoking 
status, Gleason score, BMI, physical activity, energy intake and randomized 
group).  
 
 
 
 
OBJECTIVE 2 & 3 
All analyses were conducted separately for African Americans and African 
European Americans because of significant interaction between race and lycopene intake. 
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 Distributions of research subjects’ characteristics by the levels of PCa aggressiveness 
were examined using Students’ t-test and chi-square tests for continuous and categorical 
variables, respectively. Objective 2: Associations between antioxidants intake and PCa 
aggressiveness were examined using a case-control design by treating low/intermediate 
aggressive PCa cases as “control” or comparison group, and high aggressive PCa as 
“cases”. Unconditional logistic regression models were used to estimate odds ratios 
(ORs) and corresponding 95% confidence intervals (CIs). Dietary and adipose tissue 
tocopherol levels (i.e., α, β, γ and δ) as well as supplemental vitamin E intake (α-
tocopherol equivalent) were categorized into quartiles, while carotenoids (α-carotene, β-
carotene, β-cryptoxanthin, lutein, zeaxanthin and lycopene) from diet, supplements and 
adipose tissue were categorized into tertiles. These data were categorized based on 
distribution among “controls” (i.e., low/intermediate aggressive PCa cases).  
All analysis were performed in age-adjusted and multivariable models. The 
following variables were evaluated for inclusion in multivariable models: age 
(continuous), study site (NC, LA); BMI (in kg/m2); pre-diagnostic PSA screening history 
(0, 1-7, >7 screenings); comorbidities (0, 1, 2, ≥3); family history of PCa in a first degree 
relative (none vs. at least one); whether PCa treatment had started at the time of the 
interview (yes, no); smoking status (never, former, current); education (less than high 
school education, high school graduate/some college, college graduate); annual 
household income (< $20,000, $20,001 - $40,000, $40,001 - $70,000, >$70,000); 
NSAIDs use in the five years prior to diagnosis (yes, no); physical activity in the year 
prior to diagnosis [total metabolic equivalents (METs) of light, moderate, and vigorous 
exercise categorized as: ≤ 10.2, 10.3-29.0, > 29.0 METs/week]; total fat intake 
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 (grams/day); and alcohol intake (grams/day).  As with objective 1 analysis, the 
multivariable models were constructed first by evaluating the confounding effect of each 
variable based on a 10% change in effect estimate of the main exposure variables with 
the removal of the covariate from the model. Variables determined to be confounders and 
those that are biologically relevant to PCa were then placed in an elaborate model for 
final model selection. A combination of the backward elimination model selection 
method and likelihood ratio tests were then used to select covariates for the final models 
consisting of age, PSA screening history, BMI, smoking status, education, income, 
NSAIDs use, total fat intake, and study site. Further adjustment for family history of PCa, 
comorbidities, and PCa treatment status were done in models examining associations 
between adipose carotenoid/tocopherol levels and PCa aggressiveness. 
 
Statistical model for specific objective 2: 
Model-1:   ln( π  1−π    ) = β0 + β1 (antioxidanti) + ……………………………………+ βkXk  
Where β0 = intercept, 
 
            βj, j = 1…….....k, = slope (coefficient) 
 
            antioxidanti =  each antioxidant from diet, supplement and adipose tissue were 
modeled separately  
 
Xj, j = 1 ………k, covariates 
 
Objective 3: Gene-nutrients analyses were performed for α-tocopherol, γ-
tocopherol and lycopene only because of significant findings for these nutrients observed 
in the analysis of the dietary data. Similar to specific objective 2, a case-control design 
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 was used to examine whether associations between dietary intakes of  α-tocopherol, γ-
tocopherol and lycopene, and PCa aggressiveness are modulated by SNPs in DNA repair 
and oxidative stress genes, and whether the effect modification varies by race. A priori 
SNPs selected and genotyped by the PCaP consortium were utilized (see Table 4). Hardy-
Weinberg equilibrium (HWE) test was not performed in this analysis because of lack of a 
disease-free control group. The “control group” as defined by this study is not an ideal 
population for HWE test because of the possibility that some of the SNP allelic variants 
may contribute to the expression of different PCa phenotypes [336, 337]. An a priori 
decision was made to exclude SNPs with low minor allele frequency (MAF, < 0.05).  
In order to maximize sample size, a dominant model was assumed by collapsing 
the genotype variables into two groups [i.e., minor allele heterozygous + homozygous 
versus homozygous common allele (referent group)]. Effect modification of associations 
between α--tocopherol, γ-tocopherol, and lycopene with PCa aggressiveness, was 
examined in series of stratified analyses by genotype (binary groups). This was done by 
comparing high versus low levels of the nutrients intake in each stratum of genotype 
groups. Likelihood ratio tests (LRTs) were used to examine interaction on the 
multiplicative scale by comparing the difference in -2 log likelihood values of logistic 
regression models with and without the interaction terms. Interaction p-values were 
considered statistically significant at p < 0.10 to compensate for small sample size [336]. 
All results were adjusted for adjusted for multiple testing using the false discovery rate 
(FDR) method [338]. All statistical analysis described in the document were performed 
using SAS version 9.3 (SAS Inc., Cary, NC, USA) with statistical significance set at α = 
0.05 (two-tailed). 
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 Statistical model for specific objective 3: 
Model-1(stratified analysis by genotype groupings: wild-type versus variant genotype): 
      ln( π  1−π    ) = β0 + β1 (antioxidanti) +……………………………………………+ βkXk  
Where β0 = intercept, βj, j = 1…….....k, = slope (coefficient) 
 
            antioxidanti =  each dietary antioxidants (α- and γ-tocopherol, and lycopene) 
 
 
            Genotype groupings = homozygous wild-type allele (reference group) vs. 
homozygous +   heterozygous variant alleles  
Xj = j…………..k, covariates  
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 CHAPTER 4 
 
 
PLASMA CAROTENOIDS AND TOCOPHEROL LEVELS IN RELATION TO PROSTATE-SPECIFIC 
ANTIGEN (PSA) LEVELS IN MEN WITH BIOCHEMICAL PROSTATE CANCER RECURRENCE 
 
4.1     INTRODUCTION 
Prostate cancer (PCa) is the most frequently diagnosed visceral tumor and the 
second most lethal malignancy among American men [339]. Most patients diagnosed 
with PCa in the United States present with clinically localized disease (about 94%), and 
often are treated with radical prostatectomy or radiation with curative intent [340, 341]. 
Unfortunately, about 25–40% of these patients develop biochemical recurrence of the 
disease within five years of definitive treatment [342-345]. Biochemical recurrence of 
PCa is identified by rising serum prostate-specific antigen (PSA) level on three or more 
successive tests after achieving post-treatment PSA nadir (lowest detectible level) [346]. 
PSA-defined PCa relapse following definitive therapy is often an early sign of metastasis, 
and precedes pathological and radiographic evidence of metastasis by several years [347, 
348]. Thus, the identification of PSA-defined PCa recurrence provides ample time for 
intervention. 
Although there is no known cure for biochemically recurrent PCa, it is often 
managed with surgical or medical androgen ablation to delay the time to metastasis and 
prolong survival [349, 350]. Androgen ablation is often ineffective in controlling the 
disease progression as most patients become hormone-refractory within two years, 
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 resulting in continuous rise in PSA  [351, 352]. Severe side effects are also associated 
with the use of androgen ablation [349, 351]. Thus, there is continued interest in the 
search for adjuvant and neoadjuvant therapies for biochemical PCa relapse [13]. 
Epidemiologic data from migrant studies indicate that in addition to age, race/ethnicity 
and a positive family history, diet plays an important role in PCa [353, 354]. Greater 
intake of cruciferous vegetables, fruits, and specific dietary nutrients such as lycopene, 
soy isoflavones and polyhenols have been associated with modest reduction in PCa risk, 
while energy imbalance and increased consumption of fat, meat, calcium and dairy 
products have been associated with increased risk of PCa [17, 355, 356]. 
Few epidemiologic studies have investigated whether the progression of 
biochemically recurrent PCa can be altered using plant-based, dietary intervention [11, 
13, 357-361]. Most of these intervention trials incorporated supporting interventions such 
as stress reduction [11, 358-360] and physical activity [13] to reinforce the dietary 
modification. Five reported potential inhibitory effect of the intervention on PCa 
progression [11, 357-360], while two reported null results [13, 361]. However, because 
these trials involved different combinations of diet, stress reduction, and physical activity, 
it is difficult to determine whether study diet or other factors were responsible for the 
potential beneficial effects reported by some studies. Although others studies have 
investigated effects of dietary modifications alone among men with biochemical 
recurrence (reviewed in [355, 362, 363]), the diets used in these studies also had different 
components, such as increasing fruits, vegetables, legumes, and whole grains intake 
while decreasing meat and dairy intake, which also makes it difficult to examine the 
independent effects of specific food components. Thus, additional work is needed to 
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 evaluate the role of specific foods and nutrients. Of particular interest are biomarkers of 
antioxidant intake, which have been inversely associated with PCa risk in some studies 
[364, 365] and therefore may be associated with reduction in  progression of recurrent 
PCa [362].  
Our team previously reported results of a pilot intervention trial conducted in 
South Carolina to investigate whether a plant-based dietary intervention integrated with 
physical activity and stress reduction could alter the progression of PCa in men with 
biochemical recurrence of PCa after definitive therapy [13]. The current report is an 
expansion of that work. We investigated whether plasma carotenoids (including all major 
carotenoids) and tocopherol (α− and γ−tocopherols) levels were associated with PSA 
levels in these patients.   
4.2     MATERIALS AND METHODS 
Study Population 
Participants of the intervention trial were men with histologically confirmed 
localized adenocarcinoma of the prostate who had completed primary therapy (i.e., 
radical prostatectomy or radiation) and had experienced increasing serum PSA levels, a 
minimum of three successive increases of 1.5 ng/mL above the post-treatment  PSA 
nadir, with each increase at 2- to 3-month intervals [13]. Participants were deemed 
eligible if they were free of other malignancy in the previous 5 years (with the exception 
of non-malignant skin cancer); spoke English as a first language; were able to read at a 
sixth grade level; were of sound mind, memory, and understanding; had not been taking 
thyroid medication, steroids, antibiotics, or diuretics; and were willing to be randomized 
to intervention or control (with an option to obtain the intervention at the end of the 
85 
 
 study). The participants were required to enter the study with their spouse or partner of 
choice to provide support for compliance with the study protocol. Prospective 
participants were excluded if they had received post-operative hormonal therapy for 
treatment of PCa; had a current diagnosis or symptoms of active ulcerative colitis or 
cardiovascular, pulmonary, Crohn’s, or metabolic disease; had experienced weight loss of 
5 pounds or more within the previous 3 months; planned to use hormone supplements, 
fish oil, or other ω-3 fatty acids-based supplements; or had a diagnosis of post-traumatic 
stress disorder (PTSD). All participants provided informed consent prior to enrollment. 
The research protocol of the parent study was reviewed and approved by the Institutional 
Review Boards (IRBs) of the University of South Carolina (USC) and Palmetto Health; 
the current analysis also was approved by the USC IRB.  
All participants were recruited from major urological practices of seven counties 
in the Midlands region of SC (Richland, Lexington, Orangeburg, Kershaw, Sumer, 
Fairfield, and Newberry). The majority of participants were from Richland (67%) and 
Lexington (9%) counties, which are the two most densely populated counties in the 
greater Columbia area. The intervention was conducted at locations close to the 
recruitment sites under the auspices of the primary investigator (JRH). All clinical and 
anthropometric data were collected at the facilities of the Cancer Prevention and Control 
Program at USC.  
 
Study Design 
Details of the study design and methods have been published [13]. In brief, 
participants were assigned to intervention or control group using block randomization by 
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 age (± 5 years) and race (African American/European American). The study spanned 6 
months, which included a 3-month period of active intervention followed by monthly 
booster session for the following 3 months. The intervention consisted of dietary 
modifications, physical activity, and mindfulness-based stress reduction training. The 3-
month active phase of the intervention involved individual diet and physical activity 
counseling and goal setting sessions, as well as twelve weekly group meetings that 
included cooking classes and shared model meals. In addition, participants were given 
weekly assignments on how to shop for and cook study-compliant meals, attain physical 
activity goals, and practice meditation for stress reduction. The diet aspect of the 
intervention emphasized increased intake of plant-based foods such as whole grains, 
fruits, vegetables, and legumes (particularly soybeans and soybean products) along with 
decreased intake of meat and dairy products. The physical activity aspect involved 
working with participants to identify activities that they enjoyed and reinforce those 
activities to promote physical fitness and overall well-being. The goal of the exercise 
routine was to ensure that each participant attain the Centers for Disease Control and 
American College of Sports Medicine (CDC/ACSM) recommendations of at least 30 
minutes of moderate intensity physical activity for 5 days or more per week [315]. 
Because comprehensive dietary change can be difficult to maintain, participants were 
taught to meditate in a way that inculcates mindfulness about decisions concerning food 
choices in order to promote their sense of control over the change in diet and culinary 
habits [316]. Partner support was integrated to provide an encouraging environment for 
the process of change. Following the 3-month active phase, monthly booster sessions 
were held in a supportive group environment for another 3 months. These included 
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 frequent telephone calls to each participant and his partner for wellness checks and 
encouragement to sustain the intervention.  
Participants in the control group underwent the same general assessment as those 
in the intervention group. There were no attempts made to restrict their access to 
psychosocial support or educational resources available to PCa patients in the 
community. These participants and partners were given the opportunity to take the 
intervention at the end of the 6-month study period at no cost to them.  
 
Data Collection and Phlebotomy 
Data on clinical and pathologic attributes of PCa were abstracted from 
participants’ medical records obtained from referring urologists. At baseline, participants 
responded to questionnaires that solicited information on demographics and health-
related behaviors, including age, race, education, marital status, employment, and 
smoking status. Data on diet, physical activity, and anthropometry were obtained at each 
of the three study checkpoints: baseline, 3 months, and 6 months. Diet assessments used 
24-hour dietary recalls on three randomly selected days that included two weekdays and 
one weekend day, as this method has been found to be least prone to dietary measurement 
error [318, 319]. Physical activity was assessed using a questionnaire designed for older 
adults that had been tested for reliability [320]. Physical activity was expressed as 
metabolic equivalent (MET) value based on description of the activity using the 
Compendium of Physical Activities [321], with one MET being equivalent to resting 
metabolic rate. Total METs of physical activity were estimated for each participant’s sum 
of METs from light, moderate, and vigorous physical activity per week. The 
anthropometric measurements obtained were standing height (cm), weight (kg), waist-to-
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 hip ratio, and bioelectric impedance measures of percent body fat and lean body mass 
[13]. Body mass index (BMI) was subsequently calculated as weight (kg)/height (m2). 
Each participant provided a 5 ml vial of blood from venipuncture obtained by a 
trained phlebotomist at each of the three study timepoints. The samples were fractionated 
by centrifuge, frozen at –80oc within 1 hour of collection, and transported on ice within 
1week via overnight courier to Quest ® Laboratories for analysis. PSA was measured in 
serum at baseline, at 3 months and at 6 months. Carotenoids and tocopherols were 
measured in plasma using high performance liquid chromatography (HPLC). Because of 
limited availability of samples, data on carotenoids and tocopherols were only measured 
at baseline and at 3 months. The following carotenoids and tocopherols were measured: 
α- and γ-tocopherol, α-carotene, cis- and trans-β-carotene, lutein, zeaxanthin, cis-
lutein/zeaxanthin, α- and β-cryptoxanthin, cis- and trans-lycopene. 
 
Statistical Methods 
Differences in baseline characteristics were assessed using Student’s t-test to 
compare means of continuous variables and Fisher’s exact test for categorical variables. 
Means and standard deviations (SDs) of plasma carotenoids and tocopherols at baseline 
and at 3 months also were calculated and compared by intervention group. Because 
carotenoids and tocopherols are transported in the blood by lipoproteins [278], we 
corrected for circulating lipid levels by dividing each carotenoid and tocopherol (µg/ml) 
by total plasma cholesterol level (mg/dL). These variables were subsequently categorized 
into binary groups (< vs. ≥ median) because of nonlinear distribution pattern; assessed by 
the generalized additive model procedure in SAS (PROC GAM). A total antioxidant 
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 score was computed as a measure of overall antioxidant status following the method 
described by Li et al. [335]. In estimating the antioxidant score, the carotenoid and 
tocopherol variables (i.e., α- and γ-tocopherol, α-carotene, cis- and trans-β-carotene, α- 
and β-cryptoxanthin, lutein, zeaxanthin, and cis- and trans-lycopene) were categorized 
into quartiles and scores were assigned to each quartile in multiples of 3 (i.e., 3 to 12, 
from low to high). The scores were summed for each participant across all carotenoids 
and tocopherols, and then categorized into median groups (< vs. ≥ median). 
  
The relations between serum PSA levels and plasma carotenoids and tocopherols 
were examined in three sets of analyses. First, we considered how baseline carotenoid 
and tocopherol levels are related to baseline PSA level. Second, we explored whether 
carotenoid and tocopherol levels at 3 months are related to PSA levels at 3 months and at 
6 months, adjusting for baseline PSA level, as baseline PSA is related to subsequent PSA 
values [366]. Finally, we examined percent change in carotenoid and tocopherol levels 
(from baseline to 3 months) in relation to PSA levels at 3 months and at 6 months, 
adjusting for baseline PSA values. The sign for the percent change values was reserved to 
ensure that a positive value represented an increase in plasma carotenoid and tocopherol 
levels. The percent change variables also were categorized into binary (increase vs. 
decrease) as well as tertile [decrease, minimal increase (1–20%), or substantial increase 
(>20 %)] groups. Linear regression was used for all analyses to estimate least squares 
means and P values for test of difference between group means, modeling PSA values as 
continuous variable. Natural log transformation was performed on the positively skewed 
PSA data in order to achieve normality; however, results were back transformed for 
presentation. 
90 
 
 The analyses were performed in minimally adjusted (i.e., “crude model”, 
adjusting for age, race and randomized group) and in multivariable adjusted models. 
Covariates chosen for inclusion in the multivariable adjusted models were age, race, 
education, marital status, employment, smoking status, Gleason score, BMI, physical 
activity, energy intake and randomized group, and modeled as continuous or categorical 
variables as presented in Table 4.1. These variables were selected based on evaluation of 
confounding effect (>10% change in effect estimates) in conjunction with the backward 
elimination method. Additional variables considered but not included in the final analyses 
type of PCa treatment received; body fat mass; fruit, vegetables, fiber and dairy intake; 
and total dietary fat and omega-3 fatty acids intake. All statistical tests were two sided; 
statistical significance was set at α = 0.05, and all analyses performed using SAS version 
9.3 (SAS Institute Inc., Cary, NC). 
 
4.3     RESULTS   
Full details of the randomization procedure have been reported [13]. Overall, 54 
men with a history of localized PCa and rising PSA levels after definitive treatment with 
radical prostatectomy, radiation or both were successfully randomized to intervention (n 
= 29) and control (n = 25). Of these participants, seven were lost to follow-up 
(intervention, n = 3; control, n = 4). Of the remaining 47 participants, data on plasma 
carotenoid and tocopherol levels were available for 39 participants at baseline and 35 
participants at 3 months. 
Differences in the distribution of baseline characteristics and PSA levels at all 
three timepoints are presented in Table 4.1. The mean age of the study sample was 70 
years (SD = 8), with mean BMI of 29.75 kg/m2 (SD = 5.21), and included 28 (72%) 
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 European Americans and 11 (28%) African Americans. Fifteen percent of the participants 
underwent radical prostatectomy, 39% had radiation only, and 46% had both radiation 
and prostatectomy prior to enrollment in the study. Mean serum PSA levels were 3.91, 
5.01, and 4.72 ng/mL at baseline, at 3 months, and at 6 months, respectively. None of the 
baseline characteristics including education, marital status, employment, smoking status, 
and tumor grade, differed significantly by intervention status. 
The plasma carotenoid and tocopherol concentrations did not vary significantly 
between the intervention and control groups at baseline or at 3 months (Table 4.2). 
Analysis of baseline data also did not show any significant difference in mean PSA levels 
between participants with high versus low carotenoid/tocopherol levels or total 
antioxidant score (Table 4.3).  
Tables 4.4 and 4.5 presents results for associations of plasma carotenoids and 
tocopherols at 3 months in relation to serum PSA levels at 3 months and 6 months, 
respectively, after adjusting for baseline PSA level in addition to age, race, education, 
marital status, employment, smoking status, Gleason score, BMI, physical activity and 
randomization status. Participants with higher carotenoid and tocopherol levels at 3 
months, tended to have lower PSA levels at 3 months as compared to those with lower 
carotenoid and tocopherol levels at 3 months, though the association with PSA levels at 3 
months after adjustment was statistically significant only for cis-lutein/zeaxanthin (P = 
0.008). The 3-month carotenoid and tocopherol levels appeared to be more strongly 
associated with serum PSA levels at 6 months, as participants with high plasma levels of 
α-tocopherol (P = 0.01), β-cryptoxanthin (P = 0.01), all-trans-lycopene (P = 0.004), and 
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 total antioxidant score (P = 0.003) showed significantly lower mean PSA levels than 
those with low levels of these micronutrient antioxidants.  
We further examined whether percent change in carotenoid and tocopherol levels 
from baseline to month 3 was associated with PSA levels at 3 months and at 6 months, 
adjusting for baseline PSA level (Table 4.6 and 4.7, respectively). These results show that 
participants who experienced an increase in carotenoid and tocopherol levels generally 
had lower mean PSA levels at 3 months compared to those who had a decrease in 
carotenoid and tocopherol levels. The evidence of inverse relation with serum PSA at 3 
months was particularly strong for α-tocopherol (P = 0.0007). Although significantly 
lower mean PSA levels were observed for higher levels of all-trans-β-carotene and α-
cryptoxanthin in relation to PSA level at 3-months, significant findings in the tertile 
categories was confined to participants who had a minimal increase in their plasma levels 
(i.e., 1–20% increase). In the analysis of 6-month PSA values, percent increase in 
carotenoid/tocopherol level was inversely related to mean PSA level for α-tocopherol, 
trans-β-carotene, β-cryptoxanthin, cis-lutein/zeaxanthin, trans-lycopene, and total 
antioxidant score.   
 
4.4    DISCUSSION 
In this study, we examined the relations between plasma carotenoid and 
tocopherol levels, and serum PSA levels among men with biochemical recurrence of PCa 
who were enrolled in a 6-month diet and lifestyle intervention trial in South Carolina. In 
an analysis of baseline data, no significant differences in mean PSA levels were observed 
between participants with high versus low carotenoid or tocopherol levels. We further 
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 explored whether carotenoid and tocopherol levels at 3 months (during the study period) 
were associated with PSA levels at 3 months and at 6 months, adjusting for baseline PSA 
values. Results from this analysis showed that participants with higher cis-
lutein/zeaxanthin level at 3 months had statistically lower mean PSA level at 3 months. 
Additionally, participants with higher plasma levels of α-tocopherol, β-cryptoxanthin, 
all-trans-lycopene, and higher antioxidant score at 3 months, had significantly lower 
mean PSA level at 6 months. Finally, we examined whether percent change in plasma 
carotenoid and tocopherol levels from baseline to month 3 were inversely related to PSA 
levels at 3 months and at 6 months, independent of baseline PSA values. These results 
showed significantly lower mean PSA values at 3 months and at 6 months for participants 
with an increase in α-tocopherol and trans-β-carotene levels compared to who had a 
decrease in the levels of these nutrients. In addition, those with an increase in β-
cryptoxanthin, cis-lutein/zeaxanthin, trans-lycopene and antioxidant score had 
significantly lower mean PSA values at 6 months. Overall, higher plasma levels of 
certain carotenoids and tocopherols paralleled with lower PSA level at various time 
points, with stronger findings for associations with the 6-month PSA values. This 
suggests that it may take a few months before a clinical benefit on PSA is observed from 
a dietary intervention. 
The idea of using dietary agents as an alternate therapy or as a neoadjuvant to 
delay the use of more traditional therapy such as androgen ablation is a prospect that 
would be appealing to most patients because of the severe side effects associated with 
traditional therapy [349, 350]. While it is plausible that intake of certain carotenoids and 
tocopherols may influence serum PSA levels, it is possible that these nutrients could alter 
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 PSA levels without affecting cancer progression. Interestingly, declines in PSA have 
been found to correlate with inhibition of the androgen-sensitive LNCaP prostate tumor 
cell growth in animal and human studies [357, 367, 368]. Secretion of PSA and hormone-
dependent LNCaP activity are both modulated by androgens [369, 370]. Higher blood 
levels of antioxidants such as lycopene and α-tocopherol have been found to down-
regulate serum androgen levels [371-373]. Thus, the suppression of androgens may be an 
underlying mechanism for the potential effect of carotenoids and tocopherols on PSA, 
and possibly, PCa progression. Other mechanisms involving antioxidative and anti-
inflammatory activities have also been proposed [374, 375].  
Prior studies on men with biochemically recurrent PCa have focused primarily on 
multiple interventions involving diet, exercise, and stress reduction [11, 13, 357-361]. 
There is very little published literature on associations of carotenoids and tocopherols 
intake in relation to PSA levels among men with PCa relapse (reviewed in [355, 362, 
363]). Data on carotenoids and tocopherols in relation to PSA progression among men 
with PCa relapse are lacking. The vast majority of the available data are from studies 
examining the potential benefits of supplemental or dietary lycopene. In a study 
involving 71 men with biochemical recurrence who were randomized to intervention with 
supplemental lycopene alone (15 mg) or together with soy isoflavones capsule (40 mg) 
taken twice daily for 6 months, no decline in serum PSA level was observed in either 
group [376]. In that same study, however, the rate of PSA rise decreased in 95% of 
patients in the lycopene group and 67% of those in the lycopene and soy isoflavones 
group [376]. In another study where 36 men with biochemical recurrence of PCa were 
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 given varying doses of lycopene (15, 30, 45, 60, 90 and 120 mg/day) for one year, no 
change in serum PSA was observed across all the six dose groups [377].  
In a related study, Chen et al. [374] investigated the effect of lycopene on cancer 
progression among 32 patients with incident PCa treated tomato sauce-based diet 
containing 30 mg of lycopene per day for 3 weeks before their scheduled prostatectomy. 
The results showed significant reduction in serum PSA levels as well as declines in 
markers of oxidative DNA damage measured in leukocytes and prostate tissue, when 
comparing pre- and post-intervention measurements [374]. Ansari and Gupta [378] 
evaluated the effect of lycopene and orchiectomy versus lycopene alone in 54 patients 
with metastatic PCa, and found significantly lower PSA levels in the lycopene group after 
6 months of follow-up. Others have reported that supplemental lycopene intake decreases 
PSA velocity and may prolong PSA doubling time [379]. Among studies conducted in 
disease-free men, one found an inverse association between serum α-carotene levels and 
percent free PSA level (OR = 0.49, 95% CI = 0.32–0.76), but not total PSA, and no 
inverse association was found for other carotenoids [380]. Another found no association 
between  tocopherol intake and serum PSA level or PSA velocity [381]. The variability is 
these findings may be related to the source of the nutrients (e.g., supplement versus diet 
for lycopene) or the possibility that these nutrients may have varying effect on different 
disease states.  
To our knowledge, this is the first study to examine biomarkers of carotenoids and 
tocopherols in relation to PSA levels among men with biochemical recurrence of PCa. 
The results show that after controlling for baseline PSA values, certain plasma 
carotenoids and tocopherol were associated with low mean PSA values at various 
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 timepoints. Despite these findings, it is conceivable that these nutrients may have served 
as surrogates for higher consumption of fruits and vegetables which contain other 
beneficial dietary factors. Of note, the original EASE intervention study did not find a 
beneficial effect of the diet and lifestyle intervention on PSA [13]. Challenges associated 
with conducting clinical trials of lifestyle interventions, such as lack of large enough 
contrast between the intervention and control group due to contamination or suboptimal 
compliance [382], may partially explain this finding. The current study results suggest 
that higher exposure to certain dietary antioxidants may have a beneficial effect on PSA 
rise following prostatectomy and should be confirmed in other larger studies.  
Both strengths and limitation of the study deserve mention. Given the small 
sample size and the multiple comparisons made, there is a possibility that some of the 
findings could be due to chance. Because humans consume foods containing multiple 
nutrients, there is also the possibility that the study results may be reflecting interactions 
between plasma nutrients, rather than the effect of a specific nutrient per se [383]. The 
short duration of the study and lack of carotenoid and tocopherol data at 6 months 
prohibited evaluation of temporal trends over long periods. Restricting the study to a 
subgroup of PCa patients with strictly defined disease attributes precludes 
generalizability of the findings to the larger population of men with PCa. However, since 
the study participants had already undergone radical prostatectomy and/or radical 
radiation for the treatment of organ-confined disease, continuous rise in serum PSA level 
as defined in this study most likely reflect progressive disease (which was the intent of 
the study), rather than residual normal tissue left from radiation or spared during 
prostatectomy. Other strengths of the study include the use of biomarkers of nutrient 
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 intake, which are more reliable measures of nutritional status relative to self-reported 
intake [384]. Several potential confounders including BMI, smoking, physical activity, 
tumor grade and race were controlled for in the analysis. The study findings add to the 
limited data on potentially beneficial dietary factors for men with biochemically recurrent 
PCa. 
 
4.5     CONCLUSIONS  
Higher plasma levels of α-tocopherol, β-cryptoxanthin, trans-β-carotene, cis-
lutein/zeaxanthin, and trans-lycopene were associated with lower PSA levels among men 
with biochemically defined PCa recurrence. A higher antioxidant score, used as a 
measure of total antioxidant status, also was associated with lower PSA levels at various 
timepoints. These findings suggest that increasing intake of these micronutrients, which 
are found in many fruits and vegetables, may slow the progression of PSA in men with a 
biochemical recurrence of PCa. Considering the small sample size and short duration, 
additional work in larger cohorts with longer follow-up time is warranted. 
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Table 4.1 Baseline characteristics of study subjects and changes in PSA levels  
 All subjects 
(n = 39)  
 
Intervention 
(n = 22) 
Control 
(n = 17) 
P § 
 Mean ± SD 
 
Mean ± SD Mean ± SD  
Age, years  70 ±  8 69 ±  9 71 ±  7 0.51 
 BMI, kg/m2  29.75  ±  5.21 29.49  ±  4.86 30.09  ±  5.77 0.73 
Energy, kcal/day 1683.90 ± 414.24 1741.24  ±  367.52 1609.68  ± 468.92   0.33 
Physical activity, total METs/week 44.60 ± 35.51   52.02 ± 41.29 35.43 ± 24.96  0.13 
  
n (%) 
 
n (%) 
 
n (%) 
 
Race      
       White/European American 28 (72) 17 (77) 11 (65) 0.48 
       Black/African American 11 (28) 5 (23) 6 (32)  
Education      
       High school graduate or less 8 (20) 4 (18) 4 (23) 0.70 
       High school and some college 12 (31) 8 (36) 4 (23)  
       College graduate  19 (49) 10 (45) 9 (53)  
Marital status      
       Married or with partner 31 (79) 16 (73) 15 (88) 0.43 
       Widowed, divorced, or single 8 (21) 6 (27) 2 (12)  
Employment      
       Yes, full time 7 (18) 3 (14) 4 (23) 0.68 
       Yes, part time 4 (10) 2 (9) 2 (12)  
       No 28 (72) 17 (77) 11 (65)  
Smoking status     
       Never 14 (37) 8 (36) 7 (41) 0.80 
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       Former 21 (53) 11 (50) 9 (53)  
       Current 4 (10) 3 (14) 1 (6)  
Tumor grade (Gleason score)      
       Well differentiated (<5) 1 (3) 1 (5) 0 (0) 0.95 
       Moderately differentiated (5–6) 9 (23) 5 (23) 4 (24)  
       Poorly differentiated (≥7) 20 (51) 12 (54) 8 (47)  
       Missing 9 (23) 4 (18) 5 (29)  
Type of treatment      
       Prostatectomy 6 (15) 3 (14) 3 (18) 0.99 
       Prostatectomy and radiation 18 (46) 10 (45) 8 (47)  
       Radiation only 15 (39) 9 (41) 6 (35)  
PSA levels, mean (range) ng/mL a     
       Baseline 3.91 (0.10-52.00) 3.24 (0.10-37.90) 4.78 (0.10-52.00) 0.61 
       At 3-months 5.01 (0.10-68.30) 4.37 (0.10-44.70) 5.85 (0.10-68.30) 0.70 
       At 6-months   4.72 (0.10-67.20) 4.26 (0.10-54.40) 5.27 (0.10-67.20) 0.80 
 
Abbreviations: PSA – prostate-specific antigen; SD – standard deviation; METs – metabolic equivalent task per week from physical 
activity 
 
a Data represents actual PSA values, not logarithm transformed values. 
 
§ P value comparing intervention and control groups using Student’s t-test for continuous variables and Fisher's exact test for 
categorical variables 
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Table 4.2 Means and standard deviations of plasma carotenoid and tocopherol levels at baseline and at 3 months post-intervention   
 Baseline  Post-intervention (at 3 months) 
Plasma carotenoids  
and tocopherols 
(µg/ml) 
 
All subjects 
(n = 39) 
Intervention 
(n = 22) 
Control 
(n = 17) 
P § All subjects 
(n = 35) 
Intervention 
(n = 20) 
Control 
(n = 15) 
P § 
α-tocopherol 14.91 ± 5.15 15.23 ± 5.56 14.51 ± 4.71 0.67 14.35 ± 5.17 14.64 ± 5.48 13.96 ± 
4.87 
0.71 
γ-tocopherol 1.70 ± 1.01 1.67 ± 1.01 1.73 ± 1.04 0.86 1.65 ± 0.99 1.60 ± 0.89 1.70 ± 1.13 0.78 
α-carotene 0.04 ± 0.03 0.04 ± 0.03 0.05 ± 0.03 0.60 0.05 ± 0.04 0.04 ± 0.03 0.05 ± 0.05 0.64 
cis-β-carotene 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.07 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.32 
Trans-β-carotene 0.20 ± 0.13 0.18 ± 0.12 0.24 ± 0.15 0.17 0.20 ± 0.14 0.20 ± 0.16 0.21 ± 0.12 0.83 
α-cryptoxanthin 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.77 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.86 
β-cryptoxanthin 0.11 ± 0.08 0.11 ± 0.09 0.10 ± 0.07 0.71 0.10 ± 0.07 0.10 ± 0.08 0.09 ± 0.06 0.87 
Lutein 0.11 ± 0.06 0.10 ± 0.06 0.12 ± 0.07 0.40 0.12 ± 0.07 0.12 ± 0.07 0.12 ± 0.08 0.92 
Zeaxanthin 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.02 0.30 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.47 
Cis-lutein/zeaxanthin 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.59 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.07 
Cis-lycopene 0.18 ± 0.13 0.18 ± 0.11 0.18 ± 0.15 0.94 0.17 ± 0.11 0.19 ± 0.10 0.15 ± 0.13 0.26 
Trans-lycopene 0.19 ± 0.12 0.20 ± 0.11 0.19 ± 0.14 0.81 0.19 ± 0.11 0.22 ± 0.10 0.16 ± 0.12 0.12 
 
Abbreviation: SD, standard deviation 
§ P value comparing intervention and control groups based on Student’s t-test 
 
 Table 4.3 Baseline PSA levels by baseline carotenoid and tocopherol levels  
  Crude model a Adjusted model b 
 Plasma tocopherols and 
carotenoids at baseline c  
n Mean (95% CI) d P § Mean (95% CI) d  P § 
α-tocopherol low 19 0.80 (0.39-1.62) 0.35 0.53 (0.25-1.16) 0.40 
high 20 1.34 (0.57-3.14) 0.79 (0.30-2.07) 
γ-tocopherol low 20 1.40 (0.59-3.30) 0.30 0.71 (0.29-1.71) 0.50 
high 19 0.78 (0.38-1.58) 0.52 (0.23-1.20) 
α-carotene low 19 1.10 (0.52-2.34) 0.67 0.49 (0.20-1.19) 0.45 
high 20 0.88 (0.42-1.88) 0.70 (0.30-1.63) 
Cis-β-carotene low 20 0.77 (0.35-1.67) 0.37 0.67 (0.26-1.70) 0.71 
high 19 1.27 (0.58-2.78) 0.55 (0.23-1.31) 
Trans-β-
carotene 
low 20 0.91 (0.42-1.95) 0.75 0.50 (0.21-1.18) 0.44 
high 19 1.07 (0.49-2.34) 0.72 (0.30-1.74) 
α-cryptoxanthin low 21 0.94 (0.44-2.00) 0.86 0.87 (0.35-2.19) 0.20 
high 18 1.03 (0.48-2.22) 0.46 (0.20-1.05) 
β-cryptoxanthin low 20 0.92 (0.45-1.89) 0.76 0.56 (0.23-1.35) 0.80 
high 19 1.08 (0.49-2.37) 0.66 (0.23-1.89) 
Lutein low 19 0.91 (0.40-2.06) 0.79 0.70 (0.29-1.68) 0.52 
 high 20 1.05 (0.51-2.14) 0.51 (0.22-1.22) 
Zeaxanthin low 18 0.96 (0.43-2.16) 0.93 0.53 (0.20-1.43) 0.74 
high 21 1.01 (0.49-2.05) 0.63 (0.29-1.37) 
Cis-
lutein/zeaxanthin  
low 21 0.94 (0.46-1.91) 0.82 0.61 (0.28-1.34) 0.90 
high 18 1.05 (0.47-2.38) 0.58 (0.23-1.42) 
Cis-lycopene low 21 1.39 (0.60-3.22) 0.30 0.46 (0.14-1.54) 0.48 
high 18 0.72 (0.28-1.87) 0.30 (0.11-0.85) 
Trans-lycopene low 20 1.27 (0.35-2.07) 0.50 0.42 (0.16-1.07) 0.14 
high 19 0.85 (0.54-3.03) 0.22 (0.09-0.56) 
Antioxidant 
score e 
low 19 1.16 (0.55-2.42) 0.51 0.77 (0.32-1.85) 0.31 
high 20 0.82 (0.38-1.79) 0.45 (0.19-1.12) 
 
Abbreviations: PSA – prostate-specific antigen, CI – confidence interval 
a Adjusted for age, race and randomized group. 
b Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, 
body mass index, total metabolic equivalent (MET) per week of physical activity, energy  intake, and 
randomized group. 
c Categorized by median splits as less than median (low) versus greater than or equal to median (high). 
d Data are reported as least square means. 
e Antioxidant score; low : 57 – 83, high: 84 –123. 
§ P values from regression model comparing mean difference between low and high 
tocopherol/carotenoid categories  
102 
 103 
Table 4.4 Associations of carotenoid and tocopherol levels at 3 months in relation to PSA levels    
at 3 months adjusting for baseline PSA level   
  PSA levels at 3 months a 
Plasma tocopherols and 
carotenoids at 3 months b 
 
n Crude model c Adjusted model d 
Means (95% CI) P § Means (95% CI) P § 
α-tocopherol low 18 0.98 (0.74-1.29) 0.09 0.62 (0.45-0.85) 0.10 
high 17 0.68 (0.49-0.94) 0.42 (0.27-0.65) 
 γ-tocopherol low 17 0.70 (0.50-0.98) 0.16 0.56 (0.39-0.83) 0.82 
high 18 0.97 (0.73-1.28) 0.53 (0.33-0.83) 
α-carotene low 18 1.00 (0.76-1.33) 0.07 0.65 (0.45-0.93) 0.13 
high 17 0.69 (0.50-0.93) 0.44 (0.30-0.66) 
Cis-β-carotene low 17 1.04 (0.77-1.41) 0.05 0.66 (0.45-0.96) 0.16 
high 18 0.69 (0.52-0.92) 0.49 (0.34-0.68) 
Trans-β-carotene low 18 1.03 (0.78-1.35) 0.03 0.63 (0.43-0.92) 0.25 
high 17 0.66 (0.49-0.90) 0.50 (0.35-0.70) 
α-cryptoxanthin low 18 0.97 (0.73-1.30) 0.15 0.57 (0.41-0.80) 0.65 
high 17 0.72 (0.54-0.97) 0.50 (0.30-0.83) 
β-cryptoxanthin low 18 0.99 (0.74-1.32) 0.13 0.56 (0.39-0.83) 0.82 
high 17 0.72 (0.54-0.97) 0.53 (0.36-0.78) 
Lutein low 17 1.01 (0.75-1.36) 0.09 0.61 (0.41-0.93) 0.45 
high 18 0.71 (0.54-0.95) 0.51 (0.35-0.73) 
Zeaxanthin low 17 0.92 (0.66-1.29) 0.48 0.60 (0.43-0.82) 0.17 
high 18 0.79 (0.59-1.05) 0.44 (0.29-0.68) 
Cis-lutein/zeaxanthin  low 18 1.02 (0.77-1.35) 0.05 0.75 (0.52-1.07) 0.008 
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high 17 0.67 (0.49-0.92) 0.45 (0.33-0.62) 
Cis-lycopene low 17 0.97 (0.72-1.30) 0.20 0.61 (0.43-0.88) 0.29 
high 18 0.72 (0.52-0.99) 0.49 (0.34-0.71) 
Trans-lycopene low 17 0.90 (0.66-1.22) 0.57 0.58 (0.40-0.82) 0.60 
high 18 0.78 (0.56-1.10) 0.51 (0.33-0.78) 
Antioxidant score e low 17 1.03 (0.77-1.37) 0.05 0.62 (0.44-0.87) 0.18 
high 18 0.69 (0.52-0.92) 0.47 (0.32-0.68) 
 
Abbreviation: PSA – prostate-specific antigen, CI – confidence interval 
 
a Data are reported as least square means  
b Categorized by median splits as less than median (low) versus greater than or equal to median (high). 
c Adjusted for age, race randomized group and baseline PSA level.  
d Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, 
body mass index, total metabolic equivalent (MET) per week of physical activity, energy  intake,  
randomized group and baseline PSA level. 
e Antioxidant score; low : 45 – 80, high: 81 –111. 
 
§ P values from regression model comparing mean difference between low and high 
tocopherol/carotenoid categories 
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Table 4.5 Associations of carotenoid and tocopherol levels at 3 months in relation to PSA levels 
at 6 months, adjusting for baseline PSA level   
  PSA levels at 6 months a 
Plasma tocopherols and 
carotenoids at 3 months b 
 
n Crude model c Adjusted model d 
Means (95% CI) P § Means (95% CI) P § 
α-tocopherol low 18 1.00 (0.45-2.21) 0.11 0.76 (0.28-2.01) 0.01 
high 17 0.38 (0.16-0.93) 0.13 (0.03-0.48) 
 γ-tocopherol low 17 0.75 (0.32-1.72) 0.62 0.64 (0.16-2.59) 0.45 
high 18 0.55 (0.21-1.39) 0.33 (0.10-1.08) 
α-carotene low 18 1.04 (0.45-2.40) 0.12 0.88 (0.26-2.95) 0.08 
high 17 0.42 (0.19-0.95) 0.23 (0.07-0.73) 
Cis-β-carotene low 17 0.74 (0.32-1.68) 0.65 0.51 (0.18-1.50) 0.52 
high 18 0.56 (0.23-1.39) 0.33 (0.10-1.15) 
Trans-β-carotene low 18 0.85 (0.37-1.95) 0.36 0.46 (0.12-1.70) 0.87 
high 17 0.49 (0.21-1.17) 0.41 (0.14-1.23) 
α-cryptoxanthin low 18 0.67 (0.29-1.57) 0.90 0.69 (0.15-3.22) 0.46 
high 17 0.63 (0.26-1.50) 0.36 (0.12-1.04) 
β-cryptoxanthin low 18 0.69 (0.27-1.44) 0.86 0.97 (0.33-2.86) 0.01 
high 17 0.62 (0.29-1.63) 0.17 (0.05-0.53) 
Lutein low 17 0.80 (0.33-1.91) 0.53 0.77 (0.22-2.65) 0.17 
high 18 0.55 (0.24-1.26) 0.28 (0.09-0.86) 
Zeaxanthin low 17 0.56 (0.23-1.37) 0.63 0.59 (0.15-2.30) 0.55 
high 18 0.76 (0.32-1.78) 0.38 (0.13-1.08) 
Cis-lutein/zeaxanthin  low 18 1.05 (0.46-2.35) 0.09 0.76 (0.23-2.50) 0.16 
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high 17 0.37 (0.15-0.91) 0.31 (0.11-0.86)  
Cis-lycopene low 17 0.77 (0.34-1.75) 0.54 0.73 (0.25-2.15) 0.08 
high 18 0.52 (0.20-1.36) 0.43 (0.07-0.73) 
Trans-lycopene low 17 0.77 (0.34-1.75) 0.54 0.89 (0.33-2.37) 0.004 
high 18 0.51 (0.18-1.42) 0.10 (0.03-0.37) 
Antioxidant score e low 17 0.84 (0.36-1.96) 0.38 0.86 (0.32-2.25) 0.003 
high 18 0.51 (0.22-1.17) 0.14 (0.04-0.44) 
 
Abbreviation: PSA – prostate-specific antigen, CI – confidence interval 
 
a Data are reported as least square means  
b Categorized by median splits as less than median (low) versus greater than or equal to median (high). 
c Adjusted for age, race randomized group and baseline PSA level.  
d Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, body mass 
index, total metabolic equivalent (MET) per week of physical activity, energy  intake,  randomized group and baseline 
PSA level. 
e Antioxidant score; low : 45 – 80, high: 81 –111. 
 
§ P values from regression model comparing mean difference between low and high tocopherol/carotenoid categories 
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Table 4.6 Percent change in carotenoid and tocopherol levels from baseline to 3 months in relation to PSA levels at 3 
months, adjusting for baseline PSA level  
 PSA level at 3 months a 
  Means (95% CI) 
Change in plasma tocopherols and carotenoids from 
baseline to 3 months  
n Crude model b Adjusted model c 
 P §  P § 
 α-tocopherol Decrease 13 1.13 (0.80-1.59) ref 0.84 (0.58-1.21) ref 
 Increase 21 0.73 (0.56-0.95) 0.04 0.47 (0.36-0.62) 0.0007 
      
Decrease 13 1.13 (0.53-1.03) ref 0.88 (0.61-1.26) ref 
Minimal increase (1-20%) 14 0.74 (0.53-1.03) 0.08 0.54 (0.37-0.77) 0.008 
Substantial increase (> 20%) 7 0.71 (0.45-1.12) 0.10 0.40 (0.26-0.61) 0.004 
      
γ-tocopherol Decrease 17 0.96 (0.69-1.32) ref 0.56 (0.39-0.80) ref 
Increase 17 0.77 (0.56-1.05) 0.34 0.52 (0.36-0.76) 0.73 
      
Decrease 17 0.95 (0.69-1.31) ref 0.56 (0.39-0.80) ref 
Minimal increase (1-20%) 8 0.70 (0.45-1.08) 0.25 0.50 (0.32-0.77) 0.64 
Substantial increase (> 20%) 9 0.84 (0.56-1.28) 0.66 0.55 (0.33-0.89) 0.93 
      
α-carotene Decrease 29 0.85 (0.67-1.09) ref 0.52 (0.38-0.71) ref 
Increase 5 0.88 (0.47-1.64) 0.92 0.67 (0.33-1.36) 0.50 
      
Decrease 29 0.85 (0.67-1.09) ref 0.53 (0.38-0.73) ref 
Minimal increase (1-20%) 3 0.91 (0.30-2.26) 0.39 0.79 (0.32-1.90) 0.38 
Substantial increase (> 20%) 2 0.83 (0.44-1.90) 0.53 0.54 (0.19-1.51) 0.98 
      
Cis-β-carotene Decrease 19 0.97 (0.75-1.03) ref 0.92 (0.48-0.99) ref 
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Increase 15 0.76 (0.50-0.96) 0.29 0.79(0.33-0.87) 0.52 
      
Decrease 19 0.97 (0.75-1.03) ref 0.90 (0.51-0.93) ref 
Minimal increase (1-20%) 7 0.67 (0.41-1.09) 0.16 0.68 (0.15-0.86) 0.65 
Substantial increase (> 20%) 8 0.81 (0.46-1.07) 0.28 0.87(0.53-0.98) 0.94 
      
Trans-β-carotene Decrease 19 1.08 (0.82-1.42) ref 0.72 (0.51-1.04) ref 
Increase 15 0.63 (0.47-0.86) 0.009 0.44 (0.32-0.60) 0.01 
      
Decrease 19 1.08 (0.82-1.42) ref 0.71 (0.51-0.99) ref 
Minimal increase (1-20%) 9 0.63 (0.43-0.92) 0.02 0.34 (0.23-0.49) 0.0005 
Substantial increase (> 20%) 6 0.65 (0.40-1.08) 0.08 0.67 (0.42-1.06) 0.85 
      
α-cryptoxanthin Decrease 10 1.00 (0.68-1.48) ref 0.73 (0.44-1.20) ref 
Increase 24 0.79 (0.60-1.04) 0.33 0.51 (0.38-0.69) 0.16 
      
Decrease 10 1.01 (0.68-1.48) ref 0.73 (0.45-1.18) ref 
Minimal increase (1-20%) 5 0.64 (0.37-1.10) 0.18 0.37 (0.23-0.61) 0.03 
Substantial increase (> 20%) 19 0.84 (0.62-1.15) 0.49 0.60 (0.42-0.85) 0.45 
      
β-cryptoxanthin Decrease 18 0.85 (0.63-1.16) ref 0.62 (0.43-0.89) ref 
Increase 16 0.86 (0.61-1.20) 0.97 0.47 (0.32-0.67) 0.18 
      
Decrease 18 0.84 (0.62-1.14) ref 0.62 (0.43-0.89) ref 
Minimal increase (1-20%) 7 1.00 (0.61-1.64) 0.57 0.45 (0.26-0.79) 0.29 
Substantial increase (> 20%) 9 0.77 (0.50-1.18) 0.71 0.47 (0.31-0.72) 0.25 
      
Lutein Decrease 15 0.81 (0.59-1.12) ref 0.47 (0.32-0.69) ref 
Increase 19 0.90 (0.66-1.24) 0.65 0.59 (0.42-0.83) 0.29 
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Decrease 15 0.82 (0.60-1.12) ref 0.47 (0.32-0.69) ref 
Minimal increase (1-20%) 6 0.65 (0.47-2.31) 0.22 0.64 (0.35-1.18) 0.37 
Substantial increase (> 20%) 13 0.77 (0.54-1.10) 0.80 0.58 (0.40-0.83) 0.33 
      
Zeaxanthin Decrease 22 0.82 (0.62-1.08) ref 0.48 (0.35-0.67) ref 
Increase 12 0.94 (0.64-1.37) 0.55 0.53 (0.46-0.99) 0.10 
      
Decrease 22 0.80 (0.61-1.05) ref 0.47 (0.35-0.63) ref 
Minimal increase (1-20%) 7 1.16 (0.71-1.87) 0.20 0.54 (0.40-1.00) 0.21 
Substantial increase (> 20%) 5 0.71 (0.41-1.23) 0.68 0.48 (0.29-0.77) 0.97 
      
Cis-
lutein/zeaxanthin  
Decrease 11 0.81 (0.54-1.22) ref 0.63 (0.39-1.00)  
Increase 23 0.88 (0.66-1.16) 0.76 0.51 (0.38-0.71) 0.42 
      
Decrease 11 0.81 (0.54-1.22) ref 0.63 (0.39-1.01) ref 
Minimal increase (1-20%) 8 0.83 (0.53-1.29) 0.94 0.51 (0.33-0.79) 0.48 
Substantial increase (> 20%) 15 0.90 (0.64-1.28) 0.68 0.52 (0.36-0.74) 0.45 
      
Cis-lycopene Decrease 14 0.77 (0.53-1.11) ref 0.55 (0.37-0.81) ref 
Increase 19 0.93 (0.70-1.25) 0.40 0.54 (0.37-0.79) 0.97 
      
Decrease 14 0.76 (0.54-1.07) ref 0.77 (0.44-1.36) ref 
Minimal increase (1-20%) 8 0.73 (0.61-1.11) 0.87 0.59 (0.40-0.87) 0.40 
Substantial increase (> 20%) 11 0.70 (0.49-1.00) 0.75 0.48 (0.33-0.71) 0.34 
      
Trans-lycopene Decrease 14 0.79 (0.55-1.11) ref 0.55 (0.37-0.83) ref 
Increase 20 0.91 (0.68-1.21) 0.52 0.53 (0.38-0.75) 0.89 
      
Decrease 14 0.80 (0.57-1.12) ref 0.56 (0.37-0.83) ref 
Minimal increase (1-20%) 7 1.23 (0.76-1.99) 0.14 0.64 (0.39-1.06) 0.61 
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Substantial increase (> 20%) 13 0.79 (0.56-1.10) 0.95 0.50 (0.34-0.72) 0.63 
      
Antioxidant score d Decrease 14 0.87 (0.55-0.35) ref 0.64 (0.40-1.02) ref 
Increase 19 0.85 (0.66-1.11) 0.96 0.51 (0.37-0.70) 0.37 
      
Decrease 14 0.85 (0.55-1.31) ref 0.65 (0.42-1.01) ref 
Minimal increase (1-20%) 8 1.07 (0.73-1.59) 0.43 0.73 (0.47-1.14) 0.69 
Substantial increase (> 20%) 11 0.71 (0.50-1.00) 0.53 0.43 (0.30-0.60) 0.10 
 
Abbreviation: PSA – prostate-specific antigen, CI – confidence interval 
a Data are reported as least square means and confidence intervals 
b Adjusted for age, race, randomized group and baseline PSA level 
c Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, body mass index, total 
metabolic equivalent (MET) per week of physical activity, energy  intake, randomized group and baseline PSA level 
e Antioxidant score; low : 45 – 80, high: 81 –111. 
 
§ P values from regression models comparing mean difference between decrease in tocopherol/carotenoid categories with an 
increase, minimal increase or substantial increase respectively 
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Table 4.7 Percent change in carotenoid and tocopherol levels from baseline to 3 months in relation to PSA levels at 6 months, 
adjusting for baseline PSA level  
  PSA level at 6 months a  
  Means (95% CI) 
Change in plasma tocopherols and carotenoids from 
baseline to 3 months  
 
n Crude model b Adjusted model c 
 P §  P § 
 α-tocopherol Decrease 13 0.82 (0.63-1.06) ref 0.89 (0.72-1.10) ref 
 Increase 21 0.63 (0.52-0.77) 0.11 0.51 (0.44-0.60) <0.0001 
      
Decrease 13 0.81 (0.63-1.05) ref 0.92 (0.74-1.13) ref 
Minimal increase (1-20%) 14 0.66 (0.52-0.84) 0.25 0.55 (0.45-0.67) <0.0001 
Substantial increase (> 20%) 7 0.57 (0.40-0.80) 0.09 0.45 (0.35-0.58) <0.0001 
      
γ-tocopherol Decrease 17 0.70 (0.55-0.90) ref 0.62 (0.48-0.79) ref 
Increase 17 0.68 (0.55-0.85) 0.87 0.54 (0.42-0.71) 0.38 
      
Decrease 17 0.70 (0.55-0.89) ref 0.62 (0.48-0.79) ref 
Minimal increase (1-20%) 8 0.61 (0.45-0.84) 0.20 0.50 (0.37-0.68) 0.20 
Substantial increase (> 20%) 9 0.75 (0.56-1.00) 0.19 0.60 (0.44-0.84) 0.91 
      
α-carotene Decrease 29 0.71 (0.60-0.84) ref 0.59 (0.47-0.73) ref 
Increase 5 0.52 (0.32-0.85) 0.23 0.55 (0.33-0.94) 0.82 
      
Decrease 29 0.72 (0.61-0.85) ref 0.62 (0.50-0.76) ref 
Minimal increase (1-20%) 3 0.67 (0.37-1.24) 0.32 0.82 (0.44-1.54) 0.35 
Substantial increase (> 20%) 2 0.37 (0.19-0.74) 0.36 0.34 (0.17-0.67) 0.11 
      
Cis-β-carotene Decrease 19 0.84 (0.69-1.02) ref 0.74 (0.61-0.88) ref 
Increase 15 0.73 (0.44-0.87) 0.39 0.68 (0.34-0.82) 0.84 
      
Decrease 19 0.84 (0.70-1.02) ref 0.75 (0.63-0.90) ref 
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Minimal increase (1-20%) 7 0.79 (0.42-0.89) 0.56 0.71 (0.36-0.89) 0.28 
Substantial increase (> 20%) 8 0.66 (0.39-0.78) 0.15 0.63 (0.29-0.86) 0.63  
      
Trans-β-carotene Decrease 19 0.88 (0.74-1.04) ref 0.84 (0.69-1.03) ref 
Increase 15 0.49 (0.41-0.60) <0.0001 0.45 (0.38-0.54) <0.0001  
      
Decrease 19 0.89 (0.75-1.04) ref 0.84 (0.69-1.03) ref 
Minimal increase (1-20%) 9 0.55 (0.43-0.72) 0.002 0.46 (0.37-0.58) <0.0001 
Substantial increase (> 20%) 6 0.43 (0.32-0.58) <0.0001  0.44 (0.34-0.57) <0.0001  
      
α-cryptoxanthin Decrease 10 0.76 (0.56-1.02) ref 0.90 (0.64-1.27) ref 
Increase 24 0.67 (0.55-0.81) 0.48 0.77 (0.46-0.67) 0.39 
      
Decrease 10 0.76 (0.56-1.02) ref 0.90 (0.65-1.26) ref 
Minimal increase (1-20%) 5 0.66 (0.45-0.96) 0.56 0.69 (0.48-0.92) 0.43 
Substantial increase (> 20%) 19 0.67 (0.53-0.84) 0.51 0.64 (0.41-0.64) 0.18 
      
β-cryptoxanthin Decrease 18 0.62 (0.50-0.79) ref 0.66 (0.52-0.84) ref 
Increase 16 0.77 (0.61-0.97) 0.21 0.49 (0.37-0.65) 0.07 
      
Decrease 18 0.61 (0.49-0.76) ref 0.67 (0.53-0.83) ref 
Minimal increase (1-20%) 7 1.01 (0.74-1.38) 0.21 0.70 (0.47-1.04) 0.82 
Substantial increase (> 20%) 9 0.63 (0.48-0.82) 0.89 0.44 (0.33-0.58) 0.009 
      
Lutein Decrease 15 0.76 (0.60-0.96) ref 0.60 (0.46-0.80) ref 
Increase 19 0.63 (0.51-0.79) 0.27 0.68 (0.45-0.73) 0.74 
      
Decrease 15 0.76 (0.61-0.96) ref 0.61 (0.45-0.81) ref 
Minimal increase (1-20%) 6 0.78 (0.48-1.25) 0.95 0.75 (0.35-0.98) 0.75 
Substantial increase (> 20%) 13 0.60 (0.47-0.77) 0.16 0.63 (0.44-0.86) 0.77 
      
Zeaxanthin Decrease 22 0.61 (0.50-0.74) ref 0.57 (0.45-0.70) ref 
Increase 12 0.65 (0.49-1.09) 0.33 0.63 (0.48-0.89) 0.29 
      
Decrease 22 0.61 (0.50-0.74) ref 0.55 (0.44-0.68) ref 
 
 
 113 
Minimal increase (1-20%) 7 0.66 (0.58-1.29) 0.25 0.77 (0.54-1.16) 0.65 
Substantial increase (> 20%) 5 0.64 (0.53-1.09) 0.29 0.54 (0.37-0.80) 0.86 
      
Cis-
lutein/zeaxanthin  
Decrease 11 0.84 (0.63-1.11) ref 0.80 (0.60-1.07)  
Increase 23 0.63 (0.52-0.77) 0.11 0.52 (0.42-0.64) 0.003 
      
Decrease 11 0.84 (0.64-1.11) ref 0.78 (0.60-1.02) ref 
Minimal increase (1-20%) 8 0.72 (0.52-0.98) 0.46 0.64 (0.49-0.83) 0.26 
Substantial increase (> 20%) 15 0.59 (0.47-0.75) 0.06 0.47 (0.38-0.57) 0.0004 
      
Cis-lycopene Decrease 14 0.77 (0.59-1.00) ref 0.73 (0.57-0.94) ref 
Increase 19 0.68 (0.55-0.85) 0.49 0.67 (0.39-0.86) 0.19 
      
Decrease 14 0.76 (0.59-0.99) ref 0.78 (0.65-0.98) ref 
Minimal increase (1-20%) 8 0.83 (0.60-1.14) 0.68 0.72 (0.56-1.01) 0.69 
Substantial increase (> 20%) 11 0.59 (0.45-0.78) 0.17 0.64 (0.34-0.82) 0.28 
      
Trans-lycopene Decrease 14 0.73 (0.57-0.93) ref 0.69 (0.53-0.91) ref 
Increase 20 0.67 (0.54-0.83) 0.59 0.53 (0.42-0.66) 0.07 
      
Decrease 14 0.73 (0.57-0.93) ref 0.69 (0.55-0.87) ref 
Minimal increase (1-20%) 7 0.76 (0.53-1.10) 0.85 0.73 (0.55-0.97) 0.72 
Substantial increase (> 20%) 13 0.63 (0.49-0.81) 0.39 0.45 (0.36-0.56) 0.002 
      
Antioxidant score d Decrease 14 0.81 (0.59-1.10) ref 0.93 (0.72-1.21) ref 
Increase 19 0.65 (0.54-0.79) 0.26 0.50 (0.42-0.60) <0.0001 
      
Decrease 14 0.81 (0.59-1.10) ref 0.92 (0.72-1.16) ref 
Minimal increase (1-20%) 8 0.64 (0.47-0.87) 0.31 0.62 (0.50-0.78) 0.01 
Substantial increase (> 20%) 11 0.66 (0.52-0.84) 0.30 0.44 (0.37-0.53) <0.0001 
 
Abbreviation: PSA – prostate-specific antigen, CI – confidence interval 
a Data are reported as least square means and confidence intervals 
b Adjusted for age, race, randomized group and baseline PSA level 
c Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, body mass index, total 
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metabolic equivalent (MET) per week of physical activity, energy  intake, randomized group and baseline PSA level 
d Antioxidant score; low : 45 – 80, high: 81 –111. 
 
§ P values from regression models comparing mean difference between decrease in tocopherol/carotenoid categories with an 
increase, minimal increase or substantial increase respectively 
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Table 4.8 Percent change in carotenoid and tocopherol levels from baseline to 3 months in relation to post-
intervention PSA levels ( at 3 months and at 6 months), adjusting for baseline PSA level  –– Mixed models  
 Means (95% CI) a 
Change in plasma tocopherols and carotenoids from 
baseline to 3 months  
 
n Crude model b Adjusted model c 
 P §  P § 
 α-tocopherol Decrease 13 0.91 (0.73-1.13) ref 0.84 (0.59-1.19) ref 
 Increase 21 0.72 (0.65-0.80) 0.08 0.47 (0.36-0.63) 0.003 
      
Decrease 13 0.91 (0.73-1.13) ref 0.85 (0.60-1.21) ref  
Minimal increase (1-20%) 14 0.74 (0.65-0.84) 0.13 0.52 (0.40-0.69) 0.004 
Substantial increase (> 20%) 7 0.67 (0.61-0.73) 0.02 0.39 (0.23-0.64) 0.01 
      
γ-tocopherol Decrease 17 0.83 (0.69-1.01) ref 0.56 (0.38-0.82) ref 
Increase 17 0.74 (0.66-0.84) 0.35 0.52 (0.35-0.76) 0.69 
      
Decrease 17 0.83 (0.68-1.01) ref 0.56 (0.38-0.81) ref 
Minimal increase (1-20%) 8 0.72 (0.59-0.87) 0.29 0.50 (0.35-0.72) 0.60 
Substantial increase (> 20%) 9 0.77 (0.69-0.86) 0.57 0.54 (0.32-0.90) 0.88 
      
α-carotene Decrease 29 0.85 (0.70-1.03) ref 0.62 (0.44-0.89) ref 
Increase 5 0.72 (0.65-0.80) 0.16 0.45 (0.30-0.69) 0.10 
      
Decrease 29 0.84 (0.70-1.01) ref 0.56 (0.37-0.84) ref 
Minimal increase (1-20%) 3 0.77 (0.69-0.86) 0.46 0.58 (0.39-0.87) 0.88 
Substantial increase (> 20%) 2 0.64 (0.57-0.73) 0.04 0.32 (0.18-0.60) 0.01 
      
Cis-β-carotene Decrease 19 0.87 (0.75-1.00) ref 0.67 (0.47-0.96) ref 
Increase 15 0.68 (0.61-0.76) 0.28 0.65 (0.28-0.68) 0.71 
      
Decrease 19 0.87 (0.75-1.00) ref 0.67 (0.46-0.97) ref 
Minimal increase (1-20%) 7 0.74 (0.66-0.84) 0.22 0.66 (0.24-0.88) 0.27 
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Substantial increase (> 20%) 8 0.66 (0.58-0.75) 0.18 0.65 (0.34-0.76) 0.35 
      
Trans-β-carotene Decrease 19 0.90 (0.78-1.04) ref 0.72 (0.50-1.05) ref 
Increase 15 0.65 (0.59-0.72) 0.002 0.44 (0.32-0.61) 0.01 
      
Decrease 19 0.90 (0.77-1.03) ref 0.69 (0.50-0.95) ref 
Minimal increase (1-20%) 9 0.69 (0.60-0.79) 0.03 0.61 (0.41-0.91) 0.56 
Substantial increase (> 20%) 6 0.57 (0.47-0.69) <0.0001 0.22 (0.09-0.53) 0.02 
      
α-cryptoxanthin Decrease 10 0.75 (0.68-0.83) ref 0.50 (0.34-0.73) ref 
Increase 24 0.84 (0.70-1.03) 0.26 0.60 (0.42-0.86) 0.36 
      
Decrease 10 0.75 (0.68-0.83) ref 0.54 (0.35-0.82) ref 
Minimal increase (1-20%) 5 0.91 (0.68-1.22) 0.22 0.72 (0.40-1.31) 0.25 
Substantial increase (> 20%) 19 0.74 (0.64-0.86) 0.19 0.48 (0.32-0.72) 0.71 
      
β-cryptoxanthin Decrease 18 0.78 (0.66-0.92) ref 0.62 (0.40-0.96) ref 
Increase 16 0.79 (0.72-0.87) 0.91 0.47 (0.31-0.70) 0.24 
      
Decrease 18 0.78 (0.66-0.92) ref 0.63 (0.41-0.97) ref 
Minimal increase (1-20%) 7 0.85 (0.73-0.99) 0.44 0.51 (0.29-0.89) 0.44 
Substantial increase (> 20%) 9 0.74 (0.65-0.83) 0.65 0.44 (0.29-0.66) 0.21 
      
Lutein Decrease 15 0.78 (0.70-0.86) ref 0.47 (0.32-0.68) ref 
Increase 19 0.79 (0.67-0.93) 0.83 0.59 (0.43-0.81) 0.16 
      
Decrease 15 0.77 (0.70-0.85) ref 0.46 (0.29-0.73) ref 
Minimal increase (1-20%) 6 0.91 (0.64-1.28) 0.38 0.62 (0.41-0.93) 0.35 
Substantial increase (> 20%) 13 0.71 (0.60-0.84) 0.32 0.55 (0.32-0.94) 0.27 
      
Zeaxanthin Decrease 22 0.84 (0.75-0.98) ref 0.67 (0.46-0.97) ref 
Increase 12 0.76 (0.64-0.94) 0.28 0.58 (0.42-0.88) 0.25 
      
Decrease 22 0.75 (0.66-0.86) ref 0.64 (0.42-0.93) ref 
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Minimal increase (1-20%) 7 89 (0.77-1.04) 0.09 0.60 (0.33-0.78) 0.25 
Substantial increase (> 20%) 5 0.74 (0.65-0.84) 0.84 0.58 (0.43-0.99) 0.30 
      
Cis-lutein/zeaxanthin  Decrease 11 0.79 (0.68-0.92) ref 0.63 (0.42-0.94) ref 
Increase 23 0.78 (0.68-0.90) 0.89 0.52 (0.36-0.75) 0.32 
      
Decrease 11 0.79 (0.68-0.92) ref 0.63 (0.42-0.97) ref 
Minimal increase (1-20%) 8 0.84 (0.68-1.03) 0.66 0.52 (0.36-0.74) 0.52 
Substantial increase (> 20%) 15 0.76 (0.65-0.90) 0.77 0.49 (0.25-0.94) 0.32 
      
Cis-lycopene Decrease 14 0.80 (0.68-0.94) ref 0.54 (0.35-0.83) ref 
Increase 19 0.76 (0.67-0.85) 0.56 0.54 (0.38-0.76) 0.94 
      
Decrease 14 0.80 (0.67-0.94) ref 0.58 (0.39-0.87) ref 
Minimal increase (1-20%) 8 0.75 (0.67-0.84) 0.30 0.74 (0.46-1.22) 0.39 
Substantial increase (> 20%) 11 0.70 (0.62-0.79) 0.15 0.47 (0.36-0.63) 0.24 
      
Trans-lycopene Decrease 14 0.78 (0.69-0.93) ref 0.55 (0.35-0.86) ref 
Increase 20 0.76 (0.68-0.85) 0.58 0.53 (0.38-0.75) 0.87 
      
Decrease 14 0.78 (0.69-0.93) ref 0.59 (0.39-0.87) ref 
Minimal increase (1-20%) 7 0.76 (0.68-1.85) 0.26 0.66 (0.54-1.81) 0.39 
Substantial increase (> 20%) 13 0.72 (0.55-1.09) 0.91 0.46 (0.33-0.66) 0.30 
      
Antioxidant score d Decrease 14 0.85 (0.74-0.97) ref 0.64 (0.46-0.91) ref 
Increase 19 0.65 (0.55-0.75) 0.01 0.41 (0.30-0.58) 0.004 
      
Decrease 14 0.85 (0.74-0.97) ref 0.67 (0.50-0.89) ref 
Minimal increase (1-20%) 8 0.62 (0.57-0.76) 0.06 0.62 (0.45-0.85) 0.29 
Substantial increase (> 20%) 11 0.58 (0.66-0.80) 0.02 0.31 (0.21-0.47) <0.0001 
 
Abbreviation: PSA – prostate-specific antigen, CI – confidence interval 
a Data are reported as least square means and confidence intervals 
b Adjusted for age, race, randomized group and baseline PSA level 
c Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, body mass index, total 
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metabolic equivalent task (MET) per week of physical activity, energy  intake, randomized group and baseline PSA level 
d Antioxidant score; low : 45 – 80, high: 81 –111. 
 
§ P value comparing mean difference between decrease in tocopherol/carotenoid categories with an increase, minimal increase 
or Substantial increase respectively  
 
 
 CHAPTER 5 
DIETARY, SUPPLEMENT, AND ADIPOSE TISSUE TOCOPHEROL LEVELS IN RELATION TO 
PROSTATE CANCER AGGRESSIVENESS 
 
5.1     INTRODUCTION 
Prostate cancer (PCa) is the leading invasive malignancy and the second most 
fatal cancer in American men [385]. International variations in PCa incidence as well as 
changes in the disease risk patterns among migrant populations in Western countries 
indicate the importance of environmental factors in PCa, particularly the role of dietary 
factors [354, 386, 387]. Vitamin E, a fat-soluble antioxidant found in vegetable oils, 
seeds, nuts, leafy green vegetables and whole grains, contributes to the body’s defenses 
against reactive oxygen species (ROS), which may play a role in PCa by causing 
oxidative DNA damage [117, 158, 388-390]. 
It has long been recognized that vitamin E, the collective name for eight naturally 
occurring compounds consisting of four tocopherols (i.e., α-, β-, γ- and δ-tocopherol) and 
corresponding four tocotrienols, has potent antioxidant properties that may inhibit 
carcinogenesis [158, 388, 391]. Studies examining associations between vitamin E and 
PCa have focused primarily on PCa incidence, but these yielded conflicting findings, 
including results from randomized controlled trials (reviewed in [64, 392-394]). 
Recently, there has been increasing awareness of the remarkable heterogeneity of PCa. 
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 Owing to the widespread use of prostate-specific antigen (PSA) blood test for 
early detection, most newly diagnosed PCa cases are latent disease and often remain 
indolent over a lifetime, similar to those observed at autopsy [395, 396]. Few of these 
tumors progress aggressively (approximately 30%) and are associated with poorer 
prognosis [5, 6]. There is the possibility that vitamin E may have differential effect on 
aggressive PCa versus indolent disease, and thus, prior conflicting findings on PCa 
incidence may be due to mixing of different disease states [397].  
Distinguishing the modifiable factors of virulent PCa from that of indolent disease 
is particularly important for addressing racial disparities in PCa as African Americans 
(AAs) have greater burden of virulent PCa compared to European Americans (EAs) 
[398]. Therefore, this study investigated whether higher intakes of tocopherols from diet 
and supplements (α-tocopherol equivalent), and higher adipose tissue tocopherol levels 
are inversely associated with PCa aggressiveness among AA and European American 
(EA) men. 
5.2     MATERIALS AND METHODS 
Study Population 
The North Carolina-Louisiana Prostate Cancer Project (PCaP) is a population-
based, cross-sectional, case-only, incident PCa study, designed to investigate racial and 
geographical differences in PCa aggressiveness. The methods and design of PCaP have 
been described [399]. Briefly, using a rapid case ascertainment system, men with a first 
diagnosis of histologically confirmed adenocarcinoma of the prostate were recruited in 
North Carolina (NC) and Louisiana (LA) between July 1, 2004 and August 31, 2009. 
Residents of North Carolina and Louisiana were eligible if they resided within the study 
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 catchment areas, and were (1) between 40-79 years old at diagnosis; (2) self-identified 
race as AA/Black or Caucasian/White (EA); (3) able to complete study interview in 
English; (4) did not live in an institution (e.g., nursing home); and (5) were mentally and 
physically able to complete the interview. Written informed consents were obtained from 
all research subjects prior to participation. Approximately equal numbers of AAs and 
EAs were enrolled from NC (AAs n = 505; EAs n = 527) and LA (AAs n = 632; EA n = 
603), with participation rates of 62% for NC, 72% for pre- and 63% for post-Hurricane 
Katrina Louisiana. The PCaP study protocols were approved by Institutional Review 
Boards (IRB) of the University of North Carolina at Chapel Hill, Louisiana State 
University Health Sciences Center, and the Department of Defense Prostate Cancer 
Research Program. The current analyses also were approved by the University of South 
Carolina IRB as exempt. 
Data Collection 
Consenting research subjects completed structured in-home interviews with 
trained research nurses who administered study questionnaires covering various 
information including demographics, pre-diagnostic PCa screening history, 
comorbidities, family health history, healthcare access, and behavioral factors such as 
physical activity and smoking status. The research nurses obtained anthropometric 
measurements (height and weight) using standard protocols. Medical records were 
obtained from diagnosing physicians and abstracted by trained personnel for information 
including cancer stage at diagnosis, Gleason sum and prostate-specific antigen (PSA) 
level at diagnosis. To ensure abstractor consistency, a random sample of the abstracted 
medical records (approximately 10%) were abstracted a second time by another staff 
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 member. In PCaP, PCa aggressiveness is defined by a combination of Gleason sum, 
cancer stage and PSA level at diagnosis as (1) high aggressive (Gleason sum ≥8 or PSA 
>20 ng/mL, or Gleason sum ≥ 7 and cancer stage T3–T4); (2) low aggressive (Gleason 
sum < 7 and stage T1-T2 and PSA<10 ng/ml), and (3) intermediate aggressive PCa (all 
others). For the present analyses, a case-control study design was used to contrast 
research subjects with high aggressive PCa (“cases”) to those with low/intermediate 
aggressive PCa (comparison group or “controls”).  
Dietary Assessment 
The food frequency questionnaire was based on the National Cancer Institute Diet 
History Questionnaire (NCI-DHQ) modified to include Southern foods was used to 
assess food intake in the year prior to PCa diagnosis and included questions pertaining to 
frequency of intake, portion sizes and methods of food preparation for over 124 food 
items [400]. Responses to the questions were linked to an updated NCI nutrient database 
through which food compositions of α-, β-, γ-, and δ-tocopherol were estimated using the 
NCI Diet*Calc software [401].  
 
Assessment of Dietary Supplement Use 
Information on dietary supplement use was solicited via a validated questionnaire 
[323] administered by the research nurses during in-home visits. Data on supplemental 
vitamin E intake were derived from response to questions about the use of multivitamins 
containing vitamin E and use of single-nutrient vitamin E supplements. For 
multivitamins, research subjects were asked whether they had taken multivitamin 
supplements in the 12 months prior to PCa diagnosis (no, less than once a week, yes); and 
if yes, the frequency of use (1-2, 3-4, 5-6, 7 days/week). Forty-five percent of the 
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 research subjects reported multivitamin supplement use in the previous 12 months, and 
were asked to identify the most often used brand from a list of common multivitamin 
brands in the U.S., which included an open-ended option for unlisted brands. 
Subsequently, these research subjects were asked to provide the multivitamin supplement 
bottle for recording of nutrient contents and dose. Research subjects who were unable to 
provide the multivitamin bottle (about 5% of users) were assigned the vitamin E dose 
listed on manufacturer label of the stated brand. When the manufacturer label could not 
be found (less than 1%), research subjects were assigned the vitamin E dose of the most 
commonly used brand among  multivitamin supplement users; this value was 50 IU (i.e., 
from Centrum Silver). In subsequent questions, research subjects were asked about the 
use of single nutrient supplements; and if yes (13% of subjects), the frequency of use 
(same categories as above). Research subjects who were unable to provide the 
supplement bottle were asked to indicate the usual dose taken; dose choices for single-
nutrient vitamin E supplements were 30, 100, 200, 400, 600 or 800 IU/day, and an open-
ended option for unlisted dose. Research subjects who reported using single-nutrient 
vitamin E supplement but could not provide the supplement bottle or unable to report 
usual dose (4% of users) were assigned the mode dose (i.e., 400 IU) among single-
nutrient vitamin E supplement users. Total vitamin E supplement intake was estimated as 
the sum of vitamin E from single-nutrient supplement and multivitamins, and converted 
as 1 IU = 0.45 mg of α-tocopherol [402]. Total α-tocopherol exposure was subsequently 
calculated as the sum of dietary α-tocopherol intake and total vitamin E supplement 
intake (i.e., diet + supplement). 
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 Adipose Tissue Sampling and Analysis 
Adipose tissue samples were obtained from the abdominal region of consenting 
research subjects who were not allergic to the local anesthesia solution (2% lidocaine). 
After the overlying skin was anesthetized, a 15-gauge needle was inserted into the 
subcutaneous fat and suction was applied using 15 ml vacutainer tube. The aspirated 
tissue was trapped in the needle and luer lock adapter, which was placed in separate 
cryovials for transportation. The collected samples were transported on ice to the 
assigned storage facility within 24 hours of collection and stored at -80oC. The samples 
were later transported on ice to Craft Technologies, Incorporated in Wilson, NC for high-
performance liquid chromatography (HPLC) analysis. The average time between sample 
collection and storage was 24 hours, and average time from storage to analysis was 6 
months. Adipose tissue concentrations of α-, γ- and δ-tocopherol were expressed as mcg 
per gram of tissue at tocopherols detection limit of 0.07 mcg/g.  
Statistical Methods 
The analytic population was drawn from 2,173 PCaP research subjects with data 
on PCa aggressiveness. Prior to data analysis, research subjects with implausibly low or 
high daily caloric intake (< 500 or > 6,000 kcals, n = 71) were excluded, leaving a final 
study sample of 2,102 (AAs n = 1,023, EAs n = 1,079). Of these research subjects, data 
on adipose tissue tocopherol levels were available for 945 subjects (AA n = 361, EAs n = 
584). 
Descriptive statistics were compared by level of PCa aggressiveness as means 
(continuous variables) and proportions (categorical variables) using t and χ2 tests, 
respectively. All tocopherol exposure variables were categorized into quartiles, separately 
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 for AAs and EAs, based on distribution among low/intermediate aggressive cases in the 
respective race group. Hence, analyses were conducted separately for AAs and EAs. The 
decision to categorize the exposures separately by race was informed by preliminary 
analysis indicating different dietary and supplement use patterns between AAs and EAs. 
Unconditional logistic regression was used to estimate crude (age-adjusted) and 
multivariable-adjusted odds ratios (ORs) and 95% confidence interval (CIs). 
In selecting the multivariable-adjusted models, the following variables were 
considered as potential confounders based on review of the literature: pre-diagnostic PSA 
screening history (0, 1-7, >7 screenings); family history of PCa (number of affected first 
degree relative: none vs. at least one); prevalence of comorbidities (Charlson 
Comorbidity Index: 0, 1, 2, ≥3); whether PCa treatment had started at time of interview 
(yes, no); smoking status (never, former, current); education (less than high school 
education, high school graduate/vocational school, some college/college graduate, 
graduate degree); annual household income (< $20,000, $20,001 - $40,000, $40,001 - 
$60,000, $60,001 - $80,000, >$80,000, unknown); multivitamin use in the year prior to 
diagnosis (yes, no); non-steroidal anti-inflammatory drug (NSAID) use in the five years 
prior to diagnosis (yes, no); physical activity in the year prior to diagnosis [total 
metabolic equivalents (METs) of light, moderate and vigorous exercise categorized as: ≤ 
10.2, 10.3-29.0, > 29.0 METs/week]; body mass index (BMI: kg/m2, continuous); study 
site (NC, LA);  energy intake (kcal/day); dairy intake (servings/day); and alcohol intake 
(grams/day). These variables were first examined for confounding effect (i.e., ≥10% 
change in effect estimates of each exposure variable with age in the model). Next, 
variables determined to be confounders and those that are biologically relevant to PCa 
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 were placed in an elaborate model simultaneously for final model selection using a 
combination of the backward elimination method and likelihood ratio tests to remove one 
variable at a time. Through this process, the following variables were included in the final 
adjusted model for analysis of dietary tocopherols and vitamin E supplement use 
associations: age (continuous), pre-diagnostic PSA screening history, BMI, smoking 
status, education, income, NSAIDs use, dietary fat intake, and study site. Additional 
adjustment of family history of PCa, comorbidities and PCa treatment status were done 
for associations of adipose tocopherol levels and PCa aggressiveness. Tests for linear 
trend (Ptrend) were performed by modeling the median values of each tocopherol category 
as continuous variable. Family history of PCa, pre-diagnostic PSA screening history, 
BMI and NSAIDs use were examined for potential effect modification by assessing 
stratum-specific ORs in stratified multivariable analyses, and including evaluation of 
interaction terms between these factors and the main exposures using likelihood ratio 
tests. All analyses were performed with SAS version 9.3 (Cary, NC, USA) with statistical 
significance set at α = 0.05 (two-tailed). 
5.3     RESULTS  
Differences in distribution of research subject characteristics are presented by 
level of PCa aggressiveness separately for AAs and EAs in Table 5.1. AA subjects with 
high aggressive PCa were slightly older, had higher intakes of energy and dietary fat, 
included a greater proportion of current smokers and lower incomes, more often reported 
no PSA screening prior to diagnosis, but less often reported vitamin E supplement use 
compared to those with low/intermediate aggressive disease. EA subjects with high 
aggressive PCa were older, had slightly higher BMI, higher proportion had started PCa 
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 treatment by start of study and more often reported vitamin E supplement use compared 
to those with low/intermediate aggressive PCa. In both AAs and EAs, research subjects 
with high aggressive PCa had lower educational level than those with low/intermediate 
aggressive PCa. 
Table 5.2 presents mean difference in tocopherol levels and supplemental vitamin 
E intake by race and by level of PCa aggressiveness. Overall, AA subjects tended to have 
higher dietary intakes of γ- and δ-tocopherol but lower intakes of supplemental vitamin E 
and total α-tocopherol compared to EAs. Mean adipose α-tocopherol level was 75% 
higher in EAs than to AAs. While no differences in dietary, supplement or adipose 
tocopherol levels were observed by the level of PCa aggressiveness among EAs, AA 
subjects with low/intermediate aggressive PCa had higher intakes of supplemental 
vitamin E and total α-tocopherol compared to their counterparts with high aggressive 
PCa. 
Multivariable-adjusted ORs for high aggressive PCa were estimated by quartiles 
of dietary tocopherols and supplemental vitamin E intake with lower quartiles as the 
referent group (Table 5.3). No significant associations were observed among AAs, 
although there were some suggestive inverse associations, particularly in the highest 
quartiles of dietary α-tocopherol and vitamin E supplement intake. Among EA subjects, a 
dose-response inverse association was observed between dietary α-tocopherol intake and 
PCa aggressiveness, showing 66% lower odds of high aggressive PCa in the highest 
quartile. However, neither vitamin E supplement intake nor total α-tocopherol intake was 
associated with PCa aggressiveness among EAs. Dietary δ-tocopherol intake also was 
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 inversely and linearly associated with PCa aggressiveness among EAs. A nearly 
statistically significant inverse associations was observed in the highest quartile of β-
tocopherol intake (OR = 0.56, 95% CI = 0.30-1.02). There also was a nearly significant 
trend for lower odds of high aggressive PCa with increasing consumption of γ-tocopherol 
among EAs (Ptrend = 0.05). 
Research subjects with and without data on adipose tocopherol levels did not 
differ substantially. In sensitivity analyses, similar associations were observed between 
dietary tocopherol intake and PCa aggressiveness among research subjects with and 
without data on adipose tocopherols (Table 5.5 and 5.6). Adipose tissue tocopherol levels 
also were categorized and analyzed separately for AAs and EAs (Table 5.4). While none 
of the associations was statistically significant, higher adipose α-tocopherol level 
appeared to be inversely associated with high aggressive PCa among AAs (OR = 0.66, 
95% CI = 0.27-1.62, highest vs. lowest quartile), but positively associated among EAs 
(OR = 1.43, 95% CI = 0.66-3.11, highest vs. lowest quartiles). Evaluations of potential 
modifying effects of family history of PCa, pre-diagnostic PSA screening history, 
smoking status, BMI and NSAIDs use did not show effect modification by these factors 
(data not shown). 
5.4     DISCUSSION 
In this population-based, case-only, study of PCa aggressiveness, higher dietary 
intake of α- and δ-tocopherol was inversely associated with high aggressive PCa among 
EAs. Nearly statistically significant inverse associations also were observed between 
higher dietary intake of γ- and β-tocopherol, and high aggressive PCa among EAs. None 
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 of the dietary tocopherols was associated with PCa aggressiveness among AAs. 
Similarly, no significant association was observed for supplemental and total (diet and 
supplement) α-tocopherol intake among AAs or EAs. Interestingly, there was a 
suggestion that a higher adipose tissue α-tocopherol level was inversely associated with 
high aggressive PCa among AAs, but positively associated among EAs.  
Tocopherols are thought to have strong chemopreventive properties that may 
protect against PCa by preventing or mitigating the deleterious effects of oxidative stress, 
specifically oxidative damage to DNA, proteins and lipids [158, 388, 391, 394]. Many 
reports indicate that tocopherols interact with a variety of ROS, notably peroxyl radicals, 
to form relatively innocuous compounds, thereby mitigating oxidative stress [388, 403]. 
Other proposed anticarcinogenic properties of tocopherols include enhancing the immune 
system’s surveillance and destruction of tumor cells, regulation of genes involved in 
tumor cell growth, inhibition of protein kinase C, modulation of apoptosis and cell cycle 
signaling pathways, and down-regulating inflammatory responses [158, 164, 403, 404]. 
However, clinical trials investigating the efficacy of supplemental α-tocopherol intake for 
the prevention of PCa also have yielded contradictory results with some showing 
beneficial effect [159], no benefits [74, 405], and even possible harm [164, 406]. In 
particular, the Alpha Tocopherol Beta-Carotene (ATBC) Cancer Prevention Trial, 
originally designed to investigate lung cancer incidence, reported a 32% reduced risk of 
PCa and 41% decreased mortality from PCa among Finnish male smokers taking 50 
mg/day of supplemental vitamin E (α-tocopherol) over 5-8 years compared to placebo 
[159]. In contrast, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 
reported a 17% increased risk of PCa among healthy males taking 400 IU/day of α-
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 tocopherol over a 7-year median follow-up time compared to placebo [164]. Two other 
clinical trials have reported null associations between vitamin E supplementation and 
PCa incidence [74, 405]. The epidemiologic data relating to associations of tocopherols 
intake and PCa incidence also are equivocal (reviewed in [64, 393, 394]). 
Data on tocopherols from diet, supplements, and adipose tissue provide 
complementary information about the role of tocopherols in PCa; however, as shown in 
this analysis, they can yield mixed results because these data are different measures of 
tocopherol status. While dietary and supplement use questionnaires can provide estimates 
of usual intake patterns, typically in the recent past; they do not reflect day-to-day 
variations or longer periods of intake [384]. On the other hand, fat-soluble antioxidants 
are known to selectively accumulate in human adipose tissue and turn to turn over at a 
low rate [407]. Thus, adipose tissue serves as an objective marker of tocopherol status 
and can quantify systemic exposure over longer periods, although influenced by 
individual differences in absorption and metabolism [290, 407]. 
The mean α-tocopherol intake level (10.5 mg/day) in this study population is 
comparable to that of a study conducted among AAs and EAs in NC [408]. The inverse 
association between increased dietary intake of α-tocopherol and PCa aggressiveness 
also concurs with previous literature on PCa incidence [64, 393, 409]. It was somewhat 
surprising that although AAs and EAs had similar dietary intakes of α-tocopherol (Tables 
4.2.2 and 4.2.3); α-tocopherol was not associated with PCa aggressiveness among AAs. 
This discrepancy may be explained, at least in part, by differences in food sources of α-
tocopherol between the two groups. Exploratory analysis showed that a greater 
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 proportion of EAs in the highest quartile of the dietary α-tocopherol had higher intake of 
plant-based foods containing high amounts of α-tocopherol such as nuts, seeds, olive oils 
and other healthy food sources of α-tocopherol. By contrast, AAs in this category tended 
to consume higher amounts of foods from less healthy sources of α-tocopherol, 
particularly processed foods containing high amounts of saturated fat including potato 
and corn chips, and dark green vegetables prepared with fatback and lard. Besides racial 
difference in dietary patterns, there is also the possibility of gene-nutrient interactions 
involving polymorphisms in genes that regulate α-tocopherol activity [410], those 
implicated in PCa aggressiveness [131, 411] or both, which may vary by race. 
Despite the strong inverse association for dietary α-tocopherol among EAs, 
supplemental vitamin E and total α-tocopherol intake from both diet and supplements 
were not associated with PCa aggressiveness among EAs or AAs. Epidemiologic studies 
regarding vitamin E supplement use and PCa incidence have often reported null results 
[412-414]; few have reported protective associations but this has been limited to smokers 
[68, 170] who may have greater need for vitamin E because of increased exposure to 
ROS from tobacco smoke [415]. In the present study, however, subgroup analysis did not 
show effect modification by smoking status, which may have been limited by small 
sample size especially since analyses were stratified by race. The lack of significant 
associations for total α-tocopherol may be because research subjects who consumed high 
amounts of α-tocopherol from diet may have consumed low amounts from supplements 
or vice versa, which would lead to classification differences into low and higher quartiles 
when dietary and supplemental intakes were combined into one category. 
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 The nearly significant inverse association in the highest quartile of dietary β-
tocopherol and nearly significant inverse linear trend for γ-tocopherol among EAs 
suggest a potential beneficial role for these tocopherols or food sources of these 
tocopherols in PCa aggressiveness. Dietary intakes of γ-tocopherol were actually higher 
than α-tocopherol; consistent with the general observation that the amounts of γ-
tocopherol in American diet are higher than that of α-tocopherol [416]. Nonetheless, 
blood concentrations of α-tocopherol are about ten times higher that γ-tocopherol, which 
has been attributed to the preferential transfer of α-tocopherol to the blood by the hepatic 
α-tocopherol transfer protein (α-TTP) [388, 417]. Thus, perhaps higher intakes of the 
other tocopherols may be needed to increase their bioavailability and subsequent 
antioxidant activity. Alternatively, α-tocopherol may have more potent anticarcinogenic 
properties than the other tocopherols [391]. 
There was a suggestion that higher adipose α-tocopherol levels were inversely 
associated with high aggressive PCa among AAs, but positively associated among EAs. 
A possible explanation for these seemingly conflicting results is the significant difference 
in adipose α-tocopherol levels among AAs and EAs. EAs had a 75% higher mean 
adipose α-tocopherol level than AAs (Table 5.2). It is unclear what constitutes “normal” 
adipose tocopherol levels. Mean  α-tocopherol levels in EAs in PCaP were slightly 
higher than those reported in breast tissue from Malaysian women in a previous study 
[418] and lower than those reported in adipose tissue from European males in the 
EURAMIC study [419]. It is reasonable to speculate that long-term use of dietary 
supplements (the most common source of α-tocopherol) may have been the major 
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 contributor of the adipose α-tocopherol levels among EAs, especially since a much 
greater proportion of EAs reported vitamin E supplement use compared to AAs. This 
speculation could not be verified due to lack of data on long-term duration of supplement 
use in PCaP. 
Although the mechanisms by which higher physiological levels of α-tocopherol 
may be influencing PCa aggressiveness have yet to be clarified, laboratory studies 
suggest that α-tocopherol may have dual function as an antioxidant and as a pro-oxidant 
such that at very high levels, α-tocopherol tends to exhibit pro-oxidant properties that 
promote oxidative stress [420]. A recent study in mouse model suggest that α-tocopherol 
supplementation in nutritionally replete organisms can promote cancer cell proliferation 
by suppressing the expression of p53, a major tumor suppressor gene, which can lead to 
cancer cell escape from apoptosis [421]. These reports suggest that a fine balance 
between ROS and antioxidants is needed to maintain intracellular homeostasis, and 
provide mechanistic support to the finding in SELECT where α-tocopherol 
supplementation in healthy men was associated with increased risk of PCa [164, 406]. 
Notable strengths the present study includes its design to measure PCa 
aggressiveness, which minimizes potential confounding by disease heterogeneity (i.e., the 
mixing of indolent and aggressive disease). The evaluation of three complementary 
measures of tocopherol intake allowed for a comprehensive assessment of tocopherol 
status in PCa aggressiveness. Additionally, the assessment of individual tocopherols 
rather than the mixing of tocopherols and tocotrienols helps delineate the role of each 
tocopherol in PCa aggressiveness. The use of an ethnically diverse population with 
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 approximately equal numbers of AAs and EAs also made it possible to explore whether 
associations between tocopherols and PCa aggressiveness differed by race. Moreover, the 
potential for selection bias and selective survival were minimized because participation 
rates were reasonably high at both study sites and research subjects were recruited shortly 
after diagnosis via rapid case-ascertainment; an average of five months from the time of 
diagnosis to time of interview. 
The following limitations are also worth consideration. Imprecise measurements 
of dietary tocopherols could have influenced the study results to some extent. Because 
exposure assessment for tocopherols were done independent of the extent of PCa 
aggressiveness, differential misclassification bias is unlikely; however, non-differential 
exposure misclassification may have occurred, resulting in underestimation of ORs and 
failure to show modest associations [422]. Diet was assessed using a food frequency 
questionnaire. It is known that these structured instruments may be biased according to 
response sets [423], which in turn, may be related to psychological traits that either may 
exert a direct effect on cancer outcomes or indirectly affect other factors that may 
influence carcinogenesis [424]. There is also the concern that adipose tocopherol levels 
may be altered by the presence of a tumor; however, a study examining the effect of 
breast tumor proximity on breast adipose tocopherol levels did not find significant 
differences in adipose tocopherol levels at different quadrants of breast tissue, including 
sites proximal and distal to the tumor [425].  Moreover, although adipose tocopherol 
levels are good markers for internal dose, they may not reflect prostatic tocopherol levels. 
Thus, results should be interpreted with this in mind. Other limitations include the failure 
to control for cholesterol levels, in particularly, low density lipoprotein which function as 
134 
 
 transport vehicles for tocopherols [388] and abdominal adiposity which may influence 
the adipose tocopherol levels. Nonetheless, this might have been indirectly considered by 
adjusting for total dietary fat intake and BMI. The influence of individual differences in 
metabolism and absorption, interactions between individual tocopherols compounds and 
other micronutrients, as well as potential modifying effects of genetic variants acting via 
similar mechanisms [383, 407, 426] were beyond the scope of this study. The possibility 
exists that some of the findings may be spurious owing to the sample size and multiple 
testing. 
5.5     CONCLUSIONS 
In summary, dietary intakes of α- and δ-tocopherol were inversely associated 
with PCa aggressiveness among EAs. There was no evidence that vitamin E supplement 
use protects against high aggressive PCa. However, higher adipose α-tocopherol levels 
appear to be inversely associated with high aggressive PCa among AAs, but positively 
associated among EA which may be due to a significantly higher adipose α-tocopherol 
level among EAs. Future work with larger samples and involving evaluation of 
interaction between measures of tocopherol intake and functional gene polymorphisms in 
oxidative stress and DNA repair pathways may help to elucidate the etiologic relevance 
of tocopherols on PCa aggressiveness.
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Table 5.1 Distribution of demographic and patient characteristics by race and prostate cancer aggressiveness among men in the North 
Carolina – Louisiana Prostate Cancer Project (PCaP)  
 
Characteristics 
African Americans 
n = 1,023 
European Americans 
n = 1,079 
 High 
aggressive 
 
(n=206) 
Low/intermediate 
aggressive 
 
(n=817) 
P ‡ High 
aggressive 
 
(n=164) 
Low/intermediate 
aggressive 
 
(n=915 ) 
P ‡ 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
Age, years 63 (8) 62 (8) 0.004 67 (8) 64 (8) <0.0001 
Energy Intake, kcals/day 2799.6 (1232.4) 2593.0 (1146.0) 0.02 2339.3 (952.0) 2320.5 (865.7) 0.80 
Dietary fat intake, grams/day 103.9 (52.1) 94.8 (48.4) 0.02 94.5 (42.4) 91.1 (39.2) 0.31 
Body mass index (BMI), kg/m2 29.9 (6.7) 29.2 (5.4) 0.16 30.5 (5.1) 29.0 (4.8) 0.0006 
 N % N %  N % N %  
Study Site           
     NC 92 45 386 47 0.51 73 45 448 49 0.29 
     LA (pre & post  Katrina) 114 55 431 53 91 55 467 51 
Family History of Prostate Cancer           
    No affected 1st degree 
     relative 
157 76 606 74 0.55 136 83 696 76 0.05 
    At least 1 affected 1st degree 
relative 
49 24 211 26 28 17 219 24 
Prostate Cancer Screening History           
     0 screenings 120 58 307 38 <0.0001 40 24 153 17 0.06 
     1-7 screenings 53 26 338 41 68 42 405 44 
     > 7 screenings 33 16 172 21 56 34 357 39 
Comorbidities           
0 88 43 382 47 0.39 84 51 503 55 0.07 
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1 53 26 216 26 31 19 214 23 
2 36 17 106 13 29 18 98 11 
≥ 3 29 14 113 14 20 12 100 11 
Started PCa treatment at start of 
study 
          
No 20 10 112 14 0.20 11 7 99 11 0.007 
Yes 163 79 599 73 146 89 720 79 
Unknown 23 11 106 13 7 4 96 10 
Education         
    Graduate/professional degree 6 3 59 7 0.004 29 18 197 22 0.01 
    Some college or college graduate 50 24 239 29 71 43 377 41 
    High school grad or voc/tech 
school 
65 32 275 34 37 23 260 28 
    Less than high school education 85 42 243 30 27 16 81 9 
Income Level           
    ≤ $20, 000 82 40 234 29 0.001 24 15 78 9 0.22 
    $20,001 - $40,000 52 25 212 26 33 20 184 20 
    $40,001 - $60,000 20 10 132 16 24 15 154 17 
    $60,001 - $80,000 12 6 70 8 20 12 124 13 
     >$80,000 14 7 99 12 47 29 298 33 
    Unknown  26 13 70 8 16 9 77 8 
Smoking Status           
     Never 40 19 276 34 <0.0001 59 36 330 36 0.76 
     Former smokers 107 52 390 48 87 53 501 55 
     Current smokers 59 29 151 18 18 11 84 9 
NSAID  Use           
     No 84 41 364 45 0.33 56 34 305 33 0.85 
     Yes 120 59 446 55 108 66 608 67 
Vitamin E Supplement Use a           
     No 141 68 488 60 0.02 65 40 396 43 0.38 
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     Yes 65 32 329 40 99 60 519 57 
 
Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as follows: 
High aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); Low /Intermediate aggressive: all other 
cases. 
 
a Both single nutrient vitamin E supplements and multivitamins containing vitamin E. 
Abbreviations: PCa – Prostate Cancer;  SD – Standard deviation; NC –North Carolina LA – Louisiana; NSAIDs – Nonsteroidal anti-
inflammatory drugs.  
 
‡Test for differences between low/intermediate and high aggressive cancers were done using Student’s t-test for continuous variables and chi-
square tests for categorical variables. 
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Table 5.2 Mean difference in tocopherol intake from diet and supplements, and adipose tissue tocopherol levels by race 
and level of prostate cancer aggressiveness 
  
African 
Americans 
 
n = 1,023 
 
European 
Americans 
 
n = 1,079 
 
% 
diff 
              African Americans European Americans 
High 
aggressive 
 
n = 206 
Low/intermediate 
Aggressive 
 
n = 817 
 
P † 
 
High 
aggressive 
 
n = 164 
Low/interme
diate 
Aggressive 
 
n = 915 
 
P † 
 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
Dietary intake          
 α-tocopherol (mg/day) 10.6 (5.9) 10.5 (5.3) 1 10.9 (6.5) 10.5 (5.8) 0.43 10.1 (5.3) 10.6 (5.3) 0.29 
 β-tocopherol (mg/day) 0.4 (0.2) 0.4 (0.2) 0 0.4 (0.3) 0.4 (0.2) 0.13 0.4 (0.2) 0.4 (0.2) 0.35 
 γ-tocopherol (mg/day) 21.0 (11.3) 18.6 (8.6) 11 ‡ 22.2 (11.7) 20.7 (11.2) 0.09 18.6 (9.1) 18.6 (8.5) 0.95 
 δ-tocopherol (mg/day) 3.0 (1.7) 2.7 (1.5) 10 ‡ 3.2 (1.8) 2.9 (1.7) 0.05 2.7 (1.5) 2.7 (1.5) 0.58 
Supplemental vitamin E a 
(α-tocopherol, mg/day)  
53.5 (82.4) 76.0 (100.4) - 42 ‡ 37.8 (54.2) 56.6 (86.6) 0.02 64.7 (94.2) 78.2 (101.4) 0.22 
Total α-tocopherol  
(diet + supplement)  mg/day 
31.2 (57.8) 54.1 (85.2) - 73 ‡ 22.8 (36.1) 33.3 (61.9) 0.00
2 
49.2 (79.6) 55.0 (86.2) 0.42 
Adipose tissue biomarkers b          
 α-tocopherol (mcg/g)  86.6 (144.9) 151.4 (198.0) - 75 ‡ 78.9 (138.0) 88.3 (146.6) 0.63 163.6 (221.3) 149.2 (193.7) 0.53 
 γ-tocopherol (mcg/g)  48.4 (74.1) 53.3 (54.5) - 10 38.2 (38.2) 50.8 (79.9) 0.06 55.4 (56.5) 52.9 (54.1) 0.69 
 δ-tocopherol (mcg/g)  9.3 (10.2) 8.6 (7.8) 7 8.6 (9.9) 9.4 (10.3) 0.55 8.2 (6.6) 8.7 (8.0) 0.55 
 
a Among vitamin E supplement users only (African Americans, n = 394; European Americans, n = 618). Converted as 1 IU of Vitamin E = 0.45 mg α-tocopherol 
[402]. 
b Among  research subjects with data on adipose tocopherol levels (African Americans, n = 361; European Americans, n = 584).   
‡ Significant p-values (< 0.05) for test of difference between African Americans and European Americans  
 
† Chi-square test for difference by level of prostate cancer aggressiveness 
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Table 5.3 Associations between dietary and supplemental vitamin E intake and prostate cancer aggressiveness 
among African Americans (n = 1,023) and European Americans (n = 1,079) 
  Crude a Adjusted  b 
 Cases/ 
controls c 
OR 95% C.I. P § 
 
OR 95% C.I. P § 
 
Dietary α-tocopherol mg/day (median)        
African Americans        
 Q1: 0.51 - 6.37 (4.82) 51/205 1.00 (ref) 0.35 1.00 (ref) 0.20 
Q2: 6.38 - 9.25 (7.72) 42/204 0.86 0.55-1.35  0.73 0.43-1.22  
Q3: 9.26 - 13.32 (10.85) 59/204 1.21 0.79-1.85  1.08 0.62-1.86  
Q4: 13.33 - 44.62 (17.13) 54/204 1.13 0.73-1.74  0.58 0.28-1.19  
European Americans        
 Q1: 1.67 - 7.02 (5.55) 54/229 1.00 (ref) 0.18 1.00 (ref) 0.006 
Q2: 7.03 - 9.54 (8.35) 35/229 0.66 0.41-1.06  0.54 0.32-0.91  
Q3: 9.55 - 12.79 (11.01) 39/229 0.77 0.49-1.22  0.51 0.29-0.88  
Q4: 12.80 - 53.18 (16.28) 36/228 0.68 0.43-1.09  0.34 0.17-0.69  
Vitamin E supplements d  
α-tocopherol, mg/day (median) 
       
African Americans        
 Q1: non-users 141/488 1.00 (ref) 0.01 1.00 (ref) 0.15 
Q2: 1.13 – 11.25 (10.13) 24/91 0.95 0.58-1.55  1.09 0.65-1.84  
Q3:  11.26 – 22.50 (22.50) 27/136 0.69 0.44-1.09  0.83 0.51-1.34  
Q4:  22.51 – 472.50 (180.00) 14/102 0.48 0.26-0.87  0.64 0.34-1.21  
European Americans        
 Q1: non-users 65/396 1.00 (ref) 0.26 1.00 (ref) 0.38 
Q2:  0.96 – 20.25 (13.50) 37/178 1.24 0.79-1.94  1.40 0.87-2.24  
Q3:  20.26 – 45.00 (22.50) 37/172 1.25 0.80-1.95  1.41 0.88-2.27  
Q4:  45.01 – 540.00 (193.50) 25/169 0.83 0.50-1.37  0.93 0.55-1.58  
Total α-tocopherol 
Diet + supplement,  mg/day (median) 
       
African Americans        
 Q1: 0.52 – 9.14 (6.64) 51/205 1.00 (ref) 0.27 1.00 (ref) 0.36 
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Q2: 9.15 – 15.83 (11.93) 60/204 1.24 0.81-1.89  1.27 0.78-2.06  
Q3: 15.84 – 28.54 (20.71) 52/204 1.07 0.69-1.65  0.88 0.50-1.52  
Q4: 28.55 – 482.37 (42.87) 43/204 0.87 0.55-1.37  0.89 0.51-1.58  
European Americans         
 Q1: 2.40 – 11.40 (8.04) 43/229 1.00 (ref) 0.47 1.00 (ref) 0.55 
Q2: 11.41 – 23.34 (15.56) 39/228 0.94 0.58-1.51  0.85 0.50-1.42  
Q3:23.35 – 39.69 (31.55) 44/230 0.98 0.62-1.56  0.99 0.59-1.65  
Q4:39.70 – 558.17 (190.37) 38/228 0.84 0.52-1.36  0.83 0.49-1.40  
Dietary β-tocopherol mg/day (median)        
African Americans        
 Q1: 0.03 - 0.25 (0.19) 53/208 1.00 (ref) 0.05 1.00 (ref) 0.22 
Q2: 0.26 - 0.37 (0.31) 42/204 0.85 0.54-1.33  0.92 0.56-1.50  
Q3: 0.38 - 0.52 (0.44) 46/206 0.91 0.58-1.41  1.04 0.62-1.77  
Q4: 0.53 - 1.73  (0.69) 65/199 1.03 0.92-2.12  1.08 0.73-2.59  
European Americans        
 Q1: 0.07 - 0.28 (0.22) 53/242 1.00 (ref) 0.44 1.00 (ref) 0.09 
Q2: 0.29 - 0.38 (0.33) 37/239 0.71 0.44-1.12  0.64 0.39-1.05  
Q3: 0.39 - 0.52 (0.45) 37/217 0.79 0.50-1.26  0.65 0.39-1.11  
Q4: 0.53 - 1.62 (0.63) 37/217 0.79 0.50-1.26  0.56 0.30-1.02  
Dietary  γ-tocopherol mg/day (median)        
African Americans        
 Q1: 0.03 - 12.37 (9.07) 46/204 1.00 (ref) 0.08 1.00 (ref) 0.59 
Q2: 12.38 - 18.55 (15.48) 47/205 1.08 0.68-1.70  1.02 0.61-1.71  
Q3: 18.56 - 27.04 (22.78) 51/204 1.14 0.73-1.78  0.94 0.53-1.69  
Q4: 27.05 - 67.95 (33.75) 62/204 1.44 0.94-2.22  0.83 0.39-1.80  
European Americans        
 Q1: 2.68 - 12.66 (9.83) 39/230 1.00 (ref) 0.82 1.00 (ref) 0.05 
Q2: 12.67 - 17.35 (15.14) 47/228 1.26 0.79-2.01  1.14 0.68-1.91  
Q3: 17.36 - 22.85 (19.57) 41/229 1.10 0.68-1.78  0.77 0.43-1.37  
Q4: 22.86 - 55.13 (28.34) 37/228 1.00 0.61-1.64  0.52 0.24-1.13  
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Dietary  δ-tocopherol mg/day 
(median) 
       
African Americans        
 Q1: 0.08 - 1.63 (1.22) 41/206 1.00 (ref) 0.04 1.00 (ref) 0.69 
Q2: 1.64 - 2.56 (2.11) 52/204 1.33 0.84-2.10  1.25 0.75-2.08  
Q3: 2.57 - 3.71 (3.09) 48/204 1.21 0.76-1.93  0.92 0.52-1.65  
Q4: 3.72 - 13.09 (4.92) 65/203 1.64 1.06-2.54  0.97 0.47-1.98  
European Americans        
 Q1: 0.34 - 1.69 (1.31) 36/231 1.00 (ref) 0.29 1.00 (ref) 0.007 
Q2: 1.70 - 2.37 (2.05) 56/229 1.64 1.03-2.60  1.40 0.85-2.30  
Q3: 2.38 - 3.46 (2.84) 43/228 1.24 0.76-2.01  0.91 0.52-1.60  
Q4: 3.47 - 10.92 (4.29) 29/227 0.89 0.52-1.50  0.45 0.21-0.95  
 
Cases: high aggressive prostate cancers; Controls: low and intermediate aggressive cancers 
a Adjusted for age 
b additional adjustment for PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake, 
and study site 
c Some of the categories may not sum to the total sample size due to missing data  
d Converted as 1 IU of Vitamin E = 0.45 mg α-tocopherol [402]. 
§ Trend P value 
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Table 5.4 Associations between adipose tissue tocopherol levels and prostate cancer aggressiveness among African (n = 
361) and European (n = 584) Americans.  
  Crude a Adjusted b 
 Cases/ 
Controls c 
OR 95% C.I. p 
(trend) 
OR 95% C.I. p  
(trend) 
α-tocopherol mcg/g (median)        
African Americans        
 Q1:  0.30 - 14.50 (6.45) 18/74 1.00 (ref) 0.41 1.00 (ref) 0.60 
Q2: 14.51 - 36.30 (24.10) 13/73 0.74 0.33-1.63  0.58 0.24-1.39  
Q3: 36.56 - 108.90 (61.12) 22/74 1.18 0.58-2.41  0.98 0.44-2.16  
Q4: 108.91 - 1313.10 (183.27) 13/73 0.68 0.31-1.50  0.66 0.27-1.62  
European Americans        
 Q1: 0.20 - 26.50 (12.50) 16/123 1.00 (ref) 0.71 1.00 (ref) 0.68 
Q2: 26.51 - 78.80 (45.60) 26/123 1.54 0.78-3.04  1.54 0.74-3.23  
Q3: 79.81 - 204.70 (125.70) 26/123 1.39 0.70-2.76  1.58 0.75-3.33  
Q4: 204.71 - 1585.60 (328.90) 21/123 1.12 0.55-2.27  1.43 0.66-3.11  
γ-tocopherol mcg/g (median)        
African Americans        
 Q1:  0.10 - 10.4 0 (5.29) 17/73 1.00 (ref) 0.60 1.00 (ref) 0.77 
Q2: 10.41- 28.90 (18.10) 19/72 1.21 0.58-2.54  1.03 0.45-2.35  
Q3: 28.91- 64.10 (41.70) 15/72 0.86 0.40-1.87  0.72 0.31-1.69  
Q4: 64.11 - 972.90 (92.42) 15/72 0.90 0.42-1.96  0.93 0.40-2.16  
European Americans         
 Q1: 0.20 - 13.40 (6.20) 16/122 1.00 (ref) 0.79 1.00 (ref) 0.91 
Q2: 13.41 - 37.90 (23.90) 28/122 1.70 0.87-3.32  1.39 0.68-2.83  
Q3: 37.91 - 72.08 (52.10) 27/122 1.59 0.81-3.12  1.18 0.57-2.46  
Q4: 72.34  - 318.70 (110.74) 19/122 1.14 0.55-2.33  1.20 0.56-2.55  
δ-tocopherol mcg/g (median)        
African Americans        
 Q1: 0.40 - 3.20 (2.00) 14/68 1.00 (ref) 0.45 1.00 (ref) 0.73 
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Q2: 3.21 - 6.43 (4.66) 20/67 1.39 0.64-2.99  1.46 0.63-3.36  
Q3: 6.44 - 11.54 (8.71) 14/67 0.97 0.43-2.20  1.17 0.48-2.85  
Q4: 11.55 - 101.40 (17.80) 12/67 0.86 0.37-2.01  1.01 0.40-2.55  
European Americans        
 Q1: 0.30 - 2.99 (1.60) 17/117 1.00 (ref) 0.98 1.00 (ref) 0.81 
Q2: 3.00 - 6.70 (4.60) 26/119 1.37 0.70-2.68  1.20 0.58-2.49  
Q3: 6.71 - 11.60 (8.69) 23/115 1.28 0.64-2.55  1.10 0.52-2.32  
Q4: 11.61- 54.11 (16.10) 19/116 1.12 0.55-2.29  0.99 0.46-2.13  
a Adjusted for age  
b Additional adjustment for education level, study site, BMI, smoking history, family history of PCa, PSA screening history, total fat intake,  
whether treatment started at time of interview, and comorbidities. 
c Some of the categories may not sum to the total sample size due to missing data. 
 
 
 
 
 Table 5.5 Comparison of demographic and clinical attributes of prostate cancer 
between research subjects included and those excluded from the adipose tissue 
tocopherol and prostate aggressiveness analysis 
 Included 
n = 945 
          Excluded 
           n = 1157  
 Mean (SD) Mean (SD) 
Age, years  63.4 (7.9) 63.1 (7.8) 
Energy Intake, kcals/day 2461.2 (1018.8) 2486.0 (1057.8) 
Dietary fat  intake, grams/day 94.9 (44.4) 93.4 (44.9) 
Body mass index (BMI), kg/m2 29.9 (5.2) 28.8 (5.3) 
 N % N % 
Race         
African American 361 38 662 57 
European American 584 62 495 43 
Prostate cancer aggressiveness         
      Low aggressive  485 51 589 51 
      High aggressive 304 32 354 31 
     Intermediate aggressive 156 16 214 18 
Study Site     
     NC 407 43 592 51 
     LA (pre & post  Katrina)      538 57 565 49 
Family History of Prostate Cancer     
     No affected 1st degree relative 696 74 899 78 
    At least 1 affected 1st degree relative 249 26 258 22 
Prostate Cancer Screening History     
     0 screenings 248 26 372 32 
     1-7 screenings 375 40 489 42 
     > 7 screenings 322 34 296 26 
Comorbidities     
0 497 53 560 49 
1 224 24 290 25 
2 105 11 164 14 
≥ 3 119 12 143 12 
Started PCa treatment at start of study     
No 95 10 147 13 
Yes 749 79 879 76 
Unknown 101 11 131 11 
Education     
    Graduate/professional degree 155 17 136 12 
    Some college or college graduate 351 37 386 33 
    High school grad or voc/tech school 268 28 369 32 
    Less than high school education 171 18 265 23 
Income Level     
    ≤ $20, 000 156 16 262 23 
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     $20,001 - $40,000 188 20 293 25 
    $40,001 - $60,000 148 16 182 16 
    $60,001 - $80,000 124 13 102 9 
     >$80,000 233 25 225 19 
    Unknown  96 10 93 8 
Smoking Status     
     Never 355 37 350 30 
     Former smokers 471 50 614 53 
     Current smokers 119 13 193 17 
NSAID  Use     
     No 361 38 448 39 
     Yes 584 62 698 61 
Vitamin E Supplement Use a     
     No 474 50 616 53 
     Yes 471 50 541 47 
 
Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical 
stage, and PSA level at diagnosis and classified as follows: High aggressive 
(Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); 
Low /Intermediate aggressive: all other cases. 
a Includes single nutrient vitamin E supplement and multivitamins containing 
vitamin E. 
Abbreviations: PCa – Prostate Cancer;  SD – Standard deviation; NC –North 
Carolina; LA – Louisiana; NSAIDs – Nonsteroidal anti-inflammatory drugs.  
 
‡ Student’s t test for continuous variables and chi-square tests for categorical 
variables 
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 Table 5.6 (Sensitivity Analysis) Associations between dietary vitamin E intake and 
prostate cancer aggressiveness among African Americans (n = 361) and European 
Americans (n = 584) with data on adipose tissue tocopherol levels. 
  Crude a Adjusted  b 
 Cases/ 
controls c 
OR  95% C.I. P § 
 
OR  95% C.I. P § 
 
Dietary α-tocopherol mg/day (median)        
African Americans        
 Q1: 0.51 - 6.37 (4.82) 15/69 1.00 ref 0.15 1.00 ref 0.37 
Q2: 6.38 - 9.25 (7.72) 11/78 0.69 0.29-1.61  0.50 0.19-1.32  
Q3: 9.26 - 13.32 (10.85) 21/79 1.29 0.61-2.73  0.76 0.28-2.09  
Q4: 13.33 - 44.62 (17.13) 19/69 1.44 0.67-3.11  0.43 0.11-1.64  
European Americans        
 Q1: 1.67 - 7.02 (5.55) 23/126 1.00 ref 0.65 1.00 ref 0.11 
Q2: 7.03 - 9.54 (8.35) 23/124 1.04 0.55-1.96  0.86 0.42-1.76  
Q3: 9.55 - 12.79 (11.01) 23/113 1.17 0.62-2.22  0.84 0.38-1.85  
Q4: 12.80 - 53.18 (16.28) 21/131 0.86 0.45-1.64  0.46 0.17-1.25  
Vitamin E supplements d  
α-tocopherol, mg/day (median) 
       
African Americans        
 Q1: non-users 45/185 1.00 ref 0.31 1.00 ref 0.65 
Q2: 1.13 – 11.25 (10.13) 8/28 1.32 0.55-3.12  1.04 0.40-2.70  
Q3:  11.26 – 22.50 (22.50) 8/48 0.70 0.31-1.60  0.76 0.31-1.83  
Q4:  22.51 – 472.50 (180.00) 5/34 0.61 0.22-1.66  0.79 0.27-2.34  
European Americans        
 Q1: non-users 36/208 1.00 ref 0.45 1.00 ref 0.46 
Q2:  0.96 – 20.25 (13.50) 17/94 1.09 0.58-2.06  1.22 0.62-2.42  
Q3:  20.26 – 45.00 (22.50) 23/102 1.24 0.69-2.22  1.46 0.77-2.78  
Q4:  45.01 – 540.00 (193.50) 14/90 0.83 0.42-1.63  0.89 0.43-1.85  
Total α-tocopherol  
Diet + supplement,  mg/day (median) 
       
African Americans        
 Q1: 0.52 – 9.14 (6.64) 16/74 1.00 ref 0.93 1.00 ref 0.59 
Q2: 9.15 – 15.83 (11.93) 17/81 1.05 0.49-2.25  0.81 0.33-1.97  
Q3: 15.84 – 28.54 (20.71) 18/67 1.40 0.65-3.01  0.85 0.31-2.34  
Q4: 28.55 – 482.37 (42.87) 15/73 1.03 0.47-2.25  0.71 0.25-2.03  
European Americans         
 Q1: 2.40 – 11.40 (8.04) 24/122 1.00 ref 0.65 1.00 ref 0.60 
Q2: 11.41 – 23.34 (15.56) 16/123 0.71 0.36-1.41  0.57 0.26-1.23  
Q3:23.35 – 39.69 (31.55) 29/124 1.11 0.61-2.04  1.11 0.56-2.20  
Q4:39.70 – 558.17 (190.37) 21/125 0.82 0.43-1.57  0.74 0.35-1.57  
Dietary β-tocopherol mg/day (median)        
African Americans        
 Q1: 0.03 - 0.25 (0.19) 16/71 1.00 ref 0.16 1.00 ref 0.77 
Q2: 0.26 - 0.37 (0.31) 10/75 0.63 0.27-1.50  0.61 0.24-1.57  
Q3: 0.38 - 0.52 (0.44) 19/69 1.36 0.64-2.90  1.25 0.51-3.10  
Q4: 0.53 - 1.73  (0.69) 21/80 1.39 0.66-2.92  1.02 0.35-2.99  
European Americans        
 Q1: 0.07 - 0.28 (0.22) 26/131 1.00 ref 0.71 1.00 ref 0.16 
Q2: 0.29 - 0.38 (0.33) 22/128 0.85 0.45-1.59  0.67 0.34-1.33  
Q3: 0.39 - 0.52 (0.45) 21/114 0.93 0.49-1.76  0.72 0.34-1.52  
Q4: 0.53 - 1.62 (0.63) 21/121 0.86 0.45-1.62  0.50 0.21-1.20  
Dietary  γ-tocopherol mg/day (median)        
African Americans        
 Q1: 0.03 - 12.37 (9.07) 15/70 1.00 ref 0.14 1.00 ref 0.38 
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Q2: 12.38 - 18.55 (15.48) 12/73 0.84 0.37-1.95  0.68 0.26-1.74  
Q3: 18.56 - 27.04 (22.78) 17/75 1.18 0.54-2.56  0.69 0.25-1.90  
Q4: 27.05 - 67.95 (33.75) 22/77 1.56 0.74-3.30  0.52 0.14-1.90  
European Americans        
 Q1: 2.68 - 12.66 (9.83) 20/127 1.00 ref 0.62 1.00 ref 0.29 
Q2: 12.67 - 17.35 (15.14) 21/119 1.23 0.63-2.40  1.12 0.54-2.35  
Q3: 17.36 - 22.85 (19.57) 29/134 1.49 0.79-2.79  0.98 0.44-2.18  
Q4: 22.86 - 55.13 (28.34) 20/114 1.17 0.59-2.31  0.58 0.19-1.75  
Dietary  δ-tocopherol mg/day (median)        
African Americans        
 Q1: 0.08 - 1.63 (1.22) 11/72 1.00 ref 0.02 1.00 ref 0.67 
Q2: 1.64 - 2.56 (2.11) 15/74 1.52 0.64-3.57  1.25 0.49-3.19  
Q3: 2.57 - 3.71 (3.09) 15/77 1.38 0.59-3.23  0.95 0.33-2.72  
Q4: 3.72 - 13.09 (4.92) 25/72 2.60 1.17-5.77  1.39 0.39-4.92  
European Americans        
 Q1: 0.34 - 1.69 (1.31) 18/128 1.00 ref 0.95 1.00 ref 0.21 
Q2: 1.70 - 2.37 (2.05) 25/121 1.62 0.83-3.15  1.37 0.65-2.86  
Q3: 2.38 - 3.46 (2.84) 31/128 1.85 0.97-3.50  1.57 0.73-3.37  
Q4: 3.47 - 10.92 (4.29) 16/117 1.08 0.52-2.24  0.57 0.20-1.61  
 
Cases: high aggressive prostate cancers; Controls: low and intermediate aggressive cancers 
a Adjusted for age 
b additional adjustment for PSA screening history, BMI, smoking status, education, income, NSAIDs 
use, total dietary fat intake, and study site 
c Some of the categories may not sum to the total sample size due to missing data  
d Converted as 1 IU of Vitamin E = 0.45 mg α-tocopherol [402].  
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 CHAPTER 6 
CAROTENOIDS INTAKE AND ADIPOSE TISSUE CAROTENOID LEVELS IN RELATION TO 
PROSTATE CANCER AGGRESSIVENESS 
 
6.1     INTRODUCTION 
Prostate cancer (PCa) is the most frequently diagnosed non-dermatological 
malignancy among men in Western countries [427]. Accumulated data on the relation 
between diet and cancer indicates that about 30-40% of cancer cases are preventable 
through healthy diet and weight control [428, 429]. Greater intake of fruits and 
vegetables has been associated with reduced risk of various types of cancer, including 
PCa [430-432]. Carotenoids are biologically active phytochemicals commonly found in 
fruits and vegetables, and they are thought to contribute to the inverse associations 
between fruits and vegetables intake and cancer incidence [433, 434]. However, findings 
from case-control and cohort studies summarized in recent reviews [17, 434-436], 
suggest that the pattern of association between carotenoids intake and PCa is largely 
unclear.  
β-carotene and lycopene are the most commonly studied carotenoids, with 
lycopene, a carotenoid devoid of vitamin A activity, having the most favorable 
association with PCa [437-440], although study results are not entirely consistent [413, 
441, 442]. Early studies focused primarily on β-carotene, a pro-vitamin A carotenoid; 
however, two large intervention trials failed to show a beneficial effect of β-carotene on 
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 PCa incidence in secondary data analyses [159, 188].however, two large intervention 
trials failed to show a beneficial effect of β-carotene on PCa incidence in secondary data 
analyses [159, 188]. One reported  a 23% increased risk of PCa among β-carotene 
intervention group versus placebo [159], and the other, which examined effects of β-
carotene and retinol in tandem because of their close metabolic relationship, found a 52% 
increased risk of aggressive PCa (Gleason ≥ 7 or stage III/IV) in the intervention group 
compared with placebo [188]. The elevated risks associated with β-carotene 
supplementation were not evident in follow-up studies [188, 443], and the majority of 
observational studies have conflicted on β-carotene associations with PCa [17, 434-436, 
444-447]. Carotenoids such as α-carotene, β-cryptoxanthin, lutein, and zeaxanthin have 
been associated with modest reductions in PCa risk, but as with lycopene and β-carotene, 
the study results are mixed [189, 448-451]. 
There is limited data regarding associations between carotenoids intake and PCa 
aggressiveness. As suggested by Giovannucci et al. [437], the dietary risk factors for 
aggressive PCa may differ from that of a non-aggressive disease, and thus, some 
carotenoids may differentially influence aggressive versus non-aggressive PCa. Given the 
growing interest in identifying modifiable risk factors for PCa, particularly among 
African Americans (AAs), a population with a high incidence of aggressive PCa [452], 
this study investigated associations of dietary, supplemental and adipose tissue carotenoid 
levels in relation to PCa aggressiveness among AA and European-American (EA) men in 
North Carolina and Louisiana.  
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 6.2     MATERIALS AND METHODS 
Study Population 
A population-based, case-control study was conducted using data from the North 
Carolina-Louisiana Prostate Cancer Project (PCaP). One of the primary aims of PCaP, a 
multidisciplinary, cross-sectional, case-only, incident PCa study, was to investigate and 
compare factors associated with PCa aggressiveness among AAs and EAs. Residents of 
the study catchment areas in North Carolina and Louisiana were eligible to participate in 
PCaP if they had a first, histologically confirmed, diagnosis of adenocarcinoma of the 
prostate between July 1, 2004 and August 31, 2009, were 40-79 years of age at the time 
of diagnosis, and self-identified their race as AA/Black or Caucasian American/White 
(EA). The other eligibility criteria were having sufficient cognitive and physical functions 
to consent and complete the study interview in English, and not residing in an institution 
(e.g., nursing home). PCaP enrolled 2267 research subjects of whom approximately half 
were EAs (n= 1130) and half were AAs (n = 1137). All research subjects provided 
written informed consent before participating in the study. Participation rates were 62% 
in North Carolina, 72% for pre-Hurricane Katrina Louisiana and 63% for post- Hurricane 
Katrina Louisiana. Further details of the PCaP methods and design can be found 
elsewhere [399]. The PCaP study protocols were approved by Institutional Review 
Boards of all collaborating institutions, and the current study also received institutional 
approval from the University of South Carolina.   
Data Collection 
Structured in-person interviews were conducted by trained research nurses, 
usually in the home of the research subject or at a place of his choosing, soliciting various 
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 information that included demographic and socioeconomic factors, personal health 
history, family history of PCa, pre-diagnostic PCa screening habits, smoking history, 
physical activity, usual dietary intake, and use of dietary supplements and non-steroidal 
anti-inflammatory drugs (NSAIDs). The research nurses measured each research 
subject’s height, and weight at the end of each interview using a standardized protocol. 
Information on the cancer stage, Gleason grade and prostate-specific antigen (PSA) level 
at the time of diagnosis and other health data including comorbid conditions and disease-
directed treatments were extracted from the research subjects’ medical records which 
were obtained from diagnosing physicians after receiving consent. The medical record 
abstractions were performed by trained personnel and included a double abstraction of a 
randomly selected sample (approximately 10%) to ensure consistency between 
abstractors. PCa aggressiveness is defined in PCaP as high aggressive (Gleason sum ≥8 
or PSA >20 ng/mL or Gleason sum ≥7 and cancer stage T3–T4), low aggressive (Gleason 
sum < 7 and cancer stage T1-T2 and PSA<10 ng/ml), and intermediate aggressive (all 
others). These categories were used in case-control analyses contrasting high aggressive 
PCa “cases” with low/intermediate aggressive PCa as the comparison group or 
“controls”. 
Dietary Assessment 
Dietary carotenoid intakes were assessed using the National Cancer Institute Diet 
History-Food Frequency Questionnaire (NCI-DHQ) [453], which was modified to 
include Southern foods. The modified, 124-item DHQ solicited information about usual 
diet in the year before the diagnosis of PCa, including frequency of food intake, portion 
size, and food preparation methods. Responses to the questions were linked to an updated 
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 NCI nutrient database through which the research subjects’ usual daily intakes of various 
nutrients including α- and β-carotene, β-cryptoxanthin, lutein-zeaxanthin and lycopene 
were estimated using the NCI Diet*Calc software [401].  
Data on supplemental carotenoid intake were derived using a questionnaire that 
has been tested for reliability [454]. The research subjects were asked about multivitamin 
and single-nutrient supplement use in the year preceding their diagnosis of PCa (no, less 
than once, yes) and those who answered “yes” were queried about the frequency of use 
(1-2, 3-4, 5-6, 7 days/week). Responses to the questionnaire were recorded by the nurse 
interviewers who also undertook an inventory of nutrient contents and listed dose 
information from the manufacturer label of each supplement type. When the supplement 
bottle was not available, subjects were asked to state the usual dose taken. Average daily 
intakes of supplemental β-carotene, lutein and lycopene were subsequently estimated 
based on contributions from multivitamin and single-nutrient supplements as frequency 
(days per week) x dose (in µg) x number of pills taken at each time / 7 [454]. Total daily 
intake of β-carotene, lutein and lycopene were estimated as the sum of intakes from diet 
and supplement (diet + supplement). 
Adipose Tissue Sampling and Analysis 
Approximately two grams of subcutaneous abdominal adipose tissue samples 
were obtained from consenting research subjects after anesthetizing the overlying skin 
with 2% lidocaine solution. The PCaP research nurses, who were specifically trained for 
adipose tissue sampling, followed a standardized procedure involving the insertion of a 
15-gauge needle into the subcutaneous fat and applying negative pressure by a 15 ml 
153 
 
 vacutainer tube after prepping the overlying skin. The aspirated tissue was trapped in the 
needle and luer lock adapter, which was placed in a separate cryovial and transported on 
ice immediately after collection to a designated storage facility where aliquots were 
prepared and stored at -80oC until assayed. Individual carotenoids were measured by high 
performance liquid chromatography at the Nutrition Analyses Laboratory of Craft 
Technologies, Incorporated (Wilson, NC) using methods outlined by Craft et al. [328, 
329]. The adipose tissue contents of α-carotene, cis- and trans-β-carotene, α-
cryptoxanthin, β-cryptoxanthin, lutein, zeaxanthin, and cis- and trans-lycopene were 
quantified at a minimum detection limit of 0.003 µg/g of tissue.  
 
Statistical Methods 
Before any analysis was performed, research subjects with incomplete data on 
PCa aggressiveness (n = 94) and those with implausible values for energy intake (< 500 
or ≥ 6000 kcal/day, n = 71) were excluded from the total PCaP sample of 2267. The 
remaining 2,102 research subjects were included in the analyses; however, data on 
adipose carotenoid levels were available for only 939 cases (EAs n = 581, AAs n = 358).  
Descriptive statistics were expressed as means for continuous variables and 
proportions for categorical variables using t-tests and chi-square tests, respectively. The 
carotenoid variables were categorized into tertiles according to their distributions among 
controls, and unconditional logistic regression was used to estimate odds ratios (ORs) and 
corresponding 95% confidence intervals (95% CIs) for increasing tertiles with the lowest 
tertiles as the referent group. Trend tests were performed by assigning each tertile its 
median value expressed as a continuous variable in the logistic regression models. All 
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 associations were examined in crude (age-adjusted) and multivariable-adjusted models. 
The following known or suspected risk factors for PCa were considered for inclusion in 
the multivariable-adjusted models: age (continuous), study site (NC, LA); BMI (in 
kg/m2); pre-diagnostic PSA screening history (0, 1-7, >7 screenings); comorbidities (0, 1, 
2, ≥3); family history of PCa in a first degree relative (none vs. at least one); whether PCa 
treatment had started at the time of the interview (yes, no); smoking status (never, former, 
current); education (less than high school education, high school graduate/some college, 
college graduate); annual household income (< $20,000, $20,001 - $40,000, $40,001 - 
$70,000, >$70,000); NSAIDs use in the five years prior to diagnosis (yes, no); physical 
activity in the year prior to diagnosis [total metabolic equivalents (METs) of light, 
moderate, and vigorous exercise categorized as: ≤ 10.2, 10.3-29.0, > 29.0 METs/week]; 
total fat intake (grams/day); and alcohol intake (grams/day). The multivariable models 
were constructed first by evaluating the confounding effect of each variable based on a 
10% change in effect estimate of the main exposure variables with the removal of the 
covariate from the model. Variables determined to be confounders and those that are 
biologically relevant to PCa were then placed in an elaborate model for final model 
selection. A combination of the backward elimination model selection method and 
likelihood ratio tests were then used to select covariates for the final models consisting of 
age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total 
fat intake, and study site. Further adjustment for family history of PCa, comorbidities, 
and PCa treatment status were done in models examining associations between adipose 
carotenoid levels and PCa aggressiveness.  
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 Stratified analyses by BMI (< 24.9, 25-29.9, ≥ 30 kg/m2) and smoking status 
were performed to evaluate whether the associations differed by these factors. In order to 
retain enough sample size for the stratified analyses, the carotenoid variables were 
categorized into two levels (< or ≥ median) with the lowest levels as the referent group. 
The evaluation of effect modification included interaction terms between the BMI and 
smoking status variables, and each of the carotenoids (median splits), which were 
examined by likelihood ratio tests based on models with and without an interaction term. 
All statistical tests were two-sided and a P value less than 0.05 was considered 
statistically significant except for interaction p-values in the stratified analyses, which 
were considered significant at a P value less than 0.10. All analyses were performed with 
SAS version 9.3 (SAS Institute, Cary, NC).  
6.3     RESULTS 
Characteristics of the research subjects are presented for AAs and EAs in Table 
6.1. In both AAs and EAs, the research subjects with high aggressive PCa were older and 
less educated compared to those with low/intermediate aggressive PCa. EA research 
subjects with high aggressive PCa had a slightly higher BMI and were more likely to 
have started treatment for PCa compared to EAs with low/intermediate aggressive PCa. 
The AA research subjects with high aggressive PCa tended to have a higher intake of 
energy and total fat, were less likely to have had at least one pre-diagnostic PSA 
screening, and included a greater proportion of current and former smokers and low 
incomes compared to AAs with low/intermediate aggressive PCa.  
Table 6.2 presents differences in carotenoid levels among AAs and EAs. In 
general, the daily intake of carotenoids varied significantly between AAs and EAs, such 
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 that while EAs tended to have higher intakes of α-carotene, supplemental β-carotene and 
lutein, and higher intake of lycopene from diet and supplements, AAs had a higher 
dietary intake of β-carotene, β-cryptoxanthin and lutein + zeaxanthin. Adipose tissue 
carotenoid levels were generally higher in EAs than AAs with significant differences in 
the levels of zeaxanthin and lycopene (cis and trans). Few differences in carotenoid 
intake or adipose levels were observed by the levels of PCa aggressiveness among EAs 
and AAs. 
Multivariable-adjusted ORs and corresponding 95% CIs for high aggressive PCa 
in relation to dietary and supplemental carotenoids intake are reported in Table 6.3. 
Because of the substantial differences in carotenoids intake between AAs and EAs, 
different cut-points were used to categorize each carotenoid by race, based on 
distributions among low/intermediate aggressive PCa research subjects in the respective 
race group. Hence, results are presented separately for AAs and EAs. Among EAs, 
dietary lycopene intake was associated with a 45% lower odds of high aggressive PCa in 
the highest compared with the lowest tertile. Although supplemental lycopene use was 
not independently associated with PCa aggressiveness among EAs, total lycopene intake 
from both diet and supplements was inversely related to high aggressive PCa (OR = 0.56, 
95% CI = 0.34-0.90, highest versus lowest tertile, Ptrend = 0.03). These significant 
associations were not observed among AAs. However, dietary β-cryptoxanthin intake 
was inversely associated with high aggressive PCa among AAs only (OR = 0.56, 95% CI 
= 0.36-0.87, highest versus lowest tertile, Ptrend = 0.01). None of the other carotenoids 
was significantly associated with PCa aggressiveness among AAs or EAs. 
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 Although data on adipose tissue carotenoid levels were available for a subgroup 
of the study population, this group did not differ substantially from the total study sample 
with regard to demographic and other variables (Table 6.5). Evaluation of associations 
between adipose tissue carotenoid levels and PCa aggressiveness showed a marginally 
significant linear trend toward lower odds of high aggressive PCa for the associations of 
adipose α-carotene (Ptrend = 0.07) and lycopene (cis + trans, Ptrend = 0.11) (Table 6.4). No 
apparent associations were observed between adipose carotenoid levels and PCa 
aggressiveness among AAs. To examine the impact of missing data on the observed 
associations, an alternative analysis of associations between dietary carotenoids intake 
and PCa aggressiveness was conducted among subjects with data on adipose carotenoids 
only. These results were very similar to those reported in Table 6.3 (see Table 6.6).  
In the stratified analyses, the associations between all measured carotenoids and 
PCa aggressiveness did not vary by smoking status (data not shown). However, there 
were significant effect modifications by BMI for the associations of carotenoids intake 
and PCa aggressiveness (Table 6.7). Notably, there was suggestion of reduced odds of 
high aggressive PCa among EAs who were supplemental β-carotene users in the highest 
BMI category (≥ 30 kg/m2)  but increased odds for supplemental β-carotene use was 
observed among EAs in the lowest BMI category (< 24.9 kg/m2). Among both AAs and 
EAs, a similar interaction was observed for dietary and total lutein + zeaxanthin intake 
and BMI(all P values for interaction, < 0.10). Among EAs, it appeared that the reduced 
odds of high aggressive PCa with higher dietary lycopene was lowest among obese 
research subjects (P value for interaction =0.01); whereas among AAs, a significant 
interaction between BMI and dietary and total lycopene was observed such that increased 
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 intake of lycopene was associated with increased odds of high aggressive PCa among 
research subjects in the normal weight BMI category but not in the other BMI categories.  
6.4     DISCUSSION 
This population-based, case-control study examined associations between 
carotenoid intake and adipose tissue carotenoid levels in relation to PCa aggressiveness 
among AAs and EAs in North Carolina and Louisiana. Inverse associations were 
observed between intake of lycopene and PCa aggressiveness among EAs, and between 
β-cryptoxanthin intake and PCa aggressiveness among AAs. Marginally significant linear 
trends in the direction of reduced odds of high aggressive PCa were observed for higher 
adipose levels of α-carotene and lycopene (cis + trans) among EAs only. Evaluation of 
effect modification by BMI indicated that men with higher BMI (≥ 30 kg/m2) may have a 
greater benefit from a higher intake of certain carotenoids, while higher lycopene intake 
among AAs and use of β-carotene supplements among EAs was associated with 
increased odds of high aggressive PCa among normal weight research subjects but not 
overweight or obese subjects.  
Carotenoids are broadly categorized as pro-vitamin A (i.e., α-carotene, β-
carotene, and β-cryptoxanthin) or non-pro-vitamin A (i.e., lutein, zeaxanthin and 
lycopene) depending on whether they are converted into retinol in the body [455]. These 
carotenoids have been shown in in vitro and in vivo studies to have biological functions 
that could prevent or suppress the progression of cancer [456]. Proposed mechanisms by 
which carotenoids may influence PCa aggressiveness include induction of the apoptosis 
of malignant cells, modulation of gene expression, up-regulation of gap-junctional 
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 communication, mitigation of oxidative stress, and enhancement of antitumor immune 
responses [455-457]. Despite these mechanisms, the epidemiologic data relating to 
carotenoid intake and PCa incidence are largely inconsistent [17, 434-436]. The 
populations included in previous studies were predominantly of European decent, thus, 
the results may not apply to AAs. It is worth noting that although the current study shows 
some differences in carotenoid associations between AAs and EAs, comparisons were 
made within each race. This analytic approach minimizes confounding by unmeasured 
sociocultural factors, and possibly, biological factors that are inherently different between 
AAs and EAs [452, 458]. 
The current finding on lycopene among EAs is consistent with previous studies 
suggesting that lycopene may be beneficial in reducing the risk and aggressiveness of 
PCa. In a prospective cohort study of male health professionals, higher lycopene intake 
was associated a 21% lower risk of PCa and a high intake of tomato and tomato products, 
which are primary sources of lycopene, also was association with a 53% reduced risk of 
advance-staged PCa [449]. Gann et al. [438] found a lower risk of aggressive PCa in men 
with high plasma lycopene levels. In another prospective study, Kirsh et al. [441] 
reported an inverse association between lycopene intake and PCa incidence among men 
with a family history of PCa. Reports from some case-control studies suggest that 
lycopene may reduce the risk of PCa [450, 459], although others have failed to show an 
association [413, 460-462]. Lycopene, which in addition to tomatoes and tomato products 
can be obtained in modest amounts from watermelon, guava, and papaya,  is considered 
the most potent antioxidant carotenoid due to its exceptional singlet oxygen quenching 
ability [463]. The bioavailability of lycopene increases with cooking, partly because 
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 thermal treatment of vegetables enhances the extractability of lycopene from the 
vegetable fibers [464]. The act of processing tomatoes with oil and simultaneous 
ingestion of lycopene-based foods with fat have also been shown to promote the 
dissolution, absorption and subsequent bioavailability of lycopene [465]. Thus, the 
potential benefits of lycopene are dependent on food processing methods and dietary 
habits, which may explain the discrepancy in lycopene associations between AAs and 
EAs. As indicated in Table 2, the consumption of lycopene from food and supplements, 
as well as adipose lycopene concentrations were significantly higher in EAs than AAs. 
Hence, it appears that the potential benefits of lycopene in relation to PCa aggressiveness 
may be acquired only at higher levels of intake. Differences in lycopene associations 
between AAs and EAs also may have been influenced by gene-diet interactions that may 
vary by race. As demonstrated by Goodman et al. [466], polymorphic variants in XRCC1, 
a gene involved in base excision repair of DNA damage, can alter the ability of lycopene 
to decrease PCa risk. Evaluations of such gene-diet interactions between AAs and EAs 
would help elucidate how lycopene may differentially influence PCa among different 
population subgroups.  
β-cryptoxanthin, which is commonly found in tangerines, oranges, grapefruit, 
mangoes, fruit juices and red peppers [467], was inversely related to PCa aggressiveness, 
but only among AAs. This discrepancy may be due to the greater intake of β-
cryptoxanthin among AAs relative to EAs (Table 2). Studies have reported inverse [189, 
459] as well as positive [448, 468] associations between β-cryptoxanthin and PCa risk. 
Reviews of the literature do not provide compelling evidence for or against a protective 
association between β-cryptoxanthin and PCa incidence [17, 434-436]. Plasma β-
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 cryptoxanthin has been found to correlate inversely with markers of oxidative damage to 
DNA and lipid peroxidation in humans [469]; factors that have been causally linked to 
PCa [470]. Perhaps examining β-cryptoxanthin associations with different PCa 
phenotypes, as done in this study, may help delineate the role of β-cryptoxanthin in 
prostate carcinogenesis. The associations of α-carotene, β-carotene and lutein + 
zeaxanthin, and PCa incidence have also varied across studies [17, 189, 434-436, 448-
451]. However, evaluations of these carotenoids in the context of PCa aggressiveness are 
rare [413, 438, 440], but evolving, and may help clarify their role with PCa.  
The use of adipose tissue biomarkers of nutrient intake in assessing disease risk 
has been done in a few studies [284, 471] and continues to receive increased attention 
because of the ability of adipose tissue to reflect long-term nutritional status [472]. 
Nonetheless, the uptake and turnover rates of carotenoids in adipose tissues remain 
unclear [472]. This study suggests that higher adipose α-carotene and lycopene 
concentrations are inversely related to PCa aggressiveness, which warrants further 
investigation in larger studies. However, the possibility that adipose α-carotene and 
lycopene may have acted as markers for increased consumption of fruits and vegetables 
or as surrogates for a healthy lifestyle in general cannot be ruled out.  
Cigarette smoking has been associated with depletion of circulating carotenoid 
levels [473] and a high BMI also appear to increase the body’s carotenoids requirement 
[474]; however, only BMI was found to have a modifying effect on associations between 
carotenoids intake and PCa aggressiveness. The results suggest that men with a high BMI 
may benefit from the intake of lycopene and lutein + zeaxanthin, while β-carotene 
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 supplement intake may increase odds of aggressive disease among EAs with normal BMI 
and higher dietary lycopene may increase odds among normal BMI AAs. This is the first 
study to examine effect modification of carotenoids by BMI in relation to PCa 
aggressiveness, but of note, some studies suggest that β-carotene supplements may 
increase the risk of PCa among smokers [159, 188]. It is unclear why β-carotene 
supplements or dietary lycopene may be associated with increased odds of high 
aggressive disease among normal weight men but not overweight or obese men. Given 
the number of comparisons, the role of chance cannot be ruled out in these findings. 
Diet was assessed using a food frequency questionnaire. It is known that these 
structured instruments may be biased according to response sets [475], which in turn, 
may be related to psychological traits that either may exert a direct effect on cancer 
outcomes or indirectly affect other factors that may influence carcinogenesis [476]. Other 
limitations of the current study include the fact that carotenoids likely do not act alone, 
and thus, the results shown here may reflect interactions between individual carotenoids 
or interactions with other food components or genetic variants [383, 466]. The recall of 
dietary intakes over the year prior to diagnosis of PCa also may have been influenced by 
changes in dietary patterns after the diagnosis with PCa. Such recall inaccuracies would 
have resulted in non-differential misclassification because the research subjects were not 
likely to consider the extent of their disease aggressiveness in answering questions 
relating to food and supplements intake. Moreover, laboratory personnel involved in the 
analyses of adipose carotenoid levels were blinded to the PCa attributes of the samples, 
eliminating the possibility for differential misclassification of adipose measurements. 
Therefore, non-differential, rather than differential, misclassification may have attenuated 
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 the ORs to some extent. Because it is possible that some carotenoids may exert their 
beneficial effects in the early stages of carcinogenesis [456], the one-year reference 
period for the dietary assessment may not be etiologically relevant to PCa, but can 
provide an estimate of usual dietary patterns, [453], while adipose tissue concentrations 
reflect longer-term exposure. It is conceivable that the adipose tissue carotenoid levels 
can be altered through the metabolic processes of cancer; however, studies show that 
adipose carotenoid levels are less susceptible to changes due to the presence of a tumor 
[477]. Additionally, studies show that adipose carotenoid levels correlates inversely with 
body fat percentage [296]; thus, it would have been desirable to control for body fat 
mass. However, the potential confounding effect of body fat burden was partially 
considered by adjusting for BMI (in the BMI unstratified analyses). The small sample 
size may have reduced the statistical power of the study. Furthermore, since multiple 
comparisons were made there is the possibility of chance findings. Despite these 
limitations, the design of the study uniquely captures the complex pathological and 
clinical attributes of PCa, and the findings of this analysis add to the limited knowledge 
of the potential role of carotenoids in PCa aggressiveness within specific race groups.   
6.5     CONCLUSIONS 
In summary, this analysis shows a statistically significant inverse association between 
lycopene intake and PCa aggressiveness among EAs, and between β-cryptoxanthin and 
PCa aggressiveness among AAs. Higher adipose tissue α-carotene and lycopene (cis + 
trans) levels also appear to be inversely related to PCa aggressiveness among EAs. In 
addition, the results suggest that certain carotenoids may have greater beneficial impact 
among obese individuals with the possibility of detrimental effects among normal weight 
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 men, findings that warrant further investigation in larger studies. Although some of the 
findings vary by race, this was likely due to the variations in the levels of carotenoid 
intake between AAs and EAs. Overall, the findings support suggestions that a higher 
consumption of fruits and vegetables, which are the main sources of carotenoids, may be 
inversely associated with CaP aggressiveness.  
165 
 
 166 
Table 6.1 Characteristics of research subjects by race and prostate cancer aggressiveness  
 
Characteristics 
European Americans 
n = 1,079 
African Americans 
n = 1,023 
 High 
 aggressive PCa 
 
(n=164 ) 
Low/intermediate 
aggressive PCa 
 
(n=915 ) 
 
P ‡ 
High  
aggressive PCa 
 
(n=206 ) 
Low/intermediate 
aggressive PCa 
 
(n=817) 
P ‡ 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
Age, years  67 (8) 64 (8) <0.0001 64 (8) 62 (8) 0.004 
Energy intake, kcals/day 2339.3 (952.0) 2320.5 (865.7) 0.80 2799.6 (1232.4) 2593.0 (1146.0) 0.02 
Dietary fat intake, grams/day 94.5 (42.4) 91.1 (39.2) 0.31 103.9 (52.1) 94.8 (48.4) 0.02 
Body mass index (BMI), kg/m2  30.5 (5.1) 29.0 (4.8) 0.0006 29.9 (6.7) 29.2 (5.4) 0.16 
 N % N %  N % N %  
Study Site           
 NC 73 45 448 49 0.29 92 45 386 47 0.51 
    LA (pre & post  Katrina)      
 
91 55 467 51 114 55 431 53 
Family History of Prostate Cancer           
    No affected 1st degree relative 136 83 696 76 0.05 157 76 606 74 0.55 
    At least 1 affected 1st degree relative 
 
28 17 219 24 49 24 211 26 
PSA Screening History           
0 screenings 40 24 153 17 0.06 120 58 307 38 <0.0001 
1-7 screenings 68 42 405 44 53 26 338 41 
> 7 screenings 
 
56 34 357 39 33 16 172 21 
Comorbidities           
0 84 51 503 55 0.05 88 43 382 47 0.39 
1 31 19 214 23 53 26 216 26 
2 29 18 98 11 36 17 106 13 
≥ 3 20 12 100 11 27 14 109 14 
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Started PCa treatment at start of study           
No 11 7 99 11 0.007 20 10 112 14 0.20 
Yes 146 89 720 79 163 79 599 73 
Unknown 7 4 96 10 23 11 106 13 
Education         
    Less than high school education 27 17 81 9 0.005 85 41 243 30 0.001 
    High school graduate/ some college 79 48 432 47 102 50 438 54 
    College graduate  
 
58 35 402 44 19 9 135 16 
Income Level           
    ≤ $20, 000 24 15 78 9 0.11 82 40 234 29 0.0005 
    $20,001 - $40,000 33 20 184 20 52 25 212 26 
    $40,001 - $70,000 38 23 217 24 24 12 171 21 
    >$70,000 53 32 359 39 22 11 130 16 
    Unknown  16 10 77 8 26 12 70 8 
Smoking Status           
    Never 59 36 330 36 0.76 40 19 276 34 <0.001 
    Former smoker 87 53 501 55 107 52 390 48 
    Current smoker 
 
18 11 84 9 59 29 151 18 
NSAID  Use           
    No 56 34 305 33 0.85 84 41 364 45 0.33 
    Yes 108 66 608 67 120 59 446 55 
 
Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as follows: 
high aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); low/intermediate aggressive: all other 
cases. 
 
Abbreviations: PCa – Prostate Cancer; LA – Louisiana; NC –North Carolina; NSAIDs – Nonsteroidal anti-inflammatory drugs; PSA – prostate 
specific-antigen;  
SD – Standard deviation 
 
‡Test for differences between high and low/intermediate PCa performed using t-test for continuous variables and chi-square tests for categorical 
variables.  
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Table 6.2 Mean difference in carotenoids from diet, supplements, and adipose tissue by race and prostate cancer aggressiveness 
 
 
 
European 
Americans 
 
n = 1,079 
 
African 
Americans 
 
n = 1,023 
 
% 
diff 
              European Americans African Americans 
 
High aggressive 
PCa 
 
n = 164 
 
Low/intermediate 
aggressive PCa 
 
n = 915 
 
P † 
 
 
High aggressive 
PCa 
 
n = 206 
 
Low/intermediate 
Aggressive PCa 
 
n = 817 
 
P † 
 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
α-carotene   µg/day          
 dietary 661.9 (741.7) 596.3 (730.2) 10 ‡  610.0 (874.3) 671.1 (715.5) 0.39 597.6 (829.4)  595.9 (703.6) 0.98 
β-carotene   µg/day           
 dietary 3914.5 (3028.0) 4788.6 (3898.9) -22 ‡ 3830.8 (3095.6) 3929.5 (3017.2) 0.70 4834.6 (3951.4) 4777.1 (3887.8) 0.85 
supplement  a 442.1 (1607.4) 235.0 (859.2) 47 ‡  300.9 (447.3) 467.4 (1734.2) 0.01 192.8 (1064.9) 245.6 (799.5) 0.50 
diet + supplement 4356.5 (3477.9) 5023.6 (4028.0) -15 4131.6 (3196.4) 4396.9 (3526.1) 0.37 5027.3 (4170.0) 5022.7 (3994.1) 0.99 
β-cryptoxanthin   µg/day          
 dietary 162.9 (134.3) 223.5 (204.3) -37 ‡  160.8 (117.8) 163.3 (137.1) 0.81 199.3 (171.8) 229.6 (211.4) 0.03 
Lutein + zeaxanthin   µg/day           
 dietary 3230.5 (2708.2) 4231.4 (3533.4) -31 ‡ 3204.3 (2706.8) 3235.2 (2709.9) 0.89 4133.5 (3149.9) 4256.1 (3625.1) 0.63 
supplement (lutein) a 81.7 (126.5) 45.5 (123.4) 44 ‡  84.0 (116.1) 81.3 (128.3) 080 32.8 (83.1) 48.8 (131.4) 0.03 
diet + supplement 3312.2 (2736.6) 4277.0 (3550.0) -29 ‡  3288.2 (2723.3) 3316.5 (2740.5) 0.90 4166.3 (3151.3) 4304.9 (3644.9) 0.62 
Lycopene   µg/day          
 dietary 6715.8 (7841.9) 5538.9 (7790.7) 17 ‡  5993.8 (5770.4) 6845.3 (8153.6) 0.10 5439.7 (8294.3) 5563.9 (7663.6) 0.84 
 supplement  a 85.3 (201.3) 66.7 (141.7) 22 ‡  85.0 (133.4) 85.3 (211.2) 0.97 60.5 (117.6) 68.3 (147.2) 0.42 
 diet + supplement 6801.1 (7855.4) 5605.6 (7794.4) 18 ‡ 6078.8 (5773.4) 6930.6 (8168.5) 0.10 5500.3 (8302.8) 5632.2 (7666.0) 0.83 
 
Adipose tissue carotenoid levels   
µg/day  
N = 581 
Mean (SD) 
N = 358 
Mean (SD)  
N = 89 
Mean (SD) 
N = 492 
Mean (SD)  
N = 66 
Mean (SD) 
N = 292 
Mean (SD) 
 
 α-carotene   0.04 (0.05) 0.03 (0.05) 25 0.03 (0.06) 0.04 (0.05) 0.26 0.03 (0.03) 0.03 (0.05) 0.33 
cis-β-carotene   0.10 (0.14) 0.10 (0.15) 0 0.09 (0.16) 0.10 (0.14) 0.42 0.10 (0.17) 0.09 (0.14) 0.81 
trans-β-carotene   0.19 (0.27) 0.16 (0.27) 16 0.16 (0.27) 0.19 (0.28) 0.32 0.17 (0.32) 0.16 (0.26) 0.79 
α-cryptoxanthin   0.03 (0.03) 0.02 (0.02) 33 0.02 (0.02) 0.03 (0.03) 0.16 0.02 (0.02) 0.02 (0.03) 0.49 
β-cryptoxanthin   0.09 (0.11) 0.08 (0.10) 11 0.08 (0.09) 0.09 (0.11) 0.28 0.07 (0.08) 0.08 (0.10) 0.84 
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Lutein   0.21 (0.22) 0.20 (0.24) 5 0.18 (0.17) 0.21 (0.23) 0.20 0.19 (0.23) 0.20 (0.24) 0.82 
Zeaxanthin   0.10 (0.16) 0.07 (0.08) 30 ‡ 0.08 (0.07) 0.10 (0.17) 0.03 0.07 (0.08) 0.08 (0.09) 0.46 
Lycopene 
(cis + trans) 0.35 (0.40) 0.28 (0.34) 
20 ‡ 0.28 (0.32) 0.36 (0.42) 0.04 0.28 (0.32) 0.28 (0.35) 0.93 
cis-lycopene   0.22 (0.26) 0.17 (0.21) 23 ‡ 0.17 (0.20) 0.22 (0.27) 0.05 0.17 (0.20) 0.17 (0.22) 0.96 
all-trans-lycopene    0.13 (0.15) 0.10 (0.13) 23 
‡  0.10 (0.12) 0.13 (0.15) 0.05 0.11 (0.12) 0.10 (0.13) 0.84 
 
Abbreviations: PCa – prostate cancer; SD – standard deviation 
a Among supplement users only  
‡ Significant p-values (< 0.05) for test of difference between European Americans and African Americans  
† Chi-square test for difference by level of prostate cancer aggressiveness 
 
 
 
 
 Table 6.3 Odds ratios (ORs) and 95% confidence intervals (CIs) for associations 
between dietary and supplemental carotenoids intake and prostate cancer 
aggressiveness among European-American ( n = 1,079) and African-American men 
(1,023) 
Carotenoids 
 
High aggressive/ 
low-
intermediate 
aggressive 
OR (95% CI) a OR (95% CI) b Trend p-value c 
α-carotene  
     Dietary   µg/day  
European American 
 27.20 - 324.13 64/305 1.00 (ref) 1.00 (ref) 0.33 
324.14 - 626.76 48/305 0.74 (0.49-1.12) 0.72 (0.47-1.11)  
626.77 - 9812.26 52/305 0.80 (0.53-1.20) 0.76 (0.49-1.18)  
African American     
 11.83 - 262.11 71/273 1.00 (ref) 1.00 (ref) 0.77 
262.12 - 585.99 63/272 0.89 (0.61-1.30) 0.79 (0.52-1.21)  
586.00 - 9558.28 72/272 1.05 (0.72-1.52) 0.99 (0.64-1.52)  
      
β-carotene       
European American  
     Dietary   µg/day  
 194.86 - 2327.81 61/305 1.00 (ref) 1.00 (ref) 0.96 
2327.82 - 4046.15 44/305 0.68 (0.45-1.04) 0.67 (0.43-1.05)  
4046.16 - 25124.05 59/305 0.91 (0.61-1.35) 0.92 (0.60-1.43)  
    Supplement   µg/day  
 non-users 91/536 1.00 (ref) 1.00 (ref) 0.44 
63.00 - 600.00 61/301 1.20 (0.84-1.71) 1.39 (0.96-2.02)  
600.01 - 16470.00 12/78 0.88 (0.46-1.69) 1.00 (0.50-1.97)  
    Diet + supplement   µg/day  
 346 .80 - 2566.41 60/304 1.00 (ref) 1.00 (ref) 0.75 
2566.42 - 4458.51 48/306 0.76 (0.50-1.15) 0.76 (0.49-1.18)  
4458.52 - 25512.15 56/305 0.87 (0.58-1.30) 0.88 (0.56-1.37)  
African American  
     Dietary   µg/day  
 286.48 - 2544.86 61/273 1.00 (ref) 1.00 (ref) 0.64 
2544.87 - 5156.05 69/272 1.16 (0.79-1.70) 1.07 (0.70-1.62)  
5156.06 - 32901.26 76/272 1.22 (0.84-1.78) 1.12 (0.72-1.73)  
    Supplement   µg/day  
 non-users 153/564 1.00 (ref) 1.00 (ref) 0.37 
63.00 - 590.00 26/92 1.08 (0.67-1.74) 1.22 (0.74-2.03)  
590.01 - 15600 27/161 0.62 (0.40-0.98) 0.76 (0.48-1.21)  
    Diet + supplement   µg/day  
 286.48 - 2773.39 67/273 1.00 (ref) 1.00 (ref) 0.88 
2773.40 - 5405.28 69/272 1.05 (0.72-1.53) 0.98 (0.65-1.47)  
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 5405.29 - 32901.26 70/272 1.02 (0.70-1.49) 0.96 (0.62-1.49)  
      
β-cryptoxanthin  
     Dietary   µg/day  
European American 
 6.04 - 86.14 51/305 1.00 (ref) 1.00 (ref) 0.62 
86.15 - 180.62 52/305 1.00 (0.65-1.52) 1.00 (0.64-1.55)  
180.63 - 1082.55 61/305 1.18 (0.78-1.77) 1.11 (0.71-1.72)  
African American     
 3.53 - 116.43 87/273 1.00 (ref) 1.00 (ref) 0.01 
116.44 - 243.34 65/272 0.75 (0.52-1.08) 0.74 (0.50-1.11)  
243.34 - 1594.39 54/272 0.63 (0.43-0.92) 0.56 (0.36-0.87)  
      
Lutein + Zeaxanthin  
European American  
     Dietary   µg/day  
 289.67 - 1830.51 60/305 1.00 (ref) 1.00 (ref) 0.49 
1830.52 - 3253.94 44/305 0.71 (0.47-1.09) 0.71 (0.45-1.12)  
3253.95 - 30165.13 60/305 1.01 (0.68-1.50) 1.05 (0.67-1.63)  
    Supplement   µg/day  
 non-users 106/617 1.00 (ref) 1.00 (ref)  
users 58/298 0.90 (0.64-1.28) 0.79 (0.55-1.14)  
    Diet + supplement   µg/day  
 289.67 - 1907.94 59/305 1.00 (ref) 1.00 (ref) 0.56 
1907.95 - 3318.23 46/305 0.75 (0.49-1.15) 0.75 (0.48-1.18)  
3318.23 - 31665.13 59/305 1.01 (0.69-1.50) 1.04 (0.69-1.63)  
 African American  
     Dietary   µg/day  
 112.25 - 2299.78 64/273 1.00 (ref) 1.00 (ref) 0.82 
2299.79 - 4408.18 72/272 1.15 (0.79-1.68) 1.11 (0.74-1.68)  
408.19 - 36608.75 70/272 1.10 (0.75-1.61) 1.08 (0.70-1.65)  
    Supplement   µg/day  
 non-users 177/671 1.00 (ref) 1.00 (ref)  
users  29/137 1.34 (0.87-2.06) 1.03(0.65-1.63)  
    Diet + supplement   µg/day  
 112.25 - 2309.42 63/273 1.00 (ref) 1.00 (ref) 0.85 
2309.43 - 4461.54  74/272 1.20 (0.82-1.75)  1.19 (0.78-1.79)  
4461.55 - 37558.75   69/272 1.10 (0.75-1.61) 1.09 (0.71-1.67)  
      
Lycopene    
European American  
     Dietary   µg/day  
 344.77 - 3605.57 70/305 1.00 (ref) 1.00 (ref) 0.02 
3605.58 - 6299.34 48/305 0.73 (0.48-1.09) 0.67 (0.44-1.02)  
6299.35 - 100250.76 46/305 0.74 (0.49-1.12) 0.55 (0.34-0.89)  
    Supplement   µg/day  
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  non-users 114/664 1.00 (ref) 1.00 (ref) 0.27 
64.28 - 250.00 17/126 1.91 (0.80-4.57) 2.14 (0.87-5.24)  
250.01 - 5000.00 33/125 1.09 (0.74-1.60) 1.22 (0.82-1.83)  
    Diet + supplement   µg/day  
 344.77 - 3649.40 70/305 1.00 (ref) 1.00 (ref) 0.03 
3649.41 - 6352.12 48/305 0.72 (0.48-1.08) 0.67 (0.44-1.02)  
6352.13 - 100550.76 46/305 0.74 (0.49-1.12) 0.56 (0.34-0.90)  
African American  
     Dietary   µg/day  
 21.52 - 2390.06 61/273 1.00 (ref) 1.00 (ref) 0.58 
2390.07 - 5003.81 70/272 1.23 (0.84-1.81) 1.27 (0.83-1.94)  
5003.82 - 85677.94 73/272 1.29 (0.88-1.89) 1.22 (0.77-1.93)  
    Supplement   µg/day  
 non-users 161/630 1.00 (ref) 1.00 (ref) 0.57 
64.28 - 250.00 12/88 0.86 (0.39-1.89) 0.97 (0.43-2.22)  
250.01 - 1000.00 33/99 0.97 (0.65-1.45) 1.14 (0.74-1.73)  
    Diet + supplement   µg/day  
 21.52 - 2448.39 62/273 1.00 (ref) 1.00 (ref) 0.70 
2448.39 - 5064.89 70/272 1.22 (0.83-1.79) 1.21 (0.80-1.85)  
5064.90 - 85677.94 72/272 1.25 (0.85-1.84) 1.16 (0.73-1.84)  
 
Abbreviation: PCa – prostate cancer 
a Adjusted for age 
b Additional adjustment for PSA screening history, BMI, smoking status, education, income, 
NSAIDs use, total dietary fat intake, and study site 
c Multivariable-adjusted trend p-value  
d Categorized into two levels because limited variability in dose did not allow for creation of 
meaningful tertile categories  
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 Table 6.4 Associations between adipose tissue carotenoid levels and prostate cancer 
aggressiveness among European Americans (n = 581) and African Americans ( n = 358) 
 
Carotenoids 
 
High 
aggressive/ 
low-
intermediate 
aggressive  
OR (95% CI) a OR (95% CI) b Trend p-value c 
α-carotene   µg/g 
European American 
 0.003 - 0.015 26/128 1.00 (ref) 1.00 (ref)  
0.016 - 0.039 30/116 1.15 (0.63-2.08) 1.52 (0.78-2.94)  
0.040 - 0.454 12/112 0.49 (0.24-1.03) 0.58 (0.25-1.32) 0.07 
African American     
 0.003 - 0.012 16/54 1.00 (ref) 1.00 (ref)  
0.013 - 0.025 7/53 0.34 (0.11-1.09) 0.45 (0.15-1.34)  
0.026 - 0.450 13/49 1.07 (0.39-2.92) 1.13 (0.43-3.00) 0.70 
cis-β-carotene   µg/g 
European American 
 0.003 - 0.032 28/138 1.00 (ref) 1.00 (ref)  
0.033 - 0.088 27/134 0.89 (0.49-1.61) 1.06 (0.57-1.99)  
0.089 - 1.233 27/135 0.88 (0.49-1.59) 1.16 (0.60-2.25) 0.65 
African American     
 0.003 - 0.028 23/71 1.00 (ref) 1.00 (ref)  
0.029 - 0.073 7/71 0.60 (0.12-1.74) 0.74 (0.28-1.22)  
0.074 - 1.163 24/71 0.93 (0.47-1.83) 1.13 (0.52-2.44) 0.71 
trans-β-carotene   µg/g 
European American 
 0.003 - 0.061 33/154 1.00 (ref) 1.00 (ref)  
0.062 - 0.171 34/152 0.95 (0.56-1.64) 1.11 (0.62-1.99)  
0.172 - 2.408 21/151 0.58 (0.32-1.06) 0.75 (0.39-1.45) 0.31 
African American     
 0.003 - 0.045 21/88 1.00 (ref) 1.00 (ref)  
0.046 - 0.126 17/88 0.85 (0.42-1.73) 0.70 (0.32-1.53)  
0.127 - 2.322 22/88 0.97 (0.49-1.91) 1.12 (0.52-2.39) 0.57 
 α-cryptoxanthin   µg/g 
European American 
 0.003 - 0.013 23/113 1.00 (ref) 1.00 (ref)  
0.014 - 0.025 18/112 0.73 (0.37-1.45) 0.84 (0.41-1.75)  
0.026 - 0.219 20/115 0.82 (0.42-1.60) 0.97 (0.46-2.02) 0.99 
African American     
 0.003 - 0.010 15/62 1.00 (ref) 1.00 (ref)  
0.011 - 0.024 14/62 0.92 (0.41-2.07) 0.94 (0.39-2.33)  
0.025 - 0.165 12/61 0.82 (0.35-1.90) 1.03 (0.40-2.68) 0.93 
β-cryptoxanthin   µg/g 
European American 
 0.003 - 0.037 30/151 1.00 (ref) 1.00 (ref)  
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 0.038 - 0.089 32/148 1.03 (0.59-1.79) 1.19 (0.64-2.19)  
0.090 - 0.909 25/146 0.83 (0.46-1.49) 0.92 (0.48-1.76) 0.67 
African American     
 0.003 - 0.030 22/86 1.00 (ref) 1.00 (ref)  
0.031 - 0.070 17/82 0.82 (0.41-1.67) 0.71 (0.32-1.61)  
0.071 - 0.638 19/83 0.90 (0.45-1.78) 1.00 (0.46-2.19) 0.77 
Lutein   µg/g 
European American 
 0.004 - 0.078 28/161 1.00 (ref) 1.00 (ref)  
0.079 - 0.219 31/161 1.22 (0.69-2.14) 1.26 (0.69-2.31)  
0.220 - 1.457 29/159 1.01 (0.57-1.79) 1.27 (0.68-2.35) 0.51 
African American     
 0.003 - 0.069 23/95 1.00 (ref) 1.00 (ref)  
0.070 - 0.204 22/94 0.96 (0.50-1.85) 0.95 (0.47-1.95)  
0.205 - 2.033 20/94 0.89 (0.46-1.73) 1.02 (0.49-2.12) 0.92 
Zeaxanthin   µg/g 
European American 
 0.003 - 0.038 28/156 1.00 (ref) 1.00 (ref)  
0.039 - 0.098 40/157 1.42 (0.83-2.44) 1.73 (0.96-3.09)  
0.099 - 2.985 20/154 0.76 (0.41-1.43) 0.96 (0.49-1.88) 0.78 
African American     
 0.003 - 0.028 24/93 1.00 (ref) 1.00 (ref)  
0.029 - 0.073 20/93 0.83 (0.43-1.61) 0.87 (0.42-1.83)  
0.074 - 0.713 19/91 0.83 (0.42-1.63) 1.01 (0.47-2.17) 0.89 
Lycopene (cis + trans)  µg/g 
European American 
 0.004 - 0.137 35/153 1.00 (ref) 1.00 (ref)  
0.138 - 0.371 34/152 1.02 (0.60-1.73) 1.23 (0.69-2.18)  
0.372 - 3.164 17/152 0.51 (0.27-0.96) 0.64 (0.34-1.31) 0.11 
African American     
 0.004 - 0.100 23/91 1.00 (ref) 1.00 (ref)   
0.101 - 0.272 15/87 0.74 (0.36-1.51) 0.69 (0.31-1.56)  
0.273 - 3.013 23/88 1.08 (0.56-2.07) 1.11 (0.53-2.35) 0.62 
cis-lycopene   µg/g 
European American 
 0.003 - 0.080 33/155 1.00 (ref) 1.00 (ref)  
0.081 - 0.234 37/157 1.14 (0.67-1.93) 1.52 (0.85-2.71)  
0.235 - 2.049 18/152 0.57 (0.31-1.07) 0.79 (0.40-1.54) 0.30 
African American     
 0.003 - 0.059 25/92 1.00 (ref) 1.00 (ref)  
0.060 - 0.168 16/88 0.74 (0.37-1.49) 0.74 (0.34-1.63)  
0.169 - 1.879 22/90 0.94 (0.49-1.80) 0.97 (0.46-2.02) 0.96 
all-trans-lycopene   µg/g 
European American 
 0.003 - 0.050 35/158 1.00 (ref) 1.00 (ref)  
0.051 - 0.137 33/154 0.99 (0.58-1.69) 1.11 (0.63-1.99)  
0.138 – 1.115 18/154 0.54 (0.29-1.01) 0.69 (0.36-1.36) 0.25 
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 African American     
 0.003 - 0.037 22/95 1.00 (ref) 1.00 (ref)  
0.038 - 0.102 17/90 0.84 (0.42-1.70) 0.85 (0.39-1.85)  
0.103 - 1.134 22/92 1.07 (0.55-2.07) 1.10 (0.51-2.34) 0.72 
 
a  Some categories may not sum to total number of subjects because of missing data 
 
b Adjusted for age 
 
c additional adjustment for PSA screening history, BMI, smoking status, education, income, 
NSAIDs use, total dietary fat intake, study site, family history of prostate cancer, comorbidities, 
and prostate cancer treatment status. 
 
d Multivariable-adjusted trend p-values  
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 Table 6.5 Characteristics of subsample with data on adipose carotenoids compared to 
the total study sample  
 
Characteristics 
Total study 
sample 
 
n = 2,102 
Subsample with 
data on adipose 
carotenoid levels 
n = 939 
 
 Mean (SD) Mean (SD) p-value 
Age, years  63.2 (7.9) 63.3 (7.9) 0.66 
Energy intake, kcals/day 2474.8 (1040.3) 2454.9 (1019.1) 0.62 
Dietary fat intake, grams/day 94.0 (44.7) 94.7 (44.5) 0.68 
Body mass index (BMI), kg/m2  29.7 (5.3) 29.9 (5.2) 0.29 
 n %  n %  
Race          
African American 361 38 662 57 <0.001 
European American 584 62 495 43  
Prostate cancer aggressiveness          
      Low aggressive  485 51 589 51 0.48 
      High aggressive 304 32 354 31  
     Intermediate aggressive 156 16 214 18  
Study Site      
     NC 999 48 408 43 0.04 
     LA (pre & post  Katrina)      1103 52 531 57 
Family History of Prostate Cancer      
    No affected 1st degree relative 1595 76 694 74 0.24 
    At least 1 affected 1st degree 
relative 
507 24 245 26 
PSA Screening History      
     0 screenings 620 30 244 26 0.02 
     1-7 screenings 864 41 375 40 
     > 7 screenings 618 29 320 34 
comorbidities      
0 1057 50 497 53 0.53 
1 514 25 220 24 
2 269 13 107 11 
≥ 3 255 12 115 12 
Started PCa treatment at start of 
study 
     
No 242 12 94 10 0.42 
 Yes 1628 77 745 79 
Unknown 232 11 100 11 
Education     
    Less than high school education 436 21 169 18 0.03 
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     High school graduate/ some 
college 
1051 50 455 48 
    College graduate  614 29 315 34 
Income Level      
    ≤ $20, 000 418 20 154 17 0.02 
    $20,001 - $40,000 481 23 188 20 
    $40,001 - $70,000 450 21 209 22 
     >$70,000 564 27 294 31 
    Unknown  189 9 94 10  
Smoking Status      
     Never 705 33 353 38 0.04 
     Former smoker 1085 52 470 50 
     Current smoker 312 15 116 12 
NSAID  Use      
     No 809 39 361 38 0.90 
     Yes 1282 61 578 62 
 
Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and 
PSA level at diagnosis and classified as follows: high aggressive (Gleason sum ≥8 or PSA 
>20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); low /intermediate aggressive: all 
other cases. 
 
Abbreviations: PCa – Prostate Cancer; LA – Louisiana; NC –North Carolina; NSAIDs – 
Nonsteroidal anti-inflammatory drugs; PSA – prostate specific-antigen; SD – Standard 
deviation 
 
‡Test for differences between two study populations were done using t-test for continuous 
variables and chi-square tests for categorical variables. 
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 Table 6.6 (Sensitivity Analyses) Associations between dietary carotenoids and prostate 
cancer aggressiveness among European Americans and African Americans with data on 
adipose tissue carotenoid level only (n = 939) 
 
Carotenoids 
 
High 
aggressive/ 
low-
intermediate 
aggressive 
OR (95% CI) a OR (95% CI) b 
Trend 
p-value 
c 
α-carotene  
     Dietary   µg/day  
European American 
 27.20 - 324.13 35/173 1.00 (ref) 1.00 (ref) 0.33 
324.14 – 626.76 23/157 0.71 (0.40-1.27) 0.75 (0.41-1.41)  
626.77– 9812.26 31/162 0.89 (0.52-1.52) 0.88 (0.48-1.64)  
African American     
 11.83 – 262.11 24/94 1.00 (ref) 1.00 (ref) 0.92 
262.12 – 585.99 17/107 0.60 (0.30-1.20) 0.40 (0.18-1.16)  
586.00 – 9558.28 25/91 1.07 (0.57-2.01) 0.76 (0.36-1.62)  
      
β-carotene       
European American  
     Dietary   µg/day  
 194.86 - 2327.81 34/163 1.00 (ref) 1.00 (ref) 0.44 
2327.82 - 4046.15 19/179 0.48 (0.26-1.06) 0.50 (0.26-1.04)  
4046.16 - 25124.05 36/150 1.05 (0.62-1.78) 1.07 (0.58-1.96)  
    Supplement   µg/day  
 non-users 48/277 1.00 (ref) 1.00 (ref) 0.15 
63.00 - 600.00 33/181 1.09 (0.67-1.77) 1.35 (0.80-2.28)  
600.01 - 16470.00 8/34 1.36 (0.59-3.15) 1.73 (0.70-4.24)  
    Diet + supplement   µg/day  
 346 .80 - 2566.41 31/162 1.00 (ref) 1.00 (ref) 0.50 
2566.42 - 4458.51 24/179 0.86 (0.38-1.21) 0.71 (0.38-1.33)  
4458.52 - 25512.15 34/151 1.08 (0.62-1.85) 1.10 (0.60-2.04)  
African American  
     Dietary   µg/day  
 286.48 - 2544.86 12/95 1.00 (ref) 1.00 (ref) 0.25 
2544.87 - 5156.05 27/95 2.27 (0.93-4.77) 1.64 (0.74-3.64)  
5156.06 - 32901.26 27/102 2.03 (0.97-4.24) 1.81 (0.77-4.23)  
    Supplement   µg/day  
 non-users 50/211 1.00 (ref) 1.00 (ref) 0.83 
63.00 - 590.00 7/25 1.35 (0.55-3.35) 1.24 (0.46-3.38)  
590.01 - 15600 9/56 0.69 (0.32-1.50) 0.87 (0.38-1.97)  
    Diet + supplement   µg/day  
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  286.48 - 2773.39 16/94 1.00 (ref) 1.00 (ref) 0.69 
2773.40 - 5405.28 25/95 1.54 (0.77-3.09) 1.15 (0.54-2.43)  
5405.29 - 32901.26 25/103 1.39 (0.70-2.77) 1.20 (0.54-2.68)  
      
β-cryptoxanthin  
     Dietary   µg/day  
European American 
 6.04 - 86.14 19/170 1.00 (ref) 1.00 (ref) 0.38 
86.15 - 180.62 38/159 2.10 (0.89-3.82) 1.94 (0.64-3.64)  
180.63 - 1082.55 32/163 1.70 (0.92-3.15) 1.57 (0.80-3.07)  
African American     
 3.53 - 116.43 25/101 1.00 (ref) 1.00 (ref) 0.19 
116.44 - 243.34 22/102 0.88 (0.46-1.66) 0.75 (0.37-1.53)  
243.34 - 1594.39 19/89 0.87 (0.45-1.70) 0.59 (0.27-1.28)  
      
Lutein + Zeaxanthin  
European American  
     Dietary   µg/day  
 289.67 - 1830.51 30/166 1.00 (ref) 1.00 (ref) 0.21 
1830.52 - 3253.94 24/166 0.72 (0.40-1.30) 0.82 (0.43-1.56)  
3253.95 - 30165.13 35/160 1.20 (0.70-2.07) 1.34 (0.71-2.50)  
    Supplement   µg/day  
 non-users 59/325 1.00 (ref) 1.00 (ref)  
users 30/167 1.04 (0.64-1.69) 0.90 (0.54-1.52)  
    Diet + supplement   µg/day  
 289.67 - 1907.94 28/168 1.00 (ref) 1.00 (ref) 0.26 
1907.95 - 3318.23 28/164 0.91 (0.51-1.63) 1.06 (0.57-1.99)  
3318.23 -31665.13 33/160 1.23 (0.70-2.15) 1.40 (0.73-2.66)  
 African American  
     Dietary   µg/day  
 112.25 - 2299.78 17/103 1.00 (ref) 1.00 (ref) 0.42 
2299.79 - 4408.18 24/90 1.57 (0.79-3.12) 1.11 (0.52-2.37)  
4408.19 - 36608.75 25/99 1.53 (0.78-3.02) 1.35 (0.63-2.90)  
    Supplement   µg/day  
 non-users 55/248 1.00 (ref) 1.00 (ref)  
users  11/44 0.89 (0.43-1.83) 0.69 (0.32-1.51)  
    Diet + supplement   µg/day  
 112.25 - 2309.42 17/102 1.00 (ref) 1.00 (ref) 0.42 
2309.43 - 4461.54 24/91 1.53 (0.77-3.04)  1.10 (0.51-2.35)  
4461.55 - 37558.75  25/99 1.52 (0.77-2.99) 1.35 (0.63-2.88)  
      
Lycopene    
European American  
     Dietary   µg/day  
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  344.77 - 3605.57 34/162 1.00 (ref) 1.00 (ref) 0.18 
3605.58 - 6299.34 28/154 0.87 (0.50-1.52) 0.83 (0.46-1.51)  
6299.35 -100250.76 27/176 0.81 (0.46-1.41) 0.63 (0.32-1.23)  
    Supplement   µg/day 
 non-users 54/243 1.00 (ref) 1.00 (ref) 0.95 
64.28 - 250.00 13/114 1.40 (0.38-5.15) 1.46 (0.38-5.63)  
250.01 - 5000.00 22/135 0.86 (0.51-1.47) 1.00 (0.57-1.76)  
Diet + supplement   µg/day 
 344.77 - 3649.40 33/165 1.00 (ref) 1.00 (ref) 0.26 
3649.41 - 6352.12 29/150 0.98 (0.56-1.70) 0.96 (0.53-1.74)  
6352.13 - 100550.76 27/177 0.85 (0.49-1.49) 0.69 (0.35-1.37)  
African American  
Dietary   µg/day  
 21.52 - 2390.06 15/97 1.00 (ref) 1.00 (ref) 0.79 
2390.07 - 5003.81 23/87 1.82 (0.89-3.74) 1.69 (0.76-3.75)  
5003.82 - 85677.94 26/108 1.72 (0.85-3.48) 1.36 (0.59-3.01)  
Supplement   µg/day 
 
 
non-users 42/205 1.00 (ref) 1.00 (ref) 0.70 
64.28 - 250.00 14/40 1.78 (0.60-4.76) 1.94 (0.52-6.32)  
250.01 - 1000.00 10/47 0.99 (0.46-2.10) 1.10 (0.49-2.45)  
Diet + supplement   µg/day 
 
 
21.52 - 2448.39 16/98 1.00 (ref) 1.00 (ref) 0.79 
2448.39 - 5064.89 22/87 1.72 (0.84-3.51) 1.56 (0.71-3.44)  
5064.90 - 85677.94 26/107 1.67 (0.84-3.34) 1.31 (0.58-2.96)  
 
a Adjusted for age 
b Additional adjustment for PSA screening history, BMI, smoking status, education, income, NSAIDs 
use, total dietary fat intake, and study site 
c First value represents age-adjusted trend p-values and the second is the multivariable adjusted trend 
p-value 
d  Multivariable-adjusted trend p-value  
e Categorized into two levels because limited variability in dose did not allow for creation of 
meaningful tertile categories       
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 Table 6.7 Stratified analyses of associations between dietary carotenoids and prostate cancer 
aggressiveness by BMI among European Americans (n = 1,079) and African Americans (n = 
1,023). 
 
 European Americans African Americans  
          
 
High 
aggressive/ 
low-
intermediate 
aggressive 
PCa 
OR (95% CI) ‡ 
High 
aggressive/ 
low-
intermediate 
aggressive 
PCa 
OR (95% CI) ‡ 
Dietary α-carotene (µg/day) a 
BMI 
≤ 24.9 
kg/m2 
< median 9/79 1.00 (ref) 19/92 1.00 (ref) 
≥ median 11/80 0.73 (0.24-2.21) 21/79 0.92 (0.41-2.08) 
25 – 29.9 
kg/m2 
< median 32/ 201 1.00 (ref) 36/176 1.00 (ref) 
≥ median 32/ 224 0.97 (0.55-1.72) 39/149 1.22 (0.67-2.17) 
≥ 30 kg/m2 
< median 45.174 1.00 (ref) 41/135 1.00 (ref) 
≥ median 32/153 0.76 (0.44-1.34) 43/179 0.88 (0.51-1.52) 
 interaction (BMI by α-carotene) 
= 0.32 
interaction (BMI by α-carotene) 
= 0.25 
Dietary β-carotene (µg/day)  b 
BMI 
≤ 24.9 
kg/m2 
< median 5/83 1.00 (ref) 19/99 1.00 (ref) 
≥ median 15/76 1.86 (0.55-6.32) 21/72 1.10 (0.49-2.48) 
25 – 29.9 
kg/m2 
< median 30/193 1.00 (ref) 37/167 1.00 (ref) 
≥ median 34/232 0.92 (0.51-1.64) 38/158 0.91 (0.51-1.63) 
≥ 30 kg/m2 
< median 45/178 1.00 (ref) 38/138 1.00 (ref) 
≥ median 32/149 0.93 (0.54-1.63) 46/176 0.90 (0.53-1.55) 
  interaction (BMI by β-carotene) = 
0.06 
interaction (BMI by β-carotene) 
= 0.35 
Supplemental β-carotene (µg/day)  c 
BMI 
≤ 24.9 
kg/m2 
non-users 6/88 1.00 (ref) 32/116 1.00 (ref) 
users 14/71 3.50 (1.04-11.84) 8/55 0.45 (0.17-1.20) 
25 – 29.9 
kg/m2 
non-users 32/249 1.00 (ref) 52/231 1.00 (ref) 
users 32/176 1.54 (0.87-2.73) 23/94 1.08 (0.59-1.97) 
≥ 30 kg/m2 
non-users 50/196 1.00 (ref) 62/213 1.00 (ref) 
users 27/131 0.81 (0.47-1.41) 22/101 0.85 (0.47-1.53) 
  interaction (BMI by 
supplemental β-carotene) = 0.007 
interaction (BMI by 
supplemental β-carotene) = 0.42 
Total β-carotene (diet + supplement, µg/day) d 
BMI 
≤ 24.9 
kg/m2 
< median 6/78 1.00 (ref) 19/96 1.00 (ref) 
≥ median 14/81 1.33 (0.41-4.31) 21/75 0.99 (0.43-2.28) 
25 – 29.9 
kg/m2 
< median 28/198 1.00 (ref) 37/166 1.00 (ref) 
≥ median 36/227 1.11 (0.61-2.00) 38/159 0.89 (0.50-1.59) 
≥ 30 kg/m2 
< median 44/178 1.00 (ref) 38/143 1.00 (ref) 
≥ median 33/149 0.93 (0.54-1.62) 46/171 0.94 (0.55-1.62) 
  interaction (BMI by total β-
carotene) = 0.10 
interaction (BMI by total β-
carotene) = 0.50 
Dietary β-cryptoxanthin (µg/day)  e 
BMI 
≤ 24.9 
kg/m2 
< median 
6/77 
1.00 (ref) 23/91 1.00 (ref) 
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 ≥ median 14/82 1.21 (0.37-4.00) 17/80 0.79 (0.34-1.84) 
25 – 29.9 
kg/m2 
< median 32/208 1.00 (ref) 51/153 1.00 (ref) 
≥ median 32/217 0.82 (0.46-1.46) 24/172 0.32 (0.18-1.61) 
≥ 30 kg/m2 
< median 39/171 1.00 (ref) 39/161 1.00 (ref) 
≥ median 38/156 1.22 (0.72-2.06) 45/153 1.34 (0.77-2.23) 
  interaction (BMI by dietary β-
cryptoxanthin) = 0.51 
interaction (BMI by dietary β-
cryptoxanthin) = 0.19 
Dietary lutein + zeaxanthin (µg/day)  f 
BMI 
≤ 24.9 
kg/m2 
< median 6/82 1.00 (ref) 15/99 1.00 (ref) 
≥ median 14/77 1.79 (0.51-6.35) 25/72 1.50 (0.66-3.39) 
25 – 29.9 
kg/m2 
< median 31/205 1.00 (ref) 35/163 1.00 (ref) 
≥ median 33/220 1.06 (0.60-1.87) 40/162 0.99 (0.56-1.74) 
≥ 30 kg/m2 
< median 45/168 1.00 (ref) 40/142 1.00 (ref) 
≥ median 32/159 0.80 (0.46-1.39) 44/172 0.93 (0.54-1.60) 
  interaction (BMI by dietary lutein 
+ zeaxanthin) = 0.03 
interaction (BMI by dietary 
lutein + zeaxanthin) =  0.13 
Supplemental lutein (µg/day) c 
BMI 
≤ 24.9 
kg/m2 
non-users 9/100 1.00 (ref) 34/138 1.00 (ref) 
users 11/59 1.67 (0.53-5.26) 6/33 0.84 (0.28-2.54) 
25 – 29.9 
kg/m2 
non-users 36/287 1.00 (ref) 63/274 1.00 (ref) 
users 28/138 1.74 (0.98-3.11) 12/51 1.29 (0.60-2.78) 
≥ 30 kg/m2 
non-users 59/227 1.00 (ref) 73/253 1.00 (ref) 
users 18/100 0.76 (0.42-1.39) 11/61 0.68 (0.33-1.41) 
  interaction (BMI by supplemental 
lutein) = 0.02 
interaction (BMI by 
supplemental lutein) = 0.64 
Total Lutein + Zeaxanthin (diet + supplement, µg/day) g 
 
BMI 
≤ 24.9 
kg/m2 
< median 6/77 1.00 (ref) 15/101 1.00 (ref) 
≥ median 14/82 1.40 (0.40-4.93) 25/70 1.66 (0.74-3.74) 
25 – 29.9 
kg/m2 
< median 34/207 1.00 (ref) 35/162 1.00 (ref) 
≥ median 30/218 0.92 (0.52-1.62) 40/163 1.00 (0.57-1.75) 
≥ 30 kg/m2 
< median 45/171 1.00 (ref) 41/141 1.00 (ref) 
≥ median 32/156 0.81 (0.47-1.42) 43/173 0.88 (0.51-1.50) 
  interaction (BMI by total lutein + 
zeaxanthin) = 0.08 
interaction (BMI by total lutein 
+ zeaxanthin) = 0.07 
Dietary lycopene (µg/day) h 
 
BMI 
≤ 24.9 
kg/m2 
< median 9/86 1.00 (ref) 11/90 1.00 (ref) 
≥ median 11/73 0.86 (0.26-2.80) 29/81 2.90 (1.15-7.31) 
25 – 29.9 
kg/m2 
< median 37/211 1.00 (ref) 32/168 1.00 (ref) 
≥ median 27/214 0.83 (0.46-1.50) 43/157 1.31 (0.72-2.40) 
≥ 30 kg/m2 
< median 45/158 1.00 (ref) 41/146 1.00 (ref) 
≥ median 32/169 0.68 (0.38-1.21) 43/168 1.03 (0.57-1.85) 
  interaction (BMI by dietary 
lycopene) = 0.01 
interaction (BMI by dietary 
lycopene) = 0.02 
Supplemental lycopene (µg/day) c 
BMI 
≤ 24.9 
kg/m2 
non-users 12/109 1.00 (ref) 32/126 1.00 (ref) 
users 8/50 1.51 (0.45-5.02) 8/45 0.70 (0.25-1.93) 
25 – 29.9 
kg/m2 
non-users 39/309 1.00 (ref) 58/261 1.00 (ref) 
users 25/116 1.64 (0.90-2.99) 17/64 1.24 (0.64-2.42) 
≥ 30 kg/m2 non-users 60/242 1.00 (ref) 64/237 1.00 (ref) 
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 users 17/85 0.91 (0.49-1.70) 20/77 1.01 (0.55-1.86) 
  interaction (BMI by supplemental 
lycopene) = 0.16 
interaction (BMI by 
supplemental lycopene) = 0.62 
Total Lycopene (diet + supplement, µg/day) i 
 
BMI 
≤ 24.9 
kg/m2 
< median 9/84 1.00 (ref) 12/91 1.00 (ref) 
≥ median 11/75 0.85 (0.26-2.75) 28/80 2.46 (0.99-6.07) 
25 – 29.9 
kg/m2 
< median 37/212 1.00 (ref) 32/168 1.00 (ref) 
≥ median 27/213 0.85 (0.47-1.53) 43/157 1.34 (0.74-2.44) 
≥ 30 kg/m2 
< median 44/160 1.00 (ref) 40/146 1.00 (ref) 
≥ median 33/167 0.75 (0.43-1.33) 44/168 1.10 (0.62-1.97) 
  interaction (BMI by total 
lycopene) = 0.25 
interaction (BMI by  total 
lycopene) = 0.05 
 
‡ Adjusted for age, PSA screening history, smoking status, education, income, NSAIDs use, total dietary 
fat intake, and study site 
 
a Dietary α-carotene: European Americans (range: 27.20-9812.26, median = 453.42 µg/day); African 
Americans (range: 11.83-9558.28, median = 396.03 µg/day) 
 
b Dietary β-carotene: European Americans (range: 194.86-25124.05, median =3016.49 µg/day); African 
Americans (range: 286.48-32901.26, median = 3727.51 µg/day)  
 
c Supplements: compared users to non-users because limited variability in dose did not allow for creation 
of meaningful categories        
 
d Total β-carotene: European Americans (range: 346.80-25512.15, median = 3356.11 µg/day); African 
Americans (range: 286.48-32901.26, median = 3872.02 µg/day) 
 
e Dietary β-cryptoxanthin: European Americans (range: 6.04-1082.55, median = 125.73 µg/day); African 
Americans (range: 3.53-1594.39, median = 179.15 µg/day) 
 
f Dietary Lutein + Zeaxanthin: European Americans (range: 289.67-30165.13 , median = 2423.60 µg/day); 
African Americans (range: 112.25-36608.75, median = 3140.16 µg/day) 
 
g Total Lutein + Zeaxanthin: European Americans (range: 289.6-31665.13 , median = 2535.48 µg/day); 
African Americans (range: 112.25-37558.75, median = 3185.08 µg/day) 
 
h Dietary lycopene: European Americans (range: 344.77-100250.76, median  = 4646.27 µg/day); African 
Americans (range: 4.90-106071.98, median = 3305.31 µg/day) 
 
i Total Lycopene: European Americans (range: 344.77-100550.76 , median = 4708.89 µg/day); African 
Americans (range: 4.90-106071.98, median = 3336.95 µg/day) 
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 CHAPTER 7 
POLYMORPHISMS IN DNA REPAIR AND OXIDATIVE STRESS-RELATED GENES, DIETARY 
ALPHA- AND GAMMA-TOCOPHEROL INTAKE, AND PROSTATE CANCER AGGRESSIVENESS 
 
7.1     INTRODUCTION 
Among American men, prostate cancer  (PCa) continues to have the highest 
incidence and second highest mortality of any other cancer [339]. Although the etiology 
of PCa remains largely unclear, considerable evidence indicates that oxidative stress may 
play a role in the disease initiation and progression [470, 478, 479]. Oxidative stress is a 
state of elevated intracellular levels of reactive oxygen and nitrogen species beyond 
antioxidant defense capacity, which can lead to the malignant transformation of normal 
epithelial cells [480, 481]. 
Several studies have shown parallels between oxidative stress and the known and 
potential risk factors of PCa. For example, exposure to reactive oxygen species (ROS), 
whether endogenously or exogenously generated, and accumulation of oxidative DNA 
damage are known to increase with age, which is the strongest risk factor for PCa [482]. 
Chronic inflammation, particularly chronic prostatitis, is thought to promote oxidative 
stress by activating inflammatory cells that increase the up-take of oxygen resulting in 
excessive production of ROS [483, 484]. Epidemiologic data regarding diet and PCa 
suggest that energy imbalance as well as high-fat and high-calorie diets promote PCa 
incidence and aggressiveness [17]. These factors also have been shown to increase 
oxidative stress through various metabolic pathways [470]. Studies show that  the 
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 expression of oxidative stress defense enzymes, such as superoxide dismutase (SOD), 
glutathione peroxidase (GPx), and catalase (CAT), are lower in malignant prostate tissues 
than in health prostate tissues [485-487]. Furthermore, high aggressive CaPs are found to 
have a greater degree of oxidative stress than less aggressive CaPs [479]. Together, these 
observations suggest that oxidative stress may be an underlying mechanism through 
which several risk factors influence PCa incidence and aggressiveness. 
   
Sustained oxidative stress resulting from impaired antioxidant defense or 
excessive exposure to ROS causes damage to DNA and other important cellular 
components [481]. Oxidative DNA damage is repaired through complex DNA repair 
pathways  involving base excision repair (BER) which repairs non-bulky adducts and 
single-strand breaks, nucleotide excision repair (NER) removes bulky and helix-
distorting adducts, mismatch repair (MMR) corrects mispaired DNA bases, and 
homologous recombination and end-joining DNA repair mechanisms are involved in the 
repair of double-stranded breaks [488, 489]. There is ample evidence that genes involved 
in oxidative stress, antioxidant defense, and DNA repair mechanisms harbor 
polymorphisms that may have functional significance to PCa due to their pro- or anti-
carcinogenic properties [490-492]. These polymorphisms may act in tandem with 
environmental factors to influence prostate carcinogenesis. 
Habitually low antioxidant intake may promote oxidative stress and susceptibility 
to PCa, whereas greater intakes of antioxidants can boost antioxidant defense against 
oxidative stress [470]. There has been particular interest in the cancer prevention 
potential of alpha (α) and gamma (γ) tocopherol, which have strong antioxidant 
properties and are the major forms of vitamin E [391]; however, study results are varied 
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 (reviewed in [17, 493-496]). It is possible that these nutrients offer protection only for 
men with certain genetic profiles, and are perhaps detrimental to others. Therefore, this 
study examined whether associations between α- and γ-tocopherol intake and PCa 
aggressiveness are modulated by single nucleotide polymorphisms (SNPs) in DNA repair 
and oxidative stress-related genes among African-American (AA) and European-
American (EA) men in North Carolina and Louisiana.  
 
7.2     METHODS 
Study Population 
This work was performed with data from the North Carolina-Louisiana Prostate 
Cancer Project (PCaP), which is a population-based, case-only, cross-sectional study of 
PCa aggressiveness. North Carolina (NC) and Louisiana (LA) residents with pathologist-
confirmed, first diagnosis of adenocarcinoma of the prostate between July 2004 and 
August 2009, who were 40-79 years old at diagnosis and self-identified their race to be 
Black/AA or Caucasian American/White/EA were recruited via rapid case-ascertainment. 
Other eligibility criteria included the ability to complete study interview in English and 
being mentally and physically competent to give consent and participate in the study. A 
detailed description of the PCaP research protocol has been published [399]. All research 
subjects provided written informed consent, including consent for genetic studies, prior to 
enrollment. PCaP enrolled a total of 2258 research subjects with approximately equal 
numbers of AAs (n = 1,130) and EAs (n = 1,128). Analyses were restricted to the 
research subjects with genotyped data on the polymorphisms of interest (AA, n = 948; 
EA, n = 1,016). The study protocols were approved by Institutional Review Boards 
(IRBs) of the University of North Carolina at Chapel Hill (UNC-CH), the Louisiana State 
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 University Health Sciences Center, and the Department of Defense Prostate Cancer 
Research Program. For the current analyses, additional IRB approval was obtained from 
the University of South Carolina. 
 
Data Collection 
Trained research nurses conducted structured, in-person interviews soliciting 
information on prostate-related health factors, including demographics, family history of 
PCa, pre-diagnostic PCa screening habits, personal and family health history, physical 
activity, smoking status, and use of vitamins and supplements, non-steroidal anti-
inflammatory drugs (NSAIDs), and alcohol. The research nurses obtained anthropometric 
measurements (i.e., weight and height) using standardized protocol during in-person 
interviews and collected biological specimens that included peripheral blood and buccal 
cell samples for DNA analyses. The research subjects provided consent for review of 
their medical records, which were obtained from diagnosing physicians and abstracted by 
trained personnel to yield information relating to prostate-specific antigen (PSA) tests, 
Gleason scores and cancer stage at diagnosis as well as other health status information. 
Approximately 10% of the abstracted medical records were selected at random and 
abstracted a second time by a different staff member to ensure consistency between 
abstractors. In PCaP, a research subject is considered to have high aggressive PCa if he 
had a Gleason sum ≥8, PSA >20 ng/mL or a Gleason sum ≥7 and cancer stage T3–T4 at 
diagnosis. Low aggressive PCa was defined as research subjects with Gleason sum < 7 
and cancer stage T1-T2 or PSA<10 ng/ml. All other cases are classified as intermediate 
aggressive PCa. The current analyses utilized a case-control design to compare high 
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 aggressive PCa (cases) to low/intermediate aggressive disease (comparison group or 
controls).   
Dietary Assessment 
Dietary nutrient intake in the 12 months prior to PCa diagnosis was assessed 
using a modified version of the National Cancer Institute Diet History, Food-frequency 
Questionnaire (NCI-DHQ) [400]. The NCI-DHQ was modified to include Southern foods 
and assesses frequency of intake and usual portion sizes for 144 food items/groups. 
Nutrient values were assigned to various foods by linking the questionnaire responses to 
an updated NCI nutrient database. Usual daily intakes of various nutrients were estimate 
by the NCI Diet*Calc software [401], including intakes of α- and γ-tocopherol. None of 
the research subjects included in this analysis had implausible energy intake values (i.e., 
< 500 or > 6000 kcal/day).  
 
SNP Selection 
A set of 34 SNPs across 18 candidate genes involved in oxidative stress, 
antioxidant defense, and DNA repair with known or suspected functional significance in 
cancer based on previous association studies [2, 134, 466, 490-492, 497-499] were 
selected from the PCaP GWAS data bank [500]. These included four SNPs implicated in 
oxidative stress: NOS3 (rs1799983, rs3918201, rs3918226), NOX3||ARID1B 
(rs9372014); and six SNPs involved in antioxidant defense: GPX2 (rs4902346), NQO1 
(rs689453), PPARG (rs1801282), SOD2 (rs10370, rs4880), and USP4||GPX1 
(rs8179172). SNPs in different DNA repair pathways were included, with nine in the 
BER pathway: APEX1 (rs1048945, rs1130409), APEX2 (rs28382675), MUTYH 
(rs3219489), OGG1 (rs1805373), and XRCC1 (rs1799778, rs1799782, rs2854508, 
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 rs3213247); and seven in the NER pathway: ERCC8 (rs4647100, rs4647102, rs976631), 
XPA (rs1800975, rs3176644), and XPC (rs2227998, rs2733537). Three are involved in 
homologous recombination repair: RAD51C (rs304269, rs6503874), and XRCC2 
(rs3218522). Five are in the non-homologous end-joining repair pathway: XRCC4 
(rs10474079, rs28360135, rs28360248, rs35268, rs3777018 ) [488, 489]. The selected 
SNPs were eliminated from further analysis if they had less than 5% minor allele 
frequency (MAF). Based on this criterion, the following SNPs were removed from 
analyses among AAs and EAs: APEX1 (rs1048945), NOS3 (rs3918201), and XRCC4 
(rs28360135, rs28360248). Additionally, NOS3 (rs3918226), PPARG (rs1801282), and 
XRCC1 (rs3213247, rs10474079, rs3777018) were eliminated among AAs only and 
APEX2 (rs28382675), OGG1 (rs1805373), USP4||GPX1 (rs8179172), and XPA 
(rs3176644) were eliminated among EAs only. 
Genotyping  
DNA was extracted from each research subject’s peripheral blood samples (n = 
1,630) or buccal cells (n = 118) by the UNC-CH Biospecimen Processing Facility, or 
from immortalized lymphocytes by the UNC-CH Tissue Culture Facility (n = 216). 
Genotyping was done by the Johns Hopkins University’s Center for Inherited Disease 
Research using a custom 1,536-SNP Illumina GoldenGate array. The genotyping data 
included 22 blinded duplicates and HapMap control samples consisting of a set of 11 YRI 
and 8 CEU trios for quality checks. Full details of the genotyping and quality control 
procedures has been described by Bensen et al. [500]. 
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 Statistical Methods 
Differences in the distributions of research subjects’ characteristics by their levels 
of PCa aggressiveness were assessed using t and χ2 tests for continuous and categorical 
variables, respectively. Unconditional logistic regression was use to estimate odds ratios 
(ORs) and 95% confidence intervals (CIs) in models examining main effects of SNP 
genotypes and dietary α- and γ-tocopherol. Because the frequency of minor alleles of the 
SNPs were too low to allow for meaningful analysis, the genotypes were categorized into 
two groups assuming a dominant model, by combining the heterozygous and 
homozygous variants into one group and compared to the homozygous common 
genotype (referent group).  
Associations between dietary α- and γ-tocopherol intake and PCa aggressiveness 
were examined by categorizing research subjects into “high” or “low” levels of intake 
based on median cutpoints among the low/intermediate aggressive research subjects in 
each race group. These variables were categorized separately for AAs and EAs because 
of an indication of different dietary patterns between these race groups. Accordingly, 
analyses were performed separately by race. A priori variables determined to be 
confounders in a previous PCaP study of associations between tocopherols intake and 
PCa aggressiveness were included in the multivariable-adjusted regression models. These 
include age (continuous), PSA screening history (0, 1-7, >7 screenings), body mass index 
(BMI, kg/m2), smoking status (never, former, current), education (less than high school 
education, high school graduate, some college/college graduate, graduate degree), 
household income (<$20,000, $20,001-$40,000, $40,001-$60,000, $60,001-$80,000, 
>$80,000, unknown), use of NSADs in the five years before diagnosis (no, yes), total 
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 dietary fat intake (grams/day), and study site (NC, LA). Other variables examined for 
confounding effects but not included in the final analyses were: number of first degree 
relatives with PCa (none, at least one), comorbidities (0, 1, 2, ≥3), PCa treatment status 
(started treatment, not started) and total metabolic equivalents (METs) of light, moderate 
and vigorous exercise in the year prior to diagnosis (≤ 10.2, 10.3-29.0, >29.0 MET-
hours/week). 
To examine effect modification of associations between α- and γ-tocopherol and 
PCa aggressiveness, a series of stratified analyses by genotype (categorized into two 
groups) were performed comparing high to low levels of tocopherol intake. Likelihood 
ratio tests (LRTs) were used to examine interaction on the multiplicative scale between 
the binary genotype variable for each SNP and binary tocopherol variables. In evaluating 
interaction, the difference in -2 log likelihood values of logistic regression models with 
and without the interaction terms was evaluated by χ2 test with one degree of freedom. 
Interaction p-values were considered statistically significant at p < 0.10 to compensate for 
small sample size, which limits statistical power to detect significant interaction [336]. 
Results were adjusted for multiple testing by controlling for false discovery rate at 0.05 
[338]. All statistical analyses were performed with SAS® (version 9.3, SAS Institute, 
Cary, NC).  
 
7.3     RESULTS 
Table 7.1 presents research subject characteristics by level of PCa aggressiveness 
among AAs and EAs. AA research subjects with high aggressive PCa were somewhat 
older, had higher dietary fat intake, were less educated, less likely to have had at least one 
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 PSA screening test prior to diagnosis, and included a greater percentage of lower incomes 
and current smokers as compared to AAs with low/intermediate aggressive PCa. EAs 
with high aggressive PCa also were older and less educated, and had slightly higher BMI 
than EAs with low/intermediate aggressive disease.  
Analysis of the main effect of the SNPs showed a nearly significant increased 
odds of high aggressive PCa among EAs with the heterozygous or homozygous variants 
of XRCC4 (rs377018) (OR = 1.63, 95% CI = 1.00-2.64, AG+GG versus AA), but no 
other association was observed (Table 7.2). Similarly, dietary α-tocopherol intake was 
not associated with PCa aggressiveness among AAs (OR = 1.23, 95% CI = 0.79-1.93) or 
EAs (OR = 0.70, 95% CI = 0.44-1.11) when comparing high with low intake (Table 7.3). 
In analysis stratified by genotype, statistically significant interactions were observed 
between α-tocopherol intake and certain SNP genotypes, with some variations in gene-
nutrient interaction by race (Table 7.3).  
Effect modification by NOS3 (rs1799983, G > T) was observed among EA 
research subjects, such that among the minor allele carriers, high α-tocopherol intake was 
associated with a 54% lower odds of high aggressive PCa compared to low intake, while 
no association was observed among those homozygous for the common allele (Pinteraction = 
0.08), and no evidence of effect modification among AAs. XPA (rs3176644) was 
examined among AAs only because of less variability in genotype distribution among 
EAs (i.e., MAF < 0.05). The AA research subjects who harbor the homozygous common 
allele of XPA (rs3176644, G > T) and had high α-tocopherol intake as compared to lower 
intake, had an over two-fold increased odds of high aggressive PCa, whereas no 
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 association was observed among those with one or two copies of the minor allele 
(Pinteraction = 0.08).  
Statistically significant effect modification by XRCC1 (rs2854508, T > A) was 
observed among both AAs and EAs (Pinteraction = 0.01 and 0.04, respectively). In the 
stratified analysis by XRCC1 (rs2854508) genotype, α-tocopherol intake was inversely 
related to high aggressive PCa among EA research subjects who were homozygous for 
the common allele (OR = 0.46, 95% CI = 0.22-0.85; high versus low intake), while no 
association was observed among AAs with this genotype (OR = 0.95, 95% CI = 0.54-
1.64; high versus low intake). In contrast, higher α-tocopherol intake appeared to be 
positively associated with high aggressive PCa among AA research subjects 
heterozygous or homozygous for the XRCC1 (rs2854508) minor allele, with no 
association among EA research subjects with these genotypes. The other notable 
associations were observed among EAs only, wherein higher α-tocopherol intake was 
inversely associated with PCa aggressiveness among EA research subjects homozygous 
for the common allele of APEX (rs1130409, T > G), PPARG (rs1801282, C > G), XPC 
(rs2733537, A > G), and XRCC1 (rs1799782, G > A). There were no associations among 
EA carriers of the minor alleles of these SNPs, and no evidence of interaction (all 
interaction P values > 0.10).   
ORs for high versus low γ-tocopherol intake did not show significant associations 
with PCa aggressiveness among AAs or EAs (Table 7.4). However, among EA research 
subjects, higher γ-tocopherol intake was inversely related to PCa aggressiveness among 
carriers of the minor allele of XRCC1 (rs1799782, G > A) and XRCC2 (rs3218522, C > 
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 T), but not those homozygous for the common allele of these SNPs (Pinteraction = 0.04 and 
0.02, respectively). Among AAs, higher γ-tocopherol intake appears to be inversely 
related to high aggressive PCa among those who possess the minor allele of OGG1 
(rs1805373, G > A), but not the homozygous common allele carriers (Pinteraction = 0.08). 
Similar to the findings for α-tocopherol, a suggestion of positive association between 
higher γ-tocopherol intake and PCa aggressiveness was observed among AA research 
subjects with one or two copies of the minor allele for XRCC1 (rs2854508, T > A) 
(Pinteraction = 0.03). In two instances among EAs, no interaction was observed, but higher 
γ-tocopherol intake was significantly and inversely associated with PCa aggressiveness 
among carriers of the minor allele of ERCC8 (rs4647102, T > C) and RAD51C 
(rs6503874, C > G), while no associations were observed among EAs homozygous for 
the common allele. However, neither these associations nor those reported for α-
tocopherol retained statistical significance after adjusting for multiple testing using false 
discovery rate of 0.05. 
 
7.4     DISCUSSION  
This population-based, case-only study of incident PCa showed that associations 
between dietary intakes of α- and γ-tocopherol and PCa aggressiveness may be modified 
by certain genotypes of SNPs in oxidative stress and DNA repair genes. The strongest 
evidence of effect modification for an association between α-tocopherol and PCa 
aggressiveness was observed among genotypes of NOS3 (rs1799983), XPA (rs3176644), 
and XRCC1 (rs2854508). The results indicate that higher α-tocopherol intake is 
associated with significantly lower odds of high aggressive among EAs who are 
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 heterozygous or homozygous for the minor allele of NOS3 (rs1799983, G > T), but not 
EA homozygous common allele, and there was no evidence of effect modification among 
AAs. Higher α-tocopherol intake also was associated with an increased odds of high 
aggressive PCa among AAs who harbor the homozygous common allele of XPA 
(rs3176644, G > T), with no associations observed among AAs who possess the at least 
one copy of the minor allele. Interaction by XRCC1 (rs2854508, T > A) pointed towards 
an inverse association between  higher α-tocopherol intake and PCa aggressiveness 
among EAs who were homozygous for the common allele, while a suggestion of an 
increased odds of high aggressive PCa was associated with higher intake of α- and γ-
tocopherol among AAs who were heterozygous or homozygous for  the minor allele of 
this SNP. Additional evidence of effect modification by variants in OGG1 (rs1805373), 
XRCC1 (rs1799782) and XRCC2 (rs3218522) was observed for associations between γ-
tocopherol intake and PCa aggressiveness. 
Although there is compelling evidence that oxidative stress, ineffective DNA 
repair, and habitually low antioxidant intake may act synergistically to promote PCa 
[470, 491, 494, 495], few studies have investigated interactions between genetic variants 
in oxidative stress or DNA repair genes, and antioxidants intake in relation to PCa [2, 
128, 219, 220, 466, 497]. Even fewer studies have evaluated such interactions within the 
context of PCa aggressiveness [133, 134, 335]. This is the first study to examine SNPs 
such as XPA (rs3176644), XRCC1 (rs1799782, rs2854508), and XRCC2 (rs3218522) for 
their potential modifying effect of associations between dietary tocopherols and PCa. 
Other polymorphisms in these genes have been examined in gene-nutrient interaction 
studies in relation to PCa [2, 128, 466]. 
195 
 
 In one study, van Gils et al. [2] observed that XRCC1 (rs25487, Arg399Gln) 
genotype modulates the association between dietary vitamin E intake (α-tocopherol 
equivalent) and PCa incidence, such that lower vitamin E intake was associated with an 
increased risk of PCa among carriers of Arg/Arg (OR= 2.4, 95%CI = 1.0-5.6, < versus ≥ 
median), and not those with Arg/Gln or Gln/Gln. In contrast, Goodman et al. [466] did 
not observe a modifying effect by the XRCC1 Arg399Gln genotype on association 
between α-tocopherol intake and PCa risk. However, in an evaluation of combined 
antioxidant exposure (α-tocopherol + lycopene + β-carotene), higher antioxidant 
exposure was associated with lower risk of PCa among men with Arg/Arg genotype 
(OR= 0.11, 95%CI = 0.02-0.65, < versus ≥ median), while no association was observed 
among  those with Arg/Gln or Gln/Gln genotype (Pinteraction = 0.01) [466]. However, it 
remains unclear if α-tocopherol acts differently depending on the biological activity of 
XRCC1 variants. In vitro studies suggest that the allele substitution Gln → Arg at codon 
399 appear to decrease the BER capacity of XRCC1 (rs25487) [501, 502]. Evidence from 
animal studies indicate that adequate intake of α-tocopherol as well as other antioxidants 
can boost antioxidant defense and promote DNA repair functions [503]. Thus, α-
tocopherol may compensate for defective DNA repair associated with the Arg allele 
[466]. Information on the functional effects of other XRCC1 polymorphism such as 
(rs1799782, rs2854508) are lacking. Possibly, the DNA repair functionality of allelic 
variants of other XRCC1 polymorphism also vary, and thus may differentially influence 
tocopherol associations with PCa aggressiveness.  
Genetic variations in the NOS3, an oxidative stress-related gene, have been 
associated with several malignancies including breast and prostate cancer [499, 504-506]. 
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 The results from the main effect of NOS3 (rs1799983, G > T) in the current study was 
suggestive of an increased odds of high aggressive PCa among EA who carry the minor 
allele; however, higher α-tocopherol intake in this population was associated with 
significantly lower odds of high aggressive PCa. Similar observation was made by Li et 
al. [499], where a positive relation between the NOS3 (rs1799983) T allele and breast 
cancer risk in analysis of the main effect of genotype reversed towards a lower risk of 
breast cancer in the presence of  higher fruit and vegetable intake (Pinteraction = 0.005). 
Although the biological mechanisms are not clearly elucidated, a functional 
polymorphism in NOS3 (894 G → T) at exon 7 has been shown to reduce pro-oxidant 
enzyme activity [507, 508]. Thus, it appears that the T allele may be sensitive to 
antioxidant intervention, and as suggested by the current findings, EAs who possess the 
NOS3 (rs1799983) T allele may benefit from dietary α-tocopherol intake with respect to 
PCa aggressiveness. 
The main effect of XRCC4 (rs3777018, G > A) was suggestive of an increased 
odds of high aggressive PCa among EA carriers of the minor allele; however, there was 
no evidence of interaction with α- or γ-tocopherol intake. Perhaps XRCC4 (rs3777018) 
may modulate associations of other dietary factors in relation PCa. It is also worth noting 
that while no interaction was observed between α-tocopherol intake and the genotypes of 
APEX1 (rs1130409, T > G), PPARG (rs1801282, C > G), XPC (rs2733537, A > G) or 
XRCC1 (rs1799782, G > A), higher α-tocopherol intake was associated with a 
significantly lower odds of high aggressive PCa among EA who possess the homozygous 
common alleles of these SNPs. This supports suggestions that the potential benefits of α-
tocopherol and other antioxidants may be limited to men with certain genetic variants, 
197 
 
 and may explain some of the inconsistencies in the epidemiologic literature when diet is 
examined in isolation of genetic factors [509].  
Among the major findings for γ-tocopherol were significant interactions with 
XRCC1 (rs1799782, G > A) and XRCC2 (rs3218522, C > T) wherein higher γ-tocopherol 
intake was inversely associated with PCa aggressiveness among EA carriers of the 
heterozygous and homozygous minor alleles. The minor alleles of ERCC8 (rs4647102, T 
> C), RAD51C (rs6503874, C > G), XRCC4 (rs35268, T > C) among EAs, and OGG1 
(rs1805373, G > A) among AAs also were inversely related to PCa aggressiveness with 
higher intake of γ-tocopherol. Nonetheless, results should be interpreted cautiously as 
some of the effect estimates are unstable due to the small sample size. Additionally, the 
observed associations did not retain statistical significance after correction for multiple 
comparisons. 
Other limitations that are worth consideration include the use of a food frequency 
questionnaire to measure tocopherol intake, which in addition to identified response set 
biases [510-512] does not account for the bioavailability or bioefficiency of these 
nutrients because of inter-individual variability in absorption and metabolism [278]. The 
use of a single dietary assessment interview also could have introduced some 
misclassification of tocopherol exposure. However, because this is a case-only study, 
such misclassification would likely be non-differential, resulting in conservative OR 
estimates [513]. Because this analysis was limited to research subjects with data on the 
SNPs of interest, there is the possibility of selection bias, though included versus 
excluded research subjects did not vary substantially in their demographic characteristics 
suggesting selection bias due to lack of genotyping data is likely minimal (Supplemental 
198 
 
 Table 1). Strengths of the study include its evaluation of PCa aggressiveness as opposed 
to overall risk of PCa. Aggressive PCa tends to have a strong genetic influence, and thus, 
aggressive and non-aggressive forms of PCa may differ in their etiology [458]. Hence, 
examining PCa aggressiveness reduces confounding by different disease states. The use 
of a multiethnic population spanning two states also increases the generalizability of the 
study findings. Although genotyping errors cannot be completely ruled out in any genetic 
study, the genotyped data had over 99% concordance with blinded duplicates [411], 
which adds to the strengths of the study. 
 
7.5     CONCLUSIONS  
This study provides evidence of effect modification of the association between α-
tocopherol and PCa aggressiveness by XRCC1 (rs2854508), NOS3 (rs1799983) and XPA 
(rs3176644) genotypes. The results further suggest that an association between γ-
tocopherol and PCa aggressiveness may be modified OGG1 (rs1805373), XRCC1 
(rs2854508) and XRCC2 (rs3218522) genotypes. Although the general applicability of 
these findings awaits verification in larger studies, they illustrate the complex interaction 
between α- and γ-tocopherol intake, and polymorphisms in oxidative stress and DNA 
repair genes in relation to PCa aggressiveness. The findings also underscore the 
importance of considering one’s genetic makeup in dietary intervention to identify those 
mostly likely to benefit from such interventions. 
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Table 7.1 Characteristics of prostate cancer patients by level of the disease aggressiveness among African and European 
American men  
 
Characteristics 
African Americans 
N = 948 
European Americans 
N = 1,016 
 High  
aggressive 
 
(n=188 ) 
Low/intermediate 
aggressive 
 
(n= 760) 
P ‡ High 
 aggressive 
 
(n=153) 
Low/intermediate 
aggressive 
 
(n= 863 ) 
 
P ‡ 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
Age, years  63 (7.6) 62 (7.6) 0.007 67 (7.5) 64 (7.7) <0.0001 
Energy Intake, kcals/day 2792.8 (1200.8) 2614.7 (1153.1) 0.06 2360.1 (963.4) 2322.1 (878.2) 0.63 
Dietary fat intake, grams/day 103.8 (51.6) 95.5 (48.2) 0.04 95.7 (43.2) 91.2 (39.7) 0.20 
Body mass index (BMI), kg/m2  30.0 (6.7) 29.2 (5.4) 0.10 30.3 (5.1) 29.0 (4.8) 0.002 
 N % N %  N % N %  
Study Site           
     NC 80 43 347 46 0.44 64 42 413 48 0.17 
     LA  108 57 413 54 89 58 450 52 
PSA Screening History           
     0 screenings 111 59 278 37 <0.0001 35 23 140 16 0.13 
     1-7 screenings 46 24 321 42 63 41 385 45 
     > 7 screenings 31 17 161 21 55 36 338 39 
Education         
    Graduate/professional degree 4 2 54 7 0.002 28 18 184 21 0.004 
    Some college or college graduate 49 26 227 30 65 42 361 42 
    High school grad or voc/tech 
school 
57 30 258 34 33 22 244 28 
    Less than high school education 78 42 220 29 27 18 74 9 
Income Level           
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    ≤ $20, 000 75 40 217 29 0.004 22 14 71 8 0.28 
    $20,001 - $40,000 47 25 199 26 30 20 171 20 
    $40,001 - $60,000 18 10 120 16 24 16 149 17 
    $60,001 - $80,000 11 6 65 8 19 12 120 14 
     >$80,000 14 7 94 12 44 29 278 32 
    Unknown  23 12 65 8 14 9 74 9 
Smoking Status           
     Never 37 20 258 34 0.0003 54 35 314 36 0.69 
     Former smokers 99 52 358 47 82 54 472 55 
     Current smokers 52 28 144 19 17 11 77 9 
NSAID  Use           
     No 76 41 336 44 0.38 52 34 289 34 0.92 
     Yes 110 59 420 56 101 66 572 66 
 
Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as follows: High 
aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); Low /Intermediate aggressive: all other cases. 
 
Abbreviations: LA – Louisiana; NC –North Carolina; NSAIDs – nonsteroidal anti-inflammatory drugs; PSA – prostate-specific antigen; SD – standard 
deviation 
 
‡Test for differences between low/intermediate and high aggressive cancers were done using t-test for continuous variables and chi-square tests for 
categorical variables. 
  
 
 
 202 
Table 7.2 Associations of single nucleotide polymorphisms (SNPs) in oxidative stress and DNA repair genes in relation to 
prostate cancer aggressiveness by race 
 African Americans  European Americans 
Gene (SNP ID) Genotype  
Case/ 
Controls b 
 
188/760 
OR (95% CI)  c  P 
Case/ 
Controls b 
 
153/863 
OR (95% CI) c  P  
APEX1 (rs1130409) TT 81/305 1.00 (ref)  38/230 1.00 (ref)  
GT+GG 107/455 0.88 (0.64-1.22) 0.44 115/633 1.10 (0.74-1.64) 0.63 
ERCC8 (rs4647100) AA 156/625 1.00 (ref)  87/481 1.00 (ref)  
AG+GG 32/135 0.97 (0.64-1.49) 0.91 66/382 0.96 (0.67-1.36) 0.81 
ERCC8 (rs4647102) TT 75/315 1.00 (ref)  61/324 1.00 (ref)  
CT+CC 113/443 1.10 (0.79-1.53) 0.57 92/539 0.90 (0.63-1.29) 0.57 
ERCC8 (rs976631) TT 101/434 1.00 (ref)  46/275 1.00 (ref)  
CT+CC 85/325 1.09 (0.79-1.51) 0.58 107/585 1.12 (0.77-1.63) 0.56 
GPX2 (rs4902346) AA 70/266 1.00 (ref)  86/553 1.00 (ref)  
AG+GG 118/494 0.90 (0.64-1.25) 0.53 67/310 1.39 (0.98-1.97) 0.07 
MUTYH (rs3219489) CC 107/434 1.00 (ref)  92/459 1.00 (ref)  
CC+GG 81/326 1.02 (0.74-1.41) 0.89 61/404 0.76 (0.53-1.08) 0.12 
NOS3 (rs1799983) GG 152/598 1.00 (ref)  59/382 1.00 (ref)  
GT+TT 36/160 0.89 (0.59-1.33) 0.56 94/475 1.31 (0.92-1.87) 0.13 
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NOS3 (rs3918226)  d  CC - - - 126/725 1.00 (ref)  
CT+TT - - - 27/138 1.09 (0.69-1.73) 0.70 
NOX3||ARID1B 
(rs9372014)  d 
GG - - - 77/403 1.00 (ref)  
GT+TT - - - 76/459 0.86 (0.60-1.21) 0.38 
NQO1 (rs689453) CC 171/673 1.00 (ref)  138/731 1.00 (ref)  
CT+TT 17/87 0.75 (0.44-1.31) 0.31 15/132 0.62 (0.35-1.10) 0.10 
OGG1 (rs1805373)  d GG 151/648 1.00 (ref)  - - - 
AG+AA 37/112 1.45 (0.96-2.20) 0.08 - - - 
PPARG (rs1801282) d CC - - - 122/670 1.00 (ref)  
CG+GG - - - 30/193 0.84 (0.54-1.29) 0.42 
RAD51C (rs304269) GG 104/400 1.00 (ref)  57/360 1.00 (ref)  
AG+AA 84/360 0.92 (0.67-1.27) 0.61 96/503 1.21 (0.85-1.73) 0.30 
RAD51C (rs6503874) CC 89/388 1.00 (ref)  136/767 1.00 (ref)  
CG+GG 99/371 1.20 (0.87-1.65) 0.27 17/96 1.00 (0.57-1.73) 0.99 
SOD2 (rs10370) TT 145/549 1.00 (ref)  94/515 1.00 (ref)  
GT+GG 43/209 0.79 (0.54-1.15) 0.21 59/348 0.96 (0.67-1.37) 0.83 
SOD2 (rs4880) AA 69/254 1.00 (ref)  42/197 1.00 (ref)  
AG+GG 118/505 0.88 (0.63-1.23) 0.45 111/665 0.77 (0.52-1.14) 0.19 
USP4||GPX1 
(rs8179172)  d 
AA 153/640 1.00 (ref)  - - - 
AT+TT 35/120 1.22 (0.81-1.86) 0.34 - - - 
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XPA (rs1800975) CC 121/470 1.00 (ref)  69/366 1.00 (ref)  
CT+TT 67/289 0.90 (0.64-1.25) 0.52 84/497 0.90 (0.64-1.28) 0.56 
XPA (rs3176644)  d GG 69/322 1.00 (ref)  - - - 
GT+TT 118/437 1.28 (0.92-1.79) 0.14 - - - 
XPC (rs2227998) CC 94/366 1.00 (ref)  78/480 1.00 (ref)  
CT+TT 94/394 0.92 (0.67-1.27) 0.62 75/378 1.17 (0.83-1.66) 0.36 
XPC (rs2733537) AA 131/527 1.00 (ref)  86/401 1.00 (ref)  
AG+GG 57/233 0.96 (0.68-1.37) 0.84 67/462 0.71 (0.50-1.01) 0.05 
XRCC1 (rs1799778) GG 102/462 1.00 (ref)  66/353 1.00 (ref)  
GT+TT 85/294 1.31 (0.95-1.81) 0.10 87/509 0.91 (0.64-1.29) 0.58 
XRCC1 (rs1799782) GG 165/660 1.00 (ref)  131/735 1.00 (ref)  
AG+AA 23/100 0.93 (0.57-1.52) 0.79 22/128 0.98 (0.60-1.60) 0.93 
XRCC1 (rs2854508) TT 123/478 1.00 (ref)  98/508 1.00 (ref)  
AT+AA 65/281 0.90 (0.64-1.26) 0.54 55/355 0.80 (0.56-1.14) 0.22 
XRCC1 (rs3213247)  d CC - - - 136/772 1.00 (ref)  
AC+AA - - - 17/91 1.06 (0.61-1.84) 0.84 
XRCC2 (rs3218522) CC 122/529 1.00 (ref)  38/248 1.00 (ref)  
CT+TT 66231 1.25 (0.89-1.75) 0.20 115/615 1.20 (0.80-1.78) 0.38 
XRCC4 (rs10474079 d GG - - - 115/665 1.00 (ref)  
AG+AA - - - 38/197 1.07 (0.71-1.60) 0.74 
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XRCC4 (rs28360135 d TT - - - 144/792 1.00 (ref)  
CT+CC - - - 9/71 0.77 (0.37-1.59) 0.48 
XRCC4 (rs35268) TT 100/417 1.00 (ref)  116/670 1.00 (ref)  
CT+CC 87/343 1.08 (0.78-1.49) 0.63 37/193 1.05 (0.70-1.59) 0.80 
XRCC4 (rs3777018)  d AA - - - 128/769 1.00 (ref)  
AG+GG - - - 25/94 1.63 (1.00-2.64) 0.05 
 
a The most common genotype used as the reference category 
b  Some categories may not sum to total sample because of missing data  
c Adjusted for age 
d Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group 
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Table 7.3 Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between dietary α-tocopherol 
intake and prostate cancer aggressiveness, and stratified by genotype of SNP in oxidative stress and DNA repair gene 
pathways  
 African Americans  
(n = 948) 
 Cases/ 
Controls  
OR (95% CI) b   
Dietary α-tocopherol mg/day a   low 84/379 1.00 (ref)  
high 104/381 1.23 (0.79-1.93)  
Stratified analysis by SNP 
 Homozygous Common Allele Heterozygous or Homozygous 
Minor Allele 
 
Gene (SNP ID), 
major/minor allele  
Cases/ 
Controls 
 
OR (95% CI) b 
Cases/ 
Controls 
OR (95% CI) b P ‡ 
APEX1(rs1130409)                T / G low 34/158 1.00 (ref) 50/221 1.00 (ref)  
high 47/147 1.58 (0.79-3.14) 57/234 1.06 (0.58-1.94) 0.44 
ERCC8 (rs4647100)              A / G low 74/316 1.00 (ref) 10/63 1.00 (ref)  
high 82/309 1.22 (0.74-1.99) 22/72 1.29 (0.41-4.09) 0.57 
ERCC8 (rs4647102)              T / C low 39/159 1.00 (ref) 45/220 1.00 (ref)  
high 36/156 0.80 (0.37-1.71) 68/223 1.52 (0.86-2.69) 0.60 
ERCC8 (rs976631)                 T / C low 46/212 1.00 (ref) 37/167 1.00 (ref)  
high 55/222 1.08 (0.58-1.99) 48/158 1.39 (0.70-2.75) 0.63 
GPX2 (rs4902346)                 A / G low 32/125 1.00 (ref) 52/254 1.00 (ref)  
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high 38/141 1.17 (0.54-2.52) 66/240 1.32 (0.75-2.33) 0.80 
MUTYH (rs3219489)             C / G low 44/218 1.00 (ref) 40/161 1.00 (ref)  
high 63/216 1.50 (0.82-2.72) 41/165 1.03 (0.51-2.05) 0.35 
NOS3 (rs1799983)                 G  / T low 69/308 1.00 (ref) 15/70 1.00 (ref)  
high 83/290 1.38 (0.84-2.28) 21/90 0.61 (0.20-1.85) 0.66 
NOS3 (rs3918226) c                C / T 
 
low - -  -  
high - -  -  
NOX3||ARID1B (rs9372014) c                 
                                                G / T 
low - -  -  
high - -  -  
NQO1 (rs689453)                   C / T low 75/340 1.00 (ref) 9/39 1.00 (ref)  
high 96/333 1.26 (0.79-2.00) 8/48 2.20 (0.26-18.27) 0.22 
OGG1 (rs1805373)  c             G / A 
 
low 65/329 1.00 (ref) 19/50 1.00 (ref)  
high 86/319 1.33(0.81-2.18) 18/62 1.06 (0.30-3.77) 0.15 
PPARG (rs1801282)  c           C / G  low - -  -  
high - -  -  
RAD51C (rs304269)              G / A low 48/201 1.00 (ref) 36/178 1.00 (ref)  
high 56/199 1.65 (0.89-3.05) 48/182 0.82 (0.41-1.64) 0.68 
RAD51C (rs6503874)            C / G low 40/210 1.00 (ref) 44/169 1.00 (ref)  
high 49/178 1.56 (0.78-3.12) 55/202 0.95 (0.52-1.74) 0.44 
SOD2 (rs10370)                     T / G low 61/270 1.00 (ref) 21/107 1.00 (ref)  
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high 84/279 1.24 (0.74-2.07) 22/102 1.14 (0.41-3.18) 0.75 
SOD2 (rs4880)                       A / G 
 
low 27/116 1.00 (ref) 56/262 1.00 (ref)  
high 42/138 1.18 (0.54-2.56) 62/243 1.33 (0.76-2.34) 0.81 
USP4||GPX1 (rs8179172)  c                                                  
                                                A / T 
low 68/318 1.00 (ref) 16/61 1.00 (ref)  
high 85/322 1.17 (0.72-1.92) 19/59 1.66 (0.46-6.06) 0.74 
XPA (rs1800975)                   .C / T low 54/236 1.00 (ref) 30/142 1.00 (ref)  
high 67/234 1.10 (0.63-1.95) 37/147 1.41 (0.67-2.99) 0.74 
XPA (rs3176644)  c                 G / T 
 
low 27/163 1.00 (ref) 56/213 1.00 (ref)  
high 42/159 2.19 (1.05-4.57) 62/224 0.80 (0.45-1.44) 0.08 
XPC (rs2227998)                    C / T low 43/182 1.00 (ref) 41/197 1.00 (ref)  
high 51/184 0.95 (0.49-1.83) 53/197 1.47 (0.78-2.76) 0.84 
XPC (rs2733537)                   A / G low 58/267 1.00 (ref) 26/112 1.00 (ref)  
high 73/260 1.19 (0.69-2.05) 31/121 1.55 (0.64-3.78) 0.75 
XRCC1 (rs1799778)               G / T low 47/227 1.00 (ref) 37/151 1.00 (ref)  
high 55/235 1.23 (0.68-2.20) 48/143 1.15 (0.55-2.39) 0.74 
XRCC1 (rs1799782)              G / A low 72/336 1.00 (ref) 12/43 1.00 (ref)  
high 93/324 1.33 (0.83-2.15) 112/57 0.43 (0.07-2.73) 0.19 
XRCC1 (rs2854508)               T / A low 61/229 1.00 (ref) 23/150 1.00 (ref)  
high 62/249 0.95 (0.54-1.67) 42/131 2.04 (0.94-4.42) 0.01 
XRCC1 (rs3213247)  c           C / A low - -  -  
high - -  -  
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XRCC2 (rs3218522)               C / T low 52/274 1.00 (ref) 32/105 1.00 (ref)  
high 70/255 1.54 (0.88-2.71) 34/126 0.77 (0.35-1.70) 0.11 
XRCC4 (rs10474079)  c         G / A low - -  -  
high - -  -  
XRCC4 (rs28360135)  c          T / C low - -  -  
high - -  -  
XRCC4 (rs35268)  c                T / C low 47/204 1.00 (ref) 36/175 1.00 (ref)  
high 53/213 1.08 (0.59-1.99) 51/168 1.63 (0.83-3.21) 0.16 
XRCC4 (rs3777018 ) c           A / G low - -  -  
high - -  -  
 
a Categorized based on median split  (< vs. ≥ median)  among controls for African Americans as  low: 1.54  – 9.30 mg/day 
and high: 9.31 – 44.62 mg/day; and for European Americans: 1.67 – 9.50 and 9.51 – 53.18 mg/day, respectively.  
 
b Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake, 
and study site 
 
c Results not presented for SNPs with deviation from Hardy-Weinberg equilibrium (p-value <0.05) and for SNPs with less 
than 5% minor allele frequency among controls in the respective race group. 
 
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype 
(homozygous common allele vs. homozygous variant + heterozygous) and dietary α-tocopherol level (< vs. ≥ median) in 
multivariable adjusted models.  
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Table 7.3 (continued) Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between dietary α-
tocopherol intake and prostate cancer aggressiveness, and stratified by genotype of SNP in oxidative stress and DNA repair 
gene pathways  
 European Americans 
(n = 1,016) 
 Cases/ 
Controls  
OR (95% CI) b  
Dietary α-tocopherol mg/day a   low 81/430 1.00 (ref)  
high 72/433 0.70 (0.44-1.11)  
Stratified analysis by SNP 
 Homozygous Common Allele Heterozygous or Homozygous 
Minor Allele 
 
Gene (SNP ID), 
major/minor allele  
Cases/ 
Controls 
OR (95% CI) b 
Cases/ 
Controls 
OR (95% CI) b P ‡ 
APEX1(rs1130409)             T / G low 20/102 1.00 (ref) 61/328 1.00 (ref)  
high 18/128 0.31 (0.12-0.81) 54/305 0.90 (0.53-1.54) 0.50 
ERCC8 (rs4647100)           A / G low 46/244 1.00 (ref) 35/486 1.00 (ref)  
high 41/237 0.62 (0.33-1.15) 31/196 0.71 (0.35-1.44) 0.99 
ERCC8 (rs4647102)            T / C low 34/158 1.00 (ref) 47/272 1.00 (ref)  
high 27/166 0.55 (0.26-1.16) 45/267 0.82 (0.46-1.49) 0.31 
ERCC8 (rs976631)              T / C low 25/135 1.00 (ref) 56/294 1.00 (ref)  
high 21/140 0.61 (0.26-1.40) 51/291 0.75 (0.43-1.33) 0.94 
GPX2 (rs4902346)              A / G low 46/269 1.00 (ref) 35/161 1.00 (ref)  
high 40/284 0.60 (0.32-1.09) 32/149 0.82 (0.39-1.72) 0.41 
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MUTYH (rs3219489)          C / G low 50/228 1.00 (ref) 31/202 1.00 (ref)  
high 42/231 0.57 (0.31-1.06) 30/202 0.90 (0.44-1.82) 0.77 
NOS3 (rs1799983)              G  / T low 29/205 1.00 (ref) 52/222 1.00 (ref)  
high 30/177 1.09 (0.51-2.30) 42/253 0.46 (0.25-0.84) 0.08 
NOS3 (rs3918226) c             C / T 
 
low 63/363 1.00 (ref) 18/67 1.00 (ref)  
high 63/362 0.80 (0.48-1.32) 9/71 0.39(0.11-1.37) 0.12 
NOX3||ARID1B (rs9372014) c                 
                                             G / T 
low 39/200 1.00 (ref) 42/230 1.00 (ref)  
high 38/203 0.93  (0.48-1.81) 34/229 0.52 (0.27-1.02) 0.74 
NQO1 (rs689453)                C / T low 73/369 1.00 (ref) 8/61 1.00 (ref)  
high 65/362 0.72 (0.44-1.17) 7/71 0.87 (0.17-4.40) 65 
OGG1 (rs1805373)  c          G / A 
 
low - -  -  
high - -  -  
PPARG (rs1801282)  c       C / G  low 67/329 1.00 (ref) 14/101 1.00 (ref)  
high 55/341 0.59 (0.35-0.99) 16/92 0.86 (0.26-2.80) 0.24 
RAD51C (rs304269)           G / A low 28/181 1.00 (ref) 53/249 1.00 (ref)  
high 29/179 0.86 (0.41-1.81) 43/254 0.64 (0.35-1.17) 0.42 
RAD51C (rs6503874)         C / G low 70/381 1.00 (ref) 11/49 1.00 (ref)  
high 66/386 0.74 (0.46-1.21) 6/47 0.39 (0.05-3.15) 0.53 
SOD2 (rs10370)                  T / G low 52/253 1.00 (ref) 29/177 1.00 (ref)  
high 42/262 0.56 (0.31-1.03) 30/171 0.88 (0.42-1.84) 0.54 
SOD2 (rs4880)                    A / G low 23/114 1.00 (ref) 58/316 1.00 (ref)  
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 high 19/83 1.29 (0.52-3.21) 53/349 0.59 (0.34-1.05) 0.49 
USP4||GPX1 (rs8179172)  c                                                  
 A / T 
low - -  -  
high - -  -  
XPA (rs1800975)                 C / T low 36/187 1.00 (ref) 45/243 1.00 (ref)  
high 33/179 0.65 (0.32-1.32) 39/254 0.73 (0.39-1.35) 0.63 
XPA (rs3176644)  c              G / T 
 
low - -  -  
high - -  -  
XPC (rs2227998)                 C / T low 41/247 1.00 (ref) 40/181 1.00 (ref)  
high 37/233 0.78 (0.42-1.47) 35/197 0.58 (0.29-1.16) 0.57 
XPC (rs2733537)                A / G low 50/194 1.00 (ref) 31/236 1.00 (ref)  
high 36/207 0.46 (0.24-0.88) 36/226 1.19 (0.61-2.33) 0.12 
XRCC1 (rs1799778)            G / T low 31/178 1.00 (ref) 50/251 1.00 (ref)  
high 35/175 1.04 (0.50-2.15) 37/258 0.55 (0.30-1.03) 0.19 
XRCC1 (rs1799782)           G / A low 69/357 1.00 (ref) 12/73 1.00 (ref)  
high 62/378 0.60 (0.37-0.99) 10/55 3.90 (0.68-22.32) 0.71 
XRCC1 (rs2854508)            T / A low 58/248 1.00 (ref) 23/182 1.00 (ref)  
high 40/260 0.46 (0.22-0.85) 32/173 1.11 (0.51-2.41) 0.04 
XRCC1 (rs3213247)  c        C / A low 72/386 1.00 (ref) 9/44 1.00 (ref)  
high 64/386 0.70 (0.43-1.14) 8/47 0.80 (0.14-4.41) 0.61 
XRCC2 (rs3218522)            C / T low 16/130 1.00 (ref) 65/300 1.00 (ref)  
high 22/118 0.87 (0.32-2.42) 50/315 0.63 (0.38-1.07) 0.11 
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XRCC4 (rs10474079)  c      G / A low 60/330 1.00 (ref) 21/99 1.00 (ref)  
high 55/335 0.68 (0.40-1.15) 17/98 0.80 (0.28-2.26) 0.95 
XRCC4 (rs28360135)  c       T / C low 77/399 1.00 (ref) 4/31 1.00 (ref)  
high 67/393 0.67 (0.42-1.09) 5/40 2.57 (0.20-32.89) 0.81 
XRCC4 (rs35268)  c             T / C low 61/331 1.00 (ref) 20/99 1.00 (ref)  
high 55/339 0.80 (0.47-1.36) 17/94 0.40 (0.14-1.14) 0.99 
XRCC4 (rs3777018 ) c        A / G low 67/382 1.00 (ref) 14/48 1.00 (ref)  
high 61/387 0.76 (0.46-1.24) 11/46 0.89 (0.20-4.02) 0.98 
 
a Categorized based on median split  (< vs. ≥ median)  among controls for African Americans as  low: 1.54  – 9.30 mg/day 
and high: 9.31 – 44.62 mg/day; and for European Americans: 1.67 – 9.50 and 9.51 – 53.18 mg/day, respectively.  
 
b Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake, 
and study site 
 
c Results not presented for SNPs with deviation form Hardy-Weinberg equilibrium (p-value <0.05) and for SNPs with less 
than 5% minor allele frequency among controls in the respective race group. 
 
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype 
(homozygous common allele vs. homozygous variant + heterozygous) and dietary α-tocopherol level (< vs. ≥ median) in 
multivariable adjusted models.  
 
  
 
 
 214 
Table 7.4 Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between dietary γ-tocopherol 
intake and prostate cancer aggressiveness, and stratified by genotype among African Americans  
 African Americans 
 Cases/ 
Controls  
OR (95% CI) b  
Dietary γ-tocopherol mg/day a   
low 85/379 1.00 (ref)  
high 103/381 0.89 (0.56-1.44)  
Stratified analysis by SNP 
 
Homozygous Common Allele 
Heterozygous or Homozygous 
Minor Allele 
 
Gene (SNP ID), 
major/minor allele  
Cases/ 
Controls  
OR (95% CI) b 
Cases/ 
Controls  
OR (95% CI) b P ‡ 
APEX1(rs1130409)                 T / G low 39/152 1.00 (ref) 46/227 1.00 (ref)  
high 42/153 0.78 (0.37-1.63) 61/228 1.01 (0.54-1.92) 0.62 
ERCC8 (rs4647100)               A / G low 75/310 1.00 (ref) 10/69 1.00 (ref)  
high 81/315 0.82 (0.48-1.39) 22/66 1.51 (0.46-4.94) 0.26 
ERCC8 (rs4647102)                T / C low 34/153 1.00 (ref) 51/226 1.00 (ref)  
high 41/162 0.76 (0.34-1.70 62/217 1.05 (0.57-1.94) 0.73 
ERCC8 (rs976631)                  T / C low 45/214 1.00 (ref) 38/165 1.00 (ref)  
high 56/220 0.93 (0.48-1..82) 47/160 0.98 (0.48-1.97) 0.92 
GPX2 (rs4902346)                  A / G low 32/128 1.00 (ref) 53/251 1.00 (ref)  
high 38/138 0.71 (0.31-1.64) 65/243 0.99 (0.54-1.80) 0.72 
MUTYH (rs3219489)              C / G low 46/219 1.00 (ref) 39/160 1.00 (ref)  
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high 61/215 0.91 (0.49-1.71) 42/166 0.87 (0.42-1.80) 0.68 
NOS3 (rs1799983)                 G  / T low 69/303 1.00 (ref) 16/76 1.00 (ref)  
high 83/295 1.05 (0.62-1.77) 20/84 0.42 (0.11-1.56) 0.55 
NOS3 (rs3918226) c                C / T low - -  -  
high - -  -  
NOX3||ARID1B (rs9372014) c                   
                                                 G / T 
low - -  -  
high - -  -  
NQO1 (rs689453)                    C / T low 78/341 1.00 (ref) 7/38 1.00 (ref)  
high 93/332 0.85 (0.52-1.40) 10/49 1.69 (0.17-16.36) 0.69 
OGG1 (rs1805373) c               G / A 
 
low 65/328 1.00 (ref) 20/51 1.00 (ref)  
high 86/320 1.05 (0.63-1.79) 17/61 0.30 (0.08-1.17) 0.08 
PPARG (rs1801282) c             C / G  low - -  -  
high - -  -  
RAD51C (rs304269)               G / A low 49/201 1.00 (ref) 36/178 1.00 (ref)  
high 55/199 1.26 (0.66-2.43) 48/182 0.54 (0.25-1.14) 0.70 
RAD51C (rs6503874)             C / G low 44/204 1.00 (ref) 41/175 1.00 (ref)  
high 45/184 0.63 (0.30-1.34) 58/196 1.13 (0.60-2.13) 0.61 
SOD2 (rs10370)                      T / G low 66/268 1.00 (ref) 19/111 1.00 (ref)  
high 79/281 0.77 (0.44-1.33) 24/98 1.43 (0.51-3.97) 0.59 
SOD2 (rs4880)                        A / G 
 
low 29/133 1.00 (ref) 55/245 1.00 (ref)  
high 40/121 1.39 (0.62-3.14) 63/260 0.72 (0.39-1.31) 0.25 
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USP4||GPX1 (rs8179172) c                              
 A / T 
low 69/321 1.00 (ref) 16/58 1.00 (ref)  
high 84/319 0.83 (0.49-1.41) 19/62 1.24 (0.32-4.85) 0.65 
XPA (rs1800975)                      C /T low 53/237 1.00 (ref) 32/141 1.00 (ref)  
high 68/233 0.97 (0.53-1.76) 35/148 0.76 (0.34-1.71) 0.64 
XPA (rs3176644) c                    G / T 
 
low 29/157 1.00 (ref) 55/222 1.00 (ref)  
high 40/165 1.24 (0.57-2.70) 63/215 0.76 (0.40-1.42) 0.57 
XPC (rs2227998)                     C / T low 40/186 1.00 (ref) 45/193 1.00 (ref)  
high 54/180 0.98 (0.48-1.98) 49/201 0.82 (0.42-1.59) 0.21 
XPC (rs2733537)                    A / G low 60/267 1.00 (ref) 25/112 1.00 (ref)  
high 71/260 0.82 (0.46-1.46) 32/121 1.10 (0.42-2.86) 0.72 
XRCC1 (rs1799778)                G / T low 47/226 1.00 (ref) 38/153 1.00 (ref)  
high 55/236 0.98 (0.53-1.82) 47/141 0.77 (0.35-1.71) 0.69 
XRCC1 (rs1799782)               G / A low 73/331 1.00 (ref) 12/48 1.00 (ref)  
high 92/329 0.92 (0.56-1.53) 11/52 0.86 (0.15-4.93) 0.49 
XRCC1 (rs2854508)                T / A low 64/237 1.00 (ref) 21/142 1.00 (ref)  
high 59/241 0.71 (0.39-1.29) 44/139 1.60 (0.71-3.63) 0.03 
XRCC1 (rs3213247)  c            C / A low - - - -  
high - - - -  
XRCC2 (rs3218522)                C / T low 53/266 1.00 (ref) 32/113 1.00 (ref)  
high 69/263 0.97 (0.53-1.75) 34/118 0.78 (0.34-1.81) 0.30 
XRCC4 (rs10474079)  c          G / A low - - - -  
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high - - - -  
XRCC4 (rs28360135)  c           T / C low - - - -  
high - - - -  
XRCC4 (rs35268)  c                 T / C low 46/206 1.00 (ref) 39/173 1.00 (ref)  
high 54/211 0.87 (0.46-1.65) 48/170 0.84 (0.40-1.75) 0.51 
XRCC4 (rs3777018 ) c            A / G low - - - -  
high - - - -  
 
a Categorized based on median split (< vs. ≥ median) among controls for African Americans as low: 0.78 – 18.54 mg/day 
and high: 18.55 – 67.95 mg/day; and for European Americans: 2.68 – 17.22 and  17.23 – 55.13 mg/day, respectively. 
 
b Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake, 
and study site 
 
c Results not presented for SNPs with deviation form Hardy-Weinberg equilibrium (p-value <0.05) and for SNPs with less 
than 5% minor allele frequency among controls in the respective race group. 
 
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype 
(homozygous common allele vs. homozygous variant + heterozygous) and dietary γ-tocopherol level (< vs. ≥ median) in 
multivariable adjusted models.  
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Table 7.4 (continued) Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between dietary γ-
tocopherol intake and prostate cancer aggressiveness, and stratified by genotype among European Americans   
 European Americans 
 Cases/ 
Controls  
OR (95% CI) b  
Dietary γ-tocopherol mg/day a   
low 75/431 1.00 (ref)  
high 78/432 0.77 (0.48-1.24)  
Stratified analysis by SNP 
 
Homozygous Common Allele 
Heterozygous or Homozygous 
Minor Allele 
 
Gene (SNP ID), 
major/minor allele  
Cases/ 
Controls  
OR (95% CI) b 
Cases/ 
Controls  
OR (95% CI) b P ‡ 
APEX1(rs1130409)             T / G low 17/108 1.00 (ref) 58/323 1.00 (ref)  
high 21/122 0.69 (0.25-1.92) 57/310 0.77 (0.44-1.33) 0.77 
ERCC8 (rs4647100)           A / G low 39/243 1.00 (ref) 36/188 1.00 (ref)  
high 48/238 1.06 (0.56-2.01) 30/194 0.48 (0.23-1.03) 0.20 
ERCC8 (rs4647102)           T / C low 24/152 1.00 (ref) 51/279 1.00 (ref)  
high 37/172 1.54 (0.71-3.32) 41/260 0.48 (0.25-0.91) 0.16 
ERCC8 (rs976631)             T / C low 23/133 1.00 (ref) 52/296 1.00 (ref)  
high 23/142 0.60 (0.25-1.42) 55/289 0.85 (0.48-1.52) 0.95 
GPX2 (rs4902346)             A / G low 42/273 1.00 (ref) 33/158 1.00 (ref)  
high 44/280 0.73 (0.39-1.37) 34/152 0.85 (0.39-1.82) 0.54 
MUTYH (rs3219489)          C / G low 47/232 1.00 (ref) 28/199 1.00 (ref)  
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high 45/227 0.58 (0.31-1.11) 33/205 1.15 (0.55-2.40) 0.60 
NOS3 (rs1799983)             G  / T low 26/184 1.00 (ref) 49/244 1.00 (ref)  
high 33/198 0.78 (0.36-1.69) 45/231 0.72 (0.39-1.34) 0.75 
NOS3 (rs3918226) c            C / T 
 
low 57/361 1.00 (ref) 18/70 1.00 (ref)  
high 69/364 0.88 (0.52-1.50) 9/68 0.37(0.11-1.22) 0.12 
NOX3||ARID1B (rs9372014) c 
G / T 
low 41/201 1.00 (ref) 34/229 1.00 (ref)  
high 36/202 0.58 (0.28-1.18) 42/230 0.97 (0.50-1.88) 0.17 
NQO1 (rs689453)               C / T low 69/363 1.00 (ref) 6/68 1.00 (ref)  
high 69/368 0.69 (0.41-1.14) 9/64 3.34 (0.70-15.84) 0.32 
OGG1 (rs1805373) c          G / A 
 
low - -  -  
high - -  -  
PPARG (rs1801282) c        C / G low 63/330 1.00 (ref) 12/101 1.00 (ref)  
high 59/340 0.58 (0.34-1.00) 18/92 2.02 (0.63-6.53) 0.10 
RAD51C (rs304269)           G / A low 24/179 1.00 (ref) 51/252 1.00 (ref)  
high 33/181 0.98 (0.47-2.08) 45/251 0.67 (0.35-1.26) 0.27 
RAD51C (rs6503874)         C / G low 65/388 1.00 (ref) 10/43 1.00 (ref)  
high 71/379 0.90 (0.55-1.48) 7/53 0.15 (0.03-0.90) 0.30 
SOD2 (rs10370)                  T / G low 48/249 1.00 (ref) 27/182 1.00 (ref)  
high 46/266 0.62 (0.33-1.15) 32/166 1.04 (0.47-2.27) 0.41 
SOD2 (rs4880)                   A / G 
 
low 21/111 1.00 (ref) 54/320 1.00 (ref)  
high 21/86 1.66 (0.62-4.43) 57/345 0.65 (0.37-1.13) 0.59 
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USP4||GPX1 (rs8179172) c      
A / T 
low - -  -  
high - -  -  
XPA (rs1800975)                 C / T low 33/184 1.00 (ref) 42/247 1.00 (ref)  
high 36/182 0.51 (0.23-1.11) 42/250 0.96 (0.51-1.79) 0.80 
XPA (rs3176644) c               G / T 
 
low - -  -  
high - -  -  
XPC (rs2227998)                C / T low 39/236 1.00 (ref) 36/193 1.00 (ref)  
high 39/244 0.66 (0.34-1.29) 39/185 0.92 (0.45-1.86) 0.53 
XPC (rs2733537)               A / G low 42/186 1.00 (ref) 33/245 1.00 (ref)  
high 44/215 0.64 (0.33-1.26) 34/217 0.90 (0.45-1.80) 0.32 
XRCC1 (rs1799778)           G / T low 28/178 1.00 (ref) 47/253 1.00 (ref)  
high 38/175 0.91 (0.42-1.95) 40/256 0.67 (0.36-1.26) 0.26 
XRCC1 (rs1799782)           G / A low 59/362 1.00 (ref) 16/69 1.00 (ref)  
high 72/373 1.06 (0.52-1.43) 6/59 0.23 (0.04-1.38) 0.04 
XRCC1 (rs2854508)           T / A low 51/250 1.00 (ref) 24/181 1.00 (ref)  
high 47/258 0.76 (0.42-1.36) 31/174 0.73 (0.32-1.70) 0.35 
XRCC1 (rs3213247)  c        C / A low 66/387 1.00 (ref) 9/44 1.00 (ref)  
high 70/385 0.76 (0.46-1.25) 8/47 1.39 (0.23-8.30) 0.81 
XRCC2 (rs3218522)            C / T low 13/139 1.00 (ref) 62/292 1.00 (ref)  
high 25/109 1.20 (0.42-3.42) 53/323 0.66 (0.39-1.14) 0.02 
XRCC4 (rs10474079)  c      G / A low 55/326 1.00 (ref) 20/105 1.00 (ref)  
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high 60/339 0.71 (0.41-1.24) 187/92 1.11 (0.40-3.06) 0.72 
XRCC4 (rs28360135)  c      T / C low 72/402 1.00 (ref) 3/29 1.00 (ref)  
high 72/390 0.72 (0.44-1.18) 6/42 2.48 (0.21-28.62) 0.66 
XRCC4 (rs35268)  c            T / C low 54/335 1.00 (ref) 21/97 1.00 (ref)  
high 62/335 1.04 (0.60-1.79) 16/96 0.27 (0.08-0.83) 0.19 
XRCC4 (rs3777018 ) c        A / G low 62/375 1.00 (ref) 13/56 1.00 (ref)  
high 66/394 0.75 (0.45-1.24) 12/38 1.96 (0.37-10.28) 0.72 
 
a Categorized based on median split (< vs. ≥ median) among controls for African Americans as low: 0.78 – 18.54 mg/day 
and high: 18.55 – 67.95 mg/day; and for European Americans: 2.68 – 17.22 and  17.23 – 55.13 mg/day, respectively. 
 
b Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake, 
and study site 
 
c Results not presented for SNPs with deviation form Hardy-Weinberg equilibrium (p-value <0.05) and for SNPs with less 
than 5% minor allele frequency among controls in the respective race group. 
 
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype 
(homozygous common allele vs. homozygous variant + heterozygous) and dietary γ-tocopherol level (< vs. ≥ median) in 
multivariable adjusted models.  
 
  
 
 
 CHAPTER 8 
LYCOPENE INTAKE AND PROSTATE CANCER AGGRESSIVENESS: EFFECT MODIFICATION BY 
POLYMORPHISMS IN DNA REPAIR AND OXIDATIVE STRESS RELATED GENES 
 
8.1     INTRODUCTION 
Prostate cancer (PCa) is the most common invasive cancer and a leading cause of 
cancer death among men in North America and Western Europe [514]. The aggressive 
forms of PCa occur most frequently in men of African ancestry, and these are often 
diagnosed at an early age [515, 516]. Epidemiologic studies suggest that the etiology of 
aggressive PCa may be different from that of non-aggressive PCa, including differences 
in genetic susceptibility [517, 518] and potential differences in dietary risk factors [17, 
437]. Lycopene, an antioxidant carotenoid, is among the potentially beneficial dietary 
factors associated with a reduced risk of PCa [179, 440, 519]. Some studies show that 
lycopene may have a stronger inverse association with the aggressive forms of PCa 
compared with more indolent PCa [520, 521]. Genetic variants (i.e., single nucleotide 
polymorphisms, SNPs) in oxidative stress and DNA repair genes have also been 
associated with PCa risk and aggressiveness [332, 491, 492, 522]. However, lycopene 
intake and genetic risk variants, when examined in isolation, may explain only a small 
portion of the factors contributing to PCa aggressiveness. There is some evidence that the 
association between lycopene and PCa are modulated by polymorphic variants of genes 
involved in the biological processes of PCa, such as those in the oxidative stress and 
DNA repair pathways [2, 128, 466, 470].  
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 Several reports indicate that oxidative stress-related genes may confer greater risk 
of PCa [478, 522]. Indeed, oxidative stress has been implicated in prostate tumorigenesis 
[470, 478] and is thought to promote PCa initiation and aggressiveness by causing 
damage to DNA [479]. Cellular response to oxidative DNA damage involves the 
activation of oxidative stress-mediating genes, including those involved in base excision 
repair, nucleotide excision repair, homologous re-combination repair, and non-
homologous end-joining DNA repair genes to correct the damaged parts and restore 
genomic stability [125, 523]. The ability to recognize and repair oxidatively modified 
DNA is an important determinant of an individual’s susceptibility to PCa [523]. Thus, 
individual differences in polymorphic variants of genes encoding oxidative stress and 
DNA repair functions may influence the incidence and aggressiveness of PCa [125, 478]. 
Lycopene, which is obtained mainly from tomatoes and tomato-based products, 
has been shown in laboratory studies to have many anticancer properties, including acting 
as an antioxidant and inhibitor of oxidative DNA damage [371, 524]. However, 
associations between lycopene and PCa overall are inconsistent (reviewed in [179, 393, 
440, 519]). Of five prospective dietary studies [180, 437, 449, 525, 526], three [180, 437, 
449] reported an inverse association between lycopene intake and PCa incidence, while 
two [525, 526] were not supportive of a beneficial role of lycopene in PCa. Among case-
control studies, three [450, 527, 528] reported inverse associations with higher lycopene 
intake, while several others have reported null association ([461, 462, 529], also reviewed 
in [179, 393, 440, 519]). Similarly, some [520, 521], but not all [442, 530, 531], plasma- 
and serum-based studies have reported inverse associations between lycopene levels and 
PCa incidence. These somewhat inconsistent findings might be because these studies 
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 consisted of a heterogeneous group of PCa cases, which can confound associations. It 
might also reflect the genetic risk variability of the studied populations. Examining gene-
nutrient interaction in relation to PCa phenotype may therefore help clarify the 
association between lycopene and PCa. 
The purpose of this study was to investigate whether polymorphisms in oxidative 
stress and DNA repair genes interact with lycopene to modulate PCa aggressiveness 
among African-American (AA) and European-American (EA) men in North Carolina and 
Louisiana. The hypothesis was that associations between lycopene intake and PCa 
aggressiveness are modified by SNPs in oxidative stress and DNA repair genes.    
8.2     METHODS 
Study Population 
This study was conducted using data from the North Carolina-Louisiana Prostate 
Cancer Project (PCaP) [399]. PCaP is a large, population-based, cross-sectional, case-
only study designed to examine biological, lifestyle, and socio-demographic factors 
associated with PCa aggressiveness among AAs and EAs. Between July 2004 and August 
2009, PCaP enrolled 2,258incident PCa cases (AAs, n = 1,130; EAs, n = 1,128) from 
North Carolina (NC) and Louisiana (LA), with a median time between diagnosis and 
recruitment of 3.9 months. The inclusion criteria for PCaP were having a first diagnosis 
of histologically confirmed adenocarcinoma of the prostate, being of age 40–79 years at 
diagnosis, and self-identification of race as Black/AA or Caucasian American/White/EA. 
The eligible participants were also required to be able to complete the study interview in 
English; have sufficient physical and cognitive ability to participate; and not reside in an 
institution (e.g., nursing home). Institutional Review Board (IRB) approval was obtained 
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 from all collaborating institutions, and all of the research subjects provided consent 
before enrollment  [399]. The current analysis also was approved by the IRB of the 
University of South Carolina. The PCa cases included in this analysis were drawn from 
PCaP research subjects with available data on the SNPs of interest (n = 1,964; AAs n = 
948; EAs n = 1,016).  
Data Collection 
Data on demographic, lifestyle, and health-related factors were obtained by 
trained research nurses using structured questionnaires during in-home visits [399]. The 
research nurses also obtained anthropometric measures and peripheral blood samples 
during each interview following a standardized protocol. Research subjects who could 
not provide blood samples were given the option to complete a buccal rinse for DNA 
analysis (approximately 5%). Information on the cancer stage at diagnosis, Gleason sum, 
and prostate-specific antigen (PSA) level at diagnosis were abstracted from the medical 
records obtained from diagnosing physicians. The medical records abstraction was 
standardized and performed by trained personnel, and included a duplicate abstraction of 
a random sample (about 10%) to ensure consistency between abstractors. PCa 
aggressiveness was classified as previously described [399] to be high aggressive 
(Gleason sum ≥8; PSA >20 ng/ml; or Gleason sum = 7 and stage T3–T4), low aggressive 
(Gleason sum <7 and stage T1–T2 and PSA<10 ng/ml), or intermediate aggressive (all 
other cases). These categories were used in a case-control study design to compare high 
aggressive PCa “cases” with low or intermediate aggressive PCa “controls,” as has been 
done in previous studies [532, 533]. 
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 Dietary Assessment 
Dietary data were obtained using the National Cancer Institute Dietary History, 
Food-frequency Questionnaire (NCI-DHQ) [453], which was modified to include 
Southern foods. The modified 144-item questionnaire queried on frequency of food 
intake, usual portion size, and food preparation methods in the 12 months prior to 
diagnosis with PCa. Usual daily nutrient intake was estimated using the Diet*Calc 
software, which utilizes the NCI’s nutrient database [399]. In addition, a validated 
questionnaire [454] was used to solicit information on multivitamins and single-nutrient 
supplement use in the 12 months prior to diagnosis. This information was used to 
calculate total lycopene intake by combining lycopene intake from food and supplements. 
None of the subjects included in this analysis had implausible values for calorie intake 
(i.e., < 500 or > 6000 kcal/day). 
SNP Selection 
Details of the methods used for SNP selection in PCaP has been reported [332]. 
For the current analysis, 34 candidate SNPs across 18 genes were selected from the PCaP 
genotype data repository for analyses. These include NOS3 (rs1799983, rs3918201, 
rs3918226) and NOX3||ARID1B (rs9372014), which are implicated in oxidative stress, 
and GPX2 (rs4902346), NQO1 (rs689453), PPARG (rs1801282), SOD2 (rs10370, 
rs4880), and USP4||GPX1 (rs8179172), which are involved in antioxidant defense. Also 
included were APEX1 (rs1048945, rs1130409), APEX2 (rs28382675), MUTYH 
(rs3219489), OGG1 (rs1805373), and XRCC1 (rs1799778, rs1799782, rs2854508, 
rs3213247), which are located in the base excision repair pathway, and ERCC8 
(rs4647100, rs4647102, rs976631), XPA (rs1800975, rs3176644), and XPC (rs2227998, 
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 rs2733537), which are located in the nucleotide excision DNA repair pathway. RAD51C 
(rs304269, rs6503874) and XRCC2 (rs3218522), which are involved in homologous 
recombination, and  XRCC4 (rs10474079, rs28360135, rs28360248, rs35268, 
rs3777018), which is involved in non-homologous end-joining DNA repair, were also 
analyzed [489, 534]. These SNPs were selected because of known or suspected functional 
significance in oxidative stress or DNA repair in relation to cancer based on published 
literature [491, 492, 522, 535]. An a priori decision was made to exclude SNPs with low 
minor allele frequency (MAF, < 0.05). Based on this criterion, four out of the 34 SNPs 
were removed from the analyses for both AAs and EAs: APEX1 (rs1048945), APEX2 
(rs28382675), NOS3 (rs3918201), and XRCC4 (rs28360248). Of the remaining SNPs, 
OGG1 (rs1805373), USP4||GPX1 (rs8179172), and XPA (rs3176644) were excluded 
from analyses among EAs only, while NOS3 (rs3918226), NOX3||ARID1B (rs9372014), 
PPARG (rs1801282), XRCC1 (rs3213247), and XRCC4 (rs10474079, rs28360135, 
rs3777018) were excluded among AAs only. 
Genotyping 
DNA was extracted from blood samples  (n = 1,630) or buccal cells  (n = 118) by 
the University of North Carolina (UNC, Chapel Hill) Biospecimen Processing Facility or 
from peripheral blood mononuclear cells immortalized by the UNC Tissue Culture 
Facility (n = 216). Genotyping was done at the National Institutes of Health (NIH) Center 
for Inherited Disease Research (CIDR) using a custom designed Illumina GoldenGate 
array. There was an excellent genotyping call rate (99.93%) and inter-assay agreement 
with blinded duplicates (99.99%). Further details of the genotyping process and quality 
control measures have been published [332].   
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 Statistical Methods 
All analyses were conducted separately for AAs and EAs because of significant 
interaction that was observed between race and lycopene intake. Distributions of research 
subjects’ characteristics by the levels of PCa aggressiveness were examined using 
Students’ t-test and chi-square tests for continuous and categorical variables, respectively. 
Unconditional logistic regression was used to calculate odds ratios (ORs) and 
corresponding 95% confidence intervals (CIs). In order to maximize sample size, a 
dominant model of inheritance was adopted to evaluate the effect of genotype on PCa 
aggressiveness by collapsing the three-level genotype variables into two groups. This was 
done by taking the most frequent genotype (i.e., homozygous common allele) as the 
reference category to estimate ORs for the homozygous and heterozygous variant 
genotypes (combined in one group), adjusting for age at diagnosis. The lycopene 
variables also were categorized into two groups (< versus ≥ median) to conserve sample 
size. Cutpoints for categorizing the dietary and total (diet + supplement) lycopene 
variables were based on race-specific distribution among low/intermediate aggressive 
cases. 
All multivariable logistic regression models simultaneously adjusted for the 
following variables: age (continuous), study site (NC, LA), BMI (in kg/m2), pre-
diagnostic PSA screening history (0, 1–7, >7 screenings), smoking status (never, former, 
current), education (less than high school education, high school graduate/some college, 
college graduate), annual household income (< $20,000, $20,001–$40,000, $40,001–
$70,000, >$70,000), regular NSAIDs use in the five years prior to diagnosis (yes, no), 
and total fat intake (grams/day). Other factors that were evaluated as potential 
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 confounders but not included in the final adjusted models are: comorbidities (0, 1, 2, ≥3), 
a first degree family history of PCa (none, at least one), PCa treatment status (started 
treatment, not started), and physical activity (i.e., metabolic equivalents (METs) of light, 
moderate, and vigorous exercise in the year prior to diagnosis, ≤ 10.2, 10.3–29.0, >29.0 
MET-hours/week). 
To examine potential modification of associations between lycopene intake and 
PCa aggressiveness, stratified analyses were performed comparing greater than or equal 
to median (i.e. high) with less than median (i.e., low) intake within each stratum of the 
genotype groups (homozygous common allele versus heterozygous or homozygous minor 
allele). Interaction effects were assessed on the multiplicative scale using likelihood ratio 
tests to compare models with and without interaction terms of the dichotomous genotype 
and lycopene variables following the hierarchical principle. The threshold for a 
statistically significant interaction was set at P value < 0.10 to compensate for the small 
sample size in the stratified groups [336]. All other tests were considered statistically 
significant at the 0.05 level. Results were corrected for multiple testing using the false 
discovery rate (FDR) method [338]. All statistical tests were two-sided and performed 
using SAS® version 9.3 (SAS, Inc.).  
8.3     RESULTS  
In both race groups, research subjects with high aggressive PCa were older and 
less educated as compared to those with low or intermediate aggressive PCa (Table 8.1). 
EA research subjects with high aggressive PCa had a marginally higher BMI than EAs 
with low or intermediate aggressive PCa. AA research subjects with high aggressive PCa 
tended to have higher dietary fat intake and included greater proportions of current 
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 smokers, low incomes, and those who have never had a PSA screening test prior to 
diagnosis with PCa as compared with AAs with low or intermediate aggressive PCa.  
As shown in Table 8.2, evaluation of the main effect of the SNP variants in 
relation to PCa aggressiveness did not show a statistically significant beneficial or 
harmful effect for any of the SNPs, except for a marginally significant association for the 
XRCC4 (rs3777018) SNP among EAs. The EA carriers of the minor allele of XRCC4 
(rs3777018, A > G) appeared to have greater odds of high aggressive PCa than those 
homozygous for the common allele (OR = 1.63, 95% CI = 1.00-2.64).  
Dietary lycopene intake expressed as the median split variable was not 
significantly associated with PCa aggressiveness among EAs (OR = 0.77, 95% CI = 
0.53–1.16, high versus low intake) or AAs (OR = 1.41, 95% CI = 0.96-2.07, high versus 
low intake) (Table 8.3). However, evidence existed of gene-nutrient interaction, which 
was particularly noticeable for the XRCC1 (rs2854508, T > A) (P values for interaction = 
0.01 and 0.06 for AAs and EAs, respectively). The pattern of the interaction was such 
that, in both AAs and EAs, high (compared to low) dietary lycopene intake tended to be 
associated with increased odds of high aggressive PCa among those heterozygous or 
homozygous for the minor allele, while higher lycopene intake was inversely related to 
high aggressive PCa among those homozygous for the common allele. XPA (rs1800975, 
C > T) also appeared to have a modifying effect on associations between dietary lycopene 
and PCa aggressiveness in that lycopene intake was associated with reduced odds of high 
aggressive PCa among EAs with one or two copies of the minor allele (OR = 0.56, 95% 
CI = 0.32–0.98, high versus low intake), but not those homozygous for the common 
allele (OR = 1.02, 95% CI = 0.56–1.87, high versus low intake; P value for interaction = 
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 0.07). Analogous findings were observed among AAs, although statistical interaction was 
non-significant in this group. A similar pattern of lower odds of high aggressive PCa was 
observed among EAs who harbor the minor allele of NQO1 (rs689453, C > T) and 
XRCC2 (rs3218522, C > T) and had higher lycopene intake, which was not observed 
among EAs who were homozygous for the common allele (P values for interaction = 
0.05 and 0.08, respectively). Among AAs only, higher dietary lycopene intake was 
associated with increased odds of high aggressive PCa among those homozygous for the 
common alleles of ERCC8 (rs4647102, T > C), RAD51C (rs6503874, C > G), and 
XRCC1 (rs1799778, G >T), but not those who were heterozygous or homozygous for the 
minor alleles of these SNPs. Among AAs heterozygous or homozygous for the minor 
alleles of XPA (rs3176644, G >T), XPC (rs2227998, C >T), and XPC (rs2733537, A > G) 
higher lycopene intake was associated with increased odds of high aggressive PCa.  
Table 8.4 presents associations of total lycopene intake from diet, supplements, 
and PCa aggressiveness by genotype. Similar to dietary lycopene, there were no 
significant associations between total lycopene intake and PCa aggressiveness among 
EAs or AAs. Interactions observed with total lycopene were fewer, but largely mirror 
those observed with dietary lycopene. In particular, the genetic variants in XRCC1 
(rs2854508), XPA (rs1800975), and NQO1 (rs689453) demonstrated identical interaction 
with total lycopene intake as observed with dietary lycopene. Similarly, the associations 
observed for RAD51C (rs6503874), XPA (rs3176644), and XPC (rs2733537) with dietary 
lycopene among AAs were consistent with the findings for total lycopene intake among 
AAs. 
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 8.4     DISCUSSION  
In this population-based, case-only study, there was evidence that an association 
between lycopene and PCa aggressiveness can be modified by genotype of SNPs in 
oxidative stress and DNA repair genes. The evidence was strongest for the XRCC1 
(rs2854508) SNP, whereby among research subjects with the variant genotypes (AT or 
AA), higher lycopene intake was associated with an increased odds of high aggressive 
PCa, while high lycopene intake was associated with  lower odds of high aggressive PCa 
among those with the homozygous common genotype (TT). In addition to XRCC1 
(rs2854508), other SNPs that did not have independent association with high aggressive 
PCa appeared to interact with lycopene to influence PCa aggressiveness. Notably, XPA 
(rs1800975) and NQO1 (rs689453), demonstrated statistical interaction with dietary and 
total lycopene intake, with similar patterns of association in both AAs and EAs. It is, 
however, worth noting that no study has yet examined these SNPs in gene-diet interaction 
studies. Hence, confirmatory studies are warranted.  
Few data exist for interaction between lycopene and other polymorphisms in 
DNA repair and oxidative stress-related genes [2, 128, 335, 466, 497]. Goodman and 
colleagues [466] demonstrated that the XRCC1 A399G polymorphism modifies 
association between lycopene and PCa risk such that the beneficial effect of lycopene 
was only evident in men with the AA genotype, not those with the AG or GG genotype. 
Li et al. [335] examined interaction between pre-diagnostic plasma lycopene level and 
genotype of the manganese superoxide dismutase (MnSOD, also referred to as SOD2) 
gene, but did not find independent association of MnSOD genotype or interaction with 
plasma lycopene level in relation to overall risk of PCa and risk for aggressive PCa. This 
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 finding concurs with the current results for the SOD2 SNPs (rs10370 and rs4880). 
However, in an analysis of combined plasma antioxidant status (sum of lycopene, 
selenium and α-tocopherol), the highest quartile of plasma antioxidant status (compared 
to lowest) was associated with a five-fold lower risk of PCa and ten-fold lower risk of 
aggressive PCa among men with the AA genotype, but no significant association was 
observed among those with AV or VV genotype [335]. Similar findings have been 
reported by Mikhak et al. [497]. Although different candidate SNPs have been examined 
in various studies, together, these data provide support for the gene-nutrient interactions 
observed in the current analyses, indicating that the association between lycopene and 
PCa can be modified by genotype of polymorphisms in relevant genes. 
A nearly significant positive association with PCa aggressiveness was observed 
for the XRCC4 (rs3777018) G allele though it did not modify the association of lycopene 
intake with PCa aggressiveness. While some of the SNPs did not show evidence of 
statistical interaction with lycopene, certain variants of the SNPs appear to work in 
tandem with lycopene to influence PCa aggressiveness. As suggested by Savas et al. 
[502] and Rebbeck [536], it is possible that some of these variants confer low-to-
moderate risk or protection against cancer  that becomes evident only under certain 
physiological conditions or environmental exposures.    
Limitations of the study include the use of a food frequency questionnaire to 
measure lycopene intake, which in addition to identified response set biases [510-512], 
does not account for the bioavailability or bioefficiency of carotenoids because of inter-
individual variability in absorption and metabolism [278]. The use of a single dietary 
assessment also might have introduced some misclassification of lycopene exposure. 
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 However, because this is a case-only study, such misclassification would likely be non-
differential, resulting in conservative OR estimates [384]. Another limitation includes the 
use of median cutpoints to categorized lycopene in an effort to conserve sample size; 
however, this may have resulted in too small contrast between high and low lycopene 
intake categories to observe a substantial effect of lycopene. Other limitations include the 
observational nature of the study, which precludes causal inferences. Because of the 
small sample size and multiple comparisons, chance findings cannot be excluded, 
considering that none of the P values retained statistical significance after FDR correction 
for multiple testing (data not shown). Therefore, replication of the findings in larger 
studies would be useful. Even though analyses were stratified by self-reported race, 
residual confounding by ethnicity due to genetic admixture cannot be completely ruled 
out [537, 538]. Additionally, post hoc analysis involving adjustment for African ancestry 
proportions did not materially change the study results (Supplementary Tables 3 and 4).  
8.5     CONCLUSIONS 
In summary, the results of the analysis suggest that EA men with AG or GG genotype of 
the XRCC4 (rs3777018) SNP may be at a higher risk of developing high aggressive PCa 
compared to those with the AA genotype. The results also show that an association 
between lycopene and PCa aggressiveness can be modified by genotype of SNPs in 
oxidative stress and DNA repair genes, including XRCC1 (rs2854508), XPA (rs1800975) 
and NQO1 (rs689453). Additional work is needed to verify these findings and help 
determine their potential for targeted PCa interventions.  
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Table 8.1 Demographic and health-related characteristics of the research subjects by level of prostate cancer aggressiveness  
 
Characteristics 
European Americans 
N = 1016 
African Americans 
N = 948 
 
 
High  
aggressive 
(n=153 ) 
Low/intermediate 
aggressive 
(n= 863) 
P ‡ High  aggressive 
(n=188) 
Low/intermediate 
aggressive 
(n= 760) 
P ‡ 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
Age, years  67 (7.5) 64 (7.7) <0.0001 63 (7.6) 62 (7.6) 0.007 
Energy Intake, kcals/day 2360.1 (963.4) 2322.1 (878.2) 0.63 2792.8 (1200.8) 2614.7 (1153.1) 0.06 
Dietary fat intake, 
grams/day 
95.7 (43.2) 91.2 (39.7) 0.20 103.8 (51.6) 95.5 (48.2) 0.04 
Body mass index (BMI), 
kg/m2  
30.3 (5.1) 29.0 (4.8) 0.002 30.0 (6.7) 29.2 (5.4) 0.10 
 N % N %  N % N %  
Study Site           
     NC 64 42 413 48 0.17 80 43 347 46 0.44 
     LA  89 58 450 52 108 57 413 54 
PSA Screening History           
     0 screenings 35 23 140 16 0.13 111 59 278 37 <0.0001 
     1-7 screenings 63 41 385 45 46 24 321 42 
     > 7 screenings 55 36 338 39 31 17 161 21 
Education         
     Less than high school 
education 
27 18 74 8 0.002 78 42 220 29 0.001 
     High school graduate/ 
some college 
70 46 412 48 93 49 413 54 
     College graduate  56 37 377 44 17 9 126 17 
Income Level           
     ≤ $20, 000 22 14 71 8 0.15 75 40 217 29 0.002 
     $20,001- $40,000 30 20 171 20 47 25 199 26 
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     $40,001- $70,000 37 24 211 24 22 12 158 21 
      >$70,000 50 33 336 40 21 11 121 16 
      Unknown  14 9 74 8 23 12 65 8 
Smoking Status           
     Never 54 35 314 36 0.69 37 20 258 34 0.0003 
     Former smokers 82 54 472 55 99 52 358 47 
     Current smokers 17 11 77 9 52 28 144 19 
NSAID  Use           
     No 52 34 289 34 0.92 76 41 336 44 0.38 
     Yes 101 66 572 66 110 59 420 56 
 
Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as 
follows: High aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); Low /Intermediate 
aggressive: all other cases. 
Abbreviations: PCa – prostate cancer; LA – Louisiana; NC –North Carolina; NSAIDs – nonsteroidal anti-inflammatory drugs; PSA 
– prostate-specific antigen; SD – standard deviation 
‡Test for differences between high aggressive and low/intermediate aggressive prostate cancers performed using Student’s t-test for 
continuous variables and chi-square tests for categorical variables. 
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Table 8.2 Associations of polymorphisms in DNA repair and oxidative stress-related genes in relation to prostate cancer 
aggressiveness among European Americans and African Americans 
 African Americans  European Americans 
Gene (SNP ID) Genotype  
Case/ 
Controls b 
 
188/760 
OR (95% CI)  c  P 
Case/ 
Controls b 
 
153/863 
OR (95% CI) c  P  
APEX1 
(rs1130409) 
TT 81/305 1.00 (ref)  38/230 1.00 (ref)  
GT+GG 107/455 0.88 (0.64-1.22) 0.44 115/633 1.10 (0.74-1.64) 0.63 
ERCC8 
(rs4647100) 
AA 156/625 1.00 (ref)  87/481 1.00 (ref)  
AG+GG 32/135 0.97 (0.64-1.49) 0.91 66/382 0.96 (0.67-1.36) 0.81 
ERCC8 
(rs4647102) 
TT 75/315 1.00 (ref)  61/324 1.00 (ref)  
CT+CC 113/443 1.10 (0.79-1.53) 0.57 92/539 0.90 (0.63-1.29) 0.57 
ERCC8 (rs976631) TT 101/434 1.00 (ref)  46/275 1.00 (ref)  
CT+CC 85/325 1.09 (0.79-1.51) 0.58 107/585 1.12 (0.77-1.63) 0.56 
GPX2 (rs4902346) AA 70/266 1.00 (ref)  86/553 1.00 (ref)  
AG+GG 118/494 0.90 (0.64-1.25) 0.53 67/310 1.39 (0.98-1.97) 0.07 
MUTYH 
(rs3219489) 
CC 107/434 1.00 (ref)  92/459 1.00 (ref)  
CC+GG 81/326 1.02 (0.74-1.41) 0.89 61/404 0.76 (0.53-1.08) 0.12 
NOS3 (rs1799983) GG 152/598 1.00 (ref)  59/382 1.00 (ref)  
GT+TT 36/160 0.89 (0.59-1.33) 0.56 94/475 1.31 (0.92-1.87) 0.13 
NOS3 (rs3918226)  
d  
CC - - - 126/725 1.00 (ref)  
CT+TT - - - 27/138 1.09 (0.69-1.73) 0.70 
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NOX3||ARID1B 
(rs9372014)  d 
GG - - - 77/403 1.00 (ref)  
GT+TT - - - 76/459 0.86 (0.60-1.21) 0.38 
NQO1 (rs689453) CC 171/673 1.00 (ref)  138/731 1.00 (ref)  
CT+TT 17/87 0.75 (0.44-1.31) 0.31 15/132 0.62 (0.35-1.10) 0.10 
OGG1 (rs1805373)  
d 
GG 151/648 1.00 (ref)  - - - 
AG+AA 37/112 1.45 (0.96-2.20) 0.08 - - - 
PPARG 
(rs1801282)  d 
CC - - - 122/670 1.00 (ref)  
CG+GG - - - 30/193 0.84 (0.54-1.29) 0.42 
RAD51C 
(rs304269) 
GG 104/400 1.00 (ref)  57/360 1.00 (ref)  
AG+AA 84/360 0.92 (0.67-1.27) 0.61 96/503 1.21 (0.85-1.73) 0.30 
RAD51C 
(rs6503874) 
CC 89/388 1.00 (ref)  136/767 1.00 (ref)  
CG+GG 99/371 1.20 (0.87-1.65) 0.27 17/96 1.00 (0.57-1.73) 0.99 
SOD2 (rs10370) TT 145/549 1.00 (ref)  94/515 1.00 (ref)  
GT+GG 43/209 0.79 (0.54-1.15) 0.21 59/348 0.96 (0.67-1.37) 0.83 
SOD2 (rs4880) AA 69/254 1.00 (ref)  42/197 1.00 (ref)  
AG+GG 118/505 0.88 (0.63-1.23) 0.45 111/665 0.77 (0.52-1.14) 0.19 
USP4||GPX1 
(rs8179172)  d 
AA 153/640 1.00 (ref)  - - - 
AT+TT 35/120 1.22 (0.81-1.86) 0.34 - - - 
XPA (rs1800975) CC 121/470 1.00 (ref)  69/366 1.00 (ref)  
CT+TT 67/289 0.90 (0.64-1.25) 0.52 84/497 0.90 (0.64-1.28) 0.56 
XPA (rs3176644)  d GG 69/322 1.00 (ref)  - - - 
GT+TT 118/437 1.28 (0.92-1.79) 0.14 - - - 
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XPC (rs2227998) CC 94/366 1.00 (ref)  78/480 1.00 (ref)  
CT+TT 94/394 0.92 (0.67-1.27) 0.62 75/378 1.17 (0.83-1.66) 0.36 
XPC (rs2733537) AA 131/527 1.00 (ref)  86/401 1.00 (ref)  
AG+GG 57/233 0.96 (0.68-1.37) 0.84 67/462 0.71 (0.50-1.01) 0.05 
XRCC1 
(rs1799778) 
GG 102/462 1.00 (ref)  66/353 1.00 (ref)  
GT+TT 85/294 1.31 (0.95-1.81) 0.10 87/509 0.91 (0.64-1.29) 0.58 
XRCC1 
(rs1799782) 
GG 165/660 1.00 (ref)  131/735 1.00 (ref)  
AG+AA 23/100 0.93 (0.57-1.52) 0.79 22/128 0.98 (0.60-1.60) 0.93 
XRCC1 
(rs2854508) 
TT 123/478 1.00 (ref)  98/508 1.00 (ref)  
AT+AA 65/281 0.90 (0.64-1.26) 0.54 55/355 0.80 (0.56-1.14) 0.22 
XRCC1 
(rs3213247)  d 
CC - - - 136/772 1.00 (ref)  
AC+AA - - - 17/91 1.06 (0.61-1.84) 0.84 
XRCC2 
(rs3218522) 
CC 122/529 1.00 (ref)  38/248 1.00 (ref)  
CT+TT 66231 1.25 (0.89-1.75) 0.20 115/615 1.20 (0.80-1.78) 0.38 
XRCC4 
(rs10474079)  d 
GG - - - 115/665 1.00 (ref)  
AG+AA - - - 38/197 1.07 (0.71-1.60) 0.74 
XRCC4 
(rs28360135)  d 
TT - - - 144/792 1.00 (ref)  
CT+CC - - - 9/71 0.77 (0.37-1.59) 0.48 
XRCC4 (rs35268) TT 100/417 1.00 (ref)  116/670 1.00 (ref)  
CT+CC 87/343 1.08 (0.78-1.49) 0.63 37/193 1.05 (0.70-1.59) 0.80 
XRCC4 
(rs3777018)  d 
AA - - - 128/769 1.00 (ref)  
AG+GG - - - 25/94 1.63 (1.00-2.64) 0.05 
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a The most common genotype used as the reference category 
b  Some categories may not sum to total sample because of missing data  
c Adjusted for age 
d Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group 
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Table 8.3 Associations between dietary lycopene and prostate cancer aggressiveness stratified by genotype of SNPs in 
DNA repair and oxidative stress-related genes  
 European Americans 
 (n = 1,016) 
 Cases/ 
Controls  
OR (95% CI) b   
Dietary lycopene mg/day a   low 85/431 1.00 (ref)  
high 68/432 0.77 (0.53-1.16)  
Stratified analysis by SNP  Homozygous Common 
Allele 
Heterozygous or Homozygous 
Minor Allele 
 
Gene (SNP ID), 
major/minor allele 
 Cases/ 
Controls 
 
OR (95% CI) b Cases/ 
Controls 
OR (95% CI) b P ‡ 
APEX1(rs1130409)                T / G low 20/110 1.00 (ref) 65/321 1.00 (ref)  
high 18/120 0.51 (0.22-1.18) 50/312 0.85 (0.54-1.35) 0.71 
ERCC8 (rs4647100)              A / G low 51/240 1.00 (ref) 34/191 1.00 (ref)  
high 36/241 0.62 (0.37-1.07) 32/191 0.94 (0.51-1.73) 0.43 
ERCC8 (rs4647102)               T / C low 34/155 1.00 (ref) 51/276 1.00 (ref)  
high 27/169 0.68 (0.36-1.29) 41/263 0.85 (0.51-1.42) 0.56 
ERCC8 (rs976631)                 T / C low 26/144 1.00 (ref) 59/286 1.00 (ref)  
high 20/131 0.81 (0.38-1.72) 48/299 0.76 (0.47-1.21) 0.57 
GPX2 (rs4902346)                A / G low 47/278 1.00 (ref) 38/153 1.00 (ref)  
high 39/275 0.83 (0.49-1.42) 29/157 0.65 (0.36-1.19) 0.62 
MUTYH (rs3219489)             C / G low 55/229 1.00 (ref) 30/202 1.00 (ref)  
high 37/230 0.64 (0.38-1.08) 31/202 1.04 (0.56-1.92) 0.39 
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NOS3 (rs1799983)                G  / T low 31/188 1.00 (ref) 54/240 1.00 (ref)  
high 28/194 0.99 (0.52-1.88) 40/235 0.65 (0.39-1.08) 0.45 
NOS3 (rs3918226) c               C / T 
 
low 72/371 1.00 (ref) 13/60 1.00 (ref)  
high 54/354 0.76 (0.49-1.18) 14/78 0.89 (0.33-2.41) 0.96 
NOX3||ARID1B (rs9372014) c                 
                                        G / T 
low 41/191 1.00 (ref) 44/240 1.00 (ref)  
high 36/212 0.81 (0.47-1.41) 32/219 0.71 (0.40-1.27) 0.84 
NQO1 (rs689453)                  C / T low 75/378 1.00 (ref) 10/53 1.00 (ref)  
high 63/353 0.89 (0.59-1.35) 5/79 0.19 (0.03-1.14) 0.05 
OGG1 (rs1805373)  c            G / A 
  
low - - - - - 
high - - - - - 
PPARG (rs1801282) c            C / G  low 67/336 1.00 (ref) 18/95 1.00 (ref)  
high 55/334 0.79 (0.51-1.23) 12/98 0.69 (0.26-1.86) 0.83 
RAD51C (rs304269)              G / A low 31/180 1.00 (ref) 54/251 1.00 (ref)  
high 26/180 0.90 (0.46-1.76) 42/252 0.71 (0.43-1.17) 0.57 
RAD51C (rs6503874)            C / G low 76/382 1.00 (ref) 9/49 1.00 (ref)  
high 60/385 0.76 (0.50-1.15) 8/47 1.33 (0.26-6.79) 0.91 
SOD2 (rs10370)                     T / G low 53/258 1.00 (ref) 32/173 1.00 (ref)  
high 41/257 0.77 (0.46-1.26) 27/175 0.77 (0.40-1.48) 0.97 
SOD2 (rs4880)                      A / G low 25/91 1.00 (ref) 60/339 1.00 (ref)  
high 17/106 0.56 (0.25-1.26) 51/326 0.84 (0.53-1.33) 0.27 
USP4||GPX1 (rs8179172)  c                                                  
 A / T 
low - - - - - 
high - - - - - 
XPA (rs1800975)                    C / T low 33/185 1.00 (ref) 52/246 1.00 (ref)  
high 36/181 1.02 (0.56-1.87) 32/251 0.56 (0.32-0.98) 0.07 
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XPA (rs3176644) c                 G / T 
 
low - - - - - 
high - - - - - 
XPC (rs2227998)                   C / T low 48/239 1.00 (ref) 37/190 1.00 (ref)  
high 30/241 0.65 (0.38-1.12) 38/188 0.90 (0.49-1.65) 0.37 
XPC (rs2733537)                   A / G low 51/202 1.00 (ref) 34/229 1.00 (ref)  
high 35/199 0.65 (0.37-1.14) 33/233 0.96 (0.55-1.69) 0.47 
XRCC1 (rs1799778)              G / T low 37/181 1.00 (ref) 48/249 1.00 (ref)  
high 29/172 0.74 (0.39-1.39) 39/260 0.75 (0.45-1.27) 0.82 
XRCC1 (rs1799782)              G / A low 74/365 1.00 (ref) 11/66 1.00 (ref)  
high 57/370 0.71 (0.46-1.09) 11/62 1.15 (0.34-3.66) 0.47 
XRCC1 (rs2854508)              T / A low 63/266 1.00 (ref) 22/165 1.00 (ref)  
high 35/242 0.57 (0.34-0.95) 33/190 1.22 (0.63-2.39) 0.06 
XRCC1 (rs3213247) c               C / A low 77/390 1.00 (ref) 8/41 1.00 (ref)  
high 59/382 0.73 (0.48-1.12) 9/50 1.02 (0.30-3.40) 0.69 
XRCC2 (rs3218522)               C / T low 16/126 1.00 (ref) 69/305 1.00 (ref)  
high 22/122 1.22 (0.53-2.80) 46/310 0.66 (0.42-1.05) 0.08 
XRCC4 (rs10474079) c          G / A low 65/333 1.00 (ref) 20/97 1.00 (ref)  
high 50/332 0.74 (0.47-1.16) 18/100 0.80 (0.34-1.87) 0.71 
XRCC4 (rs28360135)  c         T / C low 79/404 1.00 (ref) 6/27 1.00 (ref)  
high 65/388 0.81 (0.54-1.21) 3/44 0.44 (0.04-4.56) 0.34 
XRCC4 (rs35268)  c               T / C low 68/327 1.00 (ref) 17/104 1.00 (ref)  
high 48/343 0.95 (0.41-1.22) 20/89 1.31 (0.71-4.10) 0.27 
XRCC4 (rs3777018 ) c           A / G low 74/382 1.00 (ref) 11/49 1.00 (ref)  
high 54/387 0.68 (0.44-1.04) 14/45 1.31 (0.39-4.39) 0.23 
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a Categorized based on median split  (< versus ≥ median)  among controls for European Americans as  low: 344.77 – 4626.17 
mcg/day and high: 4626.18 – 100250.76 mcg/day; and for African Americans: 4.90 – 3319.69  and 3319.70  – 106071.98 mcg/day, 
respectively.    
 
b Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total fat intake, and study site 
c Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group  
 
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype 
(homozygous common allele vs. homozygous variant + heterozygous) and dietary lycopene intake (<versus ≥ median) in 
multivariable adjusted models. 
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Table 8.3 (continued) Associations between dietary lycopene and prostate cancer aggressiveness stratified by genotype of 
SNPs in DNA repair and oxidative stress-related genes  
 African Americans 
 (n = 948) 
 Cases/ 
Controls  
OR (95% CI) b  
Dietary lycopene mg/day a   low 80/380 1.00 (ref)  
high 108/380 1.41 (0.96-2.07)  
Stratified analysis by SNP  Homozygous Common 
Allele 
Heterozygous or Homozygous 
Minor Allele 
 
Gene (SNP ID), 
major/minor allele 
 Cases/ 
Controls 
OR (95% CI) b Cases/ 
Controls 
OR (95% CI) b P ‡ 
APEX1(rs1130409)              T /  G low 32/153 1.00 (ref) 48/227 1.00 (ref)  
high 49/152 1.71 (0.95-3.07) 59/228 1.25 (0.74-2.10) 0.50 
ERCC8 (rs4647100)             A / G low 66/312 1.00 (ref) 14/68 1.00 (ref)  
high 90/313 1.47 (0.97-2.25) 18/67 0.91 (0.33-2.49) 0.79 
ERCC8 (rs4647102)              T / C low 28/161 1.00 (ref) 52/219 1.00 (ref)  
high 47/154 1.94 (1.01-3.73) 61/224 1.13 (0.70-1.82) 0.08 
ERCC8 (rs976631)                T / C low 45/211 1.00 (ref) 35/169 1.00 (ref)  
high 56/223 1.28 (0.76-2.17) 50/156 1.45 (0.80-2.60) 0.64 
GPX2 (rs4902346)                A / G low 29/127 1.00 (ref) 51/253 1.00 (ref)  
high 41/139 1.49 (0.76-2.94) 67/241 1.39 (0.86-2.24) 0.95 
MUTYH (rs3219489)            C / G low 40/212 1.00 (ref) 40/168 1.00 (ref)  
high 67/222 1.65 (0.98-2.78) 41/158 1.19 (0.67-2.13) 0.31 
NOS3 (rs1799983)               G  / T low 68/297 1.00 (ref) 12/82 1.00 (ref)  
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high 84/301 1.25 (0.82-1.90) 24/78 1.90 (0.71-5.12) 0.20 
NOS3 (rs3918226) c              C / T 
 
low - - - - - 
high - - - - - 
NOX3||ARID1B (rs9372014) c                 
                                        G / T 
low - - - - - 
high - -  - - 
NQO1 (rs689453)                  C / T low 71/336 1.00 (ref) 9/44 1.00 (ref)  
high 100/337 1.42 (0.95-2.13) 8/43 0.16 (0.25-5.37) 0.35 
OGG1 (rs1805373)  c            G / A 
  
low 62/33 1.00 (ref) 18/47 1.00 (ref)  
high 89/315 1.56 (1.00-2.39) 19/65 0.83 (0.31-2.26) 0.11 
PPARG (rs1801282) c           C / G  low - - - - - 
high - - - - - 
RAD51C (rs304269)             G / A low 49/207 1.00 (ref) 31/173 1.00 (ref)  
high 55/193 1.27 (0.75-2.14) 53/187 1.50 (0.82-2.74) 0.50 
RAD51C (rs6503874)           C / G low 38/203 1.00 (ref) 42/177 1.00 (ref)  
high 51/185 1.86 (1.03-3.35) 57/194 1.11 (0.65-1.89) 0.37 
SOD2 (rs10370)                    T / G low 61/263 1.00 (ref) 19/116 1.00 (ref)  
high 84/286 1.32 (0.85-2.06) 24/93 1.47 (0.63-3.43) 0.81 
SOD2 (rs4880)                      A / G 
 
low 32/137 1.00 (ref) 47/242 1.00 (ref)  
high 37/117 1.28 (0.68-2.41) 71/263 1.57 (0.96-2.59) 0.83 
USP4||GPX1 (rs8179172)  c                                                  
 A / T 
low 66/321 1.00 (ref) 14/59 1.00 (ref)  
high 87/319 1.30 (0.86-1.99) 21/61 1.28 (0.43-3.79) 0.89 
XPA (rs1800975)                   C / T low 49/247 1.00 (ref) 31/133 1.00 (ref)  
high 72/223 1.28 (0.88-2.06) 36/156 0.73 (0.53-1.84) 0.14 
XPA (rs3176644) c                G / T low 36/161 1.00 (ref) 44/218 1.00 (ref)  
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 high 33/161 0.91 (0.49-1.69) 74/219 1.92 (1.16-3.20) 0.10 
XPC (rs2227998)                   C / T low 40/179 1.00 (ref) 40/201 1.00 (ref)  
high 54/187 1.12 (0.64-1.96) 54/193 1.74 (1.01-3.01) 0.84 
XPC (rs2733537)                  A / G low 59/276 1.00 (ref) 21/104 1.00 (ref)  
high 72/251 1.22 (0.77-1.94) 36/129 2.26 (1.03-4.92) 0.56 
XRCC1 (rs1799778)              G / T low 40/226 1.00 (ref) 40/152 1.00 (ref)  
high 62/236 1.77 (1.05-2.98) 45/142 1.00 (0.55-1.84) 0.42 
XRCC1 (rs1799782)             G / A low 72/332 1.00 (ref) 8/48 1.00 (ref)  
high 93/328 1.37 (0.91-2.05) 15/52 1.88 (0.42-8.37) 0.93 
XRCC1 (rs2854508)              T / A low 60/232 1.00 (ref) 20/148 1.00 (ref)  
high 63/246 0.79 (0.63-1.66) 45/133 2.50 (1.27-4.89) 0.010 
XRCC1 (rs3213247) c             C / A low - - - - - 
high - - - - - 
XRCC2 (rs3218522)              C / T low 50/265 1.00 (ref) 30/115 1.00 (ref)  
high 72/264 1.38 (0.93-2.49) 36/116 0.89 (0.53-1.48) 0.39 
XRCC4 (rs10474079) c         G / A low - - - - - 
high - - - - - 
XRCC4 (rs28360135)  c         T / C low - - - - - 
high - - - - - 
XRCC4 (rs35268)  c               T / C low 41/211 1.00 (ref) 39/169 1.00 (ref)  
high 59/206 0.99 (0.55-1.78) 48/174  1.33 (0.97-2.97) 0.38 
XRCC4 (rs3777018 ) c          A / G low - - - - - 
high - - - -  - 
a Categorized based on median split  (< versus ≥ median)  among controls for European Americans as  low: 344.77 – 
4626.17 mcg/day and high: 4626.18 – 100250.76 mcg/day; and for African Americans: 4.90 – 3319.69  and 3319.70  – 
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106071.98 mcg/day, respectively.    
b Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total fat intake, and 
study site 
c Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group  
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype 
(homozygous common allele vs. homozygous variant + heterozygous) and dietary lycopene intake (<versus ≥ median) in 
multivariable adjusted models.   
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Table 8.4 Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between total lycopene intake 
(diet + supplements) and prostate cancer aggressiveness, stratified by polymorphisms in DNA repair and oxidative stress-
related genes 
 European Americans 
 (n = 1,016) 
 Cases/ 
Controls  
OR (95% CI) b   
Total lycopene mg/day a   low 84/431 1.00 (ref)  
high 69/432 0.81 (0.55-1.20)  
Stratified analysis by SNP  Homozygous Common Allele Heterozygous or Homozygous 
Minor Allele 
 
Gene (SNP ID), 
major/minor allele 
 Cases/ 
Controls 
 
OR (95% CI) b Cases/ 
Controls 
OR (95% CI) b P ‡ 
APEX1(rs1130409)              T / G low 20/109 1.00 (ref) 64/322 1.00 (ref)  
high 18/121 0.46 (0.20-1.06) 51/311 0.90 (0.57-1.42) 0.59 
ERCC8 (rs4647100)             A / G low 51/239 1.00 (ref) 33/192 1.00 (ref)  
high 36/242 0.61 (0.36-1.05) 33/190 1.05 (0.57-1.91) 0.29 
ERCC8 (rs4647102)             T / C low 34/156 1.00 (ref) 50/275 1.00 (ref)  
high 27/168 0.68 (0.36-1.28) 42/264 0.91 (0.55-1.51) 0.47 
ERCC8 (rs976631)               T / C low 25/143 1.00 (ref) 59/287 1.00 (ref)  
high 21/132 0.87 (0.41-1.83) 48/298 0.78 (0.49-1.25) 0.52 
GPX2 (rs4902346)               A / G low 47/278 1.00 (ref) 37/153 1.00 (ref)  
high 39/275 0.82 (0.48-1.41) 30/157 0.70 (0.38-1.27) 0.76 
MUTYH (rs3219489)           C / G low 55/229 1.00 (ref) 29/202 1.00 (ref)  
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high 37/230 0.65 (0.39-1.10) 32/202 1.11 (0.60-2.07) 0.32 
NOS3 (rs1799983)               G  / T low 30/187 1.00 (ref) 54/241 1.00 (ref)  
high 29/195 1.12 (0.59-2.12) 40/234 0.64 (0.38-1.06) 0.30 
NOS3 (rs3918226) c              C / T 
 
low 71/371 1.00 (ref) 13/60 1.00 (ref)  
high 55/354 0.80 (0.51-1.24) 14/78 0.90 (0.33-2.47) 0.81 
NOX3||ARID1B (rs9372014) c                 
                                              G / T 
low 41/193 1.00 (ref) 43/238 1.00 (ref)  
high 36/210 0.83 (0.48-1.44) 33/221 0.74 (0.41-1.31) 0.82 
NQO1 (rs689453)                 C / T low 74/378 1.00 (ref) 10/53 1.00 (ref)  
high 64/353 0.92 (0.61-1.39) 5/79 0.20 (0.03-1.22) 0.06 
OGG1 (rs1805373)  c           G / A low - - - - - 
high - - - - - 
PPARG (rs1801282)  c         C / G  low 66/335 1.00 (ref) 18/96 1.00 (ref)  
high 56/335 0.82 (0.53-1.27) 12/97 0.73 (0.27-1.97) 0.82 
RAD51C (rs304269)            G / A low 30/183 1.00 (ref) 54/248 1.00 (ref)  
high 27/177 1.04 (0.53-2.03) 42/255 0.69 (0.41-1.13) 0.34 
RAD51C (rs6503874)           C / G low 78/382 1.00 (ref) 8/49 1.00 (ref)  
high 58/385 0.76 (0.50-1.16) 9/47 1.81 (0.38-8.72) 0.59 
SOD2 (rs10370)                   T / G low 52/260 1.00 (ref) 32/171 1.00 (ref)  
high 42/255 0.82 (0.50-1.35) 27/177 0.75 (0.39-1.43) 0.84 
SOD2 (rs4880)                     A / G 
      
low 25/91 1.00 (ref) 59/339 1.00 (ref)  
high 17/106 0.58 (0.26-1.29) 52/326 0.87 (0.55-1.38) 0.26 
USP4||GPX1 (rs8179172) c  A / T  low - - - - - 
high - - - - - 
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XPA (rs1800975)                  C / T low 32/187 1.00 (ref) 52/244 1.00 (ref)  
high 37/179 1.15 (0.63-2.09) 32/253 0.56 (0.32-0.97) 0.04 
XPA (rs3176644)  c               G / T low - - - - - 
high - - - - - 
XPC (rs2227998)                  C / T low 48/238 1.00 (ref) 36/190 1.00 (ref)  
high 30/242 0.64 (0.37-1.11) 39/188 0.98 (0.54-1.79) 0.26 
XPC (rs2733537)                 A / G low 50/205 1.00 (ref) 34/226 1.00 (ref)  
high 36/196 0.75 (0.43-1.31) 33/236 0.93 (0.52-1.63) 0.73 
XRCC1 (rs1799778)             G / T low 37/183 1.00 (ref) 47/247 1.00 (ref)  
high 29/170 0.76 (0.40-1.43) 40/262 0.79 (0.47-1.32) 0.89 
XRCC1 (rs1799782)             G / A low 73/364 1.00 (ref) 11/67 1.00 (ref)  
high 58/371 0.73 (0.48-1.12) 11/61 1.30 (0.39-4.33) 0.42 
XRCC1 (rs2854508)             T / A low 62/264 1.00 (ref) 62/264 1.00 (ref)  
high 36/244 0.59 (0.36-0.99) 36/244 1.24 (0.64-2.41) 0.07 
XRCC1 (rs3213247)  c          C / A low 77/390 1.00 (ref) 7/41 1.00 (ref)  
high 59/382 0.73 (0.48-1.120 10/50 1.21 (0.36-4.07) 0.41 
XRCC2 (rs3218522)             C / T low 16/125 1.00 (ref) 68/306 1.00 (ref)  
high 22/123 1.20 (0.52-2.76) 47/309 0.70 (0.45-1.11) 0.11 
XRCC4 (rs10474079)  c       G / A low 64/333 1.00 (ref) 20/97 1.00 (ref)  
high 51/332 0.77 (0.49-1.21) 18/100 0.82 (0.35-1.90) 0.76 
XRCC4 (rs28360135)  c        T / C low 78/404 1.00 (ref) 6/27 1.00 (ref)  
high 66/388 0.84 (0.56-1.26) 3/44 0.44 (0.04-4.56) 0.32 
XRCC4 (rs35268)  c              T / C low 67/327 1.00 (ref) 17/104 1.00 (ref)  
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high 49/343 0.67 (0.42-1.05) 20/89 1.46 (0.74-3.21) 0.21 
XRCC4 (rs3777018 ) c         A / G low 73/382 1.00 (ref) 11/49 1.00 (ref)  
high 55/387 0.70 (0.46-1.08) 14/45 1.31 (0.39-4.39) 0.36 
 
a Categorized based on median split  (< vs. ≥ median)  among controls for European Americans as  low: 344.77 – 4698.17 mcg/day and 
high: 4698.18 – 100250.76 mcg/day; and for African Americans: 4.90 – 3358.85  and 3358.86 – 106071.98 mcg/day, respectively.   
 
b Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total fat intake, and study site 
 
c Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group  
 
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype (homozygous 
common allele vs. homozygous variant + heterozygous) and total lycopene intake (<versus ≥ median) in multivariable adjusted models.  
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Table 8.4 (continued) Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between total 
lycopene intake (diet + supplements) and prostate cancer aggressiveness, stratified by polymorphisms in DNA repair and 
oxidative stress-related genes 
 African Americans 
 (n = 948)  
 Cases/ 
Controls  
OR (95% CI) b  
Total lycopene mg/day a   low 81/380 1.00 (ref)  
high 107/380 1.36 (0.92-1.99)  
Stratified analysis by SNP  Homozygous Common Allele Heterozygous or Homozygous 
Minor Allele 
 
Gene (SNP ID), 
major/minor allele 
 Cases/ 
Controls 
OR (95% CI) b Cases/ 
Controls 
OR (95% CI) b P ‡ 
APEX1(rs1130409)            T / G low 32/153 1.00 (ref) 49/227 1.00 (ref)  
high 49/152 1.69 (0.94-3.04) 58/228 1.15 (0.69-1.94) 0.42 
ERCC8 (rs4647100)          A / G low 67/312 1.00 (ref) 14/68 1.00 (ref)  
high 89/313 1.41 (0.92-2.14) 18/67 0.91 (0.33-2.49) 0.86 
ERCC8 (rs4647102)           T / C low 29/161 1.00 (ref) 52/219 1.00 (ref)  
high 46/154 1.77 (0.93-3.40) 61/224 1.11 (0.69-1.80) 0.11 
ERCC8 (rs976631)             T / C low 45/211 1.00 (ref) 36/169 1.00 (ref)  
high 56/223 1.25 (0.74-2.12) 49/156 1.34 (0.74-2.40) 0.74 
GPX2 (rs4902346)             A / G low 29/126 1.00 (ref) 52/254 1.00 (ref)  
high 41/140 1.48 (0.75-2.92) 66/240 1.31 (0.82-2.11) 0.87 
MUTYH (rs3219489)         C / G low 41/211 1.00 (ref) 40/169 1.00 (ref)  
high 66/223 1.53 (0.91-2.55) 41/157 1.20 (0.67-2.14) 0.42 
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NOS3 (rs1799983)            G  / T low 69/296 1.00 (ref) 12/83 1.00 (ref)  
high 83/302 1.18 (0.78-1.80) 24/77 1.94 (0.72-5.23) 0.16 
NOS3 (rs3918226) c           C / T 
 
low - - - - - 
high - -  - - 
NOX3||ARID1B (rs9372014) c                 
                                            G / T 
low - - - - - 
high - - - - - 
NQO1 (rs689453)               C / T low 72/337 1.00 (ref) 9/43 1.00 (ref)  
high 99/336 1.38 (0.92-2.07) 8/44 0.79 (0.16-3.75) 0.29 
OGG1 (rs1805373)  c        G / A 
 
low 62/332 1.00 (ref) 19/48 1.00 (ref)  
high 89/316 1.53 (0.99-2.34) 18/64 0.76 (0.28-2.09) 0.07 
PPARG (rs1801282)  c      C / G  low - - - - - 
high - - - - - 
RAD51C (rs304269)          G / A low 49/205 1.00 (ref) 32/175 1.00 (ref)  
high 55/195 1.23 (0.73-2.07) 52/185 1.42 (0.78-2.58) 0.53 
RAD51C (rs6503874)        C / G low 38/204 1.00 (ref) 43/176 1.00 (ref)  
high 51/184 1.81 (1.02-3.34) 56/195 1.03 (0.61-1.75) 0.27 
SOD2 (rs10370)                 T / G low 62/263 1.00 (ref) 19/116 1.00 (ref)  
high 83/286 1.25 (0.81-1.94) 24/93 1.47 (0.63-3.44) 0.73 
SOD2 (rs4880)                   A / G 
      
low 32/137 1.00 (ref) 48/242 1.00 (ref)  
high 37/117 1.27 (0.67-2.39) 70/263 1.46 (0.89-2.39) 0.95 
USP4||GPX1 (rs8179172)  c      
A / T  
 
low 67/319 1.00 (ref) 14/61 1.00 (ref)  
high 86/321 1.23 (0.81-1.87) 21/59 1.43 (0.48-4.29) 0.74 
XPA (rs1800975)                C / T low 50/249 1.00 (ref) 31/131 1.00 (ref)  
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high 71/221 1.79 (1.09-2.95) 36/158 0.85 (0.51-1.76) 0.13 
XPA (rs3176644)  c            G / T 
 
low 36/161 1.00 (ref) 45/218 1.00 (ref)  
high 33/161 0.91 (0.49-1.70) 73/219 1.79 (1.08-2.96) 0.13 
XPC (rs2227998)               C / T low 40/180 1.00 (ref) 41/200 1.00 (ref)  
high 54/186 1.11 (0.64-1.94) 53/194 1.63 (0.95-2.81) 0.94 
XPC (rs2733537)               A / G low 60/274 1.00 (ref) 21/106 1.00 (ref)  
high 71/253 1.14 (0.72-1.80) 36/127 2.33 (1.06-5.10) 0.43 
XRCC1 (rs1799778)           G / T low 41/225 1.00 (ref) 40/153 1.00 (ref)  
high 61/237 1.63 (0.97-2.73) 45/141 1.01 (0.55-1.85) 0.56 
XRCC1 (rs1799782)          G / A low 73/331 1.00 (ref)   8/49  1.00 (ref)  
high 92/329 1.29 (0.86-1.94) 15/51 2.24 (0.48-10.48) 0.83 
XRCC1 (rs2854508)           T / A low 61/230 1.00 (ref) 20/150 1.00 (ref)  
high 62/248 0.95 (0.59-1.53) 45/131 2.56 (1.30-5.02) 0.005 
XRCC1 (rs3213247)  c       C / A low - - - - - 
high - - - - - 
XRCC2 (rs3218522)           C / T low 50/264 1.00 (ref) 31/116 1.00 (ref)  
high 72/265 1.48 (0.90-2.42) 35/115 1.06 (0.56-2.00) 0.34 
XRCC4 (rs10474079)  c     G / A low - - - - - 
high - - - - - 
XRCC4 (rs28360135)  c      T / C low - - - - - 
high - - - - - 
XRCC4 (rs35268)  c            T / C low 42/210 1.00 (ref) 39/170 1.00 (ref)  
high 58/207 1.00 (0.56-1.80) 48/173 1.61 (0.95-2.71) 0.62 
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XRCC4 (rs3777018 ) c       A / G low - - - - - 
high - - - - - 
a Categorized based on median split  (< vs. ≥ median)  among controls for European Americans as  low: 344.77 – 4698.17 mcg/day and high: 
4698.18 – 100250.76 mcg/day; and for African Americans: 4.90 – 3358.85  and 3358.86 – 106071.98 mcg/day, respectively.   
 
b Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total fat intake, and study site 
 
c Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group  
 
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype (homozygous common 
allele vs. homozygous variant + heterozygous) and total lycopene intake (<versus ≥ median) in multivariable adjusted models. 
  
 
 
 CHAPTER 9 
SYNTHESIS 
 
9.1     ANTIOXIDANT INTAKE AND PROSTATE SPECIFIC ANTIGEN IN MEN WITH BIOCHEMICAL   
RECURRENCE OF PROSTATE CANCER    
 
It is estimated that about 94% of American men with prostate cancer present with 
clinically localized disease and often are treated with radical prostatectomy or radical 
radiation with curative intent [340, 341]. However, about 25–40% of these men develop 
biochemical recurrence of PCa within 5 years of treatment [342-345]. Biochemical 
recurrence of PCa, which is generally defined by continuous rise in serum PSA level on 
three or more successive tests, is often an early sign of metastasis and precedes metastasis 
by an average of eight years [348]. Unfortunately, there is no known cure for biochemical 
recurrence of PCa, but it is usually managed with surgical or medical androgen ablation 
with the hope of delaying the time to metastasis. Androgen ablation has been associated 
with severe and life-altering side effects [351, 539], which makes its use unappealing to 
both patients and clinics. Thus, the idea of using dietary agents as alternate therapy or a 
first line treatment to delay the use of androgen ablation is a prospect that would be 
attractive to most patients. Results from this study show that men with higher plasma 
levels of α-tocopherol, β-cryptoxanthin, trans-β-carotene, cis-lutein/zeaxanthin and 
trans-lycopene had lower PSA levels at follow-up timepoints compared to men with 
lower plasma levels of these nutrients. This suggests that greater intake of foods 
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 containing these micronutrients might be beneficial to men with biochemical recurrence 
of PCa.  
These micronutrients are abundantly available in many fruits and vegetables (food 
sources reviewed in [291, 540]), which raises the question of whether these 
micronutrients may have acted as surrogates for greater intake of fruits and vegetables, 
which contain other beneficial micronutrients and phytochemicals. Thus, replication of 
the findings in larger studies with longer follow-up would be useful. Other caveats that 
should be considered are noted below.  
 
9.2    ASSOCIATIONS OF ANTIOXIDANTS AND PROSTATE CANCER AGGRESSIVENESS  
Although the epidemiologic literature is replete with reports on associations 
between antioxidants intake and PCa incidence, much less is known about antioxidants 
effect on PCa aggressiveness. Antioxidants are thought to mitigate oxidative stress, 
thereby averting oxidative DNA damage and the potential for malignant transformation 
of normal prostate cells. Recent published data indicates that oxidative stress correlates 
with the extent of PCa aggressiveness, such that the highly aggressive forms of PCa tends 
to display markedly higher degree of oxidative stress than do the less aggressive forms 
PCa [123]. Thus, increasing antioxidant intake may boost the body’s defenses against 
oxidative stress, and by extension, protect against PCa and its aggressiveness [394, 541].  
Results from analysis of associations between antioxidants intake, supplemental 
antioxidant use, and adipose tissue antioxidants levels in relation to PCa aggressiveness 
revealed some important findings. While there were no significant findings for 
supplemental antioxidant use, higher dietary intake of α-, γ- and δ-tocopherol were 
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 inversely associated with PCa aggressiveness among European American, but not 
African Americans. These racial differences in associations are likely due to variations in 
dietary patterns and the possibility of gene-diet interaction that may vary by race. For 
example, European Americans in this study were more likely to obtained α-tocopherols 
from healthy foods sources such as olive oils, nuts, seeds and vegetables, while African 
Americans often obtained α-tocopherol from less healthy foods such as potato and corn 
chips, and dark green vegetables prepared with fatback and lard. Thus, the source of 
tocopherol intake may explain some of these differences in associations by race. Higher 
adipose tissue concentration of α-tocopherol appeared to be associated with increased 
odds of high aggressive PCa among European Americans only, albeit statistically non-
significant. It is worth noting that European Americans in this study had a 75% higher 
adipose α-tocopherol concentration than African Americans. It is, however, unclear what 
constitutes “normal” adipose α-tocopherol levels, although the mean  α-tocopherol levels 
among European Americans in this study were slightly higher than those reported in 
breast tissue from Malaysian women [418] and lower than those reported in adipose 
tissue from European males in the EURAMIC study [419].  Nonetheless, it is reasonable 
to speculate that long-term use of dietary supplements (the most common source of α-
tocopherol) may have been the major contributor of the adipose α-tocopherol levels 
among European Americans, especially since a much greater proportion of European 
Americans reported vitamin E supplement use compared to African Americans.  
Carotenoids intake varied significantly between African Americans and European 
Americans, including higher intake of lycopene among European Americans and higher 
β-cryptoxanthin intake among African Americans. Dietary lycopene was associated with 
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 lower odds of high aggressive PCa among European Americans, and β-cryptoxanthin was 
associated with lower odds of high aggressive PCa among African Americans. Adipose 
tissue α-carotene and lycopene (cis + trans) levels were higher among European 
Americans than African Americans, and marginally significant inverse linear trends were 
observed for adipose α-carotene and lycopene  in relation to PCa aggressiveness among 
European Americans only. Given that inverse associations were only observed in the race 
group with higher dietary intake or adipose concentration of these nutrients, it stands to 
reason that the potential benefits of lycopene, β-cryptoxanthin and α-carotene may be 
acquired only at higher levels of intake. However, potential interactions with genetic 
variants in relevant genes cannot be ruled out and is described in section 5.3. 
 
9.3     GENE-DIET INTERACTION 
 
Associations between antioxidant intake and PCa incidence have varied across 
studies [17]. There is some evidence that polymorphic variants in oxidative stress and 
DNA repair genes modulate associations between antioxidant intake and PCa incidence 
[128, 466]. Therefore, the inconsistency in prior studies may be reflecting genetic risk 
variability of the studied populations. In this study, we investigated whether associations 
of α-tocopherol, γ-tocopherol and lycopene in relation to PCa aggressiveness are 
modulated by single nucleotide polymorphisms (SNPs) in oxidative stress and DNA 
repair genes, and whether effect modification varies by race.  
There was evidence of effect modification by certain SNPs with some variations 
by race. XRCC1 (rs2854508) genotype significantly modified association between α-
tocopherol intake and PCa aggressiveness among African Americans and European 
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 Americans, such that among those who possess the TT genotype, higher α-tocopherol 
intake was inversely related to PCa  aggressiveness, while the opposite was observed 
among those with AA or AT genotypes. A similar pattern of effect modification by 
XRCC1 (rs2854508) was observed for association between γ-tocopherol and PCa 
aggressiveness, but only among African Americans. XRCC1 (rs2854508) genotype also 
demonstrated interaction with lycopene, in that higher lycopene intake was associated 
with increased odds of high aggressive PCa among African Americans who harbor the 
AT or AA genotype, but not African Americans with the TT genotype. By contrast, 
higher lycopene intake was inversely related to high aggressive PCa among European 
Americans with the TT genotype, and no association was observed among European 
Americans with the AT or AA genotype. Lower odds of high aggressive prostate cancer 
was observed among European Americans who had higher lycopene intake and possessed 
the CT or TT genotype of NQO1 (rs689453), but not European Americans with the CC 
genotype, and there was no evidence of effect modification among African Americans. 
Even though some of the SNPs did not show evidence of statistical interaction 
with antioxidants intake, certain variants of the SNPs appear to work in tandem with 
antioxidants to influence PCa aggressiveness. Notably, higher α-tocopherol intake was 
associated with significantly lower odds of high aggressive PCa among European 
Americans who were homozygous for the common allele of APEX1 (rs1130409, T > G), 
PPARG (rs1801282, C > G), XPC (rs2733537, A > G) or XRCC1 (rs1799782, G > A). 
This supports suggestions that the potential benefits of α-tocopherol as well as other 
antioxidants may be limited to men with certain genetic variants, and this may explain 
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 some of the inconsistencies in the epidemiologic literature when diet is examined in 
isolation of genetic factors. 
This study provides evidence of interactions between α-tocopherol, γ-tocopherol 
and lycopene intake and SNPs in oxidative stress and DNA repair genes in relation to 
PCa aggressiveness. The findings indicate that not all men may benefit equally from 
dietary interventions involving these nutrients. Thus, targeted interventions for a 
subgroup of men with certain genetic variants may be a future strategy for 
chemoprevention of aggressive PCa.  
 
9.4     STRENGTHS AND LIMITATIONS 
 
Biochemical Recurrence of Prostate Cancer 
The examination of the potential benefits of exposure to carotenoids and 
tocopherols in relation PSA rise following radical prostatectomy is appealing because 
diet interventions provide a non-invasive, relatively inexpensive, and safe treatment 
alternative for management of the disease progression in a population with limited 
treatment options. Since the study participants had already undergone radical 
prostatectomy or radical radiation for the treatment of organ-confined disease, continuous 
rise in serum PSA level as defined in this study most likely reflects progressive disease, 
rather than residual normal tissue left from radiation or spared during prostatectomy. The 
use of biomarkers of nutrient intake provides more reliable measures of nutritional status 
relative to self-reported intake [384]. Additionally, several potential risk factors of PCa 
including BMI, smoking, physical activity, tumor grade and race also were controlled for 
in the analysis, which limits potential confounding of the observed associations.  
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 Limitations of the study include the small study and the multiple comparisons 
made, thus some of the findings could be due to chance alone. There is also the 
possibility that the study results may be reflecting interactions between plasma nutrients, 
rather than the effect of a single nutrient per se [383]. Blood antioxidant levels reflect 
short-term intake rather than average intake over long periods, which may be more 
relevant to PCa progression. The short duration of the study and lack of carotenoid and 
tocopherol data at 6 months prohibited evaluation of temporal trends over long periods. 
Additionally, restricting the study to a subgroup of PCa patients with strictly defined 
disease attributes precludes generalizability of the findings to the larger population of 
men with PCa. 
 
Antioxidants and Prostate Cancer Aggressiveness 
Notable strengths the analysis of associations between antioxidants intake and 
PCa aggressiveness include the design to measure PCa aggressiveness, which minimizes 
potential confounding by disease heterogeneity (i.e., the mixing of different disease 
states). The evaluation of three complementary measures of antioxidant intake allowed 
for a more comprehensive assessment of antioxidant status in PCa aggressiveness. 
Additionally, the assessment of individual antioxidants helps delineate the role of 
different antioxidants in PCa aggressiveness. The use of an ethnically diverse population 
with approximately equal numbers of African Americans and European Americans also 
made it possible to explore whether associations between antioxidants and PCa 
aggressiveness differed by race. Moreover, the potential for selection bias and selective 
survival were minimized because participation rates were reasonably high at both study 
sites (62% for North Carolina, 72% for pre- and 63% for post-Hurricane Katrina 
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 Louisiana)  and research subjects were recruited shortly after diagnosis via rapid case-
ascertainment; an average of five months from the time of diagnosis to time of interview.  
However, imprecise measurements of dietary antioxidants could have influenced 
the study results to some extent. Because exposure assessment for antioxidants were done 
independent of the extent of PCa aggressiveness, differential misclassification bias is 
unlikely; however, non-differential exposure misclassification may have occurred, 
resulting in underestimation of ORs and failure to detect modest associations [422]. Diet 
was assessed using a food frequency questionnaire. It is known that these structured 
instruments may be biased according to response sets [423], which in turn, may be related 
to psychological traits that either may exert a direct effect on cancer outcomes or 
indirectly affect other factors that may influence carcinogenesis [424]. There is also the 
concern that adipose antioxidant levels may be altered by the presence of a tumor; 
however, a study examining the effect of breast tumor proximity on breast adipose 
antioxidant levels did not find significant differences in adipose antioxidant levels at 
different quadrants of breast tissue, including sites proximal and distal to the tumor [425].  
Moreover, although adipose antioxidant levels are good markers for internal dose, they 
may not reflect prostatic antioxidant levels; thus, results should be interpreted with this in 
mind. Other limitations include the failure to control for cholesterol levels, in particular, 
low density lipoprotein which function as transport vehicles for antioxidants [388], and 
abdominal adiposity which may influence the adipose antioxidant levels. The influence of 
individual differences in metabolism and absorption, interactions between individual 
antioxidants compounds and other micronutrients, as well as potential modifying effects 
of genetic variants acting via similar mechanisms [383, 407, 426] were beyond the scope 
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 of this study. In addition, the possibility exists that some of the findings may be spurious 
owing to the sample size and multiple testing. 
Gene-Diet Interaction  
Very few studies have examined gene-diet interaction in relation to PCa 
aggressiveness, thus this study contributes important information to the limited data. The 
aggressive forms of PCa tend to have a strong genetic influence, and thus, aggressive and 
non-aggressive forms of PCa may differ in their etiology [458]. Thus, examining PCa 
aggressiveness reduces confounding by disease heterogeneity. Considering the 
controversy over the use of antioxidant nutrients for the prevention and control of PCa, 
this study provides evidence that indicates cautious use of such interventions, with 
suggestions that it may be beneficial only to a subgroup of men dependent on genotype of 
certain polymorphisms. Although genotyping errors cannot be completely ruled out in 
any genetic study, the genotyped data had over 99% concordance with blinded duplicates 
[411], which adds to the strengths of the study.  
Limitations include the use of median cutpoints to categorize antioxidant in an 
effort to conserve sample size; however, this may have resulted in too small contrast 
between high and low antioxidant intake categories to observe a substantial effect of 
antioxidant by genotype. The observational nature of the study also precludes causal 
inferences. Because of the small sample size and multiple comparisons, chance findings 
cannot be excluded, especially considering that none of the P values retained statistical 
significance after FDR correction for multiple testing. Single dietary assessment in the 
year prior to PCa diagnosis may have resulted in misclassification of dietary intake and 
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 overall dietary pattern to some extent. However, such misclassification is not likely to 
differ by the extent of PCa aggressiveness, as it is improbable that the research subjects 
considered their disease severity in responding to questions about dietary patterns. Thus, 
nondifferential misclassification may have attenuated some of the effect estimates. Even 
though analyses were stratified by self-reported race, residual confounding by ethnicity 
due to genetic admixture cannot be completely ruled out [537, 538]. Additionally, post 
hoc analysis involving adjustment for African ancestry proportions did not materially 
change the study results.  
 
9.5   Public Health Significance 
The study findings have important public health implications. First, we observed 
that certain antioxidant micronutrients (i.e., α-tocopherol, β-cryptoxanthin, trans-β-
carotene, cis-lutein/zeaxanthin, and trans-lycopene) might slow the progression of PCa in 
men with biochemical recurrence of the disease. This was evidence by lower serum PSA 
levels among men with higher plasma concentrations of these nutrients at various 
timepoints over a 6-month period. If confirmed by other studies, dietary interventions that 
emphasize greater intake of these nutrients could serve as an alternate therapy or 
neoadjuvant to delay the use of androgen ablation in these patients. This is particularly 
encouraging because of the severe side effects associated with the use of androgen 
ablation [14-16]. 
The epidemiologic data relating to the role of antioxidants in PCa aggressiveness 
is very limited. Although the majority of PCa patients are diagnosed with indolent disease 
owing to the widespread use of PSA blood test for early detection, an estimated 30% of 
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 prostate tumors progress aggressively [6]. Men with highly aggressive PCa have about a 
14-fold increased risk of dying from the disease as compared to those with less 
aggressive disease [3]. Therefore, distinguishing the modifiable risk factors of virulent 
PCa from that of indolent disease is of particular interest. This study showed that greater 
intake of β-cryptoxanthin was inversely associated with PCa aggressiveness among 
African Americans, while greater intake of α-, γ- and δ-tocopherol as well as lycopene 
were associated with lower odds of PCa among European Americans. Given that the 
biology of PCa may be different between African Americans and European Americans, 
and the fact that populations included in previous studies were predominantly of 
European decent and thus findings may not apply to African Americans, this study 
uniquely provides information on the potentially beneficial dietary factors for the 
prevention/control of aggressive PCa in specific race groups.  
The combined work of Objective 1 & 2 also advances our understanding on how 
antioxidants may be influencing PCa aggressiveness in general, and in men with certain 
genetic profiles. The evaluation of gene-diet interaction clearly demonstrated that not all 
men would benefit from antioxidant intervention in relation to PCa aggressiveness. 
Indeed, there were suggestions of increased odds of aggressive PCa with higher intake of 
some antioxidants in men with certain genetic profiles. Although preliminary, these 
findings have much translational potential as it could help clinician in designing 
structured and monitored dietary intervention programs aimed at reducing the occurrence 
of aggressive PCa, particularly among African Americans, an underserved population 
who suffer a greater burden of virulent PCa.  
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